<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32357528</article-id>
<article-id pub-id-type="pmc">7246738</article-id>
<article-id pub-id-type="doi">10.3390/ijms21093059</article-id>
<article-id pub-id-type="publisher-id">ijms-21-03059</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>Ramon</given-names>
</name>
</contrib>
</contrib-group>
<aff id="af1-ijms-21-03059">EuroEspes Biomedical Research Center, International Center of Neuroscience and Genomic Medicine, 15165 Bergondo, Corunna, Spain; <email>rcacabelos@euroespes.com</email></aff>
<pub-date pub-type="epub">
<day>26</day>
<month>4</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>5</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<issue>9</issue>
<elocation-id>3059</elocation-id>
<history>
<date date-type="received">
<day>12</day>
<month>3</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the author.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Symptomatic interventions for patients with dementia involve anti-dementia drugs to improve cognition, psychotropic drugs for the treatment of behavioral disorders (BDs), and different categories of drugs for concomitant disorders. Demented patients may take &gt;6–10 drugs/day with the consequent risk for drug–drug interactions and adverse drug reactions (ADRs &gt;80%) which accelerate cognitive decline. The pharmacoepigenetic machinery is integrated by pathogenic, mechanistic, metabolic, transporter, and pleiotropic genes redundantly and promiscuously regulated by epigenetic mechanisms. CYP2D6, CYP2C9, CYP2C19, and CYP3A4/5 geno-phenotypes are involved in the metabolism of over 90% of drugs currently used in patients with dementia, and only 20% of the population is an extensive metabolizer for this tetragenic cluster. ADRs associated with anti-dementia drugs, antipsychotics, antidepressants, anxiolytics, hypnotics, sedatives, and antiepileptic drugs can be minimized by means of pharmacogenetic screening prior to treatment. These drugs are substrates, inhibitors, or inducers of 58, 37, and 42 enzyme/protein gene products, respectively, and are transported by 40 different protein transporters. <italic>APOE</italic> is the reference gene in most pharmacogenetic studies. <italic>APOE-3</italic> carriers are the best responders and <italic>APOE-4</italic> carriers are the worst responders; likewise, CYP2D6-normal metabolizers are the best responders and CYP2D6-poor metabolizers are the worst responders. The incorporation of pharmacogenomic strategies for a personalized treatment in dementia is an effective option to optimize limited therapeutic resources and to reduce unwanted side-effects.</p>
</abstract>
<kwd-group>
<kwd>alzheimer’s disease</kwd>
<kwd>anxiety</kwd>
<kwd>behavioral disorders</kwd>
<kwd>depression</kwd>
<kwd>epilepsy</kwd>
<kwd>neuropsychiatric disorders</kwd>
<kwd>personalized medicine</kwd>
<kwd>pharmacogenomics</kwd>
<kwd>psychosis</kwd>
<kwd>sleep disorders</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-21-03059" sec-type="intro">
<title>1. Introduction</title>
<p>Alzheimer’s disease (AD) is the most prevalent form of dementia (&gt;50%), followed by vascular (VD), mixed dementia (MXD) (30–40%), and other modalities of neurodegenerative disorders (NDDs) (Lewy body dementia (LBD), frontotemporal dementia (FTD), prion dementia, Pick’s dementia, Parkinson–dementia complex (PDC); and comorbid FTD-amyotrophic lateral sclerosis) (5–10%). MXD shows the highest prevalence (&gt;50%) in patients over 70–75 years of age. Genomic defects (<xref ref-type="table" rid="ijms-21-03059-t001">Table 1</xref>), epigenetic aberrations, cerebrovascular dysfunction, and multiple environmental factors are the major risk factors that precipitate pathogenic cascades leading to the clinical phenotype of dementia which is characterized by progressive cognitive deterioration, behavioral changes, functional decline, and classical neuropathological hallmarks (extracellular Aβ deposition in senile plaques, intracellular neurofibrillary tangles with hyperphosphorylated tau, dendritic desarborization, and neuronal loss) [<xref ref-type="bibr" rid="B1-ijms-21-03059">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-03059">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-03059">3</xref>,<xref ref-type="bibr" rid="B4-ijms-21-03059">4</xref>,<xref ref-type="bibr" rid="B5-ijms-21-03059">5</xref>,<xref ref-type="bibr" rid="B6-ijms-21-03059">6</xref>]. The main focus of pharmacological research over the past 50 years has been the identification of cognitive enhancers; however, no US Food and Drug Administration (FDA)-approved drugs for AD have been reported for the past two decades [<xref ref-type="bibr" rid="B7-ijms-21-03059">7</xref>]. Behavioral disorders (BDs) (psychotic, depressive, anxiety, sleep disorders, and inappropriate sexual behaviors) are common (10–90%) in patients with dementia and tend to increase in parallel with the cognitive deterioration [<xref ref-type="bibr" rid="B8-ijms-21-03059">8</xref>,<xref ref-type="bibr" rid="B9-ijms-21-03059">9</xref>,<xref ref-type="bibr" rid="B10-ijms-21-03059">10</xref>,<xref ref-type="bibr" rid="B11-ijms-21-03059">11</xref>,<xref ref-type="bibr" rid="B12-ijms-21-03059">12</xref>,<xref ref-type="bibr" rid="B13-ijms-21-03059">13</xref>,<xref ref-type="bibr" rid="B14-ijms-21-03059">14</xref>]. BDs increase the risk of institutionalization, impair daily functioning, reduce quality of life, and accelerate cognitive deterioration [<xref ref-type="bibr" rid="B15-ijms-21-03059">15</xref>,<xref ref-type="bibr" rid="B16-ijms-21-03059">16</xref>]. BDs also increase the costs of dementia (e.g., LBD and VD) [<xref ref-type="bibr" rid="B17-ijms-21-03059">17</xref>].</p>
<p>There is not a prototypical pattern of BDs in different dementia types; however, BDs tend to be more prevalent in FTD, in cases where the compromise of frontotemporal regions is more relevant [<xref ref-type="bibr" rid="B18-ijms-21-03059">18</xref>,<xref ref-type="bibr" rid="B19-ijms-21-03059">19</xref>,<xref ref-type="bibr" rid="B20-ijms-21-03059">20</xref>], and in cases with mild traumatic brain injury (TBI) [<xref ref-type="bibr" rid="B21-ijms-21-03059">21</xref>] where DNA damage-induced cellular senescence pathways have been identified [<xref ref-type="bibr" rid="B22-ijms-21-03059">22</xref>]. Apathy, depression, dysphoria, agitation, aggression, hallucinations, and delusions are frequent distressing symptoms in dementia [<xref ref-type="bibr" rid="B14-ijms-21-03059">14</xref>]. A current behavioral phenotype is the hyperactivity–impulsivity–irritiability–disinhibition–aggression–agitation complex, with a difficult set of symptoms to manage, causing an important psychological burden for caregivers and hospital staff [<xref ref-type="bibr" rid="B23-ijms-21-03059">23</xref>]. Some neuropsychiatric disorders may increase the risk for late-onset dementia, and dementia may increase the risk for delayed-onset BDs in specific cases [<xref ref-type="bibr" rid="B24-ijms-21-03059">24</xref>].</p>
<p>The primary causes of BDs in dementia are unclear. <italic>APP</italic>, <italic>MAPT</italic>, <italic>APOE</italic>, and other variants in pathogenic genes (<xref ref-type="table" rid="ijms-21-03059-t001">Table 1</xref>) as well as the presence of schizophrenia- and/or depression-related SNPs [<xref ref-type="bibr" rid="B25-ijms-21-03059">25</xref>,<xref ref-type="bibr" rid="B26-ijms-21-03059">26</xref>,<xref ref-type="bibr" rid="B27-ijms-21-03059">27</xref>], together with additional metabolic disorders [<xref ref-type="bibr" rid="B28-ijms-21-03059">28</xref>], cerebrovascular risk or consolidated vascular damage [<xref ref-type="bibr" rid="B4-ijms-21-03059">4</xref>,<xref ref-type="bibr" rid="B29-ijms-21-03059">29</xref>,<xref ref-type="bibr" rid="B30-ijms-21-03059">30</xref>,<xref ref-type="bibr" rid="B31-ijms-21-03059">31</xref>], premorbid personality [<xref ref-type="bibr" rid="B32-ijms-21-03059">32</xref>], and inappropriate management may contribute to BDs in AD. BDs partially correlate with conventional biomarkers of dementia [<xref ref-type="bibr" rid="B33-ijms-21-03059">33</xref>,<xref ref-type="bibr" rid="B34-ijms-21-03059">34</xref>]; however, agitation/aggression correlates with AD cerebrospinal fluid (CSF) biomarkers, and depression is inversely associated with core AD CSF pathology (low Aβ42, high Tau, and high pTau) [<xref ref-type="bibr" rid="B35-ijms-21-03059">35</xref>,<xref ref-type="bibr" rid="B36-ijms-21-03059">36</xref>]. Over 50% of AD patients show comorbidities (TDP-43 and Lewy bodies) which associate with frontotemporal lobar degeneration and LBD. Some of these comorbidities might explain BDs in dementia. TDP-43 is associated with aberrant psychomotor activity, and Lewy bodies are associated with anxiety, irritability, sleep disorders, and appetite anomalies [<xref ref-type="bibr" rid="B37-ijms-21-03059">37</xref>]. In FTD, <italic>C9orf72</italic> hexanucleotide repeat expansion with more than 80 G4C2 repeats has been associated with high frequency of psychotic symptoms [<xref ref-type="bibr" rid="B38-ijms-21-03059">38</xref>]. Limbic-predominant age-related TDP-43 encephalopathy with high pTau burden might also predispose to more severe cognitive deterioration and BDs [<xref ref-type="bibr" rid="B39-ijms-21-03059">39</xref>].</p>
<p>Most BDs in dementia are susceptible to pharmacological intervention, and though some studies suggest that psychotropic medication does not accelerate cognitive decline [<xref ref-type="bibr" rid="B40-ijms-21-03059">40</xref>], most studies indicate that inappropriate treatments and consequent adverse drug reactions (ADRs) are frequent and deleterious [<xref ref-type="bibr" rid="B41-ijms-21-03059">41</xref>,<xref ref-type="bibr" rid="B42-ijms-21-03059">42</xref>,<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>]. Current ADRs in the elderly population are associated with benzodiazepines, neuroleptics, antidepressants, and antihypertensives. These drugs may cause falls; delirium and excess mortality increase with polypharmacy; over-infections are frequent in patients with inappropriate use of broad-spectrum antibiotics; increased risk of stroke is observed in patients with dementia treated with antipsychotics; nonsteroidal anti-inflammatory drugs may cause hypertensive crises, bleeding, and cerebrovascular problems; and other ADRs have been extensively reported worldwide [<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>,<xref ref-type="bibr" rid="B44-ijms-21-03059">44</xref>,<xref ref-type="bibr" rid="B45-ijms-21-03059">45</xref>,<xref ref-type="bibr" rid="B46-ijms-21-03059">46</xref>].</p>
<p>To palliate preventable ADRs, drug information resources have been developed. Some of them are designed for analyzing drug interactions, and others are useful to help physicians for an appropriate drug prescription [<xref ref-type="bibr" rid="B47-ijms-21-03059">47</xref>,<xref ref-type="bibr" rid="B48-ijms-21-03059">48</xref>,<xref ref-type="bibr" rid="B49-ijms-21-03059">49</xref>,<xref ref-type="bibr" rid="B50-ijms-21-03059">50</xref>,<xref ref-type="bibr" rid="B51-ijms-21-03059">51</xref>]. However, few resources incorporate pharmacogenomics (PGx) as a practical tool for clinical use [<xref ref-type="bibr" rid="B45-ijms-21-03059">45</xref>,<xref ref-type="bibr" rid="B52-ijms-21-03059">52</xref>,<xref ref-type="bibr" rid="B53-ijms-21-03059">53</xref>,<xref ref-type="bibr" rid="B54-ijms-21-03059">54</xref>,<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>].</p>
<p>About 80% variability in drug pharmacokinetics and pharmacodynamics is attributed to PGx factors [<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>,<xref ref-type="bibr" rid="B57-ijms-21-03059">57</xref>]. Rare variants contribute to approximately 30–40% of functional variability in 146 pharmagenes with clinical relevance. Over 240 pharmagenes are potentially associated with ADRs, and over 400 genes and their products influence drug efficacy and safety [<xref ref-type="bibr" rid="B53-ijms-21-03059">53</xref>,<xref ref-type="bibr" rid="B54-ijms-21-03059">54</xref>]. Furthermore, the pharmacological outcome is highly influenced by components of the PGx machinery, the chemical properties of each drug, and other diverse factors (e.g., compliance, nutrition, metabolic conditions, and concomitant drugs) [<xref ref-type="bibr" rid="B58-ijms-21-03059">58</xref>,<xref ref-type="bibr" rid="B59-ijms-21-03059">59</xref>].</p>
<p>The present review explores available information for personalized treatment of dementia in the areas of cognition and BDs based on PGx principles.</p>
</sec>
<sec id="sec2-ijms-21-03059">
<title>2. The Pharmacogenomic Machinery</title>
<p>The pharmacogenomic machinery is composed by a network of gene clusters coding for proteins and enzymes responsible for drug targeting and processing as well as critical components of the epigenetic machinery that regulate gene expression [<xref ref-type="bibr" rid="B60-ijms-21-03059">60</xref>,<xref ref-type="bibr" rid="B61-ijms-21-03059">61</xref>]. The pharmagenes involved in the pharmacogenomic response to drugs can be classified into five major categories: (i) Pathogenic genes (<xref ref-type="table" rid="ijms-21-03059-t001">Table 1</xref>) which are associated with disease pathogenesis [<xref ref-type="bibr" rid="B62-ijms-21-03059">62</xref>]; (ii) mechanistic genes coding for components of enzymes, receptor subunits, transmitters, and messengers associated with the mechanism of action of drugs; (iii) metabolic genes of different categories that encode phase I–II reaction enzymes responsible for drug metabolism. Phase-I reaction enzymes include (in alphabetical order) alcohol dehydrogenases, aldehyde dehydrogenases, aldo-keto reductases, amine oxidases, carbonyl reductases, cytidine deaminases, cytochrome P450 family (CYPs) of mono-oxygenases, cytochrome b5 reductase, dihydropyrimidine dehydrogenase, esterases, epoxidases, flavin-containing monooxygenases, glutathione reductase/peroxidases, peptidases, prostaglandin endoperoxide synthases, short-chain dehydrogenases, reductases, superoxide dismutases, and xanthine dehydrogenase. The most relevant Phase-II reaction enzymes include the following: amino acid transferases, dehydrogenases, esterases, glucuronosyl transferases, glutathione transferases, methyl transferases, N-acetyl transferases, thioltransferase, and sulfotransferases; (iv) transporter genes coding for drug transporters. The most relevant categories of transporters include the following: ATPase (P-type subfamily), V-type (vacuolar H<sup>+</sup>-ATPase subunit), and ATPase (F-type subfamily); ATP-binding cassette transporters (subfamily A) (ABC1), subfamily B (MDR/TAP), subfamily C (CFTR/MRP), subfamily D (ALD), subfamily E (OABP), subfamily F (GCN20), and subfamily G (WHITE); and solute carriers (high-affinity glutamate and neutral amino acid transporter family) (SLC); and (v) pleiotropic genes which encode proteins and enzymes involved in a great variety of metabolic cascades and metabolomic networks [<xref ref-type="bibr" rid="B6-ijms-21-03059">6</xref>,<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>,<xref ref-type="bibr" rid="B61-ijms-21-03059">61</xref>,<xref ref-type="bibr" rid="B62-ijms-21-03059">62</xref>,<xref ref-type="bibr" rid="B63-ijms-21-03059">63</xref>].</p>
<p>The expression or repression of all these genes and their products are regulated in a redundant and promiscuous fashion by the epigenetic machinery (DNA methylation/demethylation, histone/chromatin remodeling, and miRNA regulation), configuring the pharmacoepigenetic apparatus. The same enzyme/protein/transporter can process a multitude of drugs, and the same drug can be processed by a vast array of gene products in an orchestrated manner to operate as a security system against xenobiotic intruders [<xref ref-type="bibr" rid="B61-ijms-21-03059">61</xref>,<xref ref-type="bibr" rid="B62-ijms-21-03059">62</xref>,<xref ref-type="bibr" rid="B63-ijms-21-03059">63</xref>,<xref ref-type="bibr" rid="B64-ijms-21-03059">64</xref>,<xref ref-type="bibr" rid="B65-ijms-21-03059">65</xref>,<xref ref-type="bibr" rid="B66-ijms-21-03059">66</xref>,<xref ref-type="bibr" rid="B67-ijms-21-03059">67</xref>]. </p>
<p>A vast array of polymorphic variants in over 600 defective human genes are potentially involved in AD pathogenesis and drug response. The presence of the ε4 allele in the <italic>APOE</italic> gene is the most important risk factor among top pathogenic genes (<xref ref-type="table" rid="ijms-21-03059-t001">Table 1</xref>) [<xref ref-type="bibr" rid="B1-ijms-21-03059">1</xref>]. However, many other SNPs in diverse genes may contribute to AD-related neurodegeneration and premature neuronal death, including genes encoding components of the pharmacogenetic machinery. Polymorphic variants in ABC and SLC transporters may affect AD pathogenesis and response to drugs [<xref ref-type="bibr" rid="B3-ijms-21-03059">3</xref>,<xref ref-type="bibr" rid="B63-ijms-21-03059">63</xref>,<xref ref-type="bibr" rid="B68-ijms-21-03059">68</xref>,<xref ref-type="bibr" rid="B69-ijms-21-03059">69</xref>,<xref ref-type="bibr" rid="B70-ijms-21-03059">70</xref>,<xref ref-type="bibr" rid="B71-ijms-21-03059">71</xref>,<xref ref-type="bibr" rid="B72-ijms-21-03059">72</xref>,<xref ref-type="bibr" rid="B73-ijms-21-03059">73</xref>]. SNPs in genes encoding transporter proteins may affect brain penetrance and accessibility to neuronal/glial targets, drug metabolism, and drug resistance [<xref ref-type="bibr" rid="B70-ijms-21-03059">70</xref>,<xref ref-type="bibr" rid="B74-ijms-21-03059">74</xref>,<xref ref-type="bibr" rid="B75-ijms-21-03059">75</xref>]. </p>
<p>Mutations in ABC transporters affect pathogenesis and therapeutics in AD. The ABCB1 transporter protein (P-gp1) and other transporters of this category are located on endothelial cells lining brain vasculature. They play important roles in limiting the movement of substances into and enhancing their efflux from the brain. ABCB1 is a very active drug transporter in the brain. It is estimated that over 1270 drugs are directly or indirectly processed via the ABCB1 transporter protein P-gp. Approximately, 490 drugs are substrates, 618 are inhibitors, and 182 are inducers [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>]. In Caucasians and African-Americans, 116 and 127 polymorphic sites, respectively, have been identified with a minor allele frequency greater than 5%. <italic>ABCB1 C1236T</italic> in exon 12, <italic>G2677T/A</italic> in exon 21, and <italic>C3435T</italic> in exon 26 are common variants. The <italic>ABCB1*13</italic> haplotype involves 3 intronic SNPs (in intron 9, 13, and 14) and the 1236, 2677, and 3435 (<italic>TTT</italic>) SNPs. The <italic>ABCB1 C1236T</italic>, <italic>G2677T/A</italic>, and <italic>C3435T</italic> variants participate in the P-gp1 function at the blood–brain barrier (BBB). AD patients carrying <italic>T</italic> in <italic>C1236T</italic>, <italic>G2677T</italic>, and <italic>C3435T</italic> have exhibited higher binding potential values than <italic>T</italic> noncarriers. <italic>ABCB1</italic> variants might be potential biomarkers and might contribute to the progression of Aβ deposition in AD brains [<xref ref-type="bibr" rid="B76-ijms-21-03059">76</xref>,<xref ref-type="bibr" rid="B77-ijms-21-03059">77</xref>]. ABCB1 transports Aβ from the brain into the blood stream, and the cholesterol transporter <italic>ABCA1</italic> neutralizes Aβ aggregation in an <italic>APOE</italic>-dependent manner, facilitating Aβ elimination from the brain [<xref ref-type="bibr" rid="B78-ijms-21-03059">78</xref>]. Other ABCs have shown potential association with AD [<xref ref-type="bibr" rid="B79-ijms-21-03059">79</xref>]. The <italic>ABCA7</italic> (<italic>G</italic> allele) rs115550680 SNP has been associated with AD in Europeans, with a comparable effect to that of the <italic>APOE-ε4</italic> SNP rs429358 [<xref ref-type="bibr" rid="B80-ijms-21-03059">80</xref>]. The <italic>ABCA7</italic> SNP rs200538373, with altered <italic>ABCA7</italic> exon 41 splicing, also shows association with AD risk [<xref ref-type="bibr" rid="B81-ijms-21-03059">81</xref>]. <italic>ABCA7</italic> methylation might be a biomarker of AD [<xref ref-type="bibr" rid="B82-ijms-21-03059">82</xref>]. In AD, <italic>ABCA7</italic> mRNA expression is higher than in controls, correlating with disease progression and cognitive decline. Alterations in lipid metabolism associated with <italic>APOE-4</italic> and several SNPs in <italic>ABCA7</italic> (rs3764650, rs3752246, and rs4147929) and loss-of-function mutations are pathogenic and PGx-dysfunctional in AD [<xref ref-type="bibr" rid="B83-ijms-21-03059">83</xref>,<xref ref-type="bibr" rid="B84-ijms-21-03059">84</xref>,<xref ref-type="bibr" rid="B85-ijms-21-03059">85</xref>]. An intronic variable number tandem repeat (VNTR) in the <italic>ABCA7</italic> locus shows strong association with AD [<xref ref-type="bibr" rid="B86-ijms-21-03059">86</xref>]. <italic>ABCA7</italic> variants cause accumulation of amyloid peptides and BBB dysfunction. <italic>ABCA7</italic> defects decrease APOE secretion and cholesterol exchange across the BBB [<xref ref-type="bibr" rid="B87-ijms-21-03059">87</xref>]. Cholesterol-related genes such as <italic>APOA5</italic> (rs662799), <italic>APOC1</italic> (rs11568822), <italic>APOD</italic> (rs1568565), <italic>CH25H</italic> (rs13500), <italic>LDLR</italic> (rs5930), and <italic>SORL1</italic> (rs2282649), which affect lipid metabolism and membrane trafficking, may also be pathogenic and PGx-disruptive [<xref ref-type="bibr" rid="B63-ijms-21-03059">63</xref>,<xref ref-type="bibr" rid="B88-ijms-21-03059">88</xref>]. Soluble low-density lipoprotein receptor-related protein-1 (sLRP1), soluble receptor of advanced glycation end products (sRAGE), and transport proteins participate in the clearance of plasma Aβ in an <italic>APOE</italic>-dependent manner [<xref ref-type="bibr" rid="B89-ijms-21-03059">89</xref>].</p>
<p>The ATP-binding cassette transporter <italic>ABCA2</italic> is an endolysosomal membrane protein with pleiotropic activities and a critical role in mediating sphingolipids and cholesterol trafficking [<xref ref-type="bibr" rid="B90-ijms-21-03059">90</xref>]. <italic>ABCA1</italic> (rs2230805 and rs2230806) and <italic>ABCA2</italic> variants are associated with AD [<xref ref-type="bibr" rid="B91-ijms-21-03059">91</xref>,<xref ref-type="bibr" rid="B92-ijms-21-03059">92</xref>]. Upregulation of <italic>ABCA2</italic> mRNA expression has been observed in AD. Methylation of specific CpG islands in the <italic>ABCA2</italic> gene negatively associates with AD risk. <italic>ABCA2</italic> mRNA expression might also be used to differentially diagnose mild cognitive impairment (MCI) from other forms of dementia (i.e., Huntington’s disease) but not AD from MCI [<xref ref-type="bibr" rid="B93-ijms-21-03059">93</xref>].</p>
<p><italic>ABCG2</italic> is a transporter of large, hydrophobic, charged molecules and different toxic compounds. Dysfunctional <italic>ABCG2</italic> variants may affect absorption, distribution, accumulation, effectiveness, and toxicity of xenobiotic compounds and drugs [<xref ref-type="bibr" rid="B94-ijms-21-03059">94</xref>]. <italic>ABCG2</italic> is upregulated in AD brains and is involved in Aβ transport. The <italic>ABCG2-C421A</italic> variant (rs2231142) (<italic>ABCG2 C/C</italic> genotype) is associated with AD. Interaction of the <italic>ABCG2 C/C</italic> genotype with the <italic>APOE ε4</italic> allele may increase AD risk [<xref ref-type="bibr" rid="B95-ijms-21-03059">95</xref>].</p>
<p>Aβ alters BBB ABC efflux transporters and BBB permeability; specifically, <italic>ABCB1</italic>, <italic>ABCC5</italic>, and <italic>ABCG2</italic>; pregnane X receptor (<italic>PXR</italic>); and constitutive androstane receptor (<italic>CAR</italic>) transcription factors are inhibited by Aβ in brain endothelial cells [<xref ref-type="bibr" rid="B96-ijms-21-03059">96</xref>].</p>
<p>Transporters encoded by genes of the solute carrier superfamily (SLC) and solute carrier organic (SLCO) transporter family are also important for AD pharmacogenomics. The human solute carrier (SLC) superfamily of transporters includes several hundred membrane-bound proteins with roles in physiological, pathological, and PGx processes. Over 200,000 exonic single-nucleotide variants (SNVs) have been identified, 99.8% of which are present in &lt;1% of analyzed alleles. In the individual genome, there are about 29.7 variants with putative functional effects, and in specific populations, interethnic variability shows over 80% deleterious SLC variants [<xref ref-type="bibr" rid="B97-ijms-21-03059">97</xref>]. </p>
<p>In addition to <italic>APP</italic>, <italic>PSEN1</italic>, and <italic>PSEN2</italic> mutations, SNPs in membrane proteins that alter the transmembrane trafficking of products also influence pathogenesis and PGx. One example of this may be SORL1. <italic>SORL1 (LR11)</italic> gene variants are associated with AD. <italic>SORL1</italic> encodes a type I transmembrane 250-kDa protein (sorLA) that belongs to both the low-density lipoprotein receptor (LDLR) family and the vacuolar protein sorting 10 (VPS10) domain receptor family, acting as a sorting receptor for APP. SorLA, which interacts with ApoE and Tau, is a central regulator of trafficking and processing of APP and of Aβ destruction [<xref ref-type="bibr" rid="B98-ijms-21-03059">98</xref>]. Another example might be the sarco/endoplasmic reticulum (SR/ER) calcium (Ca<sup>2+</sup>)-ATPase (SERCA) pump, an integral endoplasmic reticulum protein which has been associated with neuropsychiatric disorders (NPDs) and NDDs [<xref ref-type="bibr" rid="B99-ijms-21-03059">99</xref>]. Translocation of substances across the mitochondrial membranes is required for cellular survival and efficient functioning. Major components of this translocation machinery are the translocase of the outer (TOMM) and inner mitochondrial membrane (TIMM) complexes. Mutations in the <italic>TIMM8A (DDP)</italic> and <italic>DNAJC19 (TIMM14)</italic> genes are pathogenic for Mohr–Tranebjærg syndrome and dilated cardiomyopathy syndrome, and polymorphisms in the <italic>TOMM40</italic> gene are associated with AD and other NDDs [<xref ref-type="bibr" rid="B100-ijms-21-03059">100</xref>].</p>
<p>Transient receptor potential melastatin 2 (TRPM2) is a Ca<sup>2+</sup>-permeable nonselective cation channel of the TRP ion channel family. TRPM2 dysfunction linked to aberrant intracellular Ca<sup>2+</sup> accumulation and neuronal death has been implicated in AD. TRPM2 is involved in the induction of N-methyl-D-aspartate (NMDA) receptor-dependent long-term depression, a form of synaptic plasticity at glutamate synapses [<xref ref-type="bibr" rid="B101-ijms-21-03059">101</xref>].</p>
<p>Drug transporter expression is altered at the BBB and peripheral tissues in AD. Intestinal expression of multidrug resistance-associated protein 2 (Mrp2), monocarboxylate transporter 1 (Mct1), and UDP-glucuronosyltransferase (Ugt) and liver expression of Cyp51a1 and Cyp2c29 have been found altered in AD transgenic models [<xref ref-type="bibr" rid="B102-ijms-21-03059">102</xref>].</p>
</sec>
<sec id="sec3-ijms-21-03059">
<title>3. CNS Drugs</title>
<p>According to data available in the <italic>World Guide for Drug Use and Pharmacogenomics</italic> [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>] and the <italic>EuroPharmaGenics</italic> (EPG) database [<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>] concerning central nervous system (CNS) drugs (<xref ref-type="fig" rid="ijms-21-03059-f001">Figure 1</xref>), the best-known genes of the pharmacogenetic machinery involved in the processing of antiepileptic, antidepressant, anxiolytic, hypnotic, sedative, antiparkinsonian, and antipsychotic drugs are mechanistic and metabolic genes, and poorly investigated genes are those involved in pathogenic mechanisms, transporters, and pleiotropic genes (<xref ref-type="fig" rid="ijms-21-03059-f001">Figure 1</xref>). Globally, 74% pathogenic, 97% mechanistic, 94% metabolic, 68% transporter, and 40% pleiotropic genes have so far been associated with CNS drug efficacy and safety [<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>]. </p>
<p>CNS drugs can act as substrates, inhibitors, or inducers of enzymes encoded by metabolic genes (<xref ref-type="fig" rid="ijms-21-03059-f002">Figure 2</xref>). Among the 307 most frequently used CNS drugs, antiepileptics represent 14.66%, antiparkinsonians represent 10.42%, antipsychotics represent 21.82%, anxiolytics represent 11.40%, hypnotics and sedatives represent 21.17%, antidepressants represent 20.53%, and anti-dementia drugs represent 1%–2% (<xref ref-type="fig" rid="ijms-21-03059-f001">Figure 1</xref> and <xref ref-type="table" rid="ijms-21-03059-t002">Table 2</xref>). About 90% of these drugs use CYP enzymes as major metabolic pathways. CNS drugs are substrates, inhibitors, or inducers of 58, 37, and 42 enzyme/protein gene products, respectively, and are transported by 40 different protein transporters (<xref ref-type="fig" rid="ijms-21-03059-f003">Figure 3</xref>). CNS drugs are major substrates of CYP3A4 (71%), CYP3A5 (37%), CYP2D6 (60%), CYP2C19 (45%), and CYP1A2 enzymes (44%); inhibitors of CYP3A4 (22%), CYP2D6 (23%), CYP2C19 (20%), CYP1A2 (17%), and CYP2C9 (15%); and inducers of CYP2C9 (9%), CYP2D6 (7%), CYP3A4 (5%), CYP1A2 (4.5%), CYP2A6 (4.5%), and CYP2B6 (3.7%). Major transporters of CNS drugs are ABCB1 (29%), SLCA1 (20%), SLC6A4 (20%), CLCNs (15%), SLC6A3 (12%), and SLC6A2 (11%) (<xref ref-type="fig" rid="ijms-21-03059-f003">Figure 3</xref>) [<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>]. </p>
<p>Approximately 80% of patients are deficient metabolizers for the tetrategic cluster integrated by <italic>CYP2D6, 2C19, 2C9</italic>, and <italic>3A4/4</italic> variants which encode enzymes responsible for the metabolism of 60–80% of drugs of current use, showing ontogenic-, age-, sex-, circadian- and ethnic-related differences. CYP geno-phenotypes differentiate extensive (EM; normal, NM), intermediate (IM), poor (PM), or ultra-rapid metabolizers (UM) with great geographic and ethnic variability worldwide [<xref ref-type="bibr" rid="B4-ijms-21-03059">4</xref>,<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>,<xref ref-type="bibr" rid="B63-ijms-21-03059">63</xref>].</p>
<p>The integration of <italic>CYP2D6, CYP2C9, CYP2C19</italic>, and <italic>CYP3A4/5</italic> variants into tetragenic haplotypes yields 156 geno-phenotypes. <italic>H3 (1/1-1/1-1/1-3/3)</italic> (20.87%) is the most frequent haplotype, representing full extensive metabolizers. Only 17 haplotypes exhibit a frequency higher than 1% in the Caucasian population. According to this, it is very likely that about 80% of individuals are deficient for the biotransformation of current drugs metabolized via CYP2D6-2C9-2C19-3A4 enzymes [<xref ref-type="bibr" rid="B4-ijms-21-03059">4</xref>,<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>,<xref ref-type="bibr" rid="B63-ijms-21-03059">63</xref>].</p>
</sec>
<sec id="sec4-ijms-21-03059">
<title>4. Pharmacogenomics of Cognition</title>
<p>Four acetylcholinesterase inhibitors have been approved for the treatment of AD. Tacrine was introduced in 1993 and discontinued years later due to hepatoxicity; Donepezil was introduced in 1996; Galantamine was introduced in 2001; and Rivastigmine was introduced in 2002. Memantine, an NMDA partial antagonist, was approved by the FDA in 2003 [<xref ref-type="bibr" rid="B104-ijms-21-03059">104</xref>,<xref ref-type="bibr" rid="B105-ijms-21-03059">105</xref>]. Over the past decade, the most prevalent pharmacological categories currently investigated as candidate strategies for the treatment of AD included neurotransmitter enhancers (11.38%), anti-Amyloid agents (13.30%), multi-target drugs (2.45%), anti-Tau agents (2.03%), and diverse natural products (25.58%). Some novel drugs (8.13%), novel targets (5.66%), revised old drugs (11.77%), anti-inflammatory drugs (1.20%), neuroprotective peptides (1.25%), stem cell therapy (1.85%), nanocarriers/nanotherapeutics (1.52%), and others (combination treatments, cognitive enhancers/nootropics, neurotrophic factors, polyunsaturated fatty acids, hormone therapy, epigenetic drugs, RNAi/gene silencing, miRNAs, and gene therapy) (&lt;1% each) have also been investigated in exploratory studies for the treatment of AD [<xref ref-type="bibr" rid="B6-ijms-21-03059">6</xref>]. However, no new drugs have been FDA-approved for the past 20 years. Consequently, most PGx studies concentrate on acetylcholinesterase inhibitors (AChEIs) (Donepezil, Galantamine, and Rivastigmine), Memantine, and combination treatments [<xref ref-type="bibr" rid="B2-ijms-21-03059">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-03059">3</xref>,<xref ref-type="bibr" rid="B106-ijms-21-03059">106</xref>,<xref ref-type="bibr" rid="B107-ijms-21-03059">107</xref>,<xref ref-type="bibr" rid="B108-ijms-21-03059">108</xref>]. </p>
<p><italic>APOE</italic> gene variation is associated with major pathogenic events in AD [<xref ref-type="bibr" rid="B109-ijms-21-03059">109</xref>,<xref ref-type="bibr" rid="B110-ijms-21-03059">110</xref>], and <italic>APOE</italic> has been used as a reference gene in many clinical trials as a PGx marker, followed by metabolic genes (<italic>CYP</italic> geno-phenotypes) [<xref ref-type="bibr" rid="B1-ijms-21-03059">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-03059">2</xref>,<xref ref-type="bibr" rid="B4-ijms-21-03059">4</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>,<xref ref-type="bibr" rid="B106-ijms-21-03059">106</xref>,<xref ref-type="bibr" rid="B107-ijms-21-03059">107</xref>,<xref ref-type="bibr" rid="B111-ijms-21-03059">111</xref>,<xref ref-type="bibr" rid="B112-ijms-21-03059">112</xref>,<xref ref-type="bibr" rid="B113-ijms-21-03059">113</xref>,<xref ref-type="bibr" rid="B114-ijms-21-03059">114</xref>,<xref ref-type="bibr" rid="B115-ijms-21-03059">115</xref>,<xref ref-type="bibr" rid="B116-ijms-21-03059">116</xref>,<xref ref-type="bibr" rid="B117-ijms-21-03059">117</xref>,<xref ref-type="bibr" rid="B118-ijms-21-03059">118</xref>]. <italic>APOE-4</italic> carriers exhibit differential phenotypic patterns of acetylcholinesterase and butyrylcholinesterase activities as well as CYP enzyme activities with strong influence in PGx outcomes [<xref ref-type="bibr" rid="B119-ijms-21-03059">119</xref>]. SNP variation in <italic>CYP2D6</italic>, acetylcholinesterase, butyrylcholinesterase, choline acetyltransferase, and paraoxonase is associated with better clinical response to AChEIs [<xref ref-type="bibr" rid="B120-ijms-21-03059">120</xref>]. </p>
<sec id="sec4dot1-ijms-21-03059">
<title>4.1. Donepezil</title>
<p>Donepezil is the most prescribed AChEI for the treatment of AD worldwide [<xref ref-type="bibr" rid="B107-ijms-21-03059">107</xref>,<xref ref-type="bibr" rid="B121-ijms-21-03059">121</xref>]. Donepezil is a major substrate of CYP2D6, CYP3A4, ACHE, and UGTs; inhibits ACHE and BCHE; and is transported by ABCB1 [<xref ref-type="bibr" rid="B120-ijms-21-03059">120</xref>,<xref ref-type="bibr" rid="B122-ijms-21-03059">122</xref>] (<xref ref-type="table" rid="ijms-21-03059-t002">Table 2</xref>). Several <italic>CYP2D6</italic> variants may modify donepezil efficacy and safety in AD [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>], and <italic>APOE</italic> and <italic>CYP2D6</italic> variants are determinant in the effects of donepezil. <italic>APOE-4</italic> carriers tend to be the worst responders, and <italic>APOE-3</italic> carriers are the best responders to donepezil in either monotherapy or drug combination regimes; CYP2D6-EMs are the best responders, and CYP2D6-PMs are the worst responders [<xref ref-type="bibr" rid="B1-ijms-21-03059">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-03059">2</xref>,<xref ref-type="bibr" rid="B4-ijms-21-03059">4</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>,<xref ref-type="bibr" rid="B106-ijms-21-03059">106</xref>,<xref ref-type="bibr" rid="B111-ijms-21-03059">111</xref>,<xref ref-type="bibr" rid="B112-ijms-21-03059">112</xref>,<xref ref-type="bibr" rid="B113-ijms-21-03059">113</xref>,<xref ref-type="bibr" rid="B114-ijms-21-03059">114</xref>,<xref ref-type="bibr" rid="B115-ijms-21-03059">115</xref>,<xref ref-type="bibr" rid="B116-ijms-21-03059">116</xref>,<xref ref-type="bibr" rid="B117-ijms-21-03059">117</xref>,<xref ref-type="bibr" rid="B118-ijms-21-03059">118</xref>]. <italic>CYP2D6</italic> geno-phenotypes influence donepezil clearance. CYP2D6-PMs show a 32% slower elimination, and CYP2D6-UMs show a 67% faster elimination [<xref ref-type="bibr" rid="B123-ijms-21-03059">123</xref>]. AD carriers of the common variant rs1080985 of <italic>CYP2D6</italic> show poor response to donepezil [<xref ref-type="bibr" rid="B122-ijms-21-03059">122</xref>,<xref ref-type="bibr" rid="B124-ijms-21-03059">124</xref>]. In Chinese patients, CYP2D6-EMs and PMs show a similar response to donepezil; however, EMs are better responders than UMs. Patients harboring the rs1080985 G allele are poor responders to donepezil, and the worst responders accumulate in carriers of the bigenic <italic>APOE-4/rs1080985-G</italic> genotype [<xref ref-type="bibr" rid="B125-ijms-21-03059">125</xref>]. The mutated <italic>CYP2D6</italic> allele *2A is more frequent in responder than in nonresponder patients (75.38% vs. 43.48%). In Italian patients, 67% of the cases were responders, in whom abnormal enzymes accumulate, and 33% were nonresponders [<xref ref-type="bibr" rid="B126-ijms-21-03059">126</xref>]. In Chinese and Thai AD cases, carriers of the mutant <italic>CYP2D6*10</italic> allele responded better (58% responders) than carriers of the wild-type <italic>CYP2D6*1</italic> allele [<xref ref-type="bibr" rid="B127-ijms-21-03059">127</xref>]. The <italic>CYP2D6*10</italic> variant strongly affects steady-state plasma concentration of donepezil and therapeutic outcome in Asian populations [<xref ref-type="bibr" rid="B128-ijms-21-03059">128</xref>]. A recent study in China showed that <italic>CYP2D6*10</italic> carriers treated with donepezil/galantamine have less side effects and that CYP2D6*10 carriers respond better to ChEIs [<xref ref-type="bibr" rid="B129-ijms-21-03059">129</xref>].</p>
<p>Lower plasma donepezil concentration-to-dose ratios and better clinical response to donepezil have been reported in patients homozygous for the <italic>T/T/T</italic> genotype in the <italic>ABCB1</italic> haplotypes <italic>1236C/2677G/3435C</italic> (46%) and <italic>1236T/2677T/3435T</italic> (41%) [<xref ref-type="bibr" rid="B130-ijms-21-03059">130</xref>]. There is also a better response to donepezil in <italic>ABCA1 rs2230806 GG</italic> carriers than in <italic>AA</italic> or <italic>AG</italic> carriers [<xref ref-type="bibr" rid="B131-ijms-21-03059">131</xref>].</p>
<p><italic>APOE-ε4/BCHE-K*</italic> carriers show an earlier age of onset, an accelerated cognitive decline, and a differential response to donepezil therapy [<xref ref-type="bibr" rid="B132-ijms-21-03059">132</xref>]. Donepezil is not recommended in <italic>BChE-K</italic> and <italic>APOE-4</italic> carriers [<xref ref-type="bibr" rid="B133-ijms-21-03059">133</xref>].</p>
<p>Donepezil is also used for the treatment of BDs in AD, LBD, and other dementia types [<xref ref-type="bibr" rid="B14-ijms-21-03059">14</xref>,<xref ref-type="bibr" rid="B107-ijms-21-03059">107</xref>,<xref ref-type="bibr" rid="B134-ijms-21-03059">134</xref>]. Some reports indicate that AChEIs may also be beneficial in vascular dementia and cardiovascular disorders [<xref ref-type="bibr" rid="B135-ijms-21-03059">135</xref>]. Donepezil might also ameliorate oxaliplatin-induced peripheral neuropathy [<xref ref-type="bibr" rid="B136-ijms-21-03059">136</xref>] and confer protection against induced seizures in a mouse model (<italic>Scn1a+/-</italic>) of Dravet syndrome, an encephalopathy caused by de novo loss-of-function mutations in the SCN1A gene [<xref ref-type="bibr" rid="B137-ijms-21-03059">137</xref>].</p>
</sec>
<sec id="sec4dot2-ijms-21-03059">
<title>4.2. Galantamine</title>
<p>Galantamine is a major substrate of CYP2D6, CYP3A4, ABCB1, and UGT1A1 and an inhibitor of ACHE and BCHE. <italic>APOE, APP, ACHE, BCHE, CHRNA4, CHRNA7</italic>, and <italic>CHRNB2</italic> variants may also affect galantamine efficacy and safety [<xref ref-type="bibr" rid="B120-ijms-21-03059">120</xref>,<xref ref-type="bibr" rid="B138-ijms-21-03059">138</xref>,<xref ref-type="bibr" rid="B139-ijms-21-03059">139</xref>,<xref ref-type="bibr" rid="B140-ijms-21-03059">140</xref>,<xref ref-type="bibr" rid="B141-ijms-21-03059">141</xref>]. Galantamine is mainly metabolized by CYP2D6 and CYP3A4 enzymes. Major metabolic pathways are glucuronidation, O-demethylation, N-demethylation, N-oxidation, and epimerization [<xref ref-type="bibr" rid="B142-ijms-21-03059">142</xref>]. Galantamine is a substrate of ABCB1. <italic>CYP2D6</italic> variants are major determinants of galantamine pharmacokinetics, with CYP2D6-PMs presenting 45% and 61% higher dose-adjusted galantamine plasma concentrations than heterozygous and homozygous CYP2D6-EMs [<xref ref-type="bibr" rid="B120-ijms-21-03059">120</xref>,<xref ref-type="bibr" rid="B143-ijms-21-03059">143</xref>]; however, these pharmacokinetic changes might not substantially affect pharmacodynamics [<xref ref-type="bibr" rid="B144-ijms-21-03059">144</xref>]. The coadministration of galantamine with CYP2D6 and CYP3A4 strong inhibitors increases its bioavailability [<xref ref-type="bibr" rid="B48-ijms-21-03059">48</xref>,<xref ref-type="bibr" rid="B145-ijms-21-03059">145</xref>]. Galantamine bioavailability and its therapeutic effects may be modified by interaction with foods and nutritional components [<xref ref-type="bibr" rid="B146-ijms-21-03059">146</xref>].</p>
<p>Some recent studies show promising results with galantamine in cases of drug abuse (opioids, cocaine, and cannabis) [<xref ref-type="bibr" rid="B147-ijms-21-03059">147</xref>,<xref ref-type="bibr" rid="B148-ijms-21-03059">148</xref>] and TBI [<xref ref-type="bibr" rid="B149-ijms-21-03059">149</xref>]. In combination with CDP-Choline, memantine, and antipsychotics, galantamine might be useful in schizophrenia [<xref ref-type="bibr" rid="B150-ijms-21-03059">150</xref>,<xref ref-type="bibr" rid="B151-ijms-21-03059">151</xref>].</p>
</sec>
<sec id="sec4dot3-ijms-21-03059">
<title>4.3. Rivastigmine</title>
<p>Rivastigmine is a dual inhibitor of acetylcholinesterase (AChE; EC 3.1.1.7) and butyrylcholinesterase (BuChE; EC 3.1.1.8) in AD [<xref ref-type="bibr" rid="B152-ijms-21-03059">152</xref>,<xref ref-type="bibr" rid="B153-ijms-21-03059">153</xref>]. <italic>APOE, APP, CHAT, ACHE, BCHE, CHRNA4, CHRNB2</italic>, and <italic>MAPT</italic> variants may affect rivastigmine pharmacokinetics and pharmacodynamics. CYP enzymes are not involved in the metabolism of rivastigmine [<xref ref-type="bibr" rid="B120-ijms-21-03059">120</xref>,<xref ref-type="bibr" rid="B138-ijms-21-03059">138</xref>,<xref ref-type="bibr" rid="B145-ijms-21-03059">145</xref>,<xref ref-type="bibr" rid="B154-ijms-21-03059">154</xref>]. UGT2B7-PMs show higher rivastigmine levels with a poor response to treatment [<xref ref-type="bibr" rid="B155-ijms-21-03059">155</xref>]. In combination treatments with memantine, carriers of <italic>CYP2D6*3, UGT2B7</italic>, and <italic>UGT1A9*5</italic> variants show differential responses to treatment. Two SNPs on the intronic region of <italic>CHAT</italic> (rs2177370 and rs3793790) [<xref ref-type="bibr" rid="B156-ijms-21-03059">156</xref>] and <italic>CHRNA7</italic> variants may influence the response to AChEIs [<xref ref-type="bibr" rid="B157-ijms-21-03059">157</xref>]. Two SNPs, one intronic marker in <italic>PRKCE-rs6720975</italic> and an intergenic <italic>NBEA-rs17798800</italic> marker, might also contribute to differential therapeutic response to AChEIs [<xref ref-type="bibr" rid="B158-ijms-21-03059">158</xref>]. Females with the <italic>BChE-wt/wt</italic> show a better benefit with rivastigmine than males, and <italic>BChE-K*</italic> male carriers show a faster cognitive decline than females [<xref ref-type="bibr" rid="B159-ijms-21-03059">159</xref>]. AD patients harboring the <italic>BChE K</italic>-variant (rs1803274), causing a reduced enzyme activity, show low clinical response to rivastigmine. The K-variant (p. A539T) and other SNPs located outside the coding sequence in 5’UTR (rs1126680) and/or intron 2 (rs55781031) of the <italic>BCHE</italic> gene are responsible for reduced enzyme activity and poor response to rivastigmine [<xref ref-type="bibr" rid="B160-ijms-21-03059">160</xref>].</p>
<p>Rivastigmine may be useful in VD and Parkinson’s disease [<xref ref-type="bibr" rid="B161-ijms-21-03059">161</xref>,<xref ref-type="bibr" rid="B162-ijms-21-03059">162</xref>] and in combination with low-dose quetiapine can improve psychotic symptoms in LBD [<xref ref-type="bibr" rid="B163-ijms-21-03059">163</xref>].</p>
</sec>
<sec id="sec4dot4-ijms-21-03059">
<title>4.4. Memantine</title>
<p>Memantine is an N-Methyl-D-Aspartate (NMDA) receptor antagonist which binds preferentially to NMDA receptor-operated cation channels [<xref ref-type="bibr" rid="B108-ijms-21-03059">108</xref>]. Memantine inhibits the actions of glutamate via NMDA receptors and antagonizes GRIN2A, GRIN2B, GRIN3A, HTR3A, and CHRFAM7A. <italic>APOE, PSEN1</italic>, and <italic>MAPT</italic> are pathogenic genes which might influence the effects of memantine in AD, and variants in some mechanistic genes (<italic>GRIN2A, GRIN2B, GRIN3A, HTR3A, CHRFAM7A, c-Fos, Homer1b</italic>, and <italic>PSD-95</italic>) may also modify its therapeutic effects. CYP2B6 and CYP2D6 are strongly inhibited by memantine. In contrast, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 are weakly inhibited [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B120-ijms-21-03059">120</xref>,<xref ref-type="bibr" rid="B164-ijms-21-03059">164</xref>,<xref ref-type="bibr" rid="B165-ijms-21-03059">165</xref>]. Studies in human liver microsomes show that memantine inhibits CYP2B6 and CYP2D6; decreases CYP2A6 and CYP2C19; and has no effect on CYP1A2, CYP2E1, CYP2C9, or CYP3A4 [<xref ref-type="bibr" rid="B166-ijms-21-03059">166</xref>]. The coadministration of CYP2B6 substrates decreases memantine metabolism by 65%. <italic>NR1I2</italic> rs1523130 is the only genetic covariate for memantine clearance in clinical studies. <italic>NR1I2 rs1523130 CT/TT</italic> carriers show a slower memantine elimination than carriers of the <italic>CC</italic> genotype [<xref ref-type="bibr" rid="B165-ijms-21-03059">165</xref>]. NMDA receptors are glutamate receptors with Mg<sup>2+</sup>-mediated voltage-dependence effects in synaptic plasticity. Mutations in NMDA receptor subunits are present in NDDs. Patients with severe epileptic encephalopathy harbor the missense variant <italic>GluN2AN615K (GRIN2A C1845A)</italic>, which affects NMDA receptor channel blockers, including memantine [<xref ref-type="bibr" rid="B167-ijms-21-03059">167</xref>].</p>
<p>Memantine can be used alone or in combination with AChEIs in AD [<xref ref-type="bibr" rid="B168-ijms-21-03059">168</xref>,<xref ref-type="bibr" rid="B169-ijms-21-03059">169</xref>]. Proteomic studies in the hippocampus and the cerebral cortex of AD-related transgenic mice (3× Tg-AD) treated with memantine revealed alterations in the expression of 233 and 342 proteins, respectively [<xref ref-type="bibr" rid="B170-ijms-21-03059">170</xref>]. In <italic>APP23</italic> transgenic mice with cerebral amyloid angiopathy (CAA), memantine reduces cerebrovascular Aβ and hemosiderin deposits by enhancing Aβ-cleaving IDE expression [<xref ref-type="bibr" rid="B171-ijms-21-03059">171</xref>].</p>
<p>Memantine is useful for the treatment of both cognitive deterioration and BDs in AD and other forms of dementia [<xref ref-type="bibr" rid="B172-ijms-21-03059">172</xref>,<xref ref-type="bibr" rid="B173-ijms-21-03059">173</xref>]. AD patients treated with memantine plus citalopram show improvement in BDs [<xref ref-type="bibr" rid="B174-ijms-21-03059">174</xref>]; in combination with antipsychotics, it may improve verbal memory, learning, verbal letter fluency, and working memory with no effect on psychotic symptoms in patients with chronic schizophrenia [<xref ref-type="bibr" rid="B175-ijms-21-03059">175</xref>,<xref ref-type="bibr" rid="B176-ijms-21-03059">176</xref>]; at a dose of 20 mg/day, it may be effective in patients with obsessive-compulsive disorder [<xref ref-type="bibr" rid="B177-ijms-21-03059">177</xref>]; at 10 mg/day, it may be helpful in migraine [<xref ref-type="bibr" rid="B178-ijms-21-03059">178</xref>]; and, in combination with naltrexone, it enhances the efficacy of naltrexone in reducing alcohol drinking and craving [<xref ref-type="bibr" rid="B179-ijms-21-03059">179</xref>]. Memantine might also be useful in the treatment of punctate and dynamic allodynia by the blockade of the microglia Kir2.1 channel to suppress microglia activation [<xref ref-type="bibr" rid="B180-ijms-21-03059">180</xref>], and in combination with dextromethorphan, it may be beneficial in neuropathic pain [<xref ref-type="bibr" rid="B181-ijms-21-03059">181</xref>].</p>
</sec>
<sec id="sec4dot5-ijms-21-03059">
<title>4.5. Multifactorial Treatments</title>
<p>Most studies in which AD patients are treated with multifactorial combinations reveal that <italic>APOE-3/3</italic> carriers are the best responders and that <italic>APOE-4/4</italic> carriers are the worst responders. Concerning CYP-related PGx outcomes, CYP2D6-EMs are the best responders, CYP2D6-PMs are the worst responders, and CYP2D6-IMs and UMs show an intermediate response [<xref ref-type="bibr" rid="B1-ijms-21-03059">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-03059">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-03059">3</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>,<xref ref-type="bibr" rid="B71-ijms-21-03059">71</xref>,<xref ref-type="bibr" rid="B106-ijms-21-03059">106</xref>,<xref ref-type="bibr" rid="B112-ijms-21-03059">112</xref>,<xref ref-type="bibr" rid="B115-ijms-21-03059">115</xref>,<xref ref-type="bibr" rid="B116-ijms-21-03059">116</xref>,<xref ref-type="bibr" rid="B118-ijms-21-03059">118</xref>] (<xref ref-type="fig" rid="ijms-21-03059-f004">Figure 4</xref>, <xref ref-type="fig" rid="ijms-21-03059-f005">Figure 5</xref> and <xref ref-type="fig" rid="ijms-21-03059-f006">Figure 6</xref>).</p>
<p>In linkage disequilibrium with and adjacent to the <italic>APOE</italic> locus (19q13.2) is the <italic>TOMM40</italic> gene, which encodes an outer mitochondrial membrane translocase involved in the transport of Aβ and other proteins into mitochondria. A poly T repeat in an intronic polymorphism (rs10524523) (intron 6) in the <italic>TOMM40</italic> gene has been implicated in AD pathogenesis and PGx. The number of “T”-residues in the rs10524523 (“523”) locus differentiates 3 allele groups: “short” (S, T ≤ 19), “long” (L, 20 ≤ T ≤ 29), and “very long” (VL, T ≥ 30). <italic>rs10524523 L</italic> variants are associated with a higher risk for late-onset AD (LOAD). <italic>APOE-TOMM40</italic> interactions affect the risk of AD and the response to drugs. The <italic>S/VL</italic> and <italic>VL/VL TOMM40 poly T</italic> genotypes interact with all <italic>APOE</italic> genotypes; however, the <italic>APOE-4/4-TOMM40-L/L</italic> association is unique, accounting for 30% of <italic>APOE-4/4</italic> carriers. <italic>TOMM40 poly T-S/S</italic> carriers are the best responders, <italic>VL/VL</italic> and <italic>S/VL</italic> carriers are intermediate responders, and <italic>L/L</italic> carriers are the worst responders to treatment. <italic>TOMM40-L/L</italic> and <italic>S/L</italic> carriers in haplotypes with <italic>APOE-4</italic> are the worst responders to treatment. <italic>TOMM40-S/S</italic> carriers and, to a lesser extent, <italic>TOMM40-S/VL</italic> and <italic>TOMM40-VL/VL</italic> carriers in haplotypes with <italic>APOE-3</italic> are the best responders to treatment. The <italic>TOMM40-L/L</italic> genotype is exclusively associated with the <italic>APOE-4/4</italic> genotype in 100% of the cases, and this haplotype (<italic>4/4-L/L</italic>) might be responsible for premature neurodegeneration and consequent early onset of the disease, a faster cognitive deterioration, and a limited response to conventional treatments [<xref ref-type="bibr" rid="B4-ijms-21-03059">4</xref>,<xref ref-type="bibr" rid="B116-ijms-21-03059">116</xref>] (<xref ref-type="fig" rid="ijms-21-03059-f005">Figure 5</xref>). </p>
<p>Epigenetic factors are important in AD pathogenesis and response to treatment [<xref ref-type="bibr" rid="B5-ijms-21-03059">5</xref>,<xref ref-type="bibr" rid="B26-ijms-21-03059">26</xref>,<xref ref-type="bibr" rid="B57-ijms-21-03059">57</xref>,<xref ref-type="bibr" rid="B61-ijms-21-03059">61</xref>,<xref ref-type="bibr" rid="B65-ijms-21-03059">65</xref>,<xref ref-type="bibr" rid="B71-ijms-21-03059">71</xref>]. Sirtuin variants may alter the epigenetic machinery, contributing to AD pathogenesis. The <italic>SIRT2-C/T</italic> genotype (rs10410544) (50.92%) has been associated with AD susceptibility in the <italic>APOEε4</italic>-negative population (<italic>SIRT2-C/C</italic>, 34.72%; <italic>SIRT2-T/T</italic> 14.36%). <italic>SIRT2-APOE</italic> bigenic clusters yield 18 haplotypes that influence the PGx outcome. <italic>APOE-3/4</italic> and <italic>APOE-4/4</italic> genotypes accumulate in <italic>SIRT2-T/T</italic> &gt; <italic>SIRT2-C/T</italic> &gt; <italic>SIRT2-C/C</italic> carriers, and <italic>SIRT2-T/T</italic> and <italic>SIRT2-C/T</italic> genotypes accumulate in <italic>APOE-4/4</italic> carriers. <italic>SIRT2-C/T</italic> carriers tend to be the best responders, <italic>SIRT2-T/T</italic> carriers are intermediate responders, and <italic>SIRT2-C/C</italic> carriers are the worst responders to a multifactorial treatment. PGx outcomes related to <italic>APOE-SIRT2</italic> bigenic clusters show that <italic>33CC</italic> carriers respond better than <italic>33TT</italic> and <italic>34CT</italic> carriers, whereas <italic>24CC</italic> and <italic>44CC</italic> carriers are the worst responders. SIRT2-C/T-CYP2D6-EMs are the best responders [<xref ref-type="bibr" rid="B5-ijms-21-03059">5</xref>].</p>
</sec>
</sec>
<sec id="sec5-ijms-21-03059">
<title>5. Pharmacogenomics of Neuropsychiatric Disorders</title>
<sec id="sec5dot1-ijms-21-03059">
<title>5.1. Psychotic Disorders</title>
<p>Psychotic symptoms (hallucinations and delusions) are strongly related to AD-associated cognitive dysfunction, gradually progressing in parallel with disease severity [<xref ref-type="bibr" rid="B182-ijms-21-03059">182</xref>]. In addition, symptoms of personality changes, paranoia, hallucinations, cravings, agitation, and changes in appetite may represent a prodromal noncognitive phenotype of risk for dementia [<xref ref-type="bibr" rid="B183-ijms-21-03059">183</xref>]. </p>
<p>Over 500 genes are potentially associated with psychosis and schizophrenia (SCZ) [<xref ref-type="bibr" rid="B25-ijms-21-03059">25</xref>]. Several BDs in dementia incorporate SCZ genes. Major biological pathways and mechanisms associated with SCZ genes include glutaminergic receptors (GRIA1, GRIN2, GRIK4, and GRM5), serotonergic receptors (HTR2A and HTR2C), GABAergic receptors (GABRA1 and GABRB2), dopaminergic receptors (DRD1 and DRD2), calcium-related channels (CACNA1H and CACNA1B), and solute carrier transporters (SLC1A1 and SLC6A2) [<xref ref-type="bibr" rid="B184-ijms-21-03059">184</xref>]. Aberrant motor behavior is strongly associated with the <italic>APOE-4/4</italic> genotype and the presence of both Lewy bodies and cerebral amyloid angiopathy [<xref ref-type="bibr" rid="B185-ijms-21-03059">185</xref>]. </p>
<p>Antipsychotics are drugs of current use (&gt;50%) to treat BDs in dementia with limited efficacy in aggressive behaviors and psychotic symptoms. These drugs increase mortality and risk of psychomotor disorders and cerebrovascular events. Neuroleptics are prescribed for long periods of time in combination with antidepressants and anti-dementia drugs [<xref ref-type="bibr" rid="B186-ijms-21-03059">186</xref>,<xref ref-type="bibr" rid="B187-ijms-21-03059">187</xref>].</p>
<p>Antipsychotics (<xref ref-type="table" rid="ijms-21-03059-t003">Table 3</xref>) are associated with the PGx activity of less than 100 pharmagenes. The different pharmacological categories of antipsychotics (phenothiazines with aliphatic side-chain, piperazine-related phenothiazines, piperidine phenothiazines, butyrophenones, indole derivatives, thioxanthenes, diphenylbutylpiperidines, diazepines, oxazepines, thiazepines, oxepines, benzamides, and other neuroleptics) are substrates, inhibitors, or inducers of 32, 16, and 3 enzyme/protein gene products, respectively, and are transported by at least 14 different protein transporters. CYP enzymes participate in the metabolism of 90% of antipsychotics. These drugs are major substrates of CYP3A4 (75%), CYP2D6 (72%), CYP1A2 (46%), CYP2C19 (22%), and UGT1A4 (33%); inhibitors of CYP2D6 (50%), CYP3A4 (42%), ABCB1 (29%), CYP1A2 (25%), CYP2C19 (21%), and CYP2C9 (15%); and inducers of GSTM1, MAOB, and SLCO3A1 with low affinity (&lt;5%). About 50% of antipsychotics are transported by ABCB1. Other transporters responsible for the influx-efflux of neuroleptics are KCNH2 (22%); KCNE1 and KCNE2 (18%); KCNQ1 (18%); and SLC6A2, SLC6A4, and SCN5A (11%). Haloperidol is associated with 31 pharmagenes, Olanzapine is associated with 28, and Thioridazine is associated with 27 [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>].</p>
<p>The dopamine transporter (<italic>SLC6A3</italic>) gene has been the focus of attention for years in the PGx of antipsychotic drugs. The study of 6 SNPs (rs2652511 (<italic>T-844C</italic>) and rs2975226 (<italic>T-71A</italic>) in the 5’-regulatory region, rs2963238 (<italic>A1491C</italic>) in intron 1, a <italic>30-bp VNTR</italic> in intron 8, rs27072 and the <italic>40-bp VNTR</italic> in the 3’-region) showed association of allele and genotype frequencies with response to clozapine [<xref ref-type="bibr" rid="B188-ijms-21-03059">188</xref>].</p>
<p>Major ADRs with antipsychotics are extrapyramidal symptoms, tardive dyskinesia, antipsychotic-induced weight gain, and clozapine-induced agranulocytosis. Antipsychotic-induced extrapyramidal symptoms are associated with <italic>DRD2, SLC18A2, HTR2A, GRIK3</italic>, and <italic>SLC6A3 VNTR</italic> and <italic>COMT Val158Met</italic> polymorphisms [<xref ref-type="bibr" rid="B189-ijms-21-03059">189</xref>,<xref ref-type="bibr" rid="B190-ijms-21-03059">190</xref>]. SNPs in <italic>ADORA1, ADORA2A</italic>, and <italic>ADORA3</italic> have been associated with psychopathological symptoms, extrapyramidal symptoms, akathisia, and tardive dyskinesia [<xref ref-type="bibr" rid="B191-ijms-21-03059">191</xref>]. <italic>RGS2*T/*T(rs2746073), RGS2*C/*C (rs4606),</italic> and <italic>RGS2*A/*A (rs2746071)</italic> are associated with high risk for extrapyramidal symptoms in Russian patients treated with haloperidol [<xref ref-type="bibr" rid="B192-ijms-21-03059">192</xref>]. Several SNPs in genes of the mTOR pathway (<italic>AKT1, rs1130214; FCHSD1, rs456998; Raptor, rs7211818;</italic> and <italic>DDIT4, rs1053639</italic>) have also been associated with extrapyramidal disorders in Spanish patients under antipsychotic treatment [<xref ref-type="bibr" rid="B193-ijms-21-03059">193</xref>].</p>
<p>Tardive dyskinesia (TD) is an involuntary movement disorder that occurs in over 20% of patients after chronic treatment with antipsychotics. Disrupted in schizophrenia 1 (<italic>DISC1</italic>) gene variants, SNP variation in several CYPs, especially <italic>CYP2D6</italic>, and in <italic>HSPG2, CNR1, DPP6, LC18A2, MTNR1A, PIP5K2A, DRD2, DRD3, VMAT2, HSPG2, HTR2A, HTR2C</italic>, and <italic>SOD2</italic> variants influence TD [<xref ref-type="bibr" rid="B194-ijms-21-03059">194</xref>,<xref ref-type="bibr" rid="B195-ijms-21-03059">195</xref>,<xref ref-type="bibr" rid="B196-ijms-21-03059">196</xref>]. An intron-1 SNP (rs6977820) of the <italic>DPP6</italic> (dipeptidyl peptidase-like protein-6) gene has been associated with TD in Japanese patients. DPP6 is an auxiliary subunit of Kv4 that regulates the activity of dopaminergic neurons. Decreased expression of <italic>DPP6</italic> in the brain can be reversed by haloperidol treatment [<xref ref-type="bibr" rid="B197-ijms-21-03059">197</xref>]. Another SNP (rs2445142) in the <italic>HSPG2</italic> (heparan sulfate proteoglycan 2) gene has been associated with TD in both Japanese and Caucasian populations [<xref ref-type="bibr" rid="B198-ijms-21-03059">198</xref>]. Carriers of the <italic>CNR1-rs806374 (T&gt;C) CC</italic> genotype are more likely to develop TD and severe motor dysfunction than <italic>TT</italic> or <italic>TC</italic> among Caucasians. Cannabinoid receptor 1 (CNR1) activators inhibit movement, and this effect is prevented by rimonabant and selective CNR1 antagonists [<xref ref-type="bibr" rid="B199-ijms-21-03059">199</xref>]. A number of SNPs in the <italic>SLC18A2</italic> gene that encodes VMAT2 (vesicular monoamine transporter 2) may affect TD, including the rs2015586 marker (with deleterious effects) and the rs363224 marker (with protective effects in carriers of the low-expression <italic>AA</italic> genotype) [<xref ref-type="bibr" rid="B200-ijms-21-03059">200</xref>]. Two VMAT2 inhibitors, Valbenazine and Deutetrabenazine, have been approved for treating TD [<xref ref-type="bibr" rid="B201-ijms-21-03059">201</xref>,<xref ref-type="bibr" rid="B202-ijms-21-03059">202</xref>,<xref ref-type="bibr" rid="B203-ijms-21-03059">203</xref>].</p>
<p>Hyperprolactinemia is a common ADR in users of neuroleptic drugs. Risperidone-induced prolactin response is associated with 3 <italic>UGT1A1</italic> SNPs (<italic>UGT1A1*80c.-364C&gt;T, UGT1A1*93 c.-3156G&gt;A,</italic> and <italic>UGT1A1 c.-2950A&gt;G</italic>) [<xref ref-type="bibr" rid="B204-ijms-21-03059">204</xref>].</p>
<p>Antipsychotic-induced weight gain occurs in over 30–40% of patients with SCZ. All antipsychotics are associated with weight gain in antipsychotic-naïve and first-episode patients; however, weight gain is greatest in patients treated with the second-generation antipsychotics clozapine and olanzapine. The proportion of patients with body weight gain (&gt;7% baseline) is &gt;20% for ziprasidone, &gt;30% for quetiapine, and 45% for aripiprazole [<xref ref-type="bibr" rid="B205-ijms-21-03059">205</xref>]. This ADR is caused by different factors: pharmacological properties of the drug, pharmacogenetic factors, environmental factors, and ethnicity [<xref ref-type="bibr" rid="B206-ijms-21-03059">206</xref>].</p>
<p>Over 100 permutated pathways may be involved in weight gain regulation in response to neuroleptics, and Genome-wide association studies (GWAS) analysis revealed that Peroxisome proliferator activated receptor gamma (PPARG) and Proprotein convertase, subtilisin/hexin-type 1 (PCSK1) are involved in antipsychotic-induced weight gain [<xref ref-type="bibr" rid="B207-ijms-21-03059">207</xref>]. Genetic associations between pathogenic genes and genes involved in lipid metabolism cannot be ruled out as feasible links in body weight changes in response to psychotropic treatments. In fact, lipoprotein lipase (LPL), a key enzyme in triglyceride hydrolysis, is expressed in brain regions which are structural substrates of higher activities of the CNS (learning, memory, behavior, cognition), and SNPs in the <italic>LPL</italic> gene locus (8p22) (<italic>rs253 C</italic> allele) have been associated with SCZ [<xref ref-type="bibr" rid="B208-ijms-21-03059">208</xref>].</p>
<p>Stimulation of the serotonin (5-HT)1A receptor (HTR1A) contributes to the mechanism of action of clozapine and lurasidone. rs358532 and rs6449693, tag SNPs for rs6295, may predict response to lurasidone [<xref ref-type="bibr" rid="B209-ijms-21-03059">209</xref>]. The <italic>CYP1A2*1F/*1F</italic> genotype has been associated with clozapine-induced generalized tonic-clonic seizures in Brazilian patients [<xref ref-type="bibr" rid="B210-ijms-21-03059">210</xref>]. The study of 6 SNPs in the tryptophan hydroxylase (<italic>TPH</italic>) gene (rs4570625, rs11178997, rs11178998, rs7954758, rs7305115, and rs4290270) revealed association of the rs10784941 and rs4565946 markers and the rs4570625-rs4565946 haplotype with SCZ. <italic>TPH2</italic> variants and the <italic>rs4570625-rs4565946 G-C</italic> haplotype do not affect response to antipsychotic drugs [<xref ref-type="bibr" rid="B211-ijms-21-03059">211</xref>].</p>
<p>Antipsychotic-related ADRs can be substantially reduced with the incorporation of PGx procedures into clinical practice [<xref ref-type="bibr" rid="B27-ijms-21-03059">27</xref>,<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>,<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>].</p>
</sec>
<sec id="sec5dot2-ijms-21-03059">
<title>5.2. Depressive Disorders</title>
<p>Depression is the second most common psychiatric symptom in AD, after apathy. The prevalence of depression in AD varies from 5% to &gt;40% in different studies. Patients with severe AD show a higher prevalence of depression [<xref ref-type="bibr" rid="B212-ijms-21-03059">212</xref>,<xref ref-type="bibr" rid="B213-ijms-21-03059">213</xref>] and depressive symptoms are associated with a faster rate of memory decline [<xref ref-type="bibr" rid="B214-ijms-21-03059">214</xref>]. There is evidence that early life depression can be a risk factor for later life dementia and that later life depression may represent a prodrome to dementia [<xref ref-type="bibr" rid="B215-ijms-21-03059">215</xref>], with sex-specific differences [<xref ref-type="bibr" rid="B216-ijms-21-03059">216</xref>], especially in cases with cerebral amyloidopathy (&gt;50%) [<xref ref-type="bibr" rid="B217-ijms-21-03059">217</xref>]. Furthermore, depressed patients with mild cognitive impairment (MCI) have worse cognitive performance and greater loss of gray-matter volume in the cerebellum and parahippocampal gyrus [<xref ref-type="bibr" rid="B218-ijms-21-03059">218</xref>]. Low psychomotor speed has also been associated with an increased risk of developing dementia and depressive symptoms [<xref ref-type="bibr" rid="B219-ijms-21-03059">219</xref>]. Cardiovascular risk factors may contribute to depression in patients with MCI [<xref ref-type="bibr" rid="B220-ijms-21-03059">220</xref>]. Late-life depression (LLD) affects 15% of the elderly population. <italic>CYP2D6</italic>, <italic>SLC6A4 5-HTTLPR</italic>, and brain-derived neurotrophic factor (<italic>BDNF</italic>) variants influence the PGx of this condition, as recently reported by the Clinical Pharmacogenetics Implementation Consortium [<xref ref-type="bibr" rid="B221-ijms-21-03059">221</xref>].</p>
<p>Some studies indicate that the <italic>APOE</italic> genotype may influence the incidence of BDs and treatment in dementia [<xref ref-type="bibr" rid="B111-ijms-21-03059">111</xref>,<xref ref-type="bibr" rid="B117-ijms-21-03059">117</xref>], while others did not find association of <italic>APOE-4</italic> with depression, anxiety, apathy, agitation, irritability, or sleep disturbances in cognitively impaired subjects [<xref ref-type="bibr" rid="B222-ijms-21-03059">222</xref>]. Genome-wide association studies (GWAS) identified 31 genes located in 19 risk loci for major depressive disorder (MDD). Common and rare variants of <italic>L3MBTL2</italic> are associated with AD. mRNA expression levels of <italic>SORCS3</italic> and <italic>OAT</italic> are differentially expressed in AD brain tissues, and 13 MDD risk genes may interact with core AD genes such as <italic>HACE1, NEGR1</italic>, and <italic>SLC6A15</italic> [<xref ref-type="bibr" rid="B223-ijms-21-03059">223</xref>].</p>
<p>The treatment of depression in dementia can be pharmacological, with antidepressants, especially selective serotonin reuptake inhibitors as a first choice, or nonpharmacological (emotion-oriented therapies, behavioral, and cognitive-behavioral modification programs; structured activity programs; sensory-stimulation therapies; multisensory approaches; music therapy; and mindfulness-based interventions) [<xref ref-type="bibr" rid="B224-ijms-21-03059">224</xref>]. Meta-analyses of double-blind randomized controlled trials comparing antidepressants versus placebo for depression in AD revealed inefficacy in most cases with different drugs (sertraline, mirtazapine, imipramine, fluoxetine, and clomipramine) [<xref ref-type="bibr" rid="B225-ijms-21-03059">225</xref>].</p>
<p>The mechanisms underlying depression in dementia still remain unclarified [<xref ref-type="bibr" rid="B226-ijms-21-03059">226</xref>]. About 60% of depressive patients receive an inappropriate medication according to their pharmacogenetic background [<xref ref-type="bibr" rid="B66-ijms-21-03059">66</xref>,<xref ref-type="bibr" rid="B227-ijms-21-03059">227</xref>,<xref ref-type="bibr" rid="B228-ijms-21-03059">228</xref>], and community psychiatrists and pharmacists are more accurate in their psychotropic prescriptions when they know the CYP profile of their patients [<xref ref-type="bibr" rid="B228-ijms-21-03059">228</xref>,<xref ref-type="bibr" rid="B229-ijms-21-03059">229</xref>,<xref ref-type="bibr" rid="B230-ijms-21-03059">230</xref>].</p>
<p>Antidepressants are associated with the PGx activity of over 600 genes. The different pharmacological categories of antidepressants (nonselective monoamine reuptake inhibitors, selective serotonin reuptake inhibitors, nonselective monoamine oxidase (MAO) inhibitors, and other chemical modalities) are substrates, inhibitors, or inducers of 40, 22, and 9 enzyme/protein gene products, respectively, and are transported by 13 different protein transporters (<xref ref-type="fig" rid="ijms-21-03059-f001">Figure 1</xref>, <xref ref-type="fig" rid="ijms-21-03059-f002">Figure 2</xref> and <xref ref-type="fig" rid="ijms-21-03059-f003">Figure 3</xref> and <xref ref-type="table" rid="ijms-21-03059-t004">Table 4</xref>). Enzymes of the Cytochrome P450 (CYP) family are involved in 100% of drugs approved for the treatment of depression. Antidepressants are major substrates of CYP2D6 (86%), CYP3A4 (72%), CYP2C19 (60%), CYP1A2 (57%), CYP2C9 (34%), UGT1A4 (29%), and UGT1A3 (25%); inhibitors of CYP2D6 (69%), CYP3A4 (55%), CYP1A2 (45%), CYP2C19 (45%), CYP2C9 (34%), SLC6A4 (32%), MAOA (29%), MAOB (29%), and ABCB1 (25%); and inducers of CYP3A4 (5%), CYP1A2 (5%), CYP2B6 (5%), CYP2C9 (3%), CYP2C19 (3%), CYP2D6 (3%), and ABCB1 (3%). Major transporters of antidepressants are SLC6A4 (62%), ABCB1 (55%), and SLC6A2 (40%) (<xref ref-type="table" rid="ijms-21-03059-t004">Table 4</xref>). Sertraline is associated with 31 pharmagenes, Milnacipran is associated with 31, Mirtazapine is associated with 30, Fluoxetine is associated with 28, and Imipramine is associated with 28 [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>]. The PGx of antidepressants has become quite well known over the past 20 years, with no relevant breakthroughs in the past decade [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B66-ijms-21-03059">66</xref>].</p>
<p><italic>CYP2C19</italic> and <italic>CYP2D6</italic> variants affect the occurrence of ADRs in patients treated with selective serotonin reuptake inhibitors (SSRIs) (citalopram, escitalopram, sertraline, fluvoxamine, fluoxetine, and paroxetine), including anxiety, nightmares, and panic attacks associated with CYP2D6 and electrocardiogram (ECG)-prolonged QT associated with CYP2C19 [<xref ref-type="bibr" rid="B231-ijms-21-03059">231</xref>]. Prolonged QTc interval is prevalent in patients with moderate-severe dementia, with behavioral symptoms, with global and temporal atrophy, and with leukoaraiosis [<xref ref-type="bibr" rid="B232-ijms-21-03059">232</xref>]. A pharmacogenetic risk score has been proposed with top-scoring SNPs (rs12248560, rs878567, and rs17710780). The <italic>HTR1A rs878567</italic> and <italic>CYP2C19 rs12248560</italic> variants showed association with depression severity [<xref ref-type="bibr" rid="B233-ijms-21-03059">233</xref>]. <italic>ACE</italic> variants influence mood in AD [<xref ref-type="bibr" rid="B111-ijms-21-03059">111</xref>]. The coadministration of ACE inhibitors and statins with antidepressants may affect therapeutic outcomes [<xref ref-type="bibr" rid="B234-ijms-21-03059">234</xref>].</p>
<p>The influence of PGx factors on the pharmacogenetics and pharmacodynamics of many antidepressants has been reasonably well documented [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B66-ijms-21-03059">66</xref>,<xref ref-type="bibr" rid="B235-ijms-21-03059">235</xref>,<xref ref-type="bibr" rid="B236-ijms-21-03059">236</xref>,<xref ref-type="bibr" rid="B237-ijms-21-03059">237</xref>]; however, important aspects such as body weight gain, suicidality, cyclothymic reactions, cardiovascular risks, and potential neurotoxicity still remain obscure [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>].</p>
<p>Lithium is the gold standard for the treatment of bipolar disorder (BPD) and BPD-like symptoms in a reduced number of cases with dementia. The response to lithium is very variable and depends on the PGx background of each patient [<xref ref-type="bibr" rid="B238-ijms-21-03059">238</xref>]. Lithium PGx is very complex. Caution and personalized dose adjustment is highly recommended in patients with the following genotypes: <italic>BCR</italic> (Asn796Ser), <italic>BDNF</italic> (C/G (rs988748) and G/A (Val66Met)), <italic>CACNG2</italic> (rs2284017, rs2284018, and rs5750285), <italic>GSK3B</italic> (T-50C and GSK3-beta*C), <italic>INPP1</italic> (C973A and rs1882891), mtDNA (carriers of the 0398A polymorphism show a better response to lithium), <italic>NTRK2</italic> (rs1387923 and rs1565445), and variants in other genes (<italic>ABCG2, CCND1, CREB1, DRD1, ESR1, FMR1, GRIK2, IMPA1, IMPA2, NR3C1, PTGES, SLC6A4,</italic> and <italic>VEGFA</italic>) [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>,<xref ref-type="bibr" rid="B238-ijms-21-03059">238</xref>].</p>
</sec>
<sec id="sec5dot3-ijms-21-03059">
<title>5.3. Anxiety Disorders</title>
<p>Anxiety-like disorders are present in 30–40% of cases with dementia during the disease process. Anxiety is a risk factor for dementia [<xref ref-type="bibr" rid="B239-ijms-21-03059">239</xref>,<xref ref-type="bibr" rid="B240-ijms-21-03059">240</xref>], and anxiety-like behaviors are persistent in patients with dementia. Early-onset AD patients exhibit greater prevalence of all BDs, especially anxiety, irritability, and sleep disorders [<xref ref-type="bibr" rid="B241-ijms-21-03059">241</xref>].</p>
<p>The neurobiology of anxiety in dementia is unknown. Subjective cognitive decline (SCD) (self-reported cognitive deficits), without measurable cognitive impairment, has been associated with brain structural alterations and <italic>APOE-4</italic>. SCD cases show decreased total cortical volumes and cortical surface area, which are especially prominent in <italic>APOE-4</italic> carriers. Anxiety symptoms are negatively associated with the right cortical surface area in <italic>APOE-4</italic> noncarriers with SCD [<xref ref-type="bibr" rid="B242-ijms-21-03059">242</xref>]. Depression, anxiety, and cerebrovascular risk contribute to SCD [<xref ref-type="bibr" rid="B243-ijms-21-03059">243</xref>].</p>
<p>Benzodiazepines are currently prescribed for ameliorating this symptomatology; however, benzodiazepines contribute to cognitive and psychomotor dysfunction [<xref ref-type="bibr" rid="B244-ijms-21-03059">244</xref>].</p>
</sec>
<sec id="sec5dot4-ijms-21-03059">
<title>5.4. Sleep Disorders</title>
<p>Chronic sleep disorders might represent a risk factor for dementia, and alterations in circadian rhythms and consequent sleep disorders are common in AD and age-related disorders [<xref ref-type="bibr" rid="B245-ijms-21-03059">245</xref>,<xref ref-type="bibr" rid="B246-ijms-21-03059">246</xref>,<xref ref-type="bibr" rid="B247-ijms-21-03059">247</xref>,<xref ref-type="bibr" rid="B248-ijms-21-03059">248</xref>]. The neurobiology of circadian rhythms in AD is not well documented. Different neurotransmitters influence circadian changes and sleep disorders (insomnia, parasomnias, circadian rhythm sleep-wake disorders, hypersomnolence, sleep-related movement disorders, and sleep-related breathing disorders), including melatonin, histamine, GABA, hypocretin, dopamine, noradrenaline, serotonin, and adenosine. Genomic alterations in these systems (e.g., pathogenic genes) may affect the efficacy and safety of anxiolytics and hypnotics used in the treatment of some of these disorders [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>].</p>
<p>Over 100 genes have been associated with sleep disorders in AD [<xref ref-type="bibr" rid="B249-ijms-21-03059">249</xref>]. In the triple transgenic AD mouse model (3× Tg-AD), there is an abnormal expression of <italic>Per</italic> genes in the suprachiasmatic nucleus (SCN) [<xref ref-type="bibr" rid="B250-ijms-21-03059">250</xref>]. The glymphatic system might be an effective mechanism of brain Aβ-amyloid clearance particularly effective during sleep. Aquaporin-4 may play a role in glymphatic function, since ablation of Aquaporin-4 results in impairment of Aβ clearance mechanism and increased brain Aβ-amyloid deposition. The <italic>AQP4</italic> variant rs72878776 is associated with poorer overall sleep quality, and other SNPs might moderate the effect of sleep latency (rs491148, rs9951307, rs7135406, rs3875089, and rs151246) and duration (rs72878776, rs491148, and rs2339214) on brain Aβ-amyloid burden [<xref ref-type="bibr" rid="B251-ijms-21-03059">251</xref>]. Homer1a and mGluR1/5 are implicated in sleep function to weaken synapses during sleep and to restore synapse homeostasis [<xref ref-type="bibr" rid="B252-ijms-21-03059">252</xref>]. </p>
<p>Evening secretion of melatonin is delayed and mildly impaired in patients with AD [<xref ref-type="bibr" rid="B253-ijms-21-03059">253</xref>]. Rapid eye movement (REM) sleep influences memory consolidation. Noradrenaline participates in the regulation of REM sleep to maintain neuronal integrity and brain house-keeping functions [<xref ref-type="bibr" rid="B254-ijms-21-03059">254</xref>].</p>
<p>Sleep dysfunction and Aβ deposition show synergistic effects to impair brain function. Brain Aβ deposition is associated with subjective measures of sleep quality and cognition. Nocturnal awakenings are associated with Aβ deposition in the precuneus and poor cognitive performance [<xref ref-type="bibr" rid="B255-ijms-21-03059">255</xref>]. Extracellular levels of Aβ and tau show a fluctuating pattern during the normal sleep-wake cycle. Increased wakefulness and disturbed sleep lead to increased Aβ production and decreased Aβ clearance; additionally, chronic wakefulness increases Aβ aggregation and deposition, and Aβ accumulation results in disturbed sleep. Sleep deprivation increases brain and CSF tau levels and the spread of tau protein aggregates in neural tissues, correlating with decreased nonrapid eye movement (NREM) sleep slow wave activity [<xref ref-type="bibr" rid="B256-ijms-21-03059">256</xref>,<xref ref-type="bibr" rid="B257-ijms-21-03059">257</xref>].</p>
<p>Sleep disorders may precede cognitive impairment. Sleep disturbances alter periodic sleep architecture and electroencephalogram (EEG) patterns in prodromal stages [<xref ref-type="bibr" rid="B258-ijms-21-03059">258</xref>]. Age-related cognitive impairment is associated with reduced delta, theta, and sigma power as well as spindle maximal amplitude during NREM sleep. Early sleep biomarkers of potential cognitive decline are poor sleep consolidation, lower amplitude, and faster frequency of spindles [<xref ref-type="bibr" rid="B259-ijms-21-03059">259</xref>]. Decreased nonrapid eye movement (NREM) sleep slow wave activity associates with Aβ deposition and tauopathy. Aβ decreases nonrapid eye movement sleep and increases wakefulness. Aβ upregulates the expression levels of tau, pTau, orexin A, and adenosine A1 receptor [<xref ref-type="bibr" rid="B260-ijms-21-03059">260</xref>]. Orexin receptor antagonists (e.g., Suvorexant) have been proposed as potential candidates for the treatment of sleep disorders and BDs in AD [<xref ref-type="bibr" rid="B261-ijms-21-03059">261</xref>]. </p>
<p>Anxiolytics, hypnotics, and sedatives are associated with the PGx activity of 445 genes. Different categories of anxiolytics (benzodiazepines, diphenylmethane derivatives, carbamates, dibenzo-bicyclo-octadiene derivatives, and azaspirodecanodiones), hypnotics, and sedatives (barbiturates, aldehydes, benzodiazepines, piperidinediones, melatonin receptor agonists, and other chemicals, alone or in combination) are substrates, inhibitors, or inducers of 47, 18, and 30 enzyme/protein gene products, respectively, and are transported by at least 30 protein transporters (<xref ref-type="fig" rid="ijms-21-03059-f002">Figure 2</xref> and <xref ref-type="fig" rid="ijms-21-03059-f003">Figure 3</xref> and <xref ref-type="table" rid="ijms-21-03059-t005">Table 5</xref>). CYP enzymes participate in the metabolism of over 92% of drugs of these pharmacological categories. About 70% of drugs currently used for the treatment of anxiety, panic attacks, sleep disorders, agitation, and behavioral anomalies are major substrates of CYP3A4, followed by CYP2C19 (41%); CYP3A5 (38%); CYP2D6 (36%); CYP2C9 (30%); CYP1A2 (27%); CYP2B6 (19%); UGT1A4 (14%); UGT2B15 (11%); and UGT1A1, UGT1A3, UGT1A6, UGT1A10, and UGT2B7 (8%); only 10% are inhibitors of CYP3A4 and CYP2C9; 8% are inducers of CYP3A4, and about 5% are inducers of CYP1A2, CYP2A6, CYP7A1, and ABCC2. Over 50% of these drugs are transported by proteins of the CLCN family, 16% are transported by ABCB1, 9% are transported by NQ1I2, and 5% are transported by ABCC2, KCNE1, KCNH2, and SLCO1B1. Phenobarbital is associated with 80 pharmagenes, Midazolam is associated with 24, Temazepam is associated with 20, Diazepam is associated with 23, and Alprazolam is associated with 14 [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>]. </p>
</sec>
<sec id="sec5dot5-ijms-21-03059">
<title>5.5. Epilepsy</title>
<p>Epilepsy is a prevalent disorder in dementia with prevalence and incidence rates 2–6-fold higher than in age-matched healthy subjects. Subclinical epileptiform activity can lead to accelerated cognitive decline. Aβ deposition may influence the propagation of synchronized abnormal discharges via excitatory pathways [<xref ref-type="bibr" rid="B262-ijms-21-03059">262</xref>].</p>
<p>There is a complex epileptogenesis-associated dysregulation of proteins involved in amyloid β processing and regulation in the hippocampus (HC) and parahippocampal cortex during epileptogenesis, in which there is also involvement of tau and proteins of the mitochondrial complexes I, III, IV, and V [<xref ref-type="bibr" rid="B263-ijms-21-03059">263</xref>]. Seizures are more prevalent in early-onset AD with rapid progression [<xref ref-type="bibr" rid="B264-ijms-21-03059">264</xref>], correlating with high CSF total tau protein levels [<xref ref-type="bibr" rid="B265-ijms-21-03059">265</xref>]. A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), which is an α-secretase in APP processing, has been associated with epilepsy as a stage-dependent modulator of epileptogenesis [<xref ref-type="bibr" rid="B266-ijms-21-03059">266</xref>].</p>
<p>Potential pathogenic genes for epilepsy include ion channel genes (e.g., <italic>SCN1A, KCNQ2, SCN2A,</italic> and <italic>SCN8A</italic>), which account for nearly half of epilepsy genes, together with a number of additional genes, such as <italic>CDKL5, STXBP1, PCDH19, PRRT2, LGI1, ALDH7A1, MECP2, EPM2A, ARX</italic>, and <italic>SLC2A1</italic> [<xref ref-type="bibr" rid="B267-ijms-21-03059">267</xref>]. There is also an association of <italic>MTHFR rs1801133</italic> and <italic>ABCC2 rs717620</italic> with susceptibility to generalized tonic-clonic epilepsy, while <italic>ABCB1 rs717620</italic> is associated with poor response to antiepileptics [<xref ref-type="bibr" rid="B268-ijms-21-03059">268</xref>]. The influence of some of these genes in PGx has been investigated under different therapeutic paradigms [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>]. </p>
<p>Treatment of seizures in AD with low-dose antiepileptic drugs (AEDs) is usually well tolerated and efficacious, and selected AEDs might also help in slowing-down disease progression [<xref ref-type="bibr" rid="B269-ijms-21-03059">269</xref>,<xref ref-type="bibr" rid="B270-ijms-21-03059">270</xref>]. Anticonvulsants may suppress seizures in up to two-thirds of all patients, with no apparent effects on long-term prognosis [<xref ref-type="bibr" rid="B271-ijms-21-03059">271</xref>]. </p>
<p>Antiepileptics are associated with the PGx activity of approximately 150 genes (<xref ref-type="table" rid="ijms-21-03059-t006">Table 6</xref>). The <italic>GABRG2</italic> gene encodes one of the subunits of the GABA-A receptor, the most abundant receptor of fast synaptic inhibition in the brain. <italic>GABRAG2</italic> variants (rs211037, rs210987, rs440218, rs2422106, rs211014, and rs401750) and several <italic>PRRT2</italic> mutations (<italic>c.649delC (p.R217Efs*12), c.649_650insC (p.R217Pfs*8), c.412C&gt;G (p.Pro138Ala), c.439G&gt;C (p.Asp147His)</italic>, and <italic>c.623C&gt;A (p.Ser208Tyr</italic>)) are associated with febrile seizures [<xref ref-type="bibr" rid="B272-ijms-21-03059">272</xref>]. There is a clear association of rs211037 with epilepsy in Asian patients and of rs211037-rs210987 and rs2422106-rs211014-rs401750 haplotypes with susceptibility to symptomatic epilepsy in Chinese [<xref ref-type="bibr" rid="B273-ijms-21-03059">273</xref>].</p>
<p>Different categories of anticonvulsants (barbiturates, hydantoin derivatives, oxazolidines, succinimides, benzodiazepines, carboxamides, fatty acid derivatives, and miscellaneous antiepileptics) are substrates, inhibitors, or inducers of 40, 15, and 24 enzyme/protein gene products, respectively, and are transported by at least 16 protein transporters (<xref ref-type="table" rid="ijms-21-03059-t006">Table 6</xref>). CYP enzymes participate in the metabolism of over 69% of drugs of these pharmacological categories. Over 65% of drugs currently used for the treatment of epilepsy and related disorders are major substrates of CYP3A4, followed by CYP3A5, CYP2E1, and UGT1A1 (32%); CYP2C8 and CYP2B6 (26%); CYP1A2, CYP2C9, CYP2C19, UGT1A3, UGT1A9, and UGT2B7 (22%); CYP1A1, CYP1A6, CYP2D6, CYP3A7, UGT1A4, and UGT1A6 (16%); and CYP2C18, CYP4B1, UGT1A10, and UGT2B15 (11%). These drugs tend to be strong inhibitors of CYP2C9 (&gt;25%) and, to a lesser extent, of CYP1A6 and SULT1A1 (10%), and they are also potent inducers of CYP3A4 (37%). ABCB1 is the major transporter of 42% of antiepileptics, followed by ABCC2 (16%), SLC6A1 (11%), and SLCO2A1 and SLCO1B1 (10%). Phenobarbital, Valproic acid, and Carbamazepine are the three best-characterized drugs for their pharmacogenomic profile, with over 100 genes involved in their biotransformation and metabolism [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>,<xref ref-type="bibr" rid="B274-ijms-21-03059">274</xref>,<xref ref-type="bibr" rid="B275-ijms-21-03059">275</xref>].</p>
<p><italic>UGT2B7 G211T</italic> and <italic>C161T</italic> polymorphisms affect the pharmacokinetics and pharmacodynamics of valproic acid (VPA) [<xref ref-type="bibr" rid="B276-ijms-21-03059">276</xref>]. Carriers of the variant <italic>UGT1A6 19T&gt;G, 541A&gt;G</italic>, and <italic>552A&gt;C</italic> allele require higher VPA dosages than noncarriers, and carriers of the variant <italic>GRIN2B -200T&gt;G</italic> allele are more likely to require lower VPA dosages than noncarriers [<xref ref-type="bibr" rid="B277-ijms-21-03059">277</xref>]. VPA-related liver damage has been associated with the formation of a hepatotoxic 4-ene metabolite mediated by CYP2C9 and CYP2A6 enzymes [<xref ref-type="bibr" rid="B278-ijms-21-03059">278</xref>]. <italic>ABAT rs1731017, SCN2A rs2304016</italic>, and <italic>ALDH5A1 rs1054899</italic> are associated with VPA response in Chinese patients [<xref ref-type="bibr" rid="B279-ijms-21-03059">279</xref>]. Female CYP2C19-PMs are more susceptible to VPA-induced weight gain in the Japanese population [<xref ref-type="bibr" rid="B280-ijms-21-03059">280</xref>], and SNPs in the leptin receptor (<italic>LEPR</italic>) (rs1137101) and ankyrin repeat kinase domain containing 1 (<italic>ANKK1</italic>) (rs1800497) show associations with VPA-induced weight gain in the Chinese population [<xref ref-type="bibr" rid="B281-ijms-21-03059">281</xref>]. Oral clearance (CL/F) of VPA in patients with the <italic>LEPR-A668G</italic> and <italic>G668G (rs1137101)</italic> variants is lower than in patients with the <italic>LEPR-A668A</italic> genotype [<xref ref-type="bibr" rid="B282-ijms-21-03059">282</xref>]. Meropenem decreases VPA plasma levels when coadministered together. This interaction is triggered by inhibition of acylpeptide hydrolase (APEH) activity with meropenem. The study of VPA-d6 β-D-glucuronide (VPA-G) concentration in <italic>APEH rs3816877</italic> and <italic>rs1131095</italic> carriers revealed that patients with the <italic>APEH rs3816877 C/C</italic> genotype show higher levels than <italic>C/T</italic> carriers in the Chinese population [<xref ref-type="bibr" rid="B283-ijms-21-03059">283</xref>]. Valproate-related neuroprotection in experimentally triggered epileptic seizures has been associated with PKC-dependent GABAAR γ2 phosphorylation at serine 327 residue [<xref ref-type="bibr" rid="B284-ijms-21-03059">284</xref>]. <italic>SOD2 Val16Ala</italic> polymorphism may affect γ-glutamyltransferase (GGT) elevation in epileptic patients treated with VPA [<xref ref-type="bibr" rid="B285-ijms-21-03059">285</xref>].</p>
<p>High initial serum concentrations of lamotrigine increase the risk of cutaneous ADRs. Genetic variants of uridine diphosphate glucuronosyltransferase (UGT) 1A4 influence lamotrigine elimination. <italic>UGT1A4*2 (P24T)</italic> and <italic>*3 (L48V)</italic> variants are associated with skin reactions but probably not in Caucasians [<xref ref-type="bibr" rid="B286-ijms-21-03059">286</xref>]. <italic>UGT2B7-161C&gt;T</italic> variants influence lamotrigine pharmacokinetics; specifically, the <italic>UGT2B7-161TT</italic> genotype changes lamotrigine clearance and may be useful in titrating the optimal lamotrigine dose [<xref ref-type="bibr" rid="B287-ijms-21-03059">287</xref>]. <italic>OCT1 rs628031</italic> and <italic>ABCG2 rs2231142</italic> affect lamotrigine metabolism, and SNPs in <italic>ABCG2 rs2231142, rs3114020, HNF4α rs2071197</italic>, and <italic>ABCB1 rs1128503</italic> are associated with lamotrigine CDR (concentration/dose normalized by body weight) in Chinese patients [<xref ref-type="bibr" rid="B288-ijms-21-03059">288</xref>,<xref ref-type="bibr" rid="B289-ijms-21-03059">289</xref>].</p>
<p>Treatment with carbamazepine, oxcarbazepine, or phenytoin is associated with delayed-hypersensitivity reactions (e.g., eosinophilia, Stevens–Johnson syndrome, and toxic epidermal necrolysis) [<xref ref-type="bibr" rid="B290-ijms-21-03059">290</xref>]. The FDA-approved label for oxcarbazepine indicates a pharmacogenomic association with hypersensitivity reactions and the HLA antigen allele <italic>HLA-B*15:02</italic>. Oxcarbazepine has structural similarities with carbamazepine, and <italic>HLA-B*15:02</italic> is a risk factor for both carbamazepine- and oxcarbazepine-induced severe cutaneous ADRs, especially in the Asian population [<xref ref-type="bibr" rid="B290-ijms-21-03059">290</xref>,<xref ref-type="bibr" rid="B291-ijms-21-03059">291</xref>]. <italic>HLA-B*15:02</italic> is highly associated with carbamazepine-related Stevens–Johnson syndrome/toxic epidermal necrolysis cases as well as phenytoin-related cutaneous ADRs and, to a lesser extent, lamotrigine ADRs; in contrast, <italic>HLA-B*40:01</italic> and <italic>HLA-B*58:01</italic> carriers show a lower frequency of carbamazepine-related skin complications [<xref ref-type="bibr" rid="B292-ijms-21-03059">292</xref>]. <italic>HLA-A*31:01</italic> has also been reported to be a genetic marker for carbamazepine-induced ADRs in both Japanese and European populations [<xref ref-type="bibr" rid="B293-ijms-21-03059">293</xref>,<xref ref-type="bibr" rid="B294-ijms-21-03059">294</xref>]. <italic>SCN1A rs3812718 A/G</italic> and <italic>rs2290732 A/G</italic> polymorphisms influence carbamazepine tolerability, and <italic>rs2298771 A/G</italic> is associated with carbamazepine efficacy [<xref ref-type="bibr" rid="B295-ijms-21-03059">295</xref>]. <italic>ABCB1 rs1045642</italic> and <italic>UGT2B7 rs7439366</italic> affect oxcarbazepine pharmacokinetics and pharmacodynamics in Han Chinese epileptic patients [<xref ref-type="bibr" rid="B296-ijms-21-03059">296</xref>]. <italic>PXR*1B, HNF4a rs2071197, CYP1A2*1F, ABCC2 1249G&gt;A</italic>, and <italic>PRRT2 c.649dupC</italic> influence the pharmacokinetics and pharmacodynamics of carbamazepine [<xref ref-type="bibr" rid="B297-ijms-21-03059">297</xref>]. <italic>ABCB1 c.3435C&gt;T, CYP3A4*1G, CYP3A5*3, POR*28</italic>, and <italic>EPHX1 c.416A&gt;G</italic> and <italic>c.128G&gt;C</italic> variants influence carbamazepine metabolism in Chinese patients [<xref ref-type="bibr" rid="B298-ijms-21-03059">298</xref>]. rs776746 and rs15524 in <italic>CYP3A5</italic> affect carbamazepine metabolism, and rs2032582 and rs10234411 in <italic>ABCB1</italic> contribute to interindividual variation in carbamazepine and in carbamazepine-10,11-epoxide transport in epileptic patients treated with carbamazepine in combination with phenytoin or phenobarbital [<xref ref-type="bibr" rid="B298-ijms-21-03059">298</xref>]. <italic>SCN1A IVS5-91G&gt;A, UGT2B7 c.802T&gt;C, ABCC2 c.1249G&gt;A</italic>, and <italic>EPHX1 c.337T&gt;C</italic> carriers require higher maintenance doses of oxcarbamazepine [<xref ref-type="bibr" rid="B299-ijms-21-03059">299</xref>,<xref ref-type="bibr" rid="B300-ijms-21-03059">300</xref>]. Carriers of the variant <italic>SCN1A IVS5-91G&gt;A</italic> and <italic>EPHX1 c.337T&gt;C</italic> allele require higher carbamazepine dosages than noncarriers, and genetic variants in the <italic>SCN1A, EPHX1</italic>, and <italic>UGT2B7</italic> genes interactively affect the concentration–dose ratio of carbamazepine [<xref ref-type="bibr" rid="B301-ijms-21-03059">301</xref>].</p>
<p><italic>SCN1A, CYP2C9, CYP2C19</italic>, and <italic>ABCB1</italic> variants affect phenytoin metabolism. <italic>CYP2C9</italic> and <italic>CYP2C19</italic> polymorphisms are associated with lower phenytoin maintenance dosage in Asian patients. <italic>CYP2C19*2/*2, CYP2C19*3/*3, CYP2C19*2/*3</italic>, and heterozygous <italic>CYP2C9*3</italic> variants require lower phenytoin maintenance dosage [<xref ref-type="bibr" rid="B301-ijms-21-03059">301</xref>,<xref ref-type="bibr" rid="B302-ijms-21-03059">302</xref>]. Phenytoin may cause cutaneous ADRs with variable severity (maculopapular exanthema, eosinophilia, Stevens–Johnson syndrome, and toxic epidermal necrolysis). At least 16 SNPs in <italic>CYP2C</italic> genes at 10q23.33 may contribute to this adverse effect. <italic>CYP2C9*3</italic> carriers show a clear propensity to phenytoin-related severe cutaneous ADRs [<xref ref-type="bibr" rid="B303-ijms-21-03059">303</xref>]. There is an association between a rare variant in the complement factor H-related 4 (<italic>CFHR4</italic>) gene and phenytoin-induced maculopapular exanthema in Europeans [<xref ref-type="bibr" rid="B304-ijms-21-03059">304</xref>].</p>
<p><italic>CACNA1G, CACNA1H, CACNA1I</italic>, and <italic>ABCB1</italic> variants are associated with differential short-term seizure outcome in childhood absence epilepsy. In patients treated with ethosuximide, <italic>CACNA1H rs61734410/P640L</italic> and <italic>CACNA1I rs3747178</italic> are more prevalent among not-seizure-free patients, and in patients treated with lamotrigine, <italic>ABCB1 rs2032582/S893A</italic> is more frequent in not-seizure-free patients, whereas <italic>CACNA1H rs2753326</italic> and <italic>rs2753325</italic> are more common in seizure-free patients [<xref ref-type="bibr" rid="B305-ijms-21-03059">305</xref>].</p>
<p>Resistant epilepsy is an important problem in over 20% of patients treated with antiepileptics [<xref ref-type="bibr" rid="B306-ijms-21-03059">306</xref>]. Pharmaco-resistance is directly linked to dysfunctions in the pharmacoepigenetic machinery [<xref ref-type="bibr" rid="B61-ijms-21-03059">61</xref>]. The <italic>C3435T</italic> variant of the <italic>ABCB1</italic> gene has been proposed as a crucial factor for drug resistance in epilepsy. <italic>ABCB1-C3435C</italic> carriers show a risk of pharmacoresistance in some studies, but this association has been questioned after further analyses [<xref ref-type="bibr" rid="B307-ijms-21-03059">307</xref>]. The <italic>ABCB1 G2677T T</italic> (rs1128503) and <italic>C3435T T</italic> (rs1045642) alleles and the <italic>TT, CTT</italic>, and <italic>TTT</italic> haplotypes are associated with drug-resistant epilepsy in specific populations [<xref ref-type="bibr" rid="B308-ijms-21-03059">308</xref>]. <italic>ABCC2 rs717620 -24 CT+TT</italic> genotypes and <italic>ABCC2 rs3740066 (3972C&gt;T) CT+TT</italic> genotypes are overrepresented in epileptic patients resistant to antiepileptic drugs in the Chinese population, whereas <italic>ABCC2 rs2273697 (1249G&gt;A)</italic> and <italic>ABCB1 rs1045642 (3435C&gt;T)</italic> polymorphisms were not found to be associated with drug-resistant epilepsy in this population. The frequency of the haplotype <italic>TGT (ABCC2 -24C&gt;T/ABCC2 1249G&gt;A/ABCC2 3972C&gt;T)</italic> in resistant patients is double that of responsive patients [<xref ref-type="bibr" rid="B309-ijms-21-03059">309</xref>]. The <italic>TAGAA</italic> haplotype in <italic>CACNA1A</italic> accumulates in drug-resistant patients in the Chinese population [<xref ref-type="bibr" rid="B310-ijms-21-03059">310</xref>]. Glucose type-1 transporter (GLUT1) deficiency syndrome, caused by mutations in the <italic>SLC2A1</italic> gene, exhibits pharmacoresistance to antiepileptics. Screening of <italic>SLC2A1</italic> pathogenic variants can predict drug response and optimization of antiepileptic drugs for the treatment of this health condition [<xref ref-type="bibr" rid="B311-ijms-21-03059">311</xref>]. The <italic>SCN1A IVS5-91G&gt;A AA</italic> and <italic>ABCC2 c.1249G&gt;A GA</italic> genotypes have been shown to be associated with carbamazepine/oxcarbamazepine-resistant epilepsy in the Chinese Han population. The frequency of <italic>SCN1A-AA</italic> and <italic>ABCC2-AC</italic> haplotypes is higher in drug-resistant patients than in responsive patients [<xref ref-type="bibr" rid="B312-ijms-21-03059">312</xref>]. Association of <italic>ABCC2 rs2273697</italic> and <italic>rs3740066</italic> polymorphisms and drug-resistant epilepsy has been reported in Asia Pacific epilepsy cohorts [<xref ref-type="bibr" rid="B313-ijms-21-03059">313</xref>]. <italic>PCDH19</italic> mutations may cause pharmacoresistant epilepsy and intellectual disability in Dravet-like syndromes. A retrospective study of antiepileptic therapy in females with <italic>PCDH19</italic> mutations showed that the most effective drugs in these cases are clobazam and bromide, with responder rates of 68% and 67%, respectively [<xref ref-type="bibr" rid="B314-ijms-21-03059">314</xref>]. Clobazam binds to stereospecific receptors on the postsynaptic GABA neuron at several sites within the CNS (limbic system and reticular formation) and enhances the inhibitory effect of GABA on neuronal excitability by increasing neuronal membrane permeability to chloride ions, which results in hyperpolarization and stabilization. Clobazam is extensively metabolized by CYP enzymes. Its major metabolite is N-desmethylclobazam (norclobazam), which also display antiepileptic activity. Clobazam is a major substrate of CYP2C19 and CYP3A4 and a minor substrate of CYP2B6 and CYP2C18. CYP2C19-PMs show higher plasma levels of clobazam and increased risk of ADRs. Caution and personalized dose adjustment is recommended in patients with the following genotypes: <italic>CYP2C19 (CYP2C19*2, CYP2C19*3, CYP2C19*4, CYP2C19*5, CYP2C19*6, CYP2C19*7, CYP2C19*8, CYP2C19*17), CYP3A4 (CYP3A4*1, CYP3A4*1B, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*8, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*15, CYP3A4*17, CYP3A4*18, CYP3A4*19</italic>), and <italic>CYP3A5 (CYP3A5*3</italic>) [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>] (<xref ref-type="table" rid="ijms-21-03059-t006">Table 6</xref>).</p>
<p>In Japanese patients with Dravet syndrome, it seems that <italic>CYP2C19</italic> variants may influence a positive response to the antiepileptic effects of stiripentol [<xref ref-type="bibr" rid="B315-ijms-21-03059">315</xref>]. Genotype combinations of <italic>GABRA1 rs6883877, GABRA2 rs511310</italic>, and <italic>GABRA3 rs4828696</italic> may affect responses to antiepileptic drugs [<xref ref-type="bibr" rid="B316-ijms-21-03059">316</xref>]. ɣ-aminobutyric-acid (GABA) is the principal inhibitory neurotransmitter in the CNS. Imbalances in GABAergic neurotransmission are involved in the pathophysiology of epilepsy and AD. GABA transporters (GATs) regulate the influx-efflux of GABA with sodium and chloride at the synaptic cleft. GATs belong to the solute carrier 6 (SLC6) transporter family: GAT1-3 (SLC6A1, SLC6A13, and SLC6A11) and betaine/GABA transporter 1 (BGT1 and SLC6A12). BGT1 is a potential target for the treatment of epilepsy. The GAT1/BGT1 selective inhibitor EF1502 and the BGT1 selective inhibitor RPC-425 display anticonvulsant effects [<xref ref-type="bibr" rid="B317-ijms-21-03059">317</xref>].</p>
</sec>
</sec>
<sec id="sec6-ijms-21-03059" sec-type="conclusions">
<title>6. Conclusions</title>
<p>Symptomatic interventions for patients with dementia involve anti-dementia drugs to improve cognition, psychotropic drugs for the treatment of behavioral disorders (BDs), and different categories of drugs for concomitant disorders. Demented patients may take &gt;6–10 drugs/day with the consequent risk for drug–drug interactions (DDIs) and adverse drug reactions (ADRs &gt; 80%) which accelerate cognitive decline. PGx intervention may prevent ADRs and DDIs. The pharmacoepigenetic machinery is integrated by pathogenic, mechanistic, metabolic, transporter, and pleiotropic genes redundantly and promiscuously regulated by epigenetic mechanisms (DNA methylation, chromatin remodeling/histone changes, and miRNAs). <italic>CYP2D6, CYP2C9, CYP2C19</italic>, and <italic>CYP3A4/5</italic> geno-phenotypes are involved in the metabolism of over 90% of drugs currently used in patients with dementia, and only 20% of the population is an extensive metabolizer for this tetragenic cluster. ADRs associated with anti-dementia drugs, antipsychotics, antidepressants, anxiolytics, hypnotics, sedatives, and antiepileptic drugs can be minimized by means of pharmacogenetic screening prior to treatment. These drugs are substrates, inhibitors, or inducers of 58, 37, and 42 enzyme/protein gene products, respectively, and are transported by 40 different protein transporters. APOE is the reference gene in most pharmacogenetic studies. In multifactorial treatments, APOE-3 carriers are the best responders and APOE-4 carriers are the worst responders; likewise, CYP2D6-EMs are the best responders and CYP2D6-PMs are the worst responders. ACHE-BCHE variants also affect the pharmacogenetic outcome as well as some genes encoding components of the epigenetic machinery. </p>
<p>Antipsychotics show limited efficacy in aggressive behaviors and psychotic symptoms and may increase mortality and risk of psychomotor disorders and cerebrovascular events. Major ADRs with antipsychotics are extrapyramidal symptoms, tardive dyskinesia, weight gain, hyperprolactinemia, and agranulocytosis. Antipsychotics are associated with the activity of ≈100 pharmagenes; antidepressants are associated with 600; and anxiolytics, hypnotics, and sedatives are associated with 445. CYP enzymes are involved in 100% of drugs approved for the treatment of depression, and about 60% of depressive patients are receiving an inappropriate medication according to their pharmacogenetic background. Carbamazepine, oxcarbazepine, or phenytoin may cause delayed-hypersensitivity reactions associated with the HLA antigen allele HLA-B*15:02. </p>
<p>The incorporation of pharmacogenomic strategies for a personalized treatment in dementia is an effective option to optimize limited therapeutic resources and to reduce unwanted side-effects.</p>
</sec>
<sec id="sec7-ijms-21-03059">
<title>7. Further Considerations</title>
<p>Drug efficacy and safety are fundamental issues in dementia due to the complexity of the disorder and comorbidities which require polypharmacy [<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>]. Over 50% of patients over 60 years of age suffering chronic CNS disorders currently take 6–12 drugs/day with a high risk of drug toxicity, ADRs, and DDIs [<xref ref-type="bibr" rid="B43-ijms-21-03059">43</xref>,<xref ref-type="bibr" rid="B56-ijms-21-03059">56</xref>]. Over 20% of patients with depression develop dementia in a period of approximately 10 years. The chronic use of anticholinergic antidepressants might contribute to this pathogenic transformation [<xref ref-type="bibr" rid="B318-ijms-21-03059">318</xref>]. It is also well-known that over 60% of patients chronically treated with antipsychotics develop extrapyramidal symptoms which may induce severe motor disability [<xref ref-type="bibr" rid="B319-ijms-21-03059">319</xref>]. Over 80% of nursing home residents are daily consumers of psychotropic drugs [<xref ref-type="bibr" rid="B320-ijms-21-03059">320</xref>,<xref ref-type="bibr" rid="B321-ijms-21-03059">321</xref>] which are prescribed in excessive doses, for excessive duration, and without adequate monitoring and/or indications for their use [<xref ref-type="bibr" rid="B322-ijms-21-03059">322</xref>]. Prescribing errors (≈50%) are common in patients treated with anti-dementia drugs [<xref ref-type="bibr" rid="B42-ijms-21-03059">42</xref>], and potentially inappropriate prescribing (PIP) occurs in almost 80% of patients with dementia [<xref ref-type="bibr" rid="B323-ijms-21-03059">323</xref>]. </p>
<p>With appropriate PGx intervention, the frequency and intensity of PIP and ADRs may be reduced in approximately 50% of the cases. AD patients show diverse age-related comorbidities which require polypharmacy. The implementation of PGx procedures may help to minimize drug–drug interactions. For instance, <italic>CYP2C19</italic> variants influence the effects of proton-pump inhibitors and the onset of infections [<xref ref-type="bibr" rid="B324-ijms-21-03059">324</xref>]. <italic>ACE</italic> variants affect the pharmacokinetics and pharmacodynamics of ACE inhibitors which may interact with psychotropic drugs, contributing to cerebrovascular dysfunction [<xref ref-type="bibr" rid="B229-ijms-21-03059">229</xref>]. Another important issue is the use of anticoagulants in patients with dementia [<xref ref-type="bibr" rid="B103-ijms-21-03059">103</xref>]. Different antithrombotic drugs (Acenocoumarol, Acetylsalicylic acid, Argatroban, Bivalirudin, Cilostazol, Clopidogrel, Dabigatran, Rivaroxaban, Dipyridamole, Lepirudin, Prasugel, Ticagrelor, Ticlopidine, and Warfarin) can be used in patients with atrial fibrillation, thrombophlebitis, and thromboembolic or ischemic stroke. Warfarin is one of the most common anticoagulants due to its low cost; however, its narrow therapeutic window makes it a candidate to a few ADRs in patients with dementia. Warfarin prolongs prothrombin time (PT) and activated partial thromboplastin time (APTT), and phytonadione (vitamin K1) reverses its anticoagulant effect. Warfarin is a substrate of CALU, CYP1A2, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP3A4/5, CYP4F2, EPHX1, and GGCX; an inhibitor of CYP2C9, CYP2C19, and VKORC1; and an inducer of CYP2C9; and is transported by ABCB1. <italic>CYP2C9</italic> and <italic>VKORC1</italic> variants are determinant in warfarin efficacy and safety [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>]. <italic>VKORC1</italic> variants and <italic>CYP2C9*3</italic> are clearly associated with warfarin maintenance dosages. <italic>CYP2C9</italic> and <italic>VKORC1</italic> genotypes help to identify normal responders (60%), sensitive responders (35%), and highly sensitive responders (3%) to warfarin and characterized patients who can benefit from edoxaban compared with warfarin [<xref ref-type="bibr" rid="B325-ijms-21-03059">325</xref>]. <italic>VKORC1-AG</italic> and <italic>GG</italic> carriers need higher doses than patients with <italic>AA</italic> genotypes, and <italic>CYP2C9*1/*3</italic> carriers need doses lower than patients with the <italic>CYP2C9*1/*1</italic> wild genotype [<xref ref-type="bibr" rid="B326-ijms-21-03059">326</xref>]. In the Chinese region of Xinjiang, patients with atrial fibrillation carrying the <italic>CT</italic> and <italic>TT</italic> genotypes in the <italic>GGCX</italic> gene rs259251 loci need higher warfarin doses than <italic>GGCX-CC</italic> carriers [<xref ref-type="bibr" rid="B327-ijms-21-03059">327</xref>].</p>
<p><italic>ADRB1 Ser49Gly</italic> and <italic>Arg389Gly</italic> variants are associated with cardiovascular and β-blocker response outcomes. In patients with previous history of stroke, the <italic>ADRB1 Gly49</italic> polymorphism is associated with cardiovascular and cerebrovascular ADRs among β-blocker users [<xref ref-type="bibr" rid="B328-ijms-21-03059">328</xref>].</p>
<p>In patients with minor ischemic stroke, platelet receptor gene (<italic>P2Y12</italic> and <italic>P2Y1</italic>) and glycoprotein gene (<italic>GPIIIa</italic>) polymorphisms influence antiplatelet drug responsiveness and clinical outcomes [<xref ref-type="bibr" rid="B329-ijms-21-03059">329</xref>], and there are genetic differences (rs12143842) in the response of stroke patients to antihypertensive drugs (chlorthalidone, amlodipine, or lisinopril), especially regarding <italic>HNRNPA1P4</italic> and <italic>NOS1AP</italic> variants in African Americans and <italic>PRICKLE1</italic> and <italic>NINJ2</italic> variants in non-Hispanic Whites [<xref ref-type="bibr" rid="B330-ijms-21-03059">330</xref>].</p>
<p>Rivaroxaban is currently used in thromboprophylaxis. <italic>ABCB1 rs1045642</italic>, <italic>ABCB1 rs4148738</italic>, <italic>CYP3A4 rs35599367</italic>, and <italic>CYP3A5 rs776746</italic> variants may influence rivaroxaban pharmacokinetics and prothrombin time dynamics [<xref ref-type="bibr" rid="B331-ijms-21-03059">331</xref>].</p>
<p>The platelet-aggregation inhibitor Clopidogrel may also cause frequent complications. This antithrombotic agent is a substrate of CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5; and an inhibitor of CYP2B6, CYP2C9, and CYP2C19; and is transported by ABCB1. <italic>CYP2C19*2 (G681A</italic> and <italic>rs4244285), CYP2C19*3 (G363A</italic> and <italic>rs4986893), CYP2C19*17 (C806T</italic> and <italic>rs12248560)</italic>, and <italic>ABCB1 (C3435T</italic> and <italic>rs1045642</italic>) carriers with ischemic stroke are particularly sensitive to clopidogrel ADRs [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>]. Clopidogrel resistance is frequent in patients with chronic kidney disease. Kidney dysfunction alters the association between <italic>CYP2C19</italic> variants and clopidogrel effects in patients with stroke or transient ischemic attack. Carriers of <italic>CYP2C19</italic> loss-of-function alleles (<italic>CYP2C19*2</italic> and <italic>*3</italic>) have higher odds of new stroke than noncarriers [<xref ref-type="bibr" rid="B332-ijms-21-03059">332</xref>,<xref ref-type="bibr" rid="B333-ijms-21-03059">333</xref>] and increased risk of thromboembolic complications following neurointerventional procedures [<xref ref-type="bibr" rid="B334-ijms-21-03059">334</xref>]. The <italic>AKR1D1*36</italic> (rs1872930) allele is associated with the risk of major adverse cardiovascular and cerebrovascular events in clopidogrel-treated patients [<xref ref-type="bibr" rid="B335-ijms-21-03059">335</xref>]. About 16–50% of patients treated with clopidogrel show platelet reactivity and an increased risk of ischemic events. Some methylated CpG sites have been associated with increased stroke recurrence. Lower cg03548645 (<italic>TRAF3</italic>) DNA methylation correlates with increased platelet aggregation in patients with stroke [<xref ref-type="bibr" rid="B336-ijms-21-03059">336</xref>].</p>
<p>Studies on the PGx of anticoagulants for stroke prevention in patients with atrial fibrillation are not conclusive and deserve further investigation to optimize this currently used pharmacological intervention with still unclear results [<xref ref-type="bibr" rid="B337-ijms-21-03059">337</xref>].</p>
<p>Orthopedic surgery is relatively frequent in patients with NDDs who experience perioperative neurocognitive disorders (delirium and postoperative cognitive dysfunction) which increase mortality [<xref ref-type="bibr" rid="B338-ijms-21-03059">338</xref>]. PGx assessment is highly recommended for selection of appropriate anesthetics and postsurgical treatments in order to reduce postoperatory BDs and accelerated cognitive deterioration [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>]. </p>
<p>Opioid use disorder (OUD) is infrequent in AD; however, in AD cases treated with opioids, it is important to take into account that patients with at least one copy of the <italic>CYP3A4*1B</italic> allele exhibit an accelerated rate of metabolism compared to the wild-type allele <italic>CYP3A4*1</italic> [<xref ref-type="bibr" rid="B339-ijms-21-03059">339</xref>] and that CYP2D6-UMs show a better response to opiates than EMs, IMs, and PMs [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>].</p>
<p>Several essential elements and metals (zinc, aluminum, copper, and cadmium), environmental toxicants, air pollutants (e.g., nanoparticles, particulate matter, ozone, and traffic-related air pollution), inappropriate medications, and drugs of abuse (amphetamines, cannabis, cocaine, and heroin) may contribute to neurotoxicity and may interfere with conventional treatments in dementia. Over 30% of patients with prodromal dementia are current users of anticholinergic drugs [<xref ref-type="bibr" rid="B340-ijms-21-03059">340</xref>]. Chronic exposure to these products alters behavior and deteriorates cognition and psychomotor function in a dose-dependent fashion [<xref ref-type="bibr" rid="B341-ijms-21-03059">341</xref>,<xref ref-type="bibr" rid="B342-ijms-21-03059">342</xref>,<xref ref-type="bibr" rid="B343-ijms-21-03059">343</xref>]. The pharmacogenetic genotyping of detoxification systems may help to predict risks in susceptible subjects [<xref ref-type="bibr" rid="B55-ijms-21-03059">55</xref>].</p>
<p>It is also most important to elucidate the mechanisms underlying the drug-resistance phenomenon, which occurs in over 40% of cases with NPDs and in over 70% of cases with neoplastic processes [<xref ref-type="bibr" rid="B61-ijms-21-03059">61</xref>,<xref ref-type="bibr" rid="B71-ijms-21-03059">71</xref>]. Globally, over 20% of patients are resistant to conventional drugs [<xref ref-type="bibr" rid="B344-ijms-21-03059">344</xref>,<xref ref-type="bibr" rid="B345-ijms-21-03059">345</xref>] and it is estimated that pharmacogenetic and pharmacoepigenetic factors are important contributors to drug resistance [<xref ref-type="bibr" rid="B61-ijms-21-03059">61</xref>,<xref ref-type="bibr" rid="B346-ijms-21-03059">346</xref>,<xref ref-type="bibr" rid="B347-ijms-21-03059">347</xref>,<xref ref-type="bibr" rid="B348-ijms-21-03059">348</xref>].</p>
<p>Important issues to take into account in the coming years for the appropriate management of dementia are the identification of presymptomatic biomarkers and the discovery of effective drugs. Predictive markers associated with pathogenic genes for the presymptomatic diagnosis of dementia should incorporate both genomic and epigenetic signatures. Concerning the development of novel anti-pathogenic drugs, actual facts show that most CNS drugs are repressive rather than neuroprotective based on the regulation of a restrictive number of neurotransmitters; however, brain function depends upon the interplay of thousands of neuronal-glial factors pending full characterization. The discovery of novel anti-pathogenic drugs with neuroprotective properties is urgently needed to efficiently treat the different forms of brain dysfunction in dementia. The development of new drugs and clinically validated methods of identifying patients for a specific treatment should rely on PGx strategies.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>I would like to thank my coworkers at EuroEspes Biomedical Research Center, International Center of Neuroscience and Genomic Medicine, Corunna, for technical support in our studies on pharmacogenomics and epigenetics of dementia.</p>
</ack>
<notes>
<title>Funding</title>
<p>This paper was funded by IABRA (International Agency for Brain Research and Aging), Corunna, Spain.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The author is President of the International Center of Neuroscience and Genomic Medicine, EuroEspes Biotechnology, and IABRA (International Agency for Brain Research and Aging) and is also President of the World Association of Genomic Medicine and Editor-in-Chief of the World Guide for Drug Use and Pharmacogenomics. The author has no other relevant affiliations or financial involvement with any organization or entity with financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijms-21-03059">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fernández-Novoa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Molecular genetics of Alzheimer’s disease and aging</article-title>
<source/>Methods Find. Exp. Clin. Pharmacol.
          <year>2005</year>
<volume>27</volume>
<fpage>1</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="pmid">16470248</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-21-03059">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics in Alzheimer’s disease</article-title>
<source/>Methods Mol. Biol.
          <year>2008</year>
<volume>448</volume>
<fpage>213</fpage>
<lpage>357</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-59745-205-2_10</pub-id>
<pub-id pub-id-type="pmid">18370236</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-21-03059">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tellado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of Alzheimer’s disease: Novel therapeutic strategies for drug development</article-title>
<source/>Methods Mol. Biol.
          <year>2014</year>
<volume>1175</volume>
<fpage>323</fpage>
<lpage>556</lpage>
<pub-id pub-id-type="doi">10.1007/978-1-4939-0956-8_13</pub-id>
<pub-id pub-id-type="pmid">25150875</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-21-03059">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Teijido</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Goldgaber</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of Alzheimer’s Disease: Genetic determinants of phenotypic variation and therapeutic outcome</article-title>
<source/>J. Genom. Med. Pharmacogenom.
          <year>2016</year>
<volume>1</volume>
<fpage>151</fpage>
<lpage>209</lpage>
</element-citation>
</ref>
<ref id="B5-ijms-21-03059">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kazantsev</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Vostrov</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Corzo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Goldgaber</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>1249</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20051249</pub-id>
<pub-id pub-id-type="pmid">30871086</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-21-03059">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arvanitakis</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>D.A.</given-names>
</name>
</person-group>
<article-title>Diagnosis and Management of Dementia: Review</article-title>
<source/>JAMA
          <year>2019</year>
<volume>322</volume>
<fpage>1589</fpage>
<lpage>1599</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2019.4782</pub-id>
<pub-id pub-id-type="pmid">31638686</pub-id>
</element-citation>
</ref>
<ref id="B7-ijms-21-03059">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Have there been improvement in Alzheimer’s disease drug discovery over the past 5 years?</article-title>
<source/>Expert Opin. Drug Discov.
          <year>2018</year>
<volume>13</volume>
<fpage>523</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1080/17460441.2018.1457645</pub-id>
<pub-id pub-id-type="pmid">29607687</pub-id>
</element-citation>
</ref>
<ref id="B8-ijms-21-03059">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volicer</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Behavioral Problems and Dementia</article-title>
<source/>Clin. Geriatr. Med.
          <year>2018</year>
<volume>34</volume>
<fpage>637</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1016/j.cger.2018.06.009</pub-id>
<pub-id pub-id-type="pmid">30336992</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-21-03059">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Defrancesco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marksteiner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kemmler</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dal-Bianco</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ransmayr</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Benke</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mosbacher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Holler</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Specific Neuropsychiatric Symptoms Are Associated with Faster Progression in Alzheimer’s Disease: Results of the Prospective Dementia Registry (PRODEM-Austria)</article-title>
<source/>J. Alzheimers Dis.
          <year>2020</year>
<volume>73</volume>
<fpage>125</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-190662</pub-id>
<pub-id pub-id-type="pmid">31744004</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-21-03059">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sr</surname>
<given-names>P.A.A.</given-names>
</name>
<name>
<surname>DeFeis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>De Wit</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>O’Shea</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mejia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chandler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Locke</surname>
<given-names>D.E.C.</given-names>
</name>
<name>
<surname>Fields</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Phatak</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>P.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Functional ability is associated with higher adherence to behavioral interventions in mild cognitive impairment</article-title>
<source/>Clin. Neuropsychol.
          <year>2019</year>
<fpage>1</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1080/13854046.2019.1672792</pub-id>
<pub-id pub-id-type="pmid">31608773</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-21-03059">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ilik</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Büyükgöl</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kayhan</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ertem</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Ekiz</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Effects of Inappropriate Sexual Behaviors and Neuropsychiatric Symptoms of Patients with Alzheimer Disease and Caregivers’ Depression on Caregiver Burden</article-title>
<source/>J. Geriatr. Psychiatry Neurol.
          <year>2019</year>
<comment>891988719874123</comment>
<pub-id pub-id-type="doi">10.1177/0891988719874123</pub-id>
<pub-id pub-id-type="pmid">31526077</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-21-03059">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burhanullah</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Tschanz</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Leoutsakos</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Matyi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lyketsos</surname>
<given-names>C.G.</given-names>
</name>
<name>
<surname>Nowrangi</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Rosenberg</surname>
<given-names>P.B.</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric Symptoms as Risk Factors for Cognitive Decline in Clinically Normal Older Adults: The Cache County Study</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2020</year>
<volume>28</volume>
<fpage>64</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1016/j.jagp.2019.03.023</pub-id>
<pub-id pub-id-type="pmid">31186157</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-21-03059">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>A.X.</given-names>
</name>
<name>
<surname>Kaup</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Yaffe</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Byers</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>High Occurrence of Psychiatric Disorders and Suicidal Behavior Across Dementia Subtypes</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2018</year>
<volume>26</volume>
<fpage>1191</fpage>
<lpage>1201</lpage>
<pub-id pub-id-type="doi">10.1016/j.jagp.2018.08.012</pub-id>
<pub-id pub-id-type="pmid">30392777</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-21-03059">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cummings</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Hemrungrojn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mohandas</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yun Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dash</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer’s Disease and Dementia with Lewy Bodies</article-title>
<source/>CNS Neurosci. Ther.
          <year>2016</year>
<volume>22</volume>
<fpage>159</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="doi">10.1111/cns.12484</pub-id>
<pub-id pub-id-type="pmid">26778658</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-21-03059">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deardorff</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Grossberg</surname>
<given-names>G.T.</given-names>
</name>
</person-group>
<article-title>Behavioral and psychological symptoms in Alzheimer’s dementia and vascular dementia</article-title>
<source/>Handb. Clin. Neurol.
          <year>2019</year>
<volume>165</volume>
<fpage>5</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-444-64012-3.00002-2</pub-id>
<pub-id pub-id-type="pmid">31727229</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-21-03059">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van de Beek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>van Steenoven</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ramakers</surname>
<given-names>I.H.G.B.</given-names>
</name>
<name>
<surname>Aalten</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Koek</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Olde Rikkert</surname>
<given-names>M.G.M.</given-names>
</name>
<name>
<surname>Mannien</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>de Jong</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Lemstra</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>van der Flier</surname>
<given-names>W.M.</given-names>
</name>
</person-group>
<article-title>Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>70</volume>
<fpage>389</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-190041</pub-id>
<pub-id pub-id-type="pmid">31177218</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-21-03059">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kornak</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dudley</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Merrilees</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bonasera</surname>
<given-names>S.J.</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chiong</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>B.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The costs of dementia subtypes to California Medicare fee-for-service</article-title>
<source/>Alzheimers Dement
          <year>2019</year>
<volume>15</volume>
<fpage>899</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="doi">10.1016/j.jalz.2019.03.015</pub-id>
<pub-id pub-id-type="pmid">31175026</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-21-03059">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Llibre Guerra</surname>
<given-names>J.J.</given-names>
</name>
</person-group>
<article-title>Frontotemporal dementia</article-title>
<source/>Handb. Clin. Neurol.
          <year>2019</year>
<volume>165</volume>
<fpage>33</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-444-64012-3.00003-4</pub-id>
<pub-id pub-id-type="pmid">31727221</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-21-03059">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bussè</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pettenuzzo</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pompanin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Roiter</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>di Bernardo</surname>
<given-names>G.A.</given-names>
</name>
<name>
<surname>Zorzi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fragiacomo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gazzola</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cecchin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pigato</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric Phenocopy Syndrome of Behavioral Frontotemporal Dementia: Behavioral and Cognitive Fingerprint</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>72</volume>
<fpage>1159</fpage>
<lpage>1164</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-190332</pub-id>
<pub-id pub-id-type="pmid">31683475</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-21-03059">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Chiong</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Neurodegenerative disorders of the human frontal lobes</article-title>
<source/>Handb. Clin. Neurol.
          <year>2019</year>
<volume>163</volume>
<fpage>391</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-804281-6.00021-5</pub-id>
<pub-id pub-id-type="pmid">31590743</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-21-03059">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bailey</surname>
<given-names>K.C.</given-names>
</name>
<name>
<surname>Burmaster</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Schaffert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>LoBue</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vela</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rossetti</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cullum</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>Associations of Race-Ethnicity and History of Traumatic Brain Injury with Age at Onset of Alzheimer’s Disease</article-title>
<source/>J. Neuropsychiatry Clin. Neurosci
          <year>2019</year>
<comment>appineuropsych19010002</comment>
<pub-id pub-id-type="doi">10.1176/appi.neuropsych.19010002</pub-id>
<pub-id pub-id-type="pmid">31619118</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-21-03059">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwab</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Grenier</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hazrati</surname>
<given-names>L.N.</given-names>
</name>
</person-group>
<article-title>DNA repair deficiency and senescence in concussed professional athletes involved in contact sports</article-title>
<source/>Acta Neuropathol. Commun.
          <year>2019</year>
<volume>7</volume>
<fpage>182</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-019-0822-3</pub-id>
<pub-id pub-id-type="pmid">31727161</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-21-03059">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keszycki</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer’s Disease: Current Management and Future Directions</article-title>
<source/>Front. Pharmacol.
          <year>2019</year>
<volume>10</volume>
<fpage>1109</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2019.01109</pub-id>
<pub-id pub-id-type="pmid">31611794</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-21-03059">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desmarais</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Weidman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wassef</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bruneau</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Friedland</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bajsarowicz</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thibodeau</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Herrmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>Q.D.</given-names>
</name>
</person-group>
<article-title>The Interplay between Post-traumatic Stress Disorder and Dementia: A Systematic Review</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2020</year>
<volume>28</volume>
<fpage>46</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.1016/j.jagp.2019.08.006</pub-id>
<pub-id pub-id-type="pmid">31488352</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-21-03059">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martínez-Bouza</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Genomics and pharmacogenomics of schizophrenia</article-title>
<source/>CNS Neurosci. Ther.
          <year>2011</year>
<volume>17</volume>
<fpage>541</fpage>
<lpage>565</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00187.x</pub-id>
<pub-id pub-id-type="pmid">20718829</pub-id>
</element-citation>
</ref>
<ref id="B26-ijms-21-03059">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response</article-title>
<source/>Int. J. Mol. Sci.
          <year>2015</year>
<volume>16</volume>
<fpage>30483</fpage>
<lpage>30543</lpage>
<pub-id pub-id-type="doi">10.3390/ijms161226236</pub-id>
<pub-id pub-id-type="pmid">26703582</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-21-03059">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Aliev</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Genomics and pharmacogenomics of antipsychotic drugs</article-title>
<source/>Open J. Psychiatry
          <year>2013</year>
<volume>3</volume>
<fpage>46</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.4236/ojpsych.2013.31008</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-21-03059">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Monteze</surname>
<given-names>N.M.</given-names>
</name>
<name>
<surname>Calarge</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>A.V.M.</given-names>
</name>
<name>
<surname>Teixeira</surname>
<given-names>A.L.</given-names>
</name>
</person-group>
<article-title>Pathways linking obesity to neuropsychiatric disorders</article-title>
<source/>Nutrition
          <year>2019</year>
<volume>66</volume>
<fpage>16</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.nut.2019.03.017</pub-id>
<pub-id pub-id-type="pmid">31200298</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-21-03059">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morton</surname>
<given-names>R.E.</given-names>
</name>
<name>
<surname>St John</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Tyas</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>Migraine and the risk of all-cause dementia, Alzheimer’s disease, and vascular dementia: A prospective cohort study in community-dwelling older adults</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2019</year>
<volume>34</volume>
<fpage>1667</fpage>
<lpage>1676</lpage>
<pub-id pub-id-type="doi">10.1002/gps.5180</pub-id>
<pub-id pub-id-type="pmid">31486140</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-21-03059">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blom</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Koek</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Zwartbol</surname>
<given-names>M.H.T.</given-names>
</name>
<name>
<surname>van der Graaf</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kesseler</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Biessels</surname>
<given-names>G.J.</given-names>
</name>
<name>
<surname>Geerlings</surname>
<given-names>M.I.</given-names>
</name>
<collab>SMART Study Group</collab>
</person-group>
<article-title>Subjective cognitive decline, brain imaging biomarkers, and cognitive functioning in patients with a history of vascular disease: The SMART-Medea study</article-title>
<source/>Neurobiol. Aging
          <year>2019</year>
<volume>84</volume>
<fpage>33</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.07.011</pub-id>
<pub-id pub-id-type="pmid">31479862</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-21-03059">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Puzo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Labriola</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sugarman</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Tripodis</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Palmisano</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Steinber</surname>
<given-names>E.G.</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Kowall</surname>
<given-names>N.W.</given-names>
</name>
</person-group>
<article-title>Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: A longitudinal investigation using the National Alzheimer’s Coordinating Center Uniform Data Set</article-title>
<source/>Alzheimers Res. Ther.
          <year>2019</year>
<volume>11</volume>
<fpage>64</fpage>
<pub-id pub-id-type="doi">10.1186/s13195-019-0521-0</pub-id>
<pub-id pub-id-type="pmid">31351489</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-21-03059">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rouch</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dorey</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Padovan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Trombert-Paviot</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Benoit</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>B.</given-names>
</name>
<collab>PACO group</collab>
<name>
<surname>Boublay</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Krolak-Salmon</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Does Personality Predict Behavioral and Psychological Symptoms of Dementia? Results from PACO Prospective Study</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>69</volume>
<fpage>1099</fpage>
<lpage>1108</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-190183</pub-id>
<pub-id pub-id-type="pmid">31156171</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-21-03059">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banning</surname>
<given-names>L.C.P.</given-names>
</name>
<name>
<surname>Ramakers</surname>
<given-names>I.H.G.B.</given-names>
</name>
<name>
<surname>Deckers</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Verhey</surname>
<given-names>F.R.J.</given-names>
</name>
<name>
<surname>Aalten</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Affective symptoms and AT(N) biomarkers in mild cognitive impairment and Alzheimer’s disease: A systematic literature review</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2019</year>
<volume>107</volume>
<fpage>346</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2019.09.014</pub-id>
<pub-id pub-id-type="pmid">31525387</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-21-03059">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scaricamazza</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Colonna</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sancesario</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Assogna</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Orfei</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Franchini</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sancesario</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mercuri</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Liguori</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer’s disease patients: A retrospective observational study</article-title>
<source/>Neurol. Sci.
          <year>2019</year>
<volume>40</volume>
<fpage>1377</fpage>
<lpage>1382</lpage>
<pub-id pub-id-type="doi">10.1007/s10072-019-03840-4</pub-id>
<pub-id pub-id-type="pmid">30903419</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-21-03059">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Showraki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Murari</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ismail</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Barfett</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Fornazzari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease/Mild Cognitive Impairment: A Systematic Review</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>71</volume>
<fpage>477</fpage>
<lpage>501</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-190365</pub-id>
<pub-id pub-id-type="pmid">31424398</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-21-03059">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramusino</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Garibotto</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bacchin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Altomare</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dodich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Assal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tinazzi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morbelli</surname>
<given-names>S.D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease</article-title>
<source/>Eur. J. Nucl. Med. Mol. Imaging
          <year>2020</year>
<volume>47</volume>
<fpage>270</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="doi">10.1007/s00259-019-04466-6</pub-id>
<pub-id pub-id-type="pmid">31388720</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-21-03059">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bayram</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cummings</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>69</volume>
<fpage>953</fpage>
<lpage>961</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-181285</pub-id>
<pub-id pub-id-type="pmid">31127776</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-21-03059">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sellami</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>St-Onge</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Poulin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Laforce</surname>
<given-names>R.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Schizophrenia Phenotype Preceding Behavioral Variant Frontotemporal Dementia Related to C9orf72 Repeat Expansion</article-title>
<source/>Cogn. Behav. Neurol.
          <year>2019</year>
<volume>32</volume>
<fpage>120</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1097/WNN.0000000000000189</pub-id>
<pub-id pub-id-type="pmid">31205123</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-21-03059">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Latimer</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Liachko</surname>
<given-names>N.F.</given-names>
</name>
<name>
<surname>Currey</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Kilgore</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Gibbons</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Henriksen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Darvas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Domoto-Reilly</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Jayadev</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort</article-title>
<source/>Acta Neuropathol. Commun.
          <year>2019</year>
<volume>7</volume>
<fpage>9</fpage>
<pub-id pub-id-type="doi">10.1186/s40478-019-0743-1</pub-id>
<pub-id pub-id-type="pmid">30657060</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-21-03059">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pirker-Kees</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dal-Bianco</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer’s Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM)</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>71</volume>
<fpage>623</fpage>
<lpage>630</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-181102</pub-id>
<pub-id pub-id-type="pmid">31424389</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-21-03059">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bravo-José</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sáez-Lleó</surname>
<given-names>C.I.</given-names>
</name>
<name>
<surname>Peris-Martí</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Deprescribing antipsychotics in long term care patients with dementia</article-title>
<source/>Farm. Hosp.
          <year>2019</year>
<volume>43</volume>
<fpage>140</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.7399/fh.11217</pub-id>
<pub-id pub-id-type="pmid">31276444</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-21-03059">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fullard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Weintraub</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hubbard</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Hennessy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Willis</surname>
<given-names>A.W.</given-names>
</name>
</person-group>
<article-title>Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease</article-title>
<source/>JAMA Neurol.
          <year>2019</year>
<volume>76</volume>
<fpage>41</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2018.2820</pub-id>
<pub-id pub-id-type="pmid">30285047</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-21-03059">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>The role of pharmacogenomics in adverse drug reactions</article-title>
<source/>Expert Rev. Clin. Pharmacol.
          <year>2019</year>
<volume>12</volume>
<fpage>407</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1080/17512433.2019.1597706</pub-id>
<pub-id pub-id-type="pmid">30916581</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-21-03059">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>W.Y.</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>R.O.</given-names>
</name>
<name>
<surname>Westbrook</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Baysari</surname>
<given-names>M.T.</given-names>
</name>
</person-group>
<article-title>Drug-drug interactions and their harmful effects in hospitalised patients: A systematic review and meta-analysis</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2018</year>
<volume>74</volume>
<fpage>15</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-017-2357-5</pub-id>
<pub-id pub-id-type="pmid">29058038</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-21-03059">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patel</surname>
<given-names>R.I.</given-names>
</name>
<name>
<surname>Beckett</surname>
<given-names>R.D.</given-names>
</name>
</person-group>
<article-title>Evaluation of resources for analyzing drug interactions</article-title>
<source/>J. Med. Libr. Assoc.
          <year>2016</year>
<volume>104</volume>
<fpage>290</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.3163/1536-5050.104.4.007</pub-id>
<pub-id pub-id-type="pmid">27822150</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-21-03059">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoshi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Shoshi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ogultarhan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hofestadt</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>KALIS—An eHealth System for Biomedical Risk Analysis of Drugs</article-title>
<source/>Stud. Health Technol. Inform.
          <year>2017</year>
<volume>236</volume>
<fpage>128</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="pmid">28508788</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-21-03059">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoshi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hoppe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kormeier</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ogultarhan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hofestadt</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>GraphSAW: A web-based system for graphical analysis of drug interactions and side effects using pharmaceutical and molecular data</article-title>
<source/>BMC Med. Inform. Decis. Mak.
          <year>2015</year>
<volume>15</volume>
<elocation-id>15</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12911-015-0139-5</pub-id>
<pub-id pub-id-type="pmid">25881043</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-21-03059">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, in healthy subjects and patients</article-title>
<source/>Curr. Clin. Pharmacol.
          <year>2010</year>
<volume>5</volume>
<fpage>115</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.2174/157488410791110805</pub-id>
<pub-id pub-id-type="pmid">20156150</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-21-03059">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samwald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miñarro Giménez</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Boyce</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Frimuth</surname>
<given-names>R.R.</given-names>
</name>
<name>
<surname>Adlassnig</surname>
<given-names>K.P.</given-names>
</name>
<name>
<surname>Dumontier</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies</article-title>
<source/>BMC Med. Inform. Decis. Mak.
          <year>2015</year>
<volume>15</volume>
<elocation-id>12</elocation-id>
<pub-id pub-id-type="doi">10.1186/s12911-015-0130-1</pub-id>
<pub-id pub-id-type="pmid">25880555</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-21-03059">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Web resources for pharmacogenomics</article-title>
<source/>Genom. Proteom. Bioinform.
          <year>2015</year>
<volume>13</volume>
<fpage>51</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.gpb.2015.01.002</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-21-03059">
<label>51.</label>
<element-citation publication-type="web">
<article-title>PharmGKB</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org">https://www.pharmgkb.org</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2020-01-05">(accessed on 5 January 2020)</date-in-citation>
</element-citation>
</ref>
<ref id="B52-ijms-21-03059">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weinshilboum</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics: Precision Medicine and Drug Response</article-title>
<source/>Mayo Clin. Proc.
          <year>2017</year>
<volume>92</volume>
<fpage>1711</fpage>
<lpage>1722</lpage>
<pub-id pub-id-type="doi">10.1016/j.mayocp.2017.09.001</pub-id>
<pub-id pub-id-type="pmid">29101939</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-21-03059">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kozyra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ingelman-Sundberg</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lauschke</surname>
<given-names>V.M.</given-names>
</name>
</person-group>
<article-title>Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response</article-title>
<source/>Genet. Med.
          <year>2017</year>
<volume>19</volume>
<fpage>20</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2016.33</pub-id>
<pub-id pub-id-type="pmid">27101133</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-21-03059">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Z.W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.W.</given-names>
</name>
<name>
<surname>Sneed</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Z.X.</given-names>
</name>
<name>
<surname>Chow</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.F.</given-names>
</name>
</person-group>
<article-title>Clinical association between pharmacogenomics and adverse drug reactions</article-title>
<source/>Drugs
          <year>2015</year>
<volume>75</volume>
<fpage>589</fpage>
<lpage>631</lpage>
<pub-id pub-id-type="doi">10.1007/s40265-015-0375-0</pub-id>
<pub-id pub-id-type="pmid">25895462</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-21-03059">
<label>55.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<source/>World Guide for Drug Use and Pharmacogenomics
          <publisher-name>EuroEspes Publishing</publisher-name>
<publisher-loc>Corunna, Spain</publisher-loc>
<year>2012</year>
</element-citation>
</ref>
<ref id="B56-ijms-21-03059">
<label>56.</label>
<element-citation publication-type="web">
<article-title>EuroPharmaGenics (EPG)</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://europharmagenics.com/">http://europharmagenics.com/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2019-11-02">(accessed on 2 November 2019)</date-in-citation>
</element-citation>
</ref>
<ref id="B57-ijms-21-03059">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Population-level pharmacogenomics for precision drug development in dementia</article-title>
<source/>Expert Rev. Precis. Med. Drug Dev.
          <year>2018</year>
<volume>3</volume>
<fpage>163</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1080/23808993.2018.1468218</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-21-03059">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Epigenomic networking in drug development: From pathogenic mechanisms to pharmacogenomics</article-title>
<source/>Drug Dev. Res.
          <year>2014</year>
<volume>75</volume>
<fpage>348</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="doi">10.1002/ddr.21219</pub-id>
<pub-id pub-id-type="pmid">25195579</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-21-03059">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcath</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Pasternak</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Hertz</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications</article-title>
<source/>Pharmacogenom. J.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1038/s41397-019-0105-1</pub-id>
<pub-id pub-id-type="pmid">31616046</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-21-03059">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lesche</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mostafa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Everall</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pantelis</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bousman</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity</article-title>
<source/>Pharmacogenom. J.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1038/s41397-019-0108-y</pub-id>
<pub-id pub-id-type="pmid">31616047</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-21-03059">
<label>61.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tellado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>The epigenetic machinery in the life cycle and pharmacoepigenetics</article-title>
<source/>Pharmacoepigenetics
          <person-group person-group-type="editor">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<publisher-name>Academic Press/Elsevier</publisher-name>
<publisher-loc>Oxford, UK</publisher-loc>
<year>2019</year>
<fpage>1</fpage>
<lpage>100</lpage>
</element-citation>
</ref>
<ref id="B62-ijms-21-03059">
<label>62.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Sanmartín</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Pharmacoepigenetic processors: Epigenetic drugs, Drug resistance, Toxicoepigenetics, and Nutriepigenetics</article-title>
<source/>Pharmacoepigenetics
          <person-group person-group-type="editor">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<publisher-name>Academic Press/Elsevier</publisher-name>
<publisher-loc>Oxford, UK</publisher-loc>
<year>2019</year>
<fpage>191</fpage>
<lpage>424</lpage>
</element-citation>
</ref>
<ref id="B63-ijms-21-03059">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apostolova</surname>
<given-names>L.G.</given-names>
</name>
<name>
<surname>Risacher</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Duran</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stage</surname>
<given-names>E.C.</given-names>
</name>
<name>
<surname>Goukasian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>West</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Grotts</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wilhalme</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nho</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alzheimer’s Disease Neuroimaging Initiative. Associations of the Top 20 Alzheimer Disease Risk Variants with Brain Amyloidosis</article-title>
<source/>JAMA Neurol.
          <year>2018</year>
<volume>75</volume>
<fpage>328</fpage>
<lpage>341</lpage>
<pub-id pub-id-type="doi">10.1001/jamaneurol.2017.4198</pub-id>
<pub-id pub-id-type="pmid">29340569</pub-id>
</element-citation>
</ref>
<ref id="B64-ijms-21-03059">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Meyyazhagan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Teijido</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease</article-title>
<source/>J. Personalized Med.
          <year>2018</year>
<volume>8</volume>
<elocation-id>3</elocation-id>
<pub-id pub-id-type="doi">10.3390/jpm8010003</pub-id>
</element-citation>
</ref>
<ref id="B65-ijms-21-03059">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer’s disease and related risk factors</article-title>
<source/>Future Neurol.
          <year>2018</year>
<pub-id pub-id-type="doi">10.2217/fnl-2017-0038</pub-id>
</element-citation>
</ref>
<ref id="B66-ijms-21-03059">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Epigenetic drug discovery for Alzheimer’s disease</article-title>
<source/>Expert Opin. Drug Discov.
          <year>2014</year>
<volume>9</volume>
<fpage>1059</fpage>
<lpage>1086</lpage>
<pub-id pub-id-type="doi">10.1517/17460441.2014.930124</pub-id>
<pub-id pub-id-type="pmid">24989365</pub-id>
</element-citation>
</ref>
<ref id="B67-ijms-21-03059">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of antidepressants</article-title>
<source/>HSOA J. Psychiatry Depress. Anxiety
          <year>2015</year>
<volume>1</volume>
<fpage>001</fpage>
<pub-id pub-id-type="doi">10.24966/PDA-0150/100001</pub-id>
</element-citation>
</ref>
<ref id="B68-ijms-21-03059">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Foraker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Millard</surname>
<given-names>S.P.</given-names>
</name>
<name>
<surname>Leong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Thomson</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Keene</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Bekris</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.E.</given-names>
</name>
</person-group>
<article-title>The APOE Gene is Differentially Methylated in Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2015</year>
<volume>48</volume>
<fpage>745</fpage>
<lpage>755</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-143060</pub-id>
<pub-id pub-id-type="pmid">26402071</pub-id>
</element-citation>
</ref>
<ref id="B69-ijms-21-03059">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogelgesang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cascorbi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schroeder</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pahnke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kroemer</surname>
<given-names>H.K.</given-names>
</name>
<name>
<surname>Siegmund</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kunert-Keil</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>L.C.</given-names>
</name>
<name>
<surname>Warzok</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans</article-title>
<source/>Pharmacogenetics
          <year>2002</year>
<volume>12</volume>
<fpage>535</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1097/00008571-200210000-00005</pub-id>
<pub-id pub-id-type="pmid">12360104</pub-id>
</element-citation>
</ref>
<ref id="B70-ijms-21-03059">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szablewski</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Glucose Transporters in Brain: In Health and in Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>55</volume>
<fpage>1307</fpage>
<lpage>1320</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-160841</pub-id>
<pub-id pub-id-type="pmid">27858715</pub-id>
</element-citation>
</ref>
<ref id="B71-ijms-21-03059">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>López-Muñoz</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>The ABCB1 transporter in Alzheimer’s disease</article-title>
<source/>Clin. Exp. Pharmacol.
          <year>2014</year>
<volume>4</volume>
<fpage>e128</fpage>
<pub-id pub-id-type="doi">10.4172/2161-1459.1000e128</pub-id>
</element-citation>
</ref>
<ref id="B72-ijms-21-03059">
<label>72.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Epigenetics and pharmacoepigenetics of age-related neurodegenerative disorders</article-title>
<source/>Pharmacoepigenetics
          <person-group person-group-type="editor">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<publisher-name>Academic Press/Elsevier</publisher-name>
<publisher-loc>Oxford, UK</publisher-loc>
<year>2019</year>
<fpage>903</fpage>
<lpage>950</lpage>
</element-citation>
</ref>
<ref id="B73-ijms-21-03059">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>C.N.</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gluck</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>The Effects of APOE and ABCA7 on Cognitive Function and Alzheimer’s Disease Risk in African Americans: A Focused Mini Review</article-title>
<source/>Front. Hum. Neurosci.
          <year>2019</year>
<volume>13</volume>
<fpage>387</fpage>
<pub-id pub-id-type="doi">10.3389/fnhum.2019.00387</pub-id>
<pub-id pub-id-type="pmid">31749691</pub-id>
</element-citation>
</ref>
<ref id="B74-ijms-21-03059">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wiltfang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>da Cruz E Silva</surname>
<given-names>O.A.B.</given-names>
</name>
<name>
<surname>Rebelo</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>ABC Transporters Are Key Players in Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2018</year>
<volume>61</volume>
<fpage>463</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-170639</pub-id>
<pub-id pub-id-type="pmid">29171999</pub-id>
</element-citation>
</ref>
<ref id="B75-ijms-21-03059">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marquez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Van Bambeke</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>ABC multidrug transporters: Target for modulation of drug pharmacokinetics and drug-drug interactions</article-title>
<source/>Curr. Drug Targets
          <year>2011</year>
<volume>12</volume>
<fpage>600</fpage>
<lpage>620</lpage>
<pub-id pub-id-type="doi">10.2174/138945011795378504</pub-id>
<pub-id pub-id-type="pmid">21039335</pub-id>
</element-citation>
</ref>
<ref id="B76-ijms-21-03059">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haufroid</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition</article-title>
<source/>Curr. Drug Targets
          <year>2011</year>
<volume>12</volume>
<fpage>631</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.2174/138945011795378487</pub-id>
<pub-id pub-id-type="pmid">21039333</pub-id>
</element-citation>
</ref>
<ref id="B77-ijms-21-03059">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Assema</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Lubberink</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rizzu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>van Swieten</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Schuit</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Eriksson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scheltens</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Koepp</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lammertsma</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>van Berckel</surname>
<given-names>B.N.</given-names>
</name>
</person-group>
<article-title>Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer’s disease patients: Effect of polymorphisms in the ABCB1 gene</article-title>
<source/>EJNMMI Res.
          <year>2012</year>
<volume>2</volume>
<fpage>57</fpage>
<pub-id pub-id-type="doi">10.1186/2191-219X-2-57</pub-id>
<pub-id pub-id-type="pmid">23067778</pub-id>
</element-citation>
</ref>
<ref id="B78-ijms-21-03059">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>P.T.</given-names>
</name>
<name>
<surname>Ping</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P.N.</given-names>
</name>
</person-group>
<article-title>Gene expression profiling of peripheral blood leukocytes identifies and validates ABCB1 as a novel biomarker for Alzheimer’s disease</article-title>
<source/>Neurobiol. Dis.
          <year>2011</year>
<volume>43</volume>
<fpage>698</fpage>
<lpage>705</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbd.2011.05.023</pub-id>
<pub-id pub-id-type="pmid">21669286</pub-id>
</element-citation>
</ref>
<ref id="B79-ijms-21-03059">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elali</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rivest</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer’s disease</article-title>
<source/>Front. Physiol.
          <year>2013</year>
<volume>4</volume>
<fpage>45</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2013.00045</pub-id>
<pub-id pub-id-type="pmid">23494712</pub-id>
</element-citation>
</ref>
<ref id="B80-ijms-21-03059">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cascorbi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Flüh</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Remmler</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Haenisch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grumbt</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brenn</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thal</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Warzok</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Vogelgesang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Association of ATP-binding cassette transporter variants with the risk of Alzheimer’s disease</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<fpage>485</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.13.18</pub-id>
<pub-id pub-id-type="pmid">23556446</pub-id>
</element-citation>
</ref>
<ref id="B81-ijms-21-03059">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reitz</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jun</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Naj</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rajbhandary</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vardarajan</surname>
<given-names>B.N.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Valladares</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Graff-Radford</surname>
<given-names>N.R.</given-names>
</name>
</person-group>
<article-title>Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4, and the risk of late-onset Alzheimer disease in African Americans</article-title>
<source/>JAMA
          <year>2013</year>
<volume>309</volume>
<fpage>1483</fpage>
<lpage>1492</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2013.2973</pub-id>
<pub-id pub-id-type="pmid">23571587</pub-id>
</element-citation>
</ref>
<ref id="B82-ijms-21-03059">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasquez</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Harpole</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Estus</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s Disease Genetics and ABCA7 Splicing</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>59</volume>
<fpage>633</fpage>
<lpage>641</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-170872</pub-id>
<pub-id pub-id-type="pmid">28655137</pub-id>
</element-citation>
</ref>
<ref id="B83-ijms-21-03059">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamazaki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yoshino</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ochi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iga</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>S.I.</given-names>
</name>
</person-group>
<article-title>Gene Expression and Methylation Analysis of ABCA7 in Patients with Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>57</volume>
<fpage>171</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-161195</pub-id>
<pub-id pub-id-type="pmid">28222527</pub-id>
</element-citation>
</ref>
<ref id="B84-ijms-21-03059">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stepler</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>R.A.S.</given-names>
</name>
</person-group>
<article-title>The Potential of ‘Omics to Link Lipid Metabolism and Genetic and Comorbidity Risk Factors of Alzheimer’s Disease in African Americans</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>2019</year>
<volume>1118</volume>
<fpage>1</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-030-05542-4_1</pub-id>
<pub-id pub-id-type="pmid">30747415</pub-id>
</element-citation>
</ref>
<ref id="B85-ijms-21-03059">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>F.C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.F.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.T.</given-names>
</name>
</person-group>
<article-title>Meta-Analysis of the Association between Variants in ABCA7 and Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2018</year>
<volume>63</volume>
<fpage>1261</fpage>
<lpage>1267</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-180107</pub-id>
<pub-id pub-id-type="pmid">29782324</pub-id>
</element-citation>
</ref>
<ref id="B86-ijms-21-03059">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>ATP binding cassette subfamily A member 7 rs3764650 polymorphism and the risk of Alzheimer’s disease</article-title>
<source/>Pharmazie
          <year>2017</year>
<volume>72</volume>
<fpage>425</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1691/ph.2017.6862</pub-id>
<pub-id pub-id-type="pmid">29441941</pub-id>
</element-citation>
</ref>
<ref id="B87-ijms-21-03059">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Roeck</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Duchateau</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Van Dongen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cacace</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bjerke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van den Bossche</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cras</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vandernberghe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Engelborghs</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer’s disease</article-title>
<source/>Acta Neuropathol.
          <year>2018</year>
<volume>135</volume>
<fpage>827</fpage>
<lpage>837</lpage>
<pub-id pub-id-type="doi">10.1007/s00401-018-1841-z</pub-id>
<pub-id pub-id-type="pmid">29589097</pub-id>
</element-citation>
</ref>
<ref id="B88-ijms-21-03059">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamartinière</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Boucau</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Dehouck</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Krohn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pahnke</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Candela</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gosselet</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Fenart</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>ABCA7 Downregulation Modifies Cellular Cholesterol Homeostasis and Decreases Amyloid-β Peptide Efflux in an in vitro Model of the Blood-Brain Barrier</article-title>
<source/>J. Alzheimers Dis.
          <year>2018</year>
<volume>64</volume>
<fpage>1195</fpage>
<lpage>1211</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-170883</pub-id>
<pub-id pub-id-type="pmid">30010117</pub-id>
</element-citation>
</ref>
<ref id="B89-ijms-21-03059">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guven</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vurgun</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bilgic</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Hanagasi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gurvit</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ozer</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Lohnmann</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Erginel-Unaltuna</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Association between selected cholesterol-related gene polymorphisms and Alzheimer’s disease in a Turkish cohort</article-title>
<source/>Mol. Biol. Rep.
          <year>2019</year>
<volume>46</volume>
<fpage>1701</fpage>
<lpage>1707</lpage>
<pub-id pub-id-type="doi">10.1007/s11033-019-04619-8</pub-id>
<pub-id pub-id-type="pmid">30684189</pub-id>
</element-citation>
</ref>
<ref id="B90-ijms-21-03059">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The Level of Plasma Amyloid-β40 Is Correlated with Peripheral Transport Proteins in Cognitively Normal Adults: A Population-Based Cross-Sectional Study</article-title>
<source/>J. Alzheimers Dis.
          <year>2018</year>
<volume>65</volume>
<fpage>951</fpage>
<lpage>961</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-180399</pub-id>
<pub-id pub-id-type="pmid">30103331</pub-id>
</element-citation>
</ref>
<ref id="B91-ijms-21-03059">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Tew</surname>
<given-names>K.D.</given-names>
</name>
</person-group>
<article-title>ATP-binding cassette transporter-2 (ABCA2) as a therapeutic target</article-title>
<source/>Biochem. Pharmacol.
          <year>2018</year>
<volume>151</volume>
<fpage>188</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2017.11.018</pub-id>
<pub-id pub-id-type="pmid">29223352</pub-id>
</element-citation>
</ref>
<ref id="B92-ijms-21-03059">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Meta-analyses of 8 polymorphisms associated with the risk of the Alzheimer’s disease</article-title>
<source/>PLoS ONE
          <year>2013</year>
<volume>8</volume>
<elocation-id>e73129</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0073129</pub-id>
<pub-id pub-id-type="pmid">24039871</pub-id>
</element-citation>
</ref>
<ref id="B93-ijms-21-03059">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehér</surname>
<given-names>Á.</given-names>
</name>
<name>
<surname>Giricz</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Juhász</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pákáski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Janka</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kálmán</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>ABCA1 rs2230805 and rs2230806 common gene variants are associated with Alzheimer’s disease</article-title>
<source/>Neurosci Lett.
          <year>2018</year>
<volume>664</volume>
<fpage>79</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2017.11.027</pub-id>
<pub-id pub-id-type="pmid">29133174</pub-id>
</element-citation>
</ref>
<ref id="B94-ijms-21-03059">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>ATP Binding Cassette Subfamily A Member 2 (ABCA2) Expression and Methylation are Associated with Alzheimer’s Disease</article-title>
<source/>Med. Sci. Monit.
          <year>2017</year>
<volume>23</volume>
<fpage>5851</fpage>
<lpage>5861</lpage>
<pub-id pub-id-type="doi">10.12659/MSM.905524</pub-id>
<pub-id pub-id-type="pmid">29224028</pub-id>
</element-citation>
</ref>
<ref id="B95-ijms-21-03059">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Polymorphisms of ABCG2 and its impact on clinical relevance</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <year>2018</year>
<volume>503</volume>
<fpage>408</fpage>
<lpage>413</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2018.06.157</pub-id>
<pub-id pub-id-type="pmid">29964015</pub-id>
</element-citation>
</ref>
<ref id="B96-ijms-21-03059">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fehér</surname>
<given-names>Á.</given-names>
</name>
<name>
<surname>Juhász</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>László</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pákáski</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kálmán</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Janka</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Association between the ABCG2 C421A polymorphism and Alzheimer’s disease</article-title>
<source/>Neurosci. Lett.
          <year>2013</year>
<volume>550</volume>
<fpage>51</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2013.06.044</pub-id>
<pub-id pub-id-type="pmid">23827224</pub-id>
</element-citation>
</ref>
<ref id="B97-ijms-21-03059">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shubbar</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Penny</surname>
<given-names>J.I.</given-names>
</name>
</person-group>
<article-title>Effect of amyloid beta on ATP-binding cassette transporter expression and activity in porcine brain microvascular endothelial cells</article-title>
<source/>Biochim. Biophys. Acta Gen. Subj.
          <year>2018</year>
<volume>1862</volume>
<fpage>2314</fpage>
<lpage>2322</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagen.2018.07.021</pub-id>
<pub-id pub-id-type="pmid">30048740</pub-id>
</element-citation>
</ref>
<ref id="B98-ijms-21-03059">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaller</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lauschke</surname>
<given-names>V.M.</given-names>
</name>
</person-group>
<article-title>The genetic landscape of the human solute carrier (SLC) transporter superfamily</article-title>
<source/>Hum. Genet.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1007/s00439-019-02081-x</pub-id>
<pub-id pub-id-type="pmid">31679053</pub-id>
</element-citation>
</ref>
<ref id="B99-ijms-21-03059">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yin</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The Role of SORL1 in Alzheimer’s Disease</article-title>
<source/>Mol. Neurobiol.
          <year>2015</year>
<volume>51</volume>
<fpage>909</fpage>
<lpage>918</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-014-8742-5</pub-id>
<pub-id pub-id-type="pmid">24833601</pub-id>
</element-citation>
</ref>
<ref id="B100-ijms-21-03059">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Britzolaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Saurine</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Klocke</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pitychoutis</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>A Role for SERCA Pumps in the Neurobiology of Neuropsychiatric and Neurodegenerative Disorders</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>2020</year>
<volume>1131</volume>
<fpage>131</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="doi">10.1007/978-3-030-12457-1_6</pub-id>
<pub-id pub-id-type="pmid">31646509</pub-id>
</element-citation>
</ref>
<ref id="B101-ijms-21-03059">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heinemeyer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Stemmet</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bardien</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Neethling</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Underappreciated Roles of the Translocase of the Outer and Inner Mitochondrial Membrane Protein Complexes in Human Disease</article-title>
<source/>DNA Cell Biol.
          <year>2019</year>
<volume>38</volume>
<fpage>23</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1089/dna.2018.4292</pub-id>
<pub-id pub-id-type="pmid">30481057</pub-id>
</element-citation>
</ref>
<ref id="B102-ijms-21-03059">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belrose</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>M.F.</given-names>
</name>
</person-group>
<article-title>TRPM2: A candidate therapeutic target for treating neurological diseases</article-title>
<source/>Acta Pharmacol. Sin.
          <year>2018</year>
<volume>39</volume>
<fpage>722</fpage>
<lpage>732</lpage>
<pub-id pub-id-type="doi">10.1038/aps.2018.31</pub-id>
<pub-id pub-id-type="pmid">29671419</pub-id>
</element-citation>
</ref>
<ref id="B103-ijms-21-03059">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Omori</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Tachikawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Terasaki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Brouwer</surname>
<given-names>K.L.R.</given-names>
</name>
<name>
<surname>Nicolazzo</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>Altered Expression of Small Intestinal Drug Transporters and Hepatic Metabolic Enzymes in a Mouse Model of Familial Alzheimer’s Disease</article-title>
<source/>Mol. Pharm.
          <year>2018</year>
<volume>15</volume>
<fpage>4073</fpage>
<lpage>4083</lpage>
<pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.8b00500</pub-id>
<pub-id pub-id-type="pmid">30074800</pub-id>
</element-citation>
</ref>
<ref id="B104-ijms-21-03059">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of drugs used to treat brain disorders</article-title>
<source/>Expert Rev. Precis. Med. Drug Dev.
          <year>2020</year>
<pub-id pub-id-type="doi">10.1080/23808993.2020.1738217</pub-id>
</element-citation>
</ref>
<ref id="B105-ijms-21-03059">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease</article-title>
<source/>Front. Neurosci.
          <year>2019</year>
<volume>13</volume>
<fpage>472</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2019.00472</pub-id>
<pub-id pub-id-type="pmid">31156366</pub-id>
</element-citation>
</ref>
<ref id="B106-ijms-21-03059">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dekker</surname>
<given-names>M.J.H.J.</given-names>
</name>
<name>
<surname>Bouvy</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>O’Rourke</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Makady</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gispen-de Wield</surname>
<given-names>C.C.</given-names>
</name>
</person-group>
<article-title>Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer’s Disease</article-title>
<source/>Front. Med.
          <year>2019</year>
<volume>6</volume>
<fpage>73</fpage>
<pub-id pub-id-type="doi">10.3389/fmed.2019.00073</pub-id>
</element-citation>
</ref>
<ref id="B107-ijms-21-03059">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Llovo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fraile</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fernández-Novoa</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic aspects of therapy with cholinesterase inhibitors: The role of CYP2D6 in Alzheimer’s disease pharmacogenetics</article-title>
<source/>Curr. Alzheimer Res.
          <year>2007</year>
<volume>4</volume>
<fpage>479</fpage>
<lpage>500</lpage>
<pub-id pub-id-type="doi">10.2174/156720507781788846</pub-id>
<pub-id pub-id-type="pmid">17908053</pub-id>
</element-citation>
</ref>
<ref id="B108-ijms-21-03059">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics</article-title>
<source/>Neuropsychiatr. Dis. Treat.
          <year>2007</year>
<volume>3</volume>
<fpage>303</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="pmid">19300564</pub-id>
</element-citation>
</ref>
<ref id="B109-ijms-21-03059">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Winblad</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>The glutamatergic system and neurodegeneration in dementia: Preventive strategies in Alzheimer’s disease</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>1999</year>
<volume>14</volume>
<fpage>3</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1099-1166(199901)14:1&lt;3::AID-GPS897&gt;3.0.CO;2-7</pub-id>
<pub-id pub-id-type="pmid">10029935</pub-id>
</element-citation>
</ref>
<ref id="B110-ijms-21-03059">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hays</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Zlatar</surname>
<given-names>Z.Z.</given-names>
</name>
<name>
<surname>Meloy</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Osuna</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>T.T.</given-names>
</name>
<name>
<surname>Galasko</surname>
<given-names>D.R.</given-names>
</name>
<name>
<surname>Wierenga</surname>
<given-names>C.E.</given-names>
</name>
</person-group>
<article-title>Anterior Cingulate Structure and Perfusion Is Associated with Cerebrospinal Fluid Tau Among Cognitively Normal Older Adult APOEε4 Carriers</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<pub-id pub-id-type="doi">10.3233/JAD-190504</pub-id>
</element-citation>
</ref>
<ref id="B111-ijms-21-03059">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weintraub</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Teylan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rader</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>K.C.G.</given-names>
</name>
<name>
<surname>Bollenbeck</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kukull</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Coventry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rogalski</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bigio</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mesulam</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort</article-title>
<source/>Neurology
          <year>2019</year>
<volume>94</volume>
<fpage>e607</fpage>
<lpage>e612</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000008666</pub-id>
<pub-id pub-id-type="pmid">31704790</pub-id>
</element-citation>
</ref>
<ref id="B112-ijms-21-03059">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Molecular pathology and pharmacogenomics in Alzheimer’s disease: Polygenic-related effects of multifactorial treatments on cognition, anxiety and depression</article-title>
<source/>Methods Find. Exp. Clin. Pharmacol.
          <year>2007</year>
<volume>29</volume>
<fpage>1</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">17957277</pub-id>
</element-citation>
</ref>
<ref id="B113-ijms-21-03059">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Martínez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fernández-Novoa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Carrera</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Corzo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tellado</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Leszek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McKay</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics</article-title>
<source/>Int. J. Alzheimers Dis.
          <year>2012</year>
<volume>2012</volume>
<fpage>518901</fpage>
<pub-id pub-id-type="doi">10.1155/2012/518901</pub-id>
<pub-id pub-id-type="pmid">22482072</pub-id>
</element-citation>
</ref>
<ref id="B114-ijms-21-03059">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carrera</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Opportunities in Pharmacogenomics for the treatment of Alzheimer’s Disease</article-title>
<source/>Future Neurol.
          <year>2015</year>
<volume>10</volume>
<fpage>229</fpage>
<lpage>252</lpage>
<pub-id pub-id-type="doi">10.2217/fnl.15.12</pub-id>
</element-citation>
</ref>
<ref id="B115-ijms-21-03059">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Teijido</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic considerations in the treatment of Alzheimer’s disease</article-title>
<source/>Pharmacogenomics
          <year>2016</year>
<volume>17</volume>
<fpage>1041</fpage>
<lpage>1074</lpage>
<pub-id pub-id-type="doi">10.2217/pgs-2016-0031</pub-id>
<pub-id pub-id-type="pmid">27291247</pub-id>
</element-citation>
</ref>
<ref id="B116-ijms-21-03059">
<label>116.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fernández-Novoa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pichel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kubota</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomic studies with a combination therapy in Alzheimer’s disease</article-title>
<source/>Molecular Neurobiology of Alzheimer’s Disease and Related Disorders
          <person-group person-group-type="editor">
<name>
<surname>Takeda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<publisher-name>Karger</publisher-name>
<publisher-loc>Basel, Switzerland</publisher-loc>
<year>2004</year>
<fpage>94</fpage>
<lpage>107</lpage>
</element-citation>
</ref>
<ref id="B117-ijms-21-03059">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Goldgaber</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vostrov</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Matsuki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Corzo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Roses</surname>
<given-names>A.D.</given-names>
</name>
</person-group>
<article-title>APOE-TOMM40 in the Pharmacogenomics of demetia</article-title>
<source/>J. Pharmacogenom. Pharmacoproteom.
          <year>2014</year>
<volume>5</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.4172/2153-0645.1000135</pub-id>
</element-citation>
</ref>
<ref id="B118-ijms-21-03059">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Rodríguez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Carrera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Beyer</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lao</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>Behavioral changes associated with different apolipoprotein E genotypes in dementia</article-title>
<source/>Alzheimer’s Dis. Assoc. Dis.
          <year>1997</year>
<volume>11</volume>
<fpage>S27</fpage>
<lpage>S37</lpage>
</element-citation>
</ref>
<ref id="B119-ijms-21-03059">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics of Alzheimer’s and Parkinson’s diseases</article-title>
<source/>Neurosci. Lett.
          <year>2018</year>
<fpage>133807</fpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2018.09.018</pub-id>
<pub-id pub-id-type="pmid">30236877</pub-id>
</element-citation>
</ref>
<ref id="B120-ijms-21-03059">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darreh-Shori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Siawesh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mousavi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Andreasen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nordberg</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer’s disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2012</year>
<volume>28</volume>
<fpage>443</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2011-111088</pub-id>
<pub-id pub-id-type="pmid">22012848</pub-id>
</element-citation>
</ref>
<ref id="B121-ijms-21-03059">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noetzli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eap</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer’s Disease</article-title>
<source/>Clin. Pharmacokinet.
          <year>2013</year>
<volume>52</volume>
<fpage>225</fpage>
<lpage>241</lpage>
<pub-id pub-id-type="doi">10.1007/s40262-013-0038-9</pub-id>
<pub-id pub-id-type="pmid">23408070</pub-id>
</element-citation>
</ref>
<ref id="B122-ijms-21-03059">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birks</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Donepezil for dementia due to Alzheimer’s disease</article-title>
<source/>Cochrane Database Syst. Rev.
          <year>2018</year>
<volume>6</volume>
<fpage>CD001190</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD001190.pub3</pub-id>
<pub-id pub-id-type="pmid">29923184</pub-id>
</element-citation>
</ref>
<ref id="B123-ijms-21-03059">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pilotto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Franceschi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>D’Onofrio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bizzarro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mangialasche</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cascavilla</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>París</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Matera</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Pilotto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Deniele</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease</article-title>
<source/>Neurology
          <year>2009</year>
<volume>73</volume>
<fpage>761</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3181b6bbe3</pub-id>
<pub-id pub-id-type="pmid">19738170</pub-id>
</element-citation>
</ref>
<ref id="B124-ijms-21-03059">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noetzli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guidi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ebbing</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eyer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Michon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thoomazic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Stancu</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Alnawaqil</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Bula</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance</article-title>
<source/>Br. J. Clin. Pharmacol.
          <year>2014</year>
<volume>78</volume>
<fpage>135</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1111/bcp.12325</pub-id>
<pub-id pub-id-type="pmid">24433464</pub-id>
</element-citation>
</ref>
<ref id="B125-ijms-21-03059">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Albani</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Biella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Giiacalone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lupoli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Clerici</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ghidoni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Squitti</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer’s disease patients</article-title>
<source/>J. Alzheimers Dis.
          <year>2012</year>
<volume>30</volume>
<fpage>745</fpage>
<lpage>749</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-2012-112123</pub-id>
<pub-id pub-id-type="pmid">22465999</pub-id>
</element-citation>
</ref>
<ref id="B126-ijms-21-03059">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer’s Disease: A Systematic Review and Meta-Analysis</article-title>
<source/>CNS Drugs
          <year>2016</year>
<volume>30</volume>
<fpage>899</fpage>
<lpage>907</lpage>
<pub-id pub-id-type="doi">10.1007/s40263-016-0356-1</pub-id>
<pub-id pub-id-type="pmid">27282366</pub-id>
</element-citation>
</ref>
<ref id="B127-ijms-21-03059">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seripa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bizzarro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pilotto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>D’onofrio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vecchione</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>A.P.</given-names>
</name>
<name>
<surname>Cascavilla</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Paris</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Grandone</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Mecocci</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer’s disease</article-title>
<source/>Pharmacogenet. Genom.
          <year>2011</year>
<volume>21</volume>
<fpage>225</fpage>
<lpage>230</lpage>
</element-citation>
</ref>
<ref id="B128-ijms-21-03059">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Miao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer’s disease</article-title>
<source/>Am. J. Med. Sci.
          <year>2013</year>
<volume>345</volume>
<fpage>222</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="doi">10.1097/MAJ.0b013e318255a8f9</pub-id>
<pub-id pub-id-type="pmid">22986607</pub-id>
</element-citation>
</ref>
<ref id="B129-ijms-21-03059">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yaowaluk</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Senanarong</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Limwongse</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Boonprasert</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kijsanayotin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer’s disease and vascular dementia</article-title>
<source/>Pharmacogenom. Personalized Med.
          <year>2019</year>
<volume>12</volume>
<fpage>209</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.2147/PGPM.S211259</pub-id>
</element-citation>
</ref>
<ref id="B130-ijms-21-03059">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>N.L.S.</given-names>
</name>
<name>
<surname>Wat</surname>
<given-names>K.H.Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.H.Y.</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Law</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Chiue</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>C.C.W.</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>T.K.</given-names>
</name>
</person-group>
<article-title>Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer’s Disease</article-title>
<source/>Am. J. Alzheimers Dis. Other Demen.
          <year>2019</year>
<volume>34</volume>
<fpage>302</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1177/1533317519848237</pub-id>
<pub-id pub-id-type="pmid">31064198</pub-id>
</element-citation>
</ref>
<ref id="B131-ijms-21-03059">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magliulo</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dahl</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Lombardi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fallarini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Villa</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Biolcati</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Scordo</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2011</year>
<volume>67</volume>
<fpage>47</fpage>
<lpage>54</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-010-0883-5</pub-id>
<pub-id pub-id-type="pmid">20931330</pub-id>
</element-citation>
</ref>
<ref id="B132-ijms-21-03059">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer’s disease</article-title>
<source/>Brain Res. Bull.
          <year>2018</year>
<volume>140</volume>
<fpage>1</fpage>
<lpage>4</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainresbull.2018.03.014</pub-id>
<pub-id pub-id-type="pmid">29605487</pub-id>
</element-citation>
</ref>
<ref id="B133-ijms-21-03059">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Beaumont</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pelleieux</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lamarre-Théroux</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dea</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Poirier</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s Disease Cooperative Study. Butyrylcholinesterase K and Apolipoprotein E-ε4 Reduce the Age of Onset of Alzheimer’s Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects</article-title>
<source/>J. Alzheimers Dis.
          <year>2016</year>
<volume>54</volume>
<fpage>913</fpage>
<lpage>922</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-160373</pub-id>
<pub-id pub-id-type="pmid">27567841</pub-id>
</element-citation>
</ref>
<ref id="B134-ijms-21-03059">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sokolow</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Rotter</surname>
<given-names>J.I.</given-names>
</name>
<name>
<surname>Rissman</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Aisen</surname>
<given-names>P.S.</given-names>
</name>
<name>
<surname>Apostolova</surname>
<given-names>L.G.</given-names>
</name>
</person-group>
<article-title>Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>56</volume>
<fpage>229</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-160562</pub-id>
<pub-id pub-id-type="pmid">27911294</pub-id>
</element-citation>
</ref>
<ref id="B135-ijms-21-03059">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>The efficacy of a “cocktail therapy” on Parkinson’s disease with dementia</article-title>
<source/>Neuropsychiatr. Dis. Treat.
          <year>2019</year>
<volume>15</volume>
<fpage>1639</fpage>
<lpage>1647</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S179453</pub-id>
<pub-id pub-id-type="pmid">31296990</pub-id>
</element-citation>
</ref>
<ref id="B136-ijms-21-03059">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khuanjing</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Palee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chattipakorn</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Chattipakorn</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure: From cells to patient reports</article-title>
<source/>Acta Physiol.
          <year>2019</year>
<volume>228</volume>
<fpage>e13396</fpage>
<pub-id pub-id-type="doi">10.1111/apha.13396</pub-id>
</element-citation>
</ref>
<ref id="B137-ijms-21-03059">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawashiri</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shigematsu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Shimazoe</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Donepezil ameliorates oxaliplatin-induced peripheral neuropathy via a neuroprotective effect</article-title>
<source/>J. Pharmacol. Sci.
          <year>2019</year>
<volume>140</volume>
<fpage>291</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1016/j.jphs.2019.05.009</pub-id>
<pub-id pub-id-type="pmid">31377017</pub-id>
</element-citation>
</ref>
<ref id="B138-ijms-21-03059">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Thelin</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Escayg</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome</article-title>
<source/>Ann. Clin. Transl. Neurol.
          <year>2019</year>
<volume>6</volume>
<fpage>1566</fpage>
<lpage>1571</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.50848</pub-id>
<pub-id pub-id-type="pmid">31402621</pub-id>
</element-citation>
</ref>
<ref id="B139-ijms-21-03059">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jann</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Shirley</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>G.W.</given-names>
</name>
</person-group>
<article-title>Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors</article-title>
<source/>Clin. Pharmacokinet.
          <year>2002</year>
<volume>41</volume>
<fpage>719</fpage>
<lpage>739</lpage>
<pub-id pub-id-type="doi">10.2165/00003088-200241100-00003</pub-id>
<pub-id pub-id-type="pmid">12162759</pub-id>
</element-citation>
</ref>
<ref id="B140-ijms-21-03059">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lilienfeld</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer’s disease</article-title>
<source/>CNS Drug Rev.
          <year>2002</year>
<volume>8</volume>
<fpage>159</fpage>
<lpage>176</lpage>
<pub-id pub-id-type="doi">10.1111/j.1527-3458.2002.tb00221.x</pub-id>
<pub-id pub-id-type="pmid">12177686</pub-id>
</element-citation>
</ref>
<ref id="B141-ijms-21-03059">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Brett</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van Osselaer</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Raoult</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Van Peer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Verhaeghe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hust</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects</article-title>
<source/>J. Clin. Pharmacol.
          <year>2002</year>
<volume>42</volume>
<fpage>1002</fpage>
<lpage>1010</lpage>
<pub-id pub-id-type="doi">10.1177/0091270002042009007</pub-id>
<pub-id pub-id-type="pmid">12211216</pub-id>
</element-citation>
</ref>
<ref id="B142-ijms-21-03059">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farlow</surname>
<given-names>M.R.</given-names>
</name>
</person-group>
<article-title>Clinical pharmacokinetics of galantamine</article-title>
<source/>Clin. Pharmacokinet.
          <year>2003</year>
<volume>42</volume>
<fpage>1383</fpage>
<lpage>1392</lpage>
<pub-id pub-id-type="doi">10.2165/00003088-200342150-00005</pub-id>
<pub-id pub-id-type="pmid">14674789</pub-id>
</element-citation>
</ref>
<ref id="B143-ijms-21-03059">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mannens</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Snel</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Hendrickx</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Verhaeghe</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Le Jeune</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bode</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>van Beijsterveldt</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lavrijsen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Leempoels</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Van Osselaer</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The metabolism and excretion of galantamine in rats, dogs, and humans</article-title>
<source/>Drug Metab. Dispos.
          <year>2002</year>
<volume>30</volume>
<fpage>553</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1124/dmd.30.5.553</pub-id>
<pub-id pub-id-type="pmid">11950787</pub-id>
</element-citation>
</ref>
<ref id="B144-ijms-21-03059">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noetzli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guidi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ebbing</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eyer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zumbach</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giannakopoulos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>von Gunten</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Csajka</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eap</surname>
<given-names>C.B.</given-names>
</name>
</person-group>
<article-title>Relationship of CYP2D6, CYP3A, POR, and ABCB1 genotypes with galantamine plasma concentrations</article-title>
<source/>Ther. Drug Monit.
          <year>2013</year>
<volume>35</volume>
<fpage>270</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1097/FTD.0b013e318282ff02</pub-id>
<pub-id pub-id-type="pmid">23503455</pub-id>
</element-citation>
</ref>
<ref id="B145-ijms-21-03059">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Cutler</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Schwarz</surname>
<given-names>U.I.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dasgupta</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: A pilot study</article-title>
<source/>Am. J. Geriatr. Pharmacother.
          <year>2011</year>
<volume>9</volume>
<fpage>224</fpage>
<lpage>233</lpage>
<pub-id pub-id-type="doi">10.1016/j.amjopharm.2011.07.003</pub-id>
<pub-id pub-id-type="pmid">21803659</pub-id>
</element-citation>
</ref>
<ref id="B146-ijms-21-03059">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bentué-Ferrer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tribut</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Polard</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Allain</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Clinically significant drug interactions with cholinesterase inhibitors: A guide for neurologists</article-title>
<source/>CNS Drugs
          <year>2003</year>
<volume>17</volume>
<fpage>947</fpage>
<lpage>963</lpage>
<pub-id pub-id-type="doi">10.2165/00023210-200317130-00002</pub-id>
<pub-id pub-id-type="pmid">14533945</pub-id>
</element-citation>
</ref>
<ref id="B147-ijms-21-03059">
<label>147.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhai</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.N.</given-names>
</name>
</person-group>
<article-title>Food-drug interactions: Effect of capsaicin on the pharmacokinetics of galantamine in rats</article-title>
<source/>Xenobiotica
          <year>2012</year>
<volume>42</volume>
<fpage>1151</fpage>
<lpage>1155</lpage>
<pub-id pub-id-type="doi">10.3109/00498254.2012.693220</pub-id>
<pub-id pub-id-type="pmid">22668071</pub-id>
</element-citation>
</ref>
<ref id="B148-ijms-21-03059">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carroll</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>DeVito</surname>
<given-names>E.E.</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Nich</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sofuoglu</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Double-Blind Placebo-Controlled Trial of Galantamine for Methadone-Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use</article-title>
<source/>Am. J. Addict.
          <year>2019</year>
<volume>28</volume>
<fpage>238</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1111/ajad.12904</pub-id>
<pub-id pub-id-type="pmid">31165574</pub-id>
</element-citation>
</ref>
<ref id="B149-ijms-21-03059">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugarman</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>De Aquino</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Poling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sofuoglu</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Feasibility and effects of galantamine on cognition in humans with cannabis use disorder</article-title>
<source/>Pharmacol. Biochem. Behav.
          <year>2019</year>
<volume>181</volume>
<fpage>86</fpage>
<lpage>92</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2019.05.004</pub-id>
<pub-id pub-id-type="pmid">31082417</pub-id>
</element-citation>
</ref>
<ref id="B150-ijms-21-03059">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Njoku</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Radabaugh</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Nicholas</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Kutash</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>O’Neil</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>I.P.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Kline</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>Chronic treatment with galantamine rescues reversal learning in an attentional set-shifting test after experimental brain trauma</article-title>
<source/>Exp. Neurol.
          <year>2019</year>
<volume>315</volume>
<fpage>32</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.expneurol.2019.01.019</pub-id>
<pub-id pub-id-type="pmid">30711647</pub-id>
</element-citation>
</ref>
<ref id="B151-ijms-21-03059">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choueiry</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Blais</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Labelle</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Knott</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia</article-title>
<source/>Int. J. Psychophysiol.
          <year>2019</year>
<volume>145</volume>
<fpage>70</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijpsycho.2019.02.005</pub-id>
<pub-id pub-id-type="pmid">30790597</pub-id>
</element-citation>
</ref>
<ref id="B152-ijms-21-03059">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koola</surname>
<given-names>M.M.</given-names>
</name>
</person-group>
<article-title>Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia</article-title>
<source/>Mol. Neuropsychiatry
          <year>2018</year>
<volume>4</volume>
<fpage>134</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1159/000494495</pub-id>
<pub-id pub-id-type="pmid">30643787</pub-id>
</element-citation>
</ref>
<ref id="B153-ijms-21-03059">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birks</surname>
<given-names>J.S.</given-names>
</name>
<name>
<surname>Grimley Evans</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Rivastigmine for Alzheimer’s disease</article-title>
<source/>Cochrane Database Syst. Rev.
          <year>2015</year>
<volume>10</volume>
<fpage>CD001191</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD001191.pub3</pub-id>
</element-citation>
</ref>
<ref id="B154-ijms-21-03059">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kuang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<pub-id pub-id-type="doi">10.3233/JAD-190791</pub-id>
</element-citation>
</ref>
<ref id="B155-ijms-21-03059">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polinsky</surname>
<given-names>R.J.</given-names>
</name>
</person-group>
<article-title>Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease</article-title>
<source/>Clin. Ther.
          <year>1998</year>
<volume>20</volume>
<fpage>634</fpage>
<lpage>647</lpage>
<pub-id pub-id-type="doi">10.1016/S0149-2918(98)80127-6</pub-id>
<pub-id pub-id-type="pmid">9737824</pub-id>
</element-citation>
</ref>
<ref id="B156-ijms-21-03059">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonali</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sagar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Velpandian</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Subbiah</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer’s patients</article-title>
<source/>CNS Neurosci. Ther.
          <year>2013</year>
<volume>19</volume>
<fpage>91</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="doi">10.1111/cns.12036</pub-id>
<pub-id pub-id-type="pmid">23206182</pub-id>
</element-citation>
</ref>
<ref id="B157-ijms-21-03059">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Myung</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Won</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D.K.</given-names>
</name>
</person-group>
<article-title>Association of the choline acetyltransferase gene with responsiveness to acetylcholinesterase inhibitors in Alzheimer’s disease</article-title>
<source/>Pharmacopsychiatry
          <year>2015</year>
<volume>48</volume>
<fpage>111</fpage>
<lpage>117</lpage>
<pub-id pub-id-type="doi">10.1055/s-0035-1545300</pub-id>
<pub-id pub-id-type="pmid">25730470</pub-id>
</element-citation>
</ref>
<ref id="B158-ijms-21-03059">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mascia</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Santangelo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mazzeo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Giacalone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fusco</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zuffi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fenoglio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Franceschi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>CHRNA7 Gene and response to cholinesterase Inhibitors in an Italian cohort of Alzheimer’s disease patients</article-title>
<source/>J. Alzheimers Dis.
          <year>2016</year>
<volume>52</volume>
<fpage>1203</fpage>
<lpage>1208</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-160074</pub-id>
<pub-id pub-id-type="pmid">27104904</pub-id>
</element-citation>
</ref>
<ref id="B159-ijms-21-03059">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinelli-Boneschi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Giacalone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Magnani</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Biella</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Coppi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Santangelo</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Brambilla</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Esposito</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Clerici</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Benussi</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenomics in Alzheimer’s disease: A genome-wide association study of response to cholinesterase inhibitors</article-title>
<source/>Neurobiol. Aging
          <year>2013</year>
<volume>34</volume>
<fpage>1711</fpage>
<pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2012.12.008</pub-id>
<pub-id pub-id-type="pmid">23374588</pub-id>
</element-citation>
</ref>
<ref id="B160-ijms-21-03059">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferris</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nordberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Soininen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Darreh-Shori</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Progression from mild cognitive impairment to Alzheimer’s disease: Effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment</article-title>
<source/>Pharmacogenet. Genom.
          <year>2009</year>
<volume>19</volume>
<fpage>635</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e32832f8c17</pub-id>
<pub-id pub-id-type="pmid">19617863</pub-id>
</element-citation>
</ref>
<ref id="B161-ijms-21-03059">
<label>161.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jasiecki</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wasąg</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer’s Disease-Could BCHE Genotyping Be Helpful in Alzheimer’s Therapy?</article-title>
<source/>Biomolecules
          <year>2019</year>
<volume>9</volume>
<elocation-id>592</elocation-id>
<pub-id pub-id-type="doi">10.3390/biom9100592</pub-id>
<pub-id pub-id-type="pmid">31601022</pub-id>
</element-citation>
</ref>
<ref id="B162-ijms-21-03059">
<label>162.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henderson</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Lord</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Gaunt</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Lawrence</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Close</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Whone</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Ben-Shlomo</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Rivastigmine for gait stability in patients with Parkinson’s disease (ReSPonD): A randomised, double-blind, placebo-controlled, phase 2 trial</article-title>
<source/>Lancet Neurol.
          <year>2016</year>
<volume>15</volume>
<fpage>249</fpage>
<lpage>258</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(15)00389-0</pub-id>
<pub-id pub-id-type="pmid">26795874</pub-id>
</element-citation>
</ref>
<ref id="B163-ijms-21-03059">
<label>163.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kandiah</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Senanarong</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Looi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ampil</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>K.W.</given-names>
</name>
<name>
<surname>Karanam</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Christopher</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Rivastigmine: The advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia</article-title>
<source/>Clin. Interv. Aging
          <year>2017</year>
<volume>12</volume>
<fpage>697</fpage>
<lpage>707</lpage>
<pub-id pub-id-type="doi">10.2147/CIA.S129145</pub-id>
<pub-id pub-id-type="pmid">28458525</pub-id>
</element-citation>
</ref>
<ref id="B164-ijms-21-03059">
<label>164.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgett</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Farley</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Beireis</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>Acute treatment of psychotic symptoms in a newly diagnosed Lewy body dementia patient with an accelerated titration schedule of rivastigmine and de-escalation of antipsychotics</article-title>
<source/>BMJ Case Rep.
          <year>2019</year>
<volume>12</volume>
<fpage>e230193</fpage>
<pub-id pub-id-type="doi">10.1136/bcr-2019-230193</pub-id>
</element-citation>
</ref>
<ref id="B165-ijms-21-03059">
<label>165.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
</person-group>
<article-title>Effectiveness and safety of memantine treatment for Alzheimer’s disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2013</year>
<volume>36</volume>
<fpage>445</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-130395</pub-id>
<pub-id pub-id-type="pmid">23635410</pub-id>
</element-citation>
</ref>
<ref id="B166-ijms-21-03059">
<label>166.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noetzli</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guidi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ebbing</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Eyer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Michon</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Thomazic</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Alnawaqil</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Maurer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zumbach</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Population pharmacokinetic study of memantine: Effects of clinical and genetic factors</article-title>
<source/>Clin. Pharmacokinet.
          <year>2013</year>
<volume>52</volume>
<fpage>211</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1007/s40262-013-0032-2</pub-id>
<pub-id pub-id-type="pmid">23371894</pub-id>
</element-citation>
</ref>
<ref id="B167-ijms-21-03059">
<label>167.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Micuda</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mundlova</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Anzenbacherova</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Anzenbacher</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chladek</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fuksa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fuksa</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Martinova</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Inhibitory effects of memantine on human cytochrome P450 activities: Prediction of in vivo drug interactions</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2004</year>
<volume>60</volume>
<fpage>583</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-004-0825-1</pub-id>
<pub-id pub-id-type="pmid">15378224</pub-id>
</element-citation>
</ref>
<ref id="B168-ijms-21-03059">
<label>168.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marwick</surname>
<given-names>K.F.M.</given-names>
</name>
<name>
<surname>Skehel</surname>
<given-names>P.A.</given-names>
</name>
<name>
<surname>Hardingham</surname>
<given-names>G.E.</given-names>
</name>
<name>
<surname>Wyllie</surname>
<given-names>D.J.A.</given-names>
</name>
</person-group>
<article-title>The human NMDA receptor GluN2AN615K variant influences channel blocker potency</article-title>
<source/>Pharmacol. Res. Perspect.
          <year>2019</year>
<volume>7</volume>
<fpage>e00495</fpage>
<pub-id pub-id-type="doi">10.1002/prp2.495</pub-id>
<pub-id pub-id-type="pmid">31249692</pub-id>
</element-citation>
</ref>
<ref id="B169-ijms-21-03059">
<label>169.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Matsunaga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Oya</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ikuta</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>60</volume>
<fpage>401</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-170424</pub-id>
<pub-id pub-id-type="pmid">28922160</pub-id>
</element-citation>
</ref>
<ref id="B170-ijms-21-03059">
<label>170.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glinz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gloy</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Monsch</surname>
<given-names>A.U.</given-names>
</name>
<name>
<surname>Kressig</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>McCord</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Ademi</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tomonafa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Schwenkglenks</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bucher</surname>
<given-names>H.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer’s disease: A meta-analysis</article-title>
<source/>Swiss Med. Wkly.
          <year>2019</year>
<volume>149</volume>
<fpage>w20093</fpage>
<pub-id pub-id-type="doi">10.4414/smw.2019.20093</pub-id>
<pub-id pub-id-type="pmid">31269225</pub-id>
</element-citation>
</ref>
<ref id="B171-ijms-21-03059">
<label>171.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hoi</surname>
<given-names>M.P.U.</given-names>
</name>
</person-group>
<article-title>Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer’s Disease</article-title>
<source/>Exp. Neurobiol.
          <year>2019</year>
<volume>28</volume>
<fpage>390</fpage>
<lpage>403</lpage>
<pub-id pub-id-type="doi">10.5607/en.2019.28.3.390</pub-id>
<pub-id pub-id-type="pmid">31308798</pub-id>
</element-citation>
</ref>
<ref id="B172-ijms-21-03059">
<label>172.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoue</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Masuda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Misumi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ando</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression</article-title>
<source/>Mol. Neurobiol.
          <year>2019</year>
<volume>56</volume>
<fpage>8573</fpage>
<lpage>8588</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-019-01678-7</pub-id>
<pub-id pub-id-type="pmid">31280448</pub-id>
</element-citation>
</ref>
<ref id="B173-ijms-21-03059">
<label>173.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tahami Monfared</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Meier</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Joe</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Burden of Disease and Current Management of Dementia with Lewy Bodies: A Literature Review</article-title>
<source/>Neurol. Ther.
          <year>2019</year>
<volume>8</volume>
<fpage>289</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1007/s40120-019-00154-7</pub-id>
<pub-id pub-id-type="pmid">31512165</pub-id>
</element-citation>
</ref>
<ref id="B174-ijms-21-03059">
<label>174.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsunaga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kishi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nomura</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sakuma</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Okuya</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ikuta</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Iwata</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The efficacy and safety of memantine for the treatment of Alzheimer’s disease</article-title>
<source/>Expert. Opin. Drug Saf.
          <year>2018</year>
<volume>17</volume>
<fpage>1053</fpage>
<lpage>1061</lpage>
<pub-id pub-id-type="doi">10.1080/14740338.2018.1524870</pub-id>
<pub-id pub-id-type="pmid">30222469</pub-id>
</element-citation>
</ref>
<ref id="B175-ijms-21-03059">
<label>175.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavretsky</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Laird</surname>
<given-names>K.T.</given-names>
</name>
<name>
<surname>Krause-Sorio</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Heimberg</surname>
<given-names>B.F.</given-names>
</name>
<name>
<surname>Yeargin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Grzenda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Thana-Udom</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ercoli</surname>
<given-names>L.M.</given-names>
</name>
<name>
<surname>Siddarth</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>A Randomized Double-Blind Placebo-Controlled Trial of Combined Escitalopram and Memantine for Older Adults with Major Depression and Subjective Memory Complaints</article-title>
<source/>Am. J. Geriatr. Psychiatry
          <year>2020</year>
<volume>28</volume>
<fpage>178</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/j.jagp.2019.08.011</pub-id>
<pub-id pub-id-type="pmid">31519517</pub-id>
</element-citation>
</ref>
<ref id="B176-ijms-21-03059">
<label>176.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassanpour</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zarghami</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mouodi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Moosazadeh</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Barzegar</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bagheri</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Adjunctive Memantine Treatment of Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Study</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2019</year>
<volume>39</volume>
<fpage>634</fpage>
<lpage>638</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0000000000001115</pub-id>
<pub-id pub-id-type="pmid">31688396</pub-id>
</element-citation>
</ref>
<ref id="B177-ijms-21-03059">
<label>177.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaefer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Theophil</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Leopold</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Heinz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gallinat</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia</article-title>
<source/>Pharmacopsychiatry
          <year>2019</year>
<pub-id pub-id-type="doi">10.1055/a-0970-9310</pub-id>
</element-citation>
</ref>
<ref id="B178-ijms-21-03059">
<label>178.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modarresi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Chaibakhsh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Koulaeinejad</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Koupaei</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder</article-title>
<source/>Psychiatry Res.
          <year>2019</year>
<volume>282</volume>
<fpage>112602</fpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2019.112602</pub-id>
<pub-id pub-id-type="pmid">31630042</pub-id>
</element-citation>
</ref>
<ref id="B179-ijms-21-03059">
<label>179.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shanmugam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Karunaikadal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Varadarajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Memantine Ameliorates Migraine Headache</article-title>
<source/>Ann. Indian Acad. Neurol.
          <year>2019</year>
<volume>22</volume>
<fpage>286</fpage>
<lpage>290</lpage>
<pub-id pub-id-type="doi">10.4103/aian.AIAN_294_18</pub-id>
<pub-id pub-id-type="pmid">31359939</pub-id>
</element-citation>
</ref>
<ref id="B180-ijms-21-03059">
<label>180.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krishnan-Sarin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>O’Malley</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cavallo</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Tetrault</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gueorguieva</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pittman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: A phase II randomized crossover trial</article-title>
<source/>Neuropsychopharmacology
          <year>2019</year>
<pub-id pub-id-type="doi">10.1038/s41386-019-0536-z</pub-id>
<pub-id pub-id-type="pmid">31590179</pub-id>
</element-citation>
</ref>
<ref id="B181-ijms-21-03059">
<label>181.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Memantine selectively prevented the induction of dynamic allodynia by blocking Kir2.1 channel and inhibiting the activation of microglia in spinal dorsal horn of mice in spared nerve injury model</article-title>
<source/>Mol. Pain
          <year>2019</year>
<volume>15</volume>
<fpage>1744806919838947</fpage>
<pub-id pub-id-type="doi">10.1177/1744806919838947</pub-id>
<pub-id pub-id-type="pmid">30845882</pub-id>
</element-citation>
</ref>
<ref id="B182-ijms-21-03059">
<label>182.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sorel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Morel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Marcaillou</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Delage</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tiberghien</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Crosmary</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Najjar</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Colamarino</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dextromethorphan and memantine after ketamine analgesia: A randomized control trial</article-title>
<source/>Drug Des. Dev. Ther.
          <year>2019</year>
<volume>13</volume>
<fpage>2677</fpage>
<lpage>2688</lpage>
<pub-id pub-id-type="doi">10.2147/DDDT.S207350</pub-id>
</element-citation>
</ref>
<ref id="B183-ijms-21-03059">
<label>183.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuller</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Choudhury</surname>
<given-names>T.K.</given-names>
</name>
<name>
<surname>Lowe</surname>
<given-names>D.A.</given-names>
</name>
<name>
<surname>Balsis</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Alzheimer’s Disease Neuroimaging Initiative. Hallucinations and delusions signal Alzheimer’s associated cognitive dysfunction more strongly compared to other neuropsychiatric symptoms</article-title>
<source/>J. Gerontol. B Psychol. Sci. Soc. Sci.
          <year>2019</year>
<fpage>gbz032</fpage>
<pub-id pub-id-type="doi">10.1093/geronb/gbz032</pub-id>
<pub-id pub-id-type="pmid">30877750</pub-id>
</element-citation>
</ref>
<ref id="B184-ijms-21-03059">
<label>184.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seifan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ganzer</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Ryon</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mahmudur</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Adolfo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jacobs</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Greenwald</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Isaacson</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases</article-title>
<source/>Curr. Aging Sci.
          <year>2019</year>
<volume>11</volume>
<fpage>242</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.2174/1874609812666190204094233</pub-id>
<pub-id pub-id-type="pmid">30845903</pub-id>
</element-citation>
</ref>
<ref id="B185-ijms-21-03059">
<label>185.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sundararajan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Manzardo</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>M.G.</given-names>
</name>
</person-group>
<article-title>Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases</article-title>
<source/>Gene
          <year>2018</year>
<volume>641</volume>
<fpage>25</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.gene.2017.10.035</pub-id>
<pub-id pub-id-type="pmid">29032150</pub-id>
</element-citation>
</ref>
<ref id="B186-ijms-21-03059">
<label>186.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garcia-Segura</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Schweizer</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>APOE ε4/ε4 Is Associated with Aberrant Motor Behavior Through Both Lewy Body and Cerebral Amyloid Angiopathy Pathology in High Alzheimer’s Disease Pathological Load</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<pub-id pub-id-type="doi">10.3233/JAD-190643</pub-id>
</element-citation>
</ref>
<ref id="B187-ijms-21-03059">
<label>187.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bargagli</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Cascini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Agabiti</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kirchmayer</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Davoli</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Determinants Of Antipsychotic Drugs Prescription Among Community Living Older Adults With Dementia A Population Based Study Using Health Information Systems In The Lazio Region, Italy</article-title>
<source/>Clin. Interv. Aging
          <year>2019</year>
<volume>14</volume>
<fpage>2071</fpage>
<lpage>2083</lpage>
<pub-id pub-id-type="doi">10.2147/CIA.S218641</pub-id>
<pub-id pub-id-type="pmid">31819389</pub-id>
</element-citation>
</ref>
<ref id="B188-ijms-21-03059">
<label>188.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohno</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kunisawa</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Antipsychotic Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): Management of Extrapyramidal Side Effects</article-title>
<source/>Front. Pharmacol.
          <year>2019</year>
<volume>10</volume>
<fpage>1045</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2019.01045</pub-id>
<pub-id pub-id-type="pmid">31607910</pub-id>
</element-citation>
</ref>
<ref id="B189-ijms-21-03059">
<label>189.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia</article-title>
<source/>Prog. Neuropsychopharmacol. Biol. Psychiatry
          <year>2010</year>
<volume>34</volume>
<fpage>1026</fpage>
<lpage>1032</lpage>
<pub-id pub-id-type="doi">10.1016/j.pnpbp.2010.05.017</pub-id>
<pub-id pub-id-type="pmid">20580759</pub-id>
</element-citation>
</ref>
<ref id="B190-ijms-21-03059">
<label>190.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zivković</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mihaljević-Peles</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bozina</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sagud</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mikolac-Perkovic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vuksan-Cusa</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Muck-Seler</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol</article-title>
<source/>J. Clin. Psychopharmacol.
          <year>2013</year>
<volume>33</volume>
<fpage>593</fpage>
<lpage>599</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e31829abec9</pub-id>
<pub-id pub-id-type="pmid">23963056</pub-id>
</element-citation>
</ref>
<ref id="B191-ijms-21-03059">
<label>191.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gassó</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lafuente</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bioque</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>González-Pinto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Olmeda</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Corropio</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Llerena</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cabrera</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: Role of dopamine, serotonin and glutamate candidate genes</article-title>
<source/>Pharmacogenom. J.
          <year>2016</year>
<volume>16</volume>
<fpage>439</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1038/tpj.2016.44</pub-id>
</element-citation>
</ref>
<ref id="B192-ijms-21-03059">
<label>192.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turčin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dolžan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Porcelli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Serretti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Plesničar</surname>
<given-names>B.K.</given-names>
</name>
</person-group>
<article-title>Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia</article-title>
<source/>OMICS
          <year>2016</year>
<volume>20</volume>
<fpage>283</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="doi">10.1089/omi.2016.0003</pub-id>
<pub-id pub-id-type="pmid">27195966</pub-id>
</element-citation>
</ref>
<ref id="B193-ijms-21-03059">
<label>193.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gareeva</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Zakirov</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Valinurov</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Polymorphism of RGS2 gene: Genetic markers of risk for schizophrenia and pharmacogenetic markers of typical neuroleptics efficiency</article-title>
<source/>Mol. Biol.
          <year>2013</year>
<volume>47</volume>
<fpage>934</fpage>
<lpage>941</lpage>
<pub-id pub-id-type="doi">10.1134/S0026893313060046</pub-id>
</element-citation>
</ref>
<ref id="B194-ijms-21-03059">
<label>194.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gassó</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ritter</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Malagelada</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lafuente</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway</article-title>
<source/>Eur. Neuropsychopharmacol.
          <year>2015</year>
<volume>25</volume>
<fpage>51</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.11.011</pub-id>
<pub-id pub-id-type="pmid">25499605</pub-id>
</element-citation>
</ref>
<ref id="B195-ijms-21-03059">
<label>195.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>S.G.</given-names>
</name>
</person-group>
<article-title>Genetics of tardive dyskinesia</article-title>
<source/>Int. Rev. Neurobiol.
          <year>2011</year>
<volume>98</volume>
<fpage>231</fpage>
<lpage>264</lpage>
<pub-id pub-id-type="doi">10.1016/B978-0-12-381328-2.00010-9</pub-id>
<pub-id pub-id-type="pmid">21907090</pub-id>
</element-citation>
</ref>
<ref id="B196-ijms-21-03059">
<label>196.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koola</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Tsapakis</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kerwin Rip</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Nugent</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Aitchison</surname>
<given-names>K.J.</given-names>
</name>
</person-group>
<article-title>Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?</article-title>
<source/>J. Psychopharmacol.
          <year>2014</year>
<volume>28</volume>
<fpage>665</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="doi">10.1177/0269881114523861</pub-id>
<pub-id pub-id-type="pmid">24595968</pub-id>
</element-citation>
</ref>
<ref id="B197-ijms-21-03059">
<label>197.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanning</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of tardive dyskinesia: An updated review of the literature</article-title>
<source/>Pharmacogenomics
          <year>2016</year>
<volume>17</volume>
<fpage>1339</fpage>
<lpage>1351</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.16.26</pub-id>
<pub-id pub-id-type="pmid">27469238</pub-id>
</element-citation>
</ref>
<ref id="B198-ijms-21-03059">
<label>198.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanaka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Syu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ishiguro</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Inada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Horiuchi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ishikawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koga</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Noguchi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ozaki</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Someya</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DPP6 as a candidate gene for neuroleptic-induced tardive dyskinesia</article-title>
<source/>Pharmacogenom. J.
          <year>2013</year>
<volume>13</volume>
<fpage>27</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1038/tpj.2011.36</pub-id>
</element-citation>
</ref>
<ref id="B199-ijms-21-03059">
<label>199.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greenbaum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Alkelai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zozulinsky</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kohn</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lerer</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Support for association of HSPG2 with tardive dyskinesia in Caucasian populations</article-title>
<source/>Pharmacogenom. J.
          <year>2012</year>
<volume>12</volume>
<fpage>513</fpage>
<lpage>520</lpage>
<pub-id pub-id-type="doi">10.1038/tpj.2011.32</pub-id>
</element-citation>
</ref>
<ref id="B200-ijms-21-03059">
<label>200.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Likhodi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Voineskos</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Metzer</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Remington</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia</article-title>
<source/>Pharmacogenom. J.
          <year>2012</year>
<volume>12</volume>
<fpage>260</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="doi">10.1038/tpj.2010.93</pub-id>
<pub-id pub-id-type="pmid">21266946</pub-id>
</element-citation>
</ref>
<ref id="B201-ijms-21-03059">
<label>201.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Mazzoco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>de Luca</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Lohoff</surname>
<given-names>F.W.</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Voineskos</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>S.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia</article-title>
<source/>J. Psychiatr. Res.
          <year>2013</year>
<volume>47</volume>
<fpage>1760</fpage>
<lpage>1765</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.07.025</pub-id>
<pub-id pub-id-type="pmid">24018103</pub-id>
</element-citation>
</ref>
<ref id="B202-ijms-21-03059">
<label>202.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Remington</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>Genetics of tardive dyskinesia: Promising leads and ways forward</article-title>
<source/>J. Neurol. Sci.
          <year>2018</year>
<volume>389</volume>
<fpage>28</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1016/j.jns.2018.02.011</pub-id>
<pub-id pub-id-type="pmid">29502799</pub-id>
</element-citation>
</ref>
<ref id="B203-ijms-21-03059">
<label>203.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zai</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Maes</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</name>
</person-group>
<article-title>New findings in pharmacogenetics of schizophrenia</article-title>
<source/>Curr. Opin. Psychiatry
          <year>2018</year>
<volume>31</volume>
<fpage>200</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1097/YCO.0000000000000417</pub-id>
<pub-id pub-id-type="pmid">29528898</pub-id>
</element-citation>
</ref>
<ref id="B204-ijms-21-03059">
<label>204.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>G.C.</given-names>
</name>
<name>
<surname>Rastogi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shaikh</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Voineskos</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>S.G.</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>H.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia</article-title>
<source/>Neurosci. Lett.
          <year>2018</year>
<volume>686</volume>
<fpage>17</fpage>
<lpage>22</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2018.08.007</pub-id>
<pub-id pub-id-type="pmid">30118782</pub-id>
</element-citation>
</ref>
<ref id="B205-ijms-21-03059">
<label>205.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hongkaew</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Medhasi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pasomsub</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ngamsamut</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Puangpetch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Vanwong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Chamnanphon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Limsila</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Suthiasisang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wilffert</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder</article-title>
<source/>Pharmacogenom. J.
          <year>2018</year>
<volume>18</volume>
<fpage>740</fpage>
<lpage>748</lpage>
<pub-id pub-id-type="doi">10.1038/s41397-018-0031-7</pub-id>
<pub-id pub-id-type="pmid">29955115</pub-id>
</element-citation>
</ref>
<ref id="B206-ijms-21-03059">
<label>206.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Dima</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shulman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vancampfort</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>De Hert</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Correll</surname>
<given-names>C.U.</given-names>
</name>
</person-group>
<article-title>Weight gain and obesity in schizophrenia: Epidemiology, pathobiology, and management</article-title>
<source/>Acta Psychiatr. Scand.
          <year>2015</year>
<volume>132</volume>
<fpage>97</fpage>
<lpage>108</lpage>
<pub-id pub-id-type="doi">10.1111/acps.12445</pub-id>
<pub-id pub-id-type="pmid">26016380</pub-id>
</element-citation>
</ref>
<ref id="B207-ijms-21-03059">
<label>207.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>L.F.</given-names>
</name>
<name>
<surname>Zai</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Monda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Remington</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Role of ethnicity in antipsychotic-induced weight gain and tardive dyskinesia: Genes or environment?</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<fpage>1273</fpage>
<lpage>1281</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.13.127</pub-id>
<pub-id pub-id-type="pmid">23930674</pub-id>
</element-citation>
</ref>
<ref id="B208-ijms-21-03059">
<label>208.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corfitsen</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Krantz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Drago</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain</article-title>
<source/>Acta Neuropsychiatr.
          <year>2019</year>
<volume>17</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1017/neu.2019.41</pub-id>
</element-citation>
</ref>
<ref id="B209-ijms-21-03059">
<label>209.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Association between schizophrenia and single nucleotide polymorphisms in lipoprotein lipase gene in a Han Chinese population</article-title>
<source/>Psychiatr. Genet.
          <year>2011</year>
<volume>21</volume>
<fpage>307</fpage>
<lpage>314</lpage>
<pub-id pub-id-type="doi">10.1097/YPG.0b013e32834acc85</pub-id>
<pub-id pub-id-type="pmid">21862952</pub-id>
</element-citation>
</ref>
<ref id="B210-ijms-21-03059">
<label>210.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshikawa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Meltzer</surname>
<given-names>H.Y.</given-names>
</name>
</person-group>
<article-title>A functional HTR1A polymorphism, rs6295, predicts short-term response to lurasidone: Confirmation with meta-analysis of other antipsychotic drugs</article-title>
<source/>Pharmacogenom. J.
          <year>2020</year>
<volume>20</volume>
<fpage>260</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1038/s41397-019-0101-5</pub-id>
<pub-id pub-id-type="pmid">31636356</pub-id>
</element-citation>
</ref>
<ref id="B211-ijms-21-03059">
<label>211.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kohlrausch</surname>
<given-names>F.B.</given-names>
</name>
<name>
<surname>Severino-Gama</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lobato</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Belmonte-de-Abreu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carracedo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hutz</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>The CYP1A2 -163C&gt;A polymorphism is associated with clozapine-induced generalized tonic-clonic seizures in Brazilian schizophrenia patients</article-title>
<source/>Psychiatry Res.
          <year>2013</year>
<volume>209</volume>
<fpage>242</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2013.02.030</pub-id>
<pub-id pub-id-type="pmid">23601795</pub-id>
</element-citation>
</ref>
<ref id="B212-ijms-21-03059">
<label>212.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuhmacher</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rujescu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Quednow</surname>
<given-names>B.B.</given-names>
</name>
<name>
<surname>Lennertz</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Benninghoff</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rietschel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hafner</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Franke</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Investigation of tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics</article-title>
<source/>J. Psychiatr. Res.
          <year>2012</year>
<volume>46</volume>
<fpage>1073</fpage>
<lpage>1080</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2012.04.021</pub-id>
<pub-id pub-id-type="pmid">22655589</pub-id>
</element-citation>
</ref>
<ref id="B213-ijms-21-03059">
<label>213.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>X.C.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The prevalence of depression in Alzheimer’s disease: A systematic review and meta-analysis</article-title>
<source/>Curr. Alzheimer Res.
          <year>2015</year>
<volume>12</volume>
<fpage>189</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.2174/1567205012666150204124310</pub-id>
<pub-id pub-id-type="pmid">25654505</pub-id>
</element-citation>
</ref>
<ref id="B214-ijms-21-03059">
<label>214.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuring</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Mathias</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Prevalence of Depression, Anxiety and PTSD in People with Dementia: A Systematic Review and Meta-Analysis</article-title>
<source/>Neuropsychol. Rev.
          <year>2018</year>
<volume>28</volume>
<fpage>393</fpage>
<lpage>416</lpage>
<pub-id pub-id-type="doi">10.1007/s11065-018-9396-2</pub-id>
<pub-id pub-id-type="pmid">30536144</pub-id>
</element-citation>
</ref>
<ref id="B215-ijms-21-03059">
<label>215.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sol</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zaheed</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Kraal</surname>
<given-names>A.Z.</given-names>
</name>
<name>
<surname>Sharifian</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Arce Rentería</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zahodne</surname>
<given-names>L.B.</given-names>
</name>
</person-group>
<article-title>Psychological Predictors of Memory Decline in a Racially and Ethnically Diverse Longitudinal Sample of Older Adults in the United States</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2019</year>
<pub-id pub-id-type="doi">10.1002/gps.5236</pub-id>
</element-citation>
</ref>
<ref id="B216-ijms-21-03059">
<label>216.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bennett</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>A.J.</given-names>
</name>
</person-group>
<article-title>Depression and dementia: Cause, consequence or coincidence?</article-title>
<source/>Maturitas
          <year>2014</year>
<volume>79</volume>
<fpage>184</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/j.maturitas.2014.05.009</pub-id>
<pub-id pub-id-type="pmid">24931304</pub-id>
</element-citation>
</ref>
<ref id="B217-ijms-21-03059">
<label>217.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norton</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carrière</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pérès</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gabelle</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Berr</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ritchie</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ancelin</surname>
<given-names>M.L.</given-names>
</name>
</person-group>
<article-title>Sex-specific depressive symptoms as markers of pre-Alzheimer dementia: Findings from the Three-City cohort study</article-title>
<source/>Transl. Psychiatry
          <year>2019</year>
<volume>9</volume>
<fpage>291</fpage>
<pub-id pub-id-type="doi">10.1038/s41398-019-0620-5</pub-id>
<pub-id pub-id-type="pmid">31712553</pub-id>
</element-citation>
</ref>
<ref id="B218-ijms-21-03059">
<label>218.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youn</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>H.G.</given-names>
</name>
</person-group>
<article-title>Association between brain amyloid accumulation and neuropsychological characteristics in elders with depression and mild cognitive impairment</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2019</year>
<volume>34</volume>
<fpage>1907</fpage>
<lpage>1915</lpage>
<pub-id pub-id-type="doi">10.1002/gps.5209</pub-id>
<pub-id pub-id-type="pmid">31489705</pub-id>
</element-citation>
</ref>
<ref id="B219-ijms-21-03059">
<label>219.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Capogna</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Manca</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Soininen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Venneri</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Understanding the effect of cognitive/brain reserve and depression on regional atrophy in early Alzheimer’s disease</article-title>
<source/>Postgrad. Med.
          <year>2019</year>
<volume>131</volume>
<fpage>533</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1080/00325481.2019.1663127</pub-id>
<pub-id pub-id-type="pmid">31478419</pub-id>
</element-citation>
</ref>
<ref id="B220-ijms-21-03059">
<label>220.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amieva</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Meillon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Proust-Lima</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dartigues</surname>
<given-names>J.F.</given-names>
</name>
</person-group>
<article-title>Is Low Psychomotor Speed a Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of Alzheimer, Parkinson, Stroke, Disability, and Depression</article-title>
<source/>Dement. Geriatr. Cogn. Disord.
          <year>2019</year>
<volume>47</volume>
<fpage>297</fpage>
<lpage>305</lpage>
<pub-id pub-id-type="doi">10.1159/000500597</pub-id>
<pub-id pub-id-type="pmid">31466055</pub-id>
</element-citation>
</ref>
<ref id="B221-ijms-21-03059">
<label>221.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Kortebi</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Karameh</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Golas</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Munoz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Barfett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Butter</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Bowie</surname>
<given-names>C.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Examining the Link Between Cardiovascular Risk Factors and Neuropsychiatric Symptoms in Mild Cognitive Impairment and Major Depressive Disorder in Remission</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>67</volume>
<fpage>1305</fpage>
<lpage>1311</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-181099</pub-id>
<pub-id pub-id-type="pmid">30741676</pub-id>
</element-citation>
</ref>
<ref id="B222-ijms-21-03059">
<label>222.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marshe</surname>
<given-names>V.S.</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Maciukiewicz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bousman</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Eyre</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Lavretsky</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mulsant</surname>
<given-names>B.H.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>C.F.</given-names>
</name>
<name>
<surname>Lenze</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic Implications for Antidepressant Pharmacotherapy in Late-Life Depression: A Systematic Review of the Literature for Response, Pharmacokinetics and Adverse Drug Reactions</article-title>
<source/>Am. J. Geriatr. Psychiatry.
          <year>2020</year>
<pub-id pub-id-type="doi">10.1016/j.jagp.2020.01.007</pub-id>
</element-citation>
</ref>
<ref id="B223-ijms-21-03059">
<label>223.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banning</surname>
<given-names>L.C.P.</given-names>
</name>
<name>
<surname>Ramakers</surname>
<given-names>I.H.G.B.</given-names>
</name>
<name>
<surname>Deckers</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Verhey</surname>
<given-names>F.R.J.</given-names>
</name>
<name>
<surname>Aalten</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Apolipoprotein E and affective symptoms in mild cognitive impairment and Alzheimer’s disease dementia: A systematic review and meta-analysis</article-title>
<source/>Neurosci. Biobehav. Rev.
          <year>2019</year>
<volume>96</volume>
<fpage>302</fpage>
<lpage>315</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.11.020</pub-id>
<pub-id pub-id-type="pmid">30513312</pub-id>
</element-citation>
</ref>
<ref id="B224-ijms-21-03059">
<label>224.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ni</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D.F.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The GWAS Risk Genes for Depression May Be Actively Involved in Alzheimer’s Disease</article-title>
<source/>J. Alzheimers Dis.
          <year>2018</year>
<volume>64</volume>
<fpage>1149</fpage>
<lpage>1161</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-180276</pub-id>
<pub-id pub-id-type="pmid">30010129</pub-id>
</element-citation>
</ref>
<ref id="B225-ijms-21-03059">
<label>225.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burke</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Goldfarb</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bollam</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Khokher</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Diagnosing and Treating Depression in Patients with Alzheimer’s Disease</article-title>
<source/>Neurol. Ther.
          <year>2019</year>
<volume>8</volume>
<fpage>325</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="doi">10.1007/s40120-019-00148-5</pub-id>
<pub-id pub-id-type="pmid">31435870</pub-id>
</element-citation>
</ref>
<ref id="B226-ijms-21-03059">
<label>226.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orgeta</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Tabet</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nilforooshan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Howard</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Efficacy of Antidepressants for Depression in Alzheimer’s Disease: Systematic Review and Meta-Analysis</article-title>
<source/>J. Alzheimers Dis.
          <year>2017</year>
<volume>58</volume>
<fpage>725</fpage>
<lpage>733</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-161247</pub-id>
<pub-id pub-id-type="pmid">28505970</pub-id>
</element-citation>
</ref>
<ref id="B227-ijms-21-03059">
<label>227.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cassano</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Calcagnini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bukke</surname>
<given-names>V.N.</given-names>
</name>
<name>
<surname>Orkisz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Villani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Avolio</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gaetani</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Pharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task</article-title>
<source/>Front. Pharmacol.
          <year>2019</year>
<volume>10</volume>
<fpage>1067</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2019.01067</pub-id>
<pub-id pub-id-type="pmid">31611786</pub-id>
</element-citation>
</ref>
<ref id="B228-ijms-21-03059">
<label>228.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Trial-and-Error versus Personalized Treatment in Depression: The Power of Pharmacogenomics</article-title>
<source/>J. Psychiatry Depress Anxiety
          <year>2016</year>
<volume>2</volume>
<pub-id pub-id-type="doi">10.24966/PDA-0150/100004</pub-id>
</element-citation>
</ref>
<ref id="B229-ijms-21-03059">
<label>229.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torrellas</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carril</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Cacabelos</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Optimization of antidepressant use with pharmacogenetic strategies</article-title>
<source/>Curr. Genom.
          <year>2017</year>
<volume>18</volume>
<fpage>442</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.2174/1389202918666170426164940</pub-id>
<pub-id pub-id-type="pmid">29081699</pub-id>
</element-citation>
</ref>
<ref id="B230-ijms-21-03059">
<label>230.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thase</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Parikh</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Rothschild</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Dunlop</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>DeBattista</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Conway</surname>
<given-names>C.R.</given-names>
</name>
<name>
<surname>Mondimore</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Shelton</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Macaluso</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of Pharmacogenomics on Clinical Outcomes for Patients Taking Medications With Gene-Drug Interactions in a Randomized Controlled Trial</article-title>
<source/>J. Clin. Psychiatry
          <year>2019</year>
<volume>80</volume>
<fpage>19m12910</fpage>
<pub-id pub-id-type="doi">10.4088/JCP.19m12910</pub-id>
<pub-id pub-id-type="pmid">31721487</pub-id>
</element-citation>
</ref>
<ref id="B231-ijms-21-03059">
<label>231.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maggo</surname>
<given-names>S.D.S.</given-names>
</name>
<name>
<surname>Sycamore</surname>
<given-names>K.L.V.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>The Three Ps: Psychiatry, Pharmacy, and Pharmacogenomics, a Brief Report from New Zealand</article-title>
<source/>Front. Psychiatry
          <year>2019</year>
<volume>10</volume>
<fpage>690</fpage>
<pub-id pub-id-type="doi">10.3389/fpsyt.2019.00690</pub-id>
<pub-id pub-id-type="pmid">31616328</pub-id>
</element-citation>
</ref>
<ref id="B232-ijms-21-03059">
<label>232.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eugene</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>Optimizing drug selection in psychopharmacology based on 40 significant CYP2C19- and CYP2D6-biased adverse drug reactions of selective serotonin reuptake inhibitors</article-title>
<source/>PeerJ
          <year>2019</year>
<volume>7</volume>
<fpage>e7860</fpage>
<pub-id pub-id-type="doi">10.7717/peerj.7860</pub-id>
<pub-id pub-id-type="pmid">31616600</pub-id>
</element-citation>
</ref>
<ref id="B233-ijms-21-03059">
<label>233.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danese</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Federico</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Martini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mantovani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zucchella</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tagliapietra</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tamburin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Marafioti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>QTc Prolongation in Patients with Dementia and Mild Cognitive Impairment: Neuropsychological and Brain Imaging Correlations</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>72</volume>
<fpage>1241</fpage>
<lpage>1249</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-190632</pub-id>
<pub-id pub-id-type="pmid">31683480</pub-id>
</element-citation>
</ref>
<ref id="B234-ijms-21-03059">
<label>234.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanders</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Pisanu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bandstein</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jonsson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Castelao</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pistis</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gholam-Rezaee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Eap</surname>
<given-names>C.B.</given-names>
</name>
<name>
<surname>Preisig</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schioth</surname>
<given-names>H.B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants</article-title>
<source/>Drug Dev. Res.
          <year>2020</year>
<volume>81</volume>
<fpage>102</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="doi">10.1002/ddr.21609</pub-id>
<pub-id pub-id-type="pmid">31617956</pub-id>
</element-citation>
</ref>
<ref id="B235-ijms-21-03059">
<label>235.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Oliveira</surname>
<given-names>F.F.</given-names>
</name>
<name>
<surname>Berretta</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>de Almeida Junior</surname>
<given-names>G.V.</given-names>
</name>
<name>
<surname>de Almeida</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Bertolucci</surname>
<given-names>P.H.F.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer’s dementia</article-title>
<source/>Indian J. Med. Res.
          <year>2019</year>
<volume>150</volume>
<fpage>261</fpage>
<lpage>271</lpage>
<pub-id pub-id-type="doi">10.4103/ijmr.IJMR_1209_17</pub-id>
<pub-id pub-id-type="pmid">31719297</pub-id>
</element-citation>
</ref>
<ref id="B236-ijms-21-03059">
<label>236.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hicks</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Gammal</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Sangkuhl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bousman</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Leeder</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2019</year>
<pub-id pub-id-type="doi">10.1002/cpt.1661</pub-id>
</element-citation>
</ref>
<ref id="B237-ijms-21-03059">
<label>237.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caudle</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Sangkuhl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Whirl-Carrillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Swen</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Haidar</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Gammal</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Relling</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Hertz</surname>
<given-names>D.L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group</article-title>
<source/>Clin. Transl. Sci.
          <year>2020</year>
<volume>13</volume>
<fpage>116</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="doi">10.1111/cts.12692</pub-id>
<pub-id pub-id-type="pmid">31647186</pub-id>
</element-citation>
</ref>
<ref id="B238-ijms-21-03059">
<label>238.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nofziger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Sangkuhl</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Whirl-Carrillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Agúndez</surname>
<given-names>J.A.G.</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Dunnenberger</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Ruano</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>M.S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PharmVar GeneReview: CYP2D</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2020</year>
<volume>107</volume>
<fpage>154</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1002/cpt.1643</pub-id>
<pub-id pub-id-type="pmid">31544239</pub-id>
</element-citation>
</ref>
<ref id="B239-ijms-21-03059">
<label>239.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagani</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gasparini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ielmini</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Caselli</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Poloni</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Callegari</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Twenty years of Lithium pharmacogenetics: A systematic review</article-title>
<source/>Psychiatry Res.
          <year>2019</year>
<volume>278</volume>
<fpage>42</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2019.05.036</pub-id>
<pub-id pub-id-type="pmid">31146140</pub-id>
</element-citation>
</ref>
<ref id="B240-ijms-21-03059">
<label>240.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Orellana Rios</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Lahmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rücker</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Boeker</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Anxiety as a risk factor of Alzheimer’s disease and vascular dementia</article-title>
<source/>Br. J. Psychiatry
          <year>2018</year>
<volume>213</volume>
<fpage>654</fpage>
<lpage>660</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.2018.173</pub-id>
<pub-id pub-id-type="pmid">30339108</pub-id>
</element-citation>
</ref>
<ref id="B241-ijms-21-03059">
<label>241.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santabárbara</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lipnicki</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Bueno-Notivol</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Olaya-Guzmán</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Villagrasa</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>López-Antón</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Updating the evidence for an association between anxiety and risk of Alzheimer’s disease: A meta-analysis of prospective cohort studies</article-title>
<source/>J. Affect. Disord.
          <year>2019</year>
<volume>262</volume>
<fpage>397</fpage>
<lpage>404</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2019.11.065</pub-id>
<pub-id pub-id-type="pmid">31744742</pub-id>
</element-citation>
</ref>
<ref id="B242-ijms-21-03059">
<label>242.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baillon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gasper</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wilson-Morkeh</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pritchard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jesu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Velayudhan</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Prevalence and Severity of Neuropsychiatric Symptoms in Early- Versus Late-Onset Alzheimer’s Disease</article-title>
<source/>Am. J. Alzheimers Dis. Other Demen.
          <year>2019</year>
<volume>34</volume>
<fpage>433</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1177/1533317519841191</pub-id>
<pub-id pub-id-type="pmid">30935215</pub-id>
</element-citation>
</ref>
<ref id="B243-ijms-21-03059">
<label>243.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Scheininger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ewers</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jesse</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zuo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers</article-title>
<source/>Alzheimers Res. Ther.
          <year>2019</year>
<volume>11</volume>
<fpage>50</fpage>
<pub-id pub-id-type="doi">10.1186/s13195-019-0505-0</pub-id>
<pub-id pub-id-type="pmid">31159873</pub-id>
</element-citation>
</ref>
<ref id="B244-ijms-21-03059">
<label>244.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vlachos</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Cosentino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kosmidis</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Anastasiou</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Yannakoulia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dardiotis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hadjigeorgiou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sakka</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ntanasi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Scarmeas</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Prevalence and determinants of subjective cognitive decline in a representative Greek elderly population</article-title>
<source/>Int. J. Geriatr. Psychiatry.
          <year>2019</year>
<volume>34</volume>
<fpage>846</fpage>
<lpage>854</lpage>
<pub-id pub-id-type="doi">10.1002/gps.5073</pub-id>
<pub-id pub-id-type="pmid">30714214</pub-id>
</element-citation>
</ref>
<ref id="B245-ijms-21-03059">
<label>245.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nafti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sirois</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kröger</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Carmichael</surname>
<given-names>P.H.</given-names>
</name>
<name>
<surname>Laurin</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Is Benzodiazepine Use Associated With the Risk of Dementia and Cognitive Impairment-Not Dementia in Older Persons? The Canadian Study of Health and Aging</article-title>
<source/>Ann. Pharmacother.
          <year>2020</year>
<volume>54</volume>
<fpage>219</fpage>
<lpage>225</lpage>
<pub-id pub-id-type="doi">10.1177/1060028019882037</pub-id>
<pub-id pub-id-type="pmid">31595772</pub-id>
</element-citation>
</ref>
<ref id="B246-ijms-21-03059">
<label>246.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Overeem</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Claassen</surname>
<given-names>J.A.H.R.</given-names>
</name>
</person-group>
<article-title>Long-Term Occupational Sleep Loss and Post-Retirement Cognitive Decline or Dementia</article-title>
<source/>Dement. Geriatr. Cogn. Disord.
          <year>2019</year>
<volume>48</volume>
<fpage>105</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1159/000504020</pub-id>
<pub-id pub-id-type="pmid">31726459</pub-id>
</element-citation>
</ref>
<ref id="B247-ijms-21-03059">
<label>247.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Musiek</surname>
<given-names>E.S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cappuccio</surname>
<given-names>F.P.</given-names>
</name>
<name>
<surname>Yaffe</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Association between circadian rhythms and neurodegenerative diseases</article-title>
<source/>Lancet Neurol.
          <year>2019</year>
<volume>18</volume>
<fpage>307</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(18)30461-7</pub-id>
<pub-id pub-id-type="pmid">30784558</pub-id>
</element-citation>
</ref>
<ref id="B248-ijms-21-03059">
<label>248.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minakawa</surname>
<given-names>E.N.</given-names>
</name>
<name>
<surname>Wada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Sleep Disturbance as a Potential Modifiable Risk Factor for Alzheimer’s Disease</article-title>
<source/>Int. J. Mol. Sci.
          <year>2019</year>
<volume>20</volume>
<elocation-id>803</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms20040803</pub-id>
</element-citation>
</ref>
<ref id="B249-ijms-21-03059">
<label>249.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duncan</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Interacting influences of aging and Alzheimer’s disease on circadian rhythms</article-title>
<source/>Eur. J. Neurosci.
          <year>2020</year>
<volume>51</volume>
<fpage>310</fpage>
<lpage>325</lpage>
<pub-id pub-id-type="doi">10.1111/ejn.14358</pub-id>
<pub-id pub-id-type="pmid">30689226</pub-id>
</element-citation>
</ref>
<ref id="B250-ijms-21-03059">
<label>250.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yesavage</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Noda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>McNerney</surname>
<given-names>M.W.</given-names>
</name>
<name>
<surname>Domingue</surname>
<given-names>B.W.</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Benson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hallmayer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>O’Hara</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>L.M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Sleep-wake disorders in Alzheimer’s disease: Further genetic analyses in relation to objective sleep measures</article-title>
<source/>Int. Psychogeriatr.
          <year>2019</year>
<fpage>1</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="doi">10.1017/S1041610219001777</pub-id>
</element-citation>
</ref>
<ref id="B251-ijms-21-03059">
<label>251.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Abnormal circadian locomotor rhythms and Per gene expression in six-month-old triple transgenic mice model of Alzheimer’s disease</article-title>
<source/>Neurosci. Lett.
          <year>2018</year>
<volume>676</volume>
<fpage>13</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2018.04.008</pub-id>
<pub-id pub-id-type="pmid">29626648</pub-id>
</element-citation>
</ref>
<ref id="B252-ijms-21-03059">
<label>252.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rainey-Smith</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Mazzucchelli</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Villemagne</surname>
<given-names>V.L.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Weinborn</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bucks</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Milicic</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sohrabi</surname>
<given-names>H.R.</given-names>
</name>
<name>
<surname>Taddei</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain Aβ-amyloid burden</article-title>
<source/>Transl. Psychiatry
          <year>2018</year>
<volume>8</volume>
<fpage>47</fpage>
<pub-id pub-id-type="doi">10.1038/s41398-018-0094-x</pub-id>
<pub-id pub-id-type="pmid">29479071</pub-id>
</element-citation>
</ref>
<ref id="B253-ijms-21-03059">
<label>253.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Monroe</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Diering</surname>
<given-names>G.H.</given-names>
</name>
</person-group>
<article-title>Homer1a and mGluR1/5 Signaling in Homeostatic Sleep Drive and Output</article-title>
<source/>Yale J. Biol. Med.
          <year>2019</year>
<volume>92</volume>
<fpage>93</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">30923476</pub-id>
</element-citation>
</ref>
<ref id="B254-ijms-21-03059">
<label>254.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manni</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cremascoli</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Perretti</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Icco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Picascia</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ghezzi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cerri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sinforiani</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Terzaghi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity</article-title>
<source/>Sleep Med.
          <year>2019</year>
<volume>63</volume>
<fpage>122</fpage>
<lpage>126</lpage>
<pub-id pub-id-type="doi">10.1016/j.sleep.2019.04.018</pub-id>
<pub-id pub-id-type="pmid">31622953</pub-id>
</element-citation>
</ref>
<ref id="B255-ijms-21-03059">
<label>255.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chauhan</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Mallick</surname>
<given-names>B.N.</given-names>
</name>
</person-group>
<article-title>Association between autophagy and rapid eye movement sleep loss-associated neurodegenerative and patho-physio-behavioral changes</article-title>
<source/>Sleep Med.
          <year>2019</year>
<volume>63</volume>
<fpage>29</fpage>
<lpage>37</lpage>
<pub-id pub-id-type="doi">10.1016/j.sleep.2019.04.019</pub-id>
<pub-id pub-id-type="pmid">31605901</pub-id>
</element-citation>
</ref>
<ref id="B256-ijms-21-03059">
<label>256.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>You</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Lyon</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Newberg</surname>
<given-names>A.B.</given-names>
</name>
<name>
<surname>Lippa</surname>
<given-names>C.F.</given-names>
</name>
</person-group>
<article-title>Association of β-Amyloid Burden With Sleep Dysfunction and Cognitive Impairment in Elderly Individuals With Cognitive Disorders</article-title>
<source/>JAMA Netw. Open
          <year>2019</year>
<volume>2</volume>
<fpage>e1913383</fpage>
<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.13383</pub-id>
<pub-id pub-id-type="pmid">31617927</pub-id>
</element-citation>
</ref>
<ref id="B257-ijms-21-03059">
<label>257.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Holtzman</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Bidirectional relationship between sleep and Alzheimer’s disease: Role of amyloid, tau, and other factors</article-title>
<source/>Neuropsychopharmacology
          <year>2020</year>
<volume>45</volume>
<fpage>104</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1038/s41386-019-0478-5</pub-id>
<pub-id pub-id-type="pmid">31408876</pub-id>
</element-citation>
</ref>
<ref id="B258-ijms-21-03059">
<label>258.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic Sleep Restriction Induces Aβ Accumulation by Disrupting the Balance of Aβ Production and Clearance in Rats</article-title>
<source/>Neurochem. Res.
          <year>2019</year>
<volume>44</volume>
<fpage>859</fpage>
<lpage>873</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-019-02719-2</pub-id>
<pub-id pub-id-type="pmid">30632087</pub-id>
</element-citation>
</ref>
<ref id="B259-ijms-21-03059">
<label>259.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Alteration in sleep architecture and electroencephalogram as an early sign of Alzheimer’s disease preceding the disease pathology and cognitive decline</article-title>
<source/>Alzheimers Dement.
          <year>2019</year>
<volume>15</volume>
<fpage>590</fpage>
<lpage>597</lpage>
<pub-id pub-id-type="doi">10.1016/j.jalz.2018.12.004</pub-id>
<pub-id pub-id-type="pmid">30819626</pub-id>
</element-citation>
</ref>
<ref id="B260-ijms-21-03059">
<label>260.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taillard</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sagaspe</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Berthomier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Brandewinder</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Amieva</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dartigues</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Rainfrau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Harston</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Micoulaud-Franchi</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Philip</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Non-REM Sleep Characteristics Predict Early Cognitive Impairment in an Aging Population</article-title>
<source/>Front. Neurol.
          <year>2019</year>
<volume>10</volume>
<fpage>197</fpage>
<pub-id pub-id-type="doi">10.3389/fneur.2019.00197</pub-id>
<pub-id pub-id-type="pmid">30918496</pub-id>
</element-citation>
</ref>
<ref id="B261-ijms-21-03059">
<label>261.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Amyloid β and tau are involved in sleep disorder in Alzheimer’s disease by orexin A and adenosine A(1) receptor</article-title>
<source/>Int. J. Mol. Med.
          <year>2019</year>
<volume>43</volume>
<fpage>435</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.3892/ijmm.2018.3935</pub-id>
<pub-id pub-id-type="pmid">30365112</pub-id>
</element-citation>
</ref>
<ref id="B262-ijms-21-03059">
<label>262.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herring</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Krystal</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Michelson</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications</article-title>
<source/>J. Sleep Res.
          <year>2019</year>
<volume>28</volume>
<fpage>e12782</fpage>
<pub-id pub-id-type="doi">10.1111/jsr.12782</pub-id>
<pub-id pub-id-type="pmid">30338596</pub-id>
</element-citation>
</ref>
<ref id="B263-ijms-21-03059">
<label>263.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicastro</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Assal</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Seeck</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>From here to epilepsy: The risk of seizure in patients with Alzheimer’s disease</article-title>
<source/>Epileptic Disord.
          <year>2016</year>
<volume>18</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1684/epd.2016.0808</pub-id>
<pub-id pub-id-type="pmid">26907471</pub-id>
</element-citation>
</ref>
<ref id="B264-ijms-21-03059">
<label>264.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>von Rüden</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Zellinger</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gedon</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bierling</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Deeg</surname>
<given-names>C.A.</given-names>
</name>
</person-group>
<article-title>Regulation of Alzheimer’s Disease-Associated Proteins During the Course of Epileptogenesis: Differential Proteomic Analysis in a Rat Model</article-title>
<source/>Neuroscience
          <year>2020</year>
<volume>424</volume>
<fpage>102</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2019.08.037</pub-id>
<pub-id pub-id-type="pmid">31705965</pub-id>
</element-citation>
</ref>
<ref id="B265-ijms-21-03059">
<label>265.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zelano</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Brigo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Garcia-Patek</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Increased risk of epilepsy in patients registered in the Swedish Dementia Registry</article-title>
<source/>Eur. J. Neurol.
          <year>2020</year>
<volume>27</volume>
<fpage>129</fpage>
<lpage>135</lpage>
<pub-id pub-id-type="doi">10.1111/ene.14043</pub-id>
<pub-id pub-id-type="pmid">31330091</pub-id>
</element-citation>
</ref>
<ref id="B266-ijms-21-03059">
<label>266.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tábuas-Pereira</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Durães</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lopes</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sales</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bento</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Duro</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Santiago</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Leitao</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Balderias</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Increased CSF tau is associated with a higher risk of seizures in patients with Alzheimer’s disease</article-title>
<source/>Epilepsy Behav.
          <year>2019</year>
<volume>98</volume>
<fpage>207</fpage>
<lpage>209</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2019.06.033</pub-id>
<pub-id pub-id-type="pmid">31382178</pub-id>
</element-citation>
</ref>
<ref id="B267-ijms-21-03059">
<label>267.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Stage-dependent involvement of ADAM10 and its significance in epileptic seizures</article-title>
<source/>J. Cell Mol. Med.
          <year>2019</year>
<volume>23</volume>
<fpage>4494</fpage>
<lpage>4504</lpage>
<pub-id pub-id-type="doi">10.1111/jcmm.14307</pub-id>
<pub-id pub-id-type="pmid">31087543</pub-id>
</element-citation>
</ref>
<ref id="B268-ijms-21-03059">
<label>268.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Galer</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mas</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Mapping the knowledge structure and trends of epilepsy genetics over the past decade: A co-word analysis based on medical subject headings terms</article-title>
<source/>Medicine
          <year>2019</year>
<volume>98</volume>
<fpage>e16782</fpage>
<pub-id pub-id-type="doi">10.1097/MD.0000000000016782</pub-id>
<pub-id pub-id-type="pmid">31393404</pub-id>
</element-citation>
</ref>
<ref id="B269-ijms-21-03059">
<label>269.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al-Eitan</surname>
<given-names>L.N.</given-names>
</name>
<name>
<surname>Al-Dalalah</surname>
<given-names>I.M.</given-names>
</name>
<name>
<surname>Mustafa</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Alghamdi</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Elshammari</surname>
<given-names>A.K.</given-names>
</name>
<name>
<surname>Khreisat</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Aljamal</surname>
<given-names>H.A.</given-names>
</name>
</person-group>
<article-title>Effects of MTHFR and ABCC2 gene polymorphisms on antiepileptic drug responsiveness in Jordanian epileptic patients</article-title>
<source/>Pharmgenom. Personalized Med.
          <year>2019</year>
<volume>12</volume>
<fpage>87</fpage>
<lpage>95</lpage>
<pub-id pub-id-type="doi">10.2147/PGPM.S211490</pub-id>
<pub-id pub-id-type="pmid">31354331</pub-id>
</element-citation>
</ref>
<ref id="B270-ijms-21-03059">
<label>270.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vossel</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Tartaglia</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Nygaard</surname>
<given-names>H.B.</given-names>
</name>
<name>
<surname>Zeman</surname>
<given-names>A.Z.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>B.L.</given-names>
</name>
</person-group>
<article-title>Epileptic activity in Alzheimer’s disease: Causes and clinical relevance</article-title>
<source/>Lancet Neurol.
          <year>2017</year>
<volume>16</volume>
<fpage>311</fpage>
<lpage>322</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(17)30044-3</pub-id>
<pub-id pub-id-type="pmid">28327340</pub-id>
</element-citation>
</ref>
<ref id="B271-ijms-21-03059">
<label>271.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giorgi</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Guida</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vergallo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonuccelli</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Zaccara</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Treatment of epilepsy in patients with Alzheimer’s disease</article-title>
<source/>Expert Rev. Neurother.
          <year>2017</year>
<volume>17</volume>
<fpage>309</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="doi">10.1080/14737175.2017.1243469</pub-id>
<pub-id pub-id-type="pmid">27687685</pub-id>
</element-citation>
</ref>
<ref id="B272-ijms-21-03059">
<label>272.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thijs</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Surges</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J.W.</given-names>
</name>
</person-group>
<article-title>Epilepsy in adults</article-title>
<source/>Lancet
          <year>2019</year>
<volume>393</volume>
<fpage>689</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(18)32596-0</pub-id>
<pub-id pub-id-type="pmid">30686584</pub-id>
</element-citation>
</ref>
<ref id="B273-ijms-21-03059">
<label>273.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Z.W.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>C.X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.B.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>PRRT2 mutations are related to febrile seizures in epileptic patients</article-title>
<source/>Int. J. Mol. Sci.
          <year>2014</year>
<volume>15</volume>
<fpage>23408</fpage>
<lpage>23417</lpage>
<pub-id pub-id-type="doi">10.3390/ijms151223408</pub-id>
<pub-id pub-id-type="pmid">25522171</pub-id>
</element-citation>
</ref>
<ref id="B274-ijms-21-03059">
<label>274.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haerian</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cherry</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.E.</given-names>
</name>
</person-group>
<article-title>Contribution of GABRG2 polymorphisms to risk of epilepsy and febrile seizure: A multicenter cohort study and meta-analysis</article-title>
<source/>Mol. Neurobiol.
          <year>2016</year>
<volume>53</volume>
<fpage>5457</fpage>
<lpage>5467</lpage>
<pub-id pub-id-type="doi">10.1007/s12035-015-9457-y</pub-id>
<pub-id pub-id-type="pmid">26452361</pub-id>
</element-citation>
</ref>
<ref id="B275-ijms-21-03059">
<label>275.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.P.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.L.</given-names>
</name>
</person-group>
<article-title>The pharmacogenomics of valproic acid</article-title>
<source/>J. Hum. Genet.
          <year>2017</year>
<volume>62</volume>
<fpage>1009</fpage>
<lpage>1014</lpage>
<pub-id pub-id-type="doi">10.1038/jhg.2017.91</pub-id>
<pub-id pub-id-type="pmid">28878340</pub-id>
</element-citation>
</ref>
<ref id="B276-ijms-21-03059">
<label>276.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<fpage>1867</fpage>
<lpage>1879</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.14.142</pub-id>
<pub-id pub-id-type="pmid">25495409</pub-id>
</element-citation>
</ref>
<ref id="B277-ijms-21-03059">
<label>277.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>X.Q.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>W.K.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>G.H.</given-names>
</name>
</person-group>
<article-title>Effect of UGT2B7 genotypes on plasma concentration of valproic acid: A meta-analysis</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2018</year>
<volume>74</volume>
<fpage>433</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-017-2395-z</pub-id>
<pub-id pub-id-type="pmid">29243113</pub-id>
</element-citation>
</ref>
<ref id="B278-ijms-21-03059">
<label>278.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>Association of genetic variants in six candidate genes with valproic acid therapy optimization</article-title>
<source/>Pharmacogenomics
          <year>2011</year>
<volume>12</volume>
<fpage>1107</fpage>
<lpage>1117</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.11.64</pub-id>
<pub-id pub-id-type="pmid">21806385</pub-id>
</element-citation>
</ref>
<ref id="B279-ijms-21-03059">
<label>279.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balestrini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sisodiya</surname>
<given-names>S.M.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics in epilepsy</article-title>
<source/>Neurosci. Lett.
          <year>2018</year>
<volume>667</volume>
<fpage>27</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2017.01.014</pub-id>
<pub-id pub-id-type="pmid">28082152</pub-id>
</element-citation>
</ref>
<ref id="B280-ijms-21-03059">
<label>280.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>R.H.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X.Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese</article-title>
<source/>Pharmacogenomics
          <year>2016</year>
<volume>17</volume>
<fpage>2007</fpage>
<lpage>2014</lpage>
<pub-id pub-id-type="doi">10.2217/pgs-2016-0093</pub-id>
<pub-id pub-id-type="pmid">27918244</pub-id>
</element-citation>
</ref>
<ref id="B281-ijms-21-03059">
<label>281.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soraoka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kajiwara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tanamachi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oniki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ishitsu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Saruwatari</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain</article-title>
<source/>Acta Neurol. Scand.
          <year>2016</year>
<volume>133</volume>
<fpage>216</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1111/ane.12473</pub-id>
<pub-id pub-id-type="pmid">26223287</pub-id>
</element-citation>
</ref>
<ref id="B282-ijms-21-03059">
<label>282.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid</article-title>
<source/>Int. J. Neuropsychopharmacol.
          <year>2015</year>
<volume>18</volume>
<fpage>pyv021</fpage>
<pub-id pub-id-type="doi">10.1093/ijnp/pyv021</pub-id>
<pub-id pub-id-type="pmid">25740917</pub-id>
</element-citation>
</ref>
<ref id="B283-ijms-21-03059">
<label>283.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors</article-title>
<source/>Eur. J. Pharm. Sci.
          <year>2018</year>
<volume>122</volume>
<fpage>170</fpage>
<lpage>178</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejps.2018.06.033</pub-id>
<pub-id pub-id-type="pmid">29981400</pub-id>
</element-citation>
</ref>
<ref id="B284-ijms-21-03059">
<label>284.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wen</surname>
<given-names>Z.P.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Z.F.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients</article-title>
<source/>Pharmacogenomics
          <year>2016</year>
<volume>17</volume>
<fpage>1219</fpage>
<lpage>1225</lpage>
<pub-id pub-id-type="doi">10.2217/pgs-2016-0030</pub-id>
<pub-id pub-id-type="pmid">27406852</pub-id>
</element-citation>
</ref>
<ref id="B285-ijms-21-03059">
<label>285.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.Q.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Sodium valproate ameliorates neuronal apoptosis in a kainic acid model of epilepsy via enhancing PKC-dependent GABAAR γ2 serine 327 phosphorylation</article-title>
<source/>Neurochem. Res.
          <year>2018</year>
<volume>43</volume>
<fpage>2343</fpage>
<lpage>2352</lpage>
<pub-id pub-id-type="doi">10.1007/s11064-018-2659-8</pub-id>
<pub-id pub-id-type="pmid">30311181</pub-id>
</element-citation>
</ref>
<ref id="B286-ijms-21-03059">
<label>286.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogusu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Saruwatari</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Noai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Deguchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Oniki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yasui-Furokori</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kaneko</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ishitsu</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of γ-glutamyltransferase in patients with epilepsy: A population pharmacokinetic-pharmacodynamic analysis</article-title>
<source/>PLoS ONE
          <year>2014</year>
<volume>9</volume>
<elocation-id>e111066</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0111066</pub-id>
<pub-id pub-id-type="pmid">25372290</pub-id>
</element-citation>
</ref>
<ref id="B287-ijms-21-03059">
<label>287.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shirzadi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reimers</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Helde</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Sjursen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Brodtkorb</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients</article-title>
<source/>Seizure
          <year>2017</year>
<volume>45</volume>
<fpage>169</fpage>
<lpage>171</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2016.12.015</pub-id>
<pub-id pub-id-type="pmid">28068583</pub-id>
</element-citation>
</ref>
<ref id="B288-ijms-21-03059">
<label>288.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>A population Pharmacokinetic-Pharmacogenetic model of lamotrigine in Chinese children with epilepsy</article-title>
<source/>Ther. Drug Monit.
          <year>2018</year>
<volume>40</volume>
<fpage>730</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1097/FTD.0000000000000563</pub-id>
<pub-id pub-id-type="pmid">30169477</pub-id>
</element-citation>
</ref>
<ref id="B289-ijms-21-03059">
<label>289.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.X.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>R.Y.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.R.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.L.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>M.P.</given-names>
</name>
</person-group>
<article-title>Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy</article-title>
<source/>Epilepsy Res.
          <year>2016</year>
<volume>127</volume>
<fpage>186</fpage>
<lpage>190</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2016.09.004</pub-id>
<pub-id pub-id-type="pmid">27610747</pub-id>
</element-citation>
</ref>
<ref id="B290-ijms-21-03059">
<label>290.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients</article-title>
<source/>Drug Metab. Pharmacokinet.
          <year>2015</year>
<volume>30</volume>
<fpage>282</fpage>
<lpage>287</lpage>
<pub-id pub-id-type="doi">10.1016/j.dmpk.2015.05.002</pub-id>
<pub-id pub-id-type="pmid">26213157</pub-id>
</element-citation>
</ref>
<ref id="B291-ijms-21-03059">
<label>291.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Sukasem</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Whirl-Carrillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Müller</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Dunnenberger</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Chantratita</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Goldspiel</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Carleton</surname>
<given-names>B.C.</given-names>
</name>
</person-group>
<article-title>Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update</article-title>
<source/>Clin. Pharmacol. Ther.
          <year>2018</year>
<volume>103</volume>
<fpage>574</fpage>
<lpage>581</lpage>
<pub-id pub-id-type="doi">10.1002/cpt.1004</pub-id>
<pub-id pub-id-type="pmid">29392710</pub-id>
</element-citation>
</ref>
<ref id="B292-ijms-21-03059">
<label>292.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Association between HLA-B*15:02 and oxcarbazepine-induced cutaneous adverse reaction: A meta-analysis</article-title>
<source/>Pharmacogenomics
          <year>2018</year>
<volume>19</volume>
<fpage>547</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="doi">10.2217/pgs-2017-0189</pub-id>
<pub-id pub-id-type="pmid">29629814</pub-id>
</element-citation>
</ref>
<ref id="B293-ijms-21-03059">
<label>293.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheung</surname>
<given-names>Y.K.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>1307</fpage>
<lpage>1314</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12217</pub-id>
<pub-id pub-id-type="pmid">23692434</pub-id>
</element-citation>
</ref>
<ref id="B294-ijms-21-03059">
<label>294.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hosono</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nsksmura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kamatani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kubo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>New pharmacogenetic test for detecting an HLA-A*31: 01 allele using the InvaderPlus assay</article-title>
<source/>Pharmacogenet. Genom.
          <year>2012</year>
<volume>22</volume>
<fpage>441</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e3283527c40</pub-id>
</element-citation>
</ref>
<ref id="B295-ijms-21-03059">
<label>295.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simper</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Gräser</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Celik</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Kuhn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kunze-Schumacher</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hò</surname>
<given-names>G.T.</given-names>
</name>
</person-group>
<article-title>The Mechanistic Differences in HLA-Associated Carbamazepine Hypersensitivity</article-title>
<source/>Pharmaceutics
          <year>2019</year>
<volume>11</volume>
<elocation-id>536</elocation-id>
<pub-id pub-id-type="doi">10.3390/pharmaceutics11100536</pub-id>
</element-citation>
</ref>
<ref id="B296-ijms-21-03059">
<label>296.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.H.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G.L.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.Q.</given-names>
</name>
</person-group>
<article-title>Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up</article-title>
<source/>CNS Neurosci. Ther.
          <year>2012</year>
<volume>18</volume>
<fpage>566</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-5949.2012.00321.x</pub-id>
<pub-id pub-id-type="pmid">22591328</pub-id>
</element-citation>
</ref>
<ref id="B297-ijms-21-03059">
<label>297.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Effects of ABCB1, ABCC2, UGT2B7 and HNF4α genetic polymorphisms on oxcarbazepine concentrations and therapeutic efficacy in patients with epilepsy</article-title>
<source/>Seizure
          <year>2017</year>
<volume>51</volume>
<fpage>102</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2017.07.015</pub-id>
<pub-id pub-id-type="pmid">28837897</pub-id>
</element-citation>
</ref>
<ref id="B298-ijms-21-03059">
<label>298.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djordjevic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jankovic</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Milovanovic</surname>
<given-names>J.R.</given-names>
</name>
</person-group>
<article-title>Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children</article-title>
<source/>Eur. J. Drug Metab. Pharmacokinet.
          <year>2017</year>
<volume>42</volume>
<fpage>729</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1007/s13318-016-0397-3</pub-id>
<pub-id pub-id-type="pmid">28064419</pub-id>
</element-citation>
</ref>
<ref id="B299-ijms-21-03059">
<label>299.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H.Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.Q.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.T.</given-names>
</name>
</person-group>
<article-title>Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy</article-title>
<source/>Epilepsy Res.
          <year>2015</year>
<volume>117</volume>
<fpage>52</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2015.09.001</pub-id>
<pub-id pub-id-type="pmid">26421491</pub-id>
</element-citation>
</ref>
<ref id="B300-ijms-21-03059">
<label>300.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>M.K.</given-names>
</name>
</person-group>
<article-title>Association between PK/PD-involved gene polymorphisms and carbamazepine-individualized therapy</article-title>
<source/>Pharmacogenomics
          <year>2015</year>
<volume>16</volume>
<fpage>1499</fpage>
<lpage>1512</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.15.94</pub-id>
<pub-id pub-id-type="pmid">26314341</pub-id>
</element-citation>
</ref>
<ref id="B301-ijms-21-03059">
<label>301.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Jiao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>M.K.</given-names>
</name>
</person-group>
<article-title>SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy</article-title>
<source/>Pharmacogenomics
          <year>2015</year>
<volume>16</volume>
<fpage>347</fpage>
<lpage>360</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.14.186</pub-id>
<pub-id pub-id-type="pmid">25823783</pub-id>
</element-citation>
</ref>
<ref id="B302-ijms-21-03059">
<label>302.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization</article-title>
<source/>Pharmacogenomics
          <year>2012</year>
<volume>13</volume>
<fpage>159</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.11.141</pub-id>
<pub-id pub-id-type="pmid">22188362</pub-id>
</element-citation>
</ref>
<ref id="B303-ijms-21-03059">
<label>303.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>Y.H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Chiou</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients</article-title>
<source/>Pharmacogenomics
          <year>2012</year>
<volume>13</volume>
<fpage>1339</fpage>
<lpage>1349</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.12.117</pub-id>
<pub-id pub-id-type="pmid">22966884</pub-id>
</element-citation>
</ref>
<ref id="B304-ijms-21-03059">
<label>304.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W.C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Hui</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>J.C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variants associated with phenytoin-related severe cutaneous adverse reactions</article-title>
<source/>JAMA
          <year>2014</year>
<volume>312</volume>
<fpage>525</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="doi">10.1001/jama.2014.7859</pub-id>
<pub-id pub-id-type="pmid">25096692</pub-id>
</element-citation>
</ref>
<ref id="B305-ijms-21-03059">
<label>305.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCormack</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ingason</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Speed</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>G.E.B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Secolin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wolkings</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients</article-title>
<source/>Neurology
          <year>2018</year>
<volume>90</volume>
<fpage>e332</fpage>
<lpage>e341</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000004853</pub-id>
<pub-id pub-id-type="pmid">29288229</pub-id>
</element-citation>
</ref>
<ref id="B306-ijms-21-03059">
<label>306.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glauser</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Holland</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>V.P.</given-names>
</name>
<name>
<surname>Keddache</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>P.O.</given-names>
</name>
<name>
<surname>Cnaan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dlugos</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hirtz</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Shinnar</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy</article-title>
<source/>Ann. Neurol.
          <year>2017</year>
<volume>81</volume>
<fpage>444</fpage>
<lpage>453</lpage>
<pub-id pub-id-type="doi">10.1002/ana.24886</pub-id>
<pub-id pub-id-type="pmid">28165634</pub-id>
</element-citation>
</ref>
<ref id="B307-ijms-21-03059">
<label>307.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogawski</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs</article-title>
<source/>Epilepsia
          <year>2013</year>
<volume>54</volume>
<fpage>33</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12182</pub-id>
</element-citation>
</ref>
<ref id="B308-ijms-21-03059">
<label>308.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haerian</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Roslan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Raymond</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Zulkifli</surname>
<given-names>S.Z.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>E.H.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis</article-title>
<source/>Seizure
          <year>2010</year>
<volume>19</volume>
<fpage>339</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2010.05.004</pub-id>
<pub-id pub-id-type="pmid">20605481</pub-id>
</element-citation>
</ref>
<ref id="B309-ijms-21-03059">
<label>309.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ajmi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boujaafar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zouari</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Amor</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Nasr</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rejeb</surname>
<given-names>N.B.</given-names>
</name>
<name>
<surname>Amor</surname>
<given-names>S.B.</given-names>
</name>
<name>
<surname>Omezzine</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Benammou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bouslama</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Association between ABCB1 polymorphisms and response to first-generation antiepileptic drugs in a Tunisian epileptic population</article-title>
<source/>Int. J. Neurosci.
          <year>2018</year>
<volume>128</volume>
<fpage>705</fpage>
<lpage>714</lpage>
<pub-id pub-id-type="doi">10.1080/00207454.2017.1412964</pub-id>
<pub-id pub-id-type="pmid">29198163</pub-id>
</element-citation>
</ref>
<ref id="B310-ijms-21-03059">
<label>310.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>J.Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X.J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>G.H.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.Q.</given-names>
</name>
</person-group>
<article-title>ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients</article-title>
<source/>CNS Neurosci. Ther.
          <year>2012</year>
<volume>18</volume>
<fpage>647</fpage>
<lpage>651</lpage>
<pub-id pub-id-type="doi">10.1111/j.1755-5949.2012.00336.x</pub-id>
<pub-id pub-id-type="pmid">22630058</pub-id>
</element-citation>
</ref>
<ref id="B311-ijms-21-03059">
<label>311.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Qu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Association study between polymorphisms in the CACNA1A, CACNA1C, and CACNA1H genes and drug-resistant epilepsy in the Chinese Han population</article-title>
<source/>Seizure
          <year>2015</year>
<volume>30</volume>
<fpage>64</fpage>
<lpage>69</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2015.05.013</pub-id>
<pub-id pub-id-type="pmid">26216687</pub-id>
</element-citation>
</ref>
<ref id="B312-ijms-21-03059">
<label>312.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daci</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bozalija</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jashari</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Krasniqi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Individualizing treatment approaches for epileptic patients with glucose transporter type1 (GLUT-1) deficiency</article-title>
<source/>Int. J. Mol. Sci.
          <year>2018</year>
<volume>19</volume>
<elocation-id>122</elocation-id>
<pub-id pub-id-type="doi">10.3390/ijms19010122</pub-id>
</element-citation>
</ref>
<ref id="B313-ijms-21-03059">
<label>313.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X.Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Z.Y.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>M.K.</given-names>
</name>
</person-group>
<article-title>Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<fpage>1323</fpage>
<lpage>1336</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.14.89</pub-id>
<pub-id pub-id-type="pmid">25155934</pub-id>
</element-citation>
</ref>
<ref id="B314-ijms-21-03059">
<label>314.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sha’ari</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Haerian</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Saruwatari</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Rafia</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ishitu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nakagawa</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ABCC2 rs2273697 and rs3740066 polymorphisms and resistance to antiepileptic drugs in Asia Pacific epilepsy cohorts</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<fpage>459</fpage>
<lpage>466</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.13.239</pub-id>
<pub-id pub-id-type="pmid">24624913</pub-id>
</element-citation>
</ref>
<ref id="B315-ijms-21-03059">
<label>315.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lotte</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bast</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Borusiak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Dimova</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Effectiveness of antiepileptic therapy in patients with PCDH19 mutations</article-title>
<source/>Seizure
          <year>2016</year>
<volume>35</volume>
<fpage>106</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2016.01.006</pub-id>
<pub-id pub-id-type="pmid">26820223</pub-id>
</element-citation>
</ref>
<ref id="B316-ijms-21-03059">
<label>316.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kouga</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shimbo</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Iai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ihara</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hirose</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yamakawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Osaka</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome</article-title>
<source/>Brain Dev.
          <year>2015</year>
<volume>37</volume>
<fpage>243</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2014.04.003</pub-id>
<pub-id pub-id-type="pmid">24819914</pub-id>
</element-citation>
</ref>
<ref id="B317-ijms-21-03059">
<label>317.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P.L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.M.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>T.J.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>Y.W.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H.H.</given-names>
</name>
</person-group>
<article-title>Gene-wide tagging study of the effects of common genetic polymorphisms in the α subunits of the GABA(A) receptor on epilepsy treatment response</article-title>
<source/>Pharmacogenomics
          <year>2013</year>
<volume>14</volume>
<fpage>1849</fpage>
<lpage>1856</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.13.158</pub-id>
<pub-id pub-id-type="pmid">24236484</pub-id>
</element-citation>
</ref>
<ref id="B318-ijms-21-03059">
<label>318.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kickinger</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hellsberg</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Frølund</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schousboe</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ecker</surname>
<given-names>G.F.</given-names>
</name>
<name>
<surname>Wellendorph</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Structural and molecular aspects of betaine-GABA transporter 1 (BGT1) and its relation to brain function</article-title>
<source/>Neuropharmacology
          <year>2019</year>
<volume>161</volume>
<fpage>107644</fpage>
<pub-id pub-id-type="doi">10.1016/j.neuropharm.2019.05.021</pub-id>
<pub-id pub-id-type="pmid">31108110</pub-id>
</element-citation>
</ref>
<ref id="B319-ijms-21-03059">
<label>319.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heath</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gray</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Boudreau</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Thummel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Fullerton</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Crane</surname>
<given-names>P.K.</given-names>
</name>
<name>
<surname>Larson</surname>
<given-names>E.B.</given-names>
</name>
</person-group>
<article-title>Cumulative antidepressant use and risk of dementia in a prospective cohort study</article-title>
<source/>J. Am. Geriatr. Soc.
          <year>2018</year>
<volume>66</volume>
<fpage>1948</fpage>
<lpage>1955</lpage>
<pub-id pub-id-type="doi">10.1111/jgs.15508</pub-id>
<pub-id pub-id-type="pmid">30221747</pub-id>
</element-citation>
</ref>
<ref id="B320-ijms-21-03059">
<label>320.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirgaval</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Revanakar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Srirangapattna</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Prevalence of extrapyramidal side effects in patients on antipsychotics drugs at a Tertiary Care Center</article-title>
<source/>J. Psychiatry
          <year>2017</year>
<volume>20</volume>
<fpage>419</fpage>
<pub-id pub-id-type="doi">10.4172/2378-5756.1000419</pub-id>
</element-citation>
</ref>
<ref id="B321-ijms-21-03059">
<label>321.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Patterson</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Crealey</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cardwell</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lapane</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study)</article-title>
<source/>J. Am. Geriatr. Soc.
          <year>2010</year>
<volume>58</volume>
<fpage>44</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="doi">10.1111/j.1532-5415.2009.02617.x</pub-id>
<pub-id pub-id-type="pmid">20002510</pub-id>
</element-citation>
</ref>
<ref id="B322-ijms-21-03059">
<label>322.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barber</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Alldred</surname>
<given-names>D.P.</given-names>
</name>
<name>
<surname>Raynor</surname>
<given-names>D.K.</given-names>
</name>
<name>
<surname>Dickinson</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garfield</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jesson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Savagem</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Standage</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Buckle</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Care homes’ use of medicines study: Prevalence, causes and potential harm of medication errors in care homes for older people</article-title>
<source/>Qual. Saf. Health Care
          <year>2009</year>
<volume>18</volume>
<fpage>341</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="doi">10.1136/qshc.2009.034231</pub-id>
<pub-id pub-id-type="pmid">19812095</pub-id>
</element-citation>
</ref>
<ref id="B323-ijms-21-03059">
<label>323.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hughes</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Lapane</surname>
<given-names>K.L.</given-names>
</name>
</person-group>
<article-title>Pharmacy interventions on prescribing in nursing homes: From evidence to practice</article-title>
<source/>Ther. Adv. Drug Saf.
          <year>2011</year>
<volume>2</volume>
<fpage>103</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1177/2042098611406167</pub-id>
<pub-id pub-id-type="pmid">25083206</pub-id>
</element-citation>
</ref>
<ref id="B324-ijms-21-03059">
<label>324.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eshetie</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Gillam</surname>
<given-names>M.H.</given-names>
</name>
<name>
<surname>Kalisch Ellett</surname>
<given-names>L.M.</given-names>
</name>
</person-group>
<article-title>Potentially inappropriate prescribing in people with dementia: An Australian population-based study</article-title>
<source/>Int. J. Geriatr. Psychiatry
          <year>2019</year>
<volume>34</volume>
<fpage>1498</fpage>
<lpage>1505</lpage>
<pub-id pub-id-type="doi">10.1002/gps.5160</pub-id>
<pub-id pub-id-type="pmid">31173395</pub-id>
</element-citation>
</ref>
<ref id="B325-ijms-21-03059">
<label>325.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernal</surname>
<given-names>C.J.</given-names>
</name>
<name>
<surname>Aka</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Carroll</surname>
<given-names>R.J.</given-names>
</name>
<name>
<surname>Coco</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Lima</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Acra</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Roden</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Van Driest</surname>
<given-names>S.L.</given-names>
</name>
</person-group>
<article-title>CYP2C19 Phenotype and Risk of Proton Pump Inhibitor-Associated Infections</article-title>
<source/>Pediatrics
          <year>2019</year>
<volume>144</volume>
<fpage>e20190857</fpage>
<pub-id pub-id-type="doi">10.1542/peds.2019-0857</pub-id>
<pub-id pub-id-type="pmid">31699831</pub-id>
</element-citation>
</ref>
<ref id="B326-ijms-21-03059">
<label>326.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mega</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Ruff</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Vandell</surname>
<given-names>A.G.</given-names>
</name>
<name>
<surname>Nordio</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Deenadayalu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mercuri</surname>
<given-names>M.F.</given-names>
</name>
<name>
<surname>Giugliano</surname>
<given-names>R.P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetics and the clinical response to warfarin and edoxaban: Findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial</article-title>
<source/>Lancet
          <year>2015</year>
<volume>385</volume>
<fpage>2280</fpage>
<lpage>2287</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(14)61994-2</pub-id>
<pub-id pub-id-type="pmid">25769357</pub-id>
</element-citation>
</ref>
<ref id="B327-ijms-21-03059">
<label>327.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement</article-title>
<source/>Int. J. Clin. Pharmacol. Ther.
          <year>2017</year>
<volume>55</volume>
<fpage>126</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="doi">10.5414/CP202494</pub-id>
<pub-id pub-id-type="pmid">27117036</pub-id>
</element-citation>
</ref>
<ref id="B328-ijms-21-03059">
<label>328.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamali</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wulasihan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.C.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>W.H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.Q.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>P.Y.</given-names>
</name>
</person-group>
<article-title>Association of GGCX gene polymorphism with warfarin dose in atrial fibrillation population in Xinjiang</article-title>
<source/>Lipids Health Dis.
          <year>2013</year>
<volume>12</volume>
<fpage>149</fpage>
<pub-id pub-id-type="doi">10.1186/1476-511X-12-149</pub-id>
<pub-id pub-id-type="pmid">24148610</pub-id>
</element-citation>
</ref>
<ref id="B329-ijms-21-03059">
<label>329.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magvanjav</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>McDonough</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Talbert</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Horenstein</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Shuldiner</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Benavente</surname>
<given-names>O.R.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>J.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pharmacogenetic associations of β1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)</article-title>
<source/>Stroke
          <year>2017</year>
<volume>48</volume>
<fpage>1337</fpage>
<lpage>1343</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.116.015936</pub-id>
<pub-id pub-id-type="pmid">28351962</pub-id>
</element-citation>
</ref>
<ref id="B330-ijms-21-03059">
<label>330.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Platelet receptor Gene (P2Y12, P2Y1) and platelet glycoprotein Gene (GPIIIa) polymorphisms are associated with antiplatelet drug responsiveness and clinical outcomes after acute minor ischemic stroke</article-title>
<source/>Eur. J. Clin. Pharmacol.
          <year>2017</year>
<volume>73</volume>
<fpage>437</fpage>
<lpage>443</lpage>
<pub-id pub-id-type="doi">10.1007/s00228-017-2198-2</pub-id>
<pub-id pub-id-type="pmid">28091702</pub-id>
</element-citation>
</ref>
<ref id="B331-ijms-21-03059">
<label>331.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sørensen</surname>
<given-names>I.F.</given-names>
</name>
<name>
<surname>Vazquez</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Irvin</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Sørensen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>B.R.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>C.E.</given-names>
</name>
<name>
<surname>Boerwinkle</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Eckfeldt</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Arnett</surname>
<given-names>D.K.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetic effects of ‘candidate gene complexes’ on stroke in the GenHAT study</article-title>
<source/>Pharmacogenet. Genom.
          <year>2014</year>
<volume>24</volume>
<fpage>556</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0000000000000088</pub-id>
</element-citation>
</ref>
<ref id="B332-ijms-21-03059">
<label>332.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sychev</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Minnigulov</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bochkov</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ryzhikova</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Yudina</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lychagin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morozova</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery</article-title>
<source/>High Blood Press. Cardiovasc. Prev.
          <year>2019</year>
<volume>26</volume>
<fpage>413</fpage>
<lpage>420</lpage>
<pub-id pub-id-type="doi">10.1007/s40292-019-00342-4</pub-id>
<pub-id pub-id-type="pmid">31617197</pub-id>
</element-citation>
</ref>
<ref id="B333-ijms-21-03059">
<label>333.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McDonough</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>McClure</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>B.D.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Horenstein</surname>
<given-names>R.B.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Field</surname>
<given-names>T.S.</given-names>
</name>
<name>
<surname>Talbert</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Benavente</surname>
<given-names>O.R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study</article-title>
<source/>J. Am. Heart Assoc.
          <year>2015</year>
<volume>4</volume>
<fpage>e001652</fpage>
<pub-id pub-id-type="doi">10.1161/JAHA.114.001652</pub-id>
<pub-id pub-id-type="pmid">26019129</pub-id>
</element-citation>
</ref>
<ref id="B334-ijms-21-03059">
<label>334.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy</article-title>
<source/>Pharmacogenom. J.
          <year>2018</year>
<volume>18</volume>
<fpage>713</fpage>
<lpage>720</lpage>
<pub-id pub-id-type="doi">10.1038/s41397-018-0018-4</pub-id>
<pub-id pub-id-type="pmid">29520080</pub-id>
</element-citation>
</ref>
<ref id="B335-ijms-21-03059">
<label>335.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duconge</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hernandez-Suarez</surname>
<given-names>D.F.</given-names>
</name>
</person-group>
<article-title>Potential usefulness of clopidogrel Pharmacogenetics in cerebral endovascular procedures and carotid artery stenting</article-title>
<source/>Curr. Clin. Pharmacol.
          <year>2017</year>
<volume>12</volume>
<fpage>11</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.2174/1574884712666170227154654</pub-id>
<pub-id pub-id-type="pmid">28245774</pub-id>
</element-citation>
</ref>
<ref id="B336-ijms-21-03059">
<label>336.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kapedanovska-Nestorovska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dimovski</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Sterjev</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Matevska-Geskovska</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Suturkova</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ugurov</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mitrev</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Rosalia</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The AKR1D1*36 (rs1872930) allelic variant is independently associated with clopidogrel treatment outcome</article-title>
<source/>Pharmacogenom. Personalized Med.
          <year>2019</year>
<volume>12</volume>
<fpage>287</fpage>
<lpage>295</lpage>
<pub-id pub-id-type="doi">10.2147/PGPM.S222212</pub-id>
</element-citation>
</ref>
<ref id="B337-ijms-21-03059">
<label>337.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gallego-Fabrega</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carrera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reny</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Fontana</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Slowik</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pera</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pezzini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Serrano-Heras</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Segura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Martí-Fábregas</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TRAF3 epigenetic regulation is associated with vascular recurrence in patients with ischemic stroke</article-title>
<source/>Stroke
          <year>2016</year>
<volume>47</volume>
<fpage>1180</fpage>
<lpage>1186</lpage>
<pub-id pub-id-type="doi">10.1161/STROKEAHA.115.012237</pub-id>
<pub-id pub-id-type="pmid">27026631</pub-id>
</element-citation>
</ref>
<ref id="B338-ijms-21-03059">
<label>338.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kampouraki</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kamali</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation</article-title>
<source/>Expert Opin. Drug Metab. Toxicol.
          <year>2019</year>
<volume>15</volume>
<fpage>449</fpage>
<lpage>458</lpage>
<pub-id pub-id-type="doi">10.1080/17425255.2019.1623878</pub-id>
<pub-id pub-id-type="pmid">31120800</pub-id>
</element-citation>
</ref>
<ref id="B339-ijms-21-03059">
<label>339.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miller-Rhodes</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Baht</surname>
<given-names>G.S.</given-names>
</name>
<name>
<surname>Saminathan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rodriguiz</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Wetsel</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Gelbard</surname>
<given-names>H.A.</given-names>
</name>
<name>
<surname>Terrando</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>The broad spectrum mixed-lineage kinase 3 inhibitor URMC-099 prevents acute microgliosis and cognitive decline in a mouse model of perioperative neurocognitive disorders</article-title>
<source/>J. Neuroinflamm.
          <year>2019</year>
<volume>16</volume>
<fpage>193</fpage>
<pub-id pub-id-type="doi">10.1186/s12974-019-1582-5</pub-id>
</element-citation>
</ref>
<ref id="B340-ijms-21-03059">
<label>340.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ettienne</surname>
<given-names>E.B.</given-names>
</name>
<name>
<surname>Ofoegbu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Maneno</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ezeude</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chapman</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Pharmacogenomics and OUD: Clinical Decision Support in an African American Cohort</article-title>
<source/>J. Natl. Med. Assoc.
          <year>2019</year>
<volume>11</volume>
<fpage>674</fpage>
<lpage>681</lpage>
<pub-id pub-id-type="doi">10.1016/j.jnma.2019.09.006</pub-id>
<pub-id pub-id-type="pmid">31676110</pub-id>
</element-citation>
</ref>
<ref id="B341-ijms-21-03059">
<label>341.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Narayan</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Pearson</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Litchfield</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Le Couteur</surname>
<given-names>D.G.</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>McLachlan</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Zoega</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Anticholinergic medicines use among older adults before and after initiating dementia medicines</article-title>
<source/>Br. J. Clin. Pharmacol.
          <year>2019</year>
<volume>85</volume>
<fpage>1957</fpage>
<lpage>1963</lpage>
<pub-id pub-id-type="doi">10.1111/bcp.13976</pub-id>
<pub-id pub-id-type="pmid">31046175</pub-id>
</element-citation>
</ref>
<ref id="B342-ijms-21-03059">
<label>342.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshida</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fujioka</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Teramoto</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Wanibuchi</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Long-term administration of excess zinc impairs learning and memory in aged mice</article-title>
<source/>J. Toxicol. Sci.
          <year>2019</year>
<volume>44</volume>
<fpage>681</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.2131/jts.44.681</pub-id>
<pub-id pub-id-type="pmid">31588059</pub-id>
</element-citation>
</ref>
<ref id="B343-ijms-21-03059">
<label>343.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomson</surname>
<given-names>E.M.</given-names>
</name>
</person-group>
<article-title>Air Pollution, Stress, and Allostatic Load: Linking Systemic and Central Nervous System Impacts</article-title>
<source/>J. Alzheimers Dis.
          <year>2019</year>
<volume>69</volume>
<fpage>597</fpage>
<lpage>614</lpage>
<pub-id pub-id-type="doi">10.3233/JAD-190015</pub-id>
<pub-id pub-id-type="pmid">31127781</pub-id>
</element-citation>
</ref>
<ref id="B344-ijms-21-03059">
<label>344.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Exley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mold</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>Aluminium in human brain tissue: How much is too much?</article-title>
<source/>J. Biol. Inorg. Chem.
          <year>2019</year>
<volume>54</volume>
<fpage>1279</fpage>
<lpage>1282</lpage>
<pub-id pub-id-type="doi">10.1007/s00775-019-01710-0</pub-id>
</element-citation>
</ref>
<ref id="B345-ijms-21-03059">
<label>345.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalilani</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pelgrims</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Noack-Rink</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Villanueva</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis</article-title>
<source/>Epilepsia
          <year>2018</year>
<volume>59</volume>
<fpage>2179</fpage>
<lpage>2193</lpage>
<pub-id pub-id-type="doi">10.1111/epi.14596</pub-id>
<pub-id pub-id-type="pmid">30426482</pub-id>
</element-citation>
</ref>
<ref id="B346-ijms-21-03059">
<label>346.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kong</surname>
<given-names>S.T.</given-names>
</name>
<name>
<surname>Hom</surname>
<given-names>C.S.</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Lium</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Prevalence of drug resistant epilepsy in adults with epilepsy attending a neurology clinic of a tertiary referral hospital in Singapore</article-title>
<source/>Epilepsy Res.
          <year>2014</year>
<volume>108</volume>
<fpage>1253</fpage>
<lpage>1262</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2014.05.005</pub-id>
<pub-id pub-id-type="pmid">24910376</pub-id>
</element-citation>
</ref>
<ref id="B347-ijms-21-03059">
<label>347.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalozoumi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kel-Margoulis</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Vafiadaki</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Soreq</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Depaulis</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanoudou</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Glial responses during epileptogenesis in Mus musculus point to potential therapeutic targets</article-title>
<source/>PLoS ONE
          <year>2018</year>
<volume>13</volume>
<elocation-id>e0201742</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0201742</pub-id>
<pub-id pub-id-type="pmid">30114263</pub-id>
</element-citation>
</ref>
<ref id="B348-ijms-21-03059">
<label>348.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orlandi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paolino</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Striano</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Parisi</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy</article-title>
<source/>Expert Opin. Drug Metab. Toxicol.
          <year>2018</year>
<volume>14</volume>
<fpage>505</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="doi">10.1080/17425255.2018.1473377</pub-id>
<pub-id pub-id-type="pmid">29804481</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijms-21-03059-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Pharmacogenetic machinery-related pathogenic, mechanistic, metabolic, transporter, and pleiotropic genes of antiepileptics, antidepressants, anxiolytics, and antipsychotics.</p>
</caption>
<graphic xlink:href="ijms-21-03059-g001"></graphic>
</fig>
<fig id="ijms-21-03059-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Substrates of antiepileptics, antipsychotics, anxiolytics, and antidepressants.</p>
</caption>
<graphic xlink:href="ijms-21-03059-g002"></graphic>
</fig>
<fig id="ijms-21-03059-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Substrates, inhibitors, inducers, and transporters of 307 CNS drugs (antidepressants, anxiolitics, hipnotics, sedatives, antipsychotics, antiepileptics, antiparkinsonian, and anti-dementia drugs).</p>
</caption>
<graphic xlink:href="ijms-21-03059-g003"></graphic>
</fig>
<fig id="ijms-21-03059-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>APOE-related responder/nonresponder rate in patients with Alzhimer’s disease treated with a multifactorial/combination treatment for one year. Responders: Final Mini-Mental State Examination (MMSE) score &gt; basal MMSE score. NonResponders: Final MMSE score &lt; basal MMSE score. Data Source: Cacabelos et al., 2014.</p>
</caption>
<graphic xlink:href="ijms-21-03059-g004"></graphic>
</fig>
<fig id="ijms-21-03059-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>TOMM40-related responder/nonresponder rate in patients with Alzhimer’s disease treated with a multifactorial/combination treatment for one year. Responders: Final MMSE score &gt; basal MMSE score. Nonresponders: Final MMSE score &lt; basal MMSE score. Data Source: Cacabelos et al., 2014.</p>
</caption>
<graphic xlink:href="ijms-21-03059-g005"></graphic>
</fig>
<fig id="ijms-21-03059-f006" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<p>CYP2D6-related responder/nonresponder rate in patients with Alzhimer’s disease treated with a multifactorial/combination treatment for one year. Responders: Final MMSE score &gt; basal MMSE score. Nonresponders: Final MMSE score &lt; basal MMSE score. Data Source: Cacabelos et al., 2019.</p>
</caption>
<graphic xlink:href="ijms-21-03059-g006"></graphic>
</fig>
<table-wrap id="ijms-21-03059-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-03059-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Prevalent Alzheimer’s disease-related pathogenic genes.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Symbol</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene Name</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene ID</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">OMIM #</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Locus</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">dbSNP ID</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Risk Allele</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">MAF</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ABCA7</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">ATP binding cassette subfamily A member</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10347</td>
<td align="center" colspan="1" rowspan="1" valign="middle">605414</td>
<td align="center" colspan="1" rowspan="1" valign="middle">19p13.3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3764650</td>
<td align="center" colspan="1" rowspan="1" valign="middle">G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.20 (G)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>APOE</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Apolipoprotein E</td>
<td align="center" colspan="1" rowspan="1" valign="middle">348</td>
<td align="center" colspan="1" rowspan="1" valign="middle">107741</td>
<td align="center" colspan="1" rowspan="1" valign="middle">19q13.32</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs429358; rs7412</td>
<td align="center" colspan="1" rowspan="1" valign="middle"> *<italic>4</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.15 (C); 0.08 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>APP</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Amyloid beta precursor protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">351</td>
<td align="center" colspan="1" rowspan="1" valign="middle">104760</td>
<td align="center" colspan="1" rowspan="1" valign="middle">21q21.3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">52 SNPs</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">&lt;0.01</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>BIN1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Bridging integrator 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">274</td>
<td align="center" colspan="1" rowspan="1" valign="middle">601248</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2q14.3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs744373</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.36 (C)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>BUB3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">BUB3, mitotic checkpoint protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9184</td>
<td align="center" colspan="1" rowspan="1" valign="middle">603719</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10q26.13</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs4980270</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.10 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>C9ORF72</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Chromosome 9 open reading frame 72</td>
<td align="center" colspan="1" rowspan="1" valign="middle">203228</td>
<td align="center" colspan="1" rowspan="1" valign="middle">614260</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9p21.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3849942</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.22 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CD2AP</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CD2 associated protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">23607</td>
<td align="center" colspan="1" rowspan="1" valign="middle">604241</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6p12.3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs9349407</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.25 (C)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CD33</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CD33 molecule</td>
<td align="center" colspan="1" rowspan="1" valign="middle">945</td>
<td align="center" colspan="1" rowspan="1" valign="middle">159590</td>
<td align="center" colspan="1" rowspan="1" valign="middle">19q13.41</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3865444</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.01 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CLU</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Clusterin</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1191</td>
<td align="center" colspan="1" rowspan="1" valign="middle">185430</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8p21.1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs11136000</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.38 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CPZ</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Carboxypeptidase Z</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8532</td>
<td align="center" colspan="1" rowspan="1" valign="middle">603105</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4p16.1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs7436874</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.36 (C)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CR1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Complement C3b/C4b receptor 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">185430</td>
<td align="center" colspan="1" rowspan="1" valign="middle">120620</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1q32.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3818361</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.25 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>DISC1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Disrupted in schizophrenia 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">27185</td>
<td align="center" colspan="1" rowspan="1" valign="middle">605210</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1q42.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs16856202</td>
<td align="center" colspan="1" rowspan="1" valign="middle">G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.03 (G)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ENPP1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Ectonucleotide pyrophosphatase/phosphodiesterase 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5167</td>
<td align="center" colspan="1" rowspan="1" valign="middle">173335</td>
<td align="center" colspan="1" rowspan="1" valign="middle">6q23.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs7767170</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.02 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>EXO1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Exonuclease 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9156</td>
<td align="center" colspan="1" rowspan="1" valign="middle">606063</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1q43</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs1776148</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.27 (A)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>LAMA3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Laminin subunit alpha 3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">64231</td>
<td align="center" colspan="1" rowspan="1" valign="middle">606548</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11q12.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs11082762</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.47 (A)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>LHFP</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Lipoma HMGIC fusion partner</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10186</td>
<td align="center" colspan="1" rowspan="1" valign="middle">606710</td>
<td align="center" colspan="1" rowspan="1" valign="middle">13q13.3-q14.11</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs7995844</td>
<td align="center" colspan="1" rowspan="1" valign="middle">G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.35 (G)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MAPT</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Microtubule associated protein tau</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4137</td>
<td align="center" colspan="1" rowspan="1" valign="middle">157140</td>
<td align="center" colspan="1" rowspan="1" valign="middle">17q21.31</td>
<td align="center" colspan="1" rowspan="1" valign="middle">15 SNPs</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">&lt;0.01</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MS4A4E</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Membrane spanning 4-domains A4E</td>
<td align="center" colspan="1" rowspan="1" valign="middle">643680</td>
<td align="center" colspan="1" rowspan="1" valign="middle">608401</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8p21.1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs670139</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.38 (A)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MS4A6A</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Membrane spanning 4-domains A6A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">64231</td>
<td align="center" colspan="1" rowspan="1" valign="middle">606548</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11q12.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs610932</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.45 (A)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NLRP4</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NLR family pyrin domain containing 4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">147945</td>
<td align="center" colspan="1" rowspan="1" valign="middle">609645</td>
<td align="center" colspan="1" rowspan="1" valign="middle">19q13.43</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs12462372</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.08 (A)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>NTNG1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Netrin G1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3909</td>
<td align="center" colspan="1" rowspan="1" valign="middle">600805</td>
<td align="center" colspan="1" rowspan="1" valign="middle">18q11.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs11803905</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.32 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PICALM</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Phosphatidylinositol binding clathrin assembly protein</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8301</td>
<td align="center" colspan="1" rowspan="1" valign="middle">603025</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11q14.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3851179</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.31 (A)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PIWIL2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Piwi like RNA-mediated gene silencing 2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">55124</td>
<td align="center" colspan="1" rowspan="1" valign="middle">610312</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8p21.3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs4266653</td>
<td align="center" colspan="1" rowspan="1" valign="middle">G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.47 (G)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PSEN1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Presenilin 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5663</td>
<td align="center" colspan="1" rowspan="1" valign="middle">104311</td>
<td align="center" colspan="1" rowspan="1" valign="middle">14q24.2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">241 SNPs</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">&lt; 0.01</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PSEN2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Presenilin 2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5664</td>
<td align="center" colspan="1" rowspan="1" valign="middle">600759</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1q42.13</td>
<td align="center" colspan="1" rowspan="1" valign="middle">43 SNPs</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">&lt; 0.01</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>STK36</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Serine/threonine kinase 36</td>
<td align="center" colspan="1" rowspan="1" valign="middle">27148</td>
<td align="center" colspan="1" rowspan="1" valign="middle">607652</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2q35</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs2303565</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.33 (C)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>STX17</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Syntaxin 17</td>
<td align="center" colspan="1" rowspan="1" valign="middle">55014</td>
<td align="center" colspan="1" rowspan="1" valign="middle">604204</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9q31.1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs1997368</td>
<td align="center" colspan="1" rowspan="1" valign="middle">G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.32 (G)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>SUN3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Sad1 and UNC84 domain containing 3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">256979</td>
<td align="center" colspan="1" rowspan="1" valign="middle">607723</td>
<td align="center" colspan="1" rowspan="1" valign="middle">7p12.3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs2708909</td>
<td align="center" colspan="1" rowspan="1" valign="middle">G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.39 (G)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>TBC1D5</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">TBC1 domain family member 5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9779</td>
<td align="center" colspan="1" rowspan="1" valign="middle">615740</td>
<td align="center" colspan="1" rowspan="1" valign="middle">3p24.3</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs10510480</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.11 (C)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>USP6NL</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">USP6 N-terminal like</td>
<td align="center" colspan="1" rowspan="1" valign="middle">9712</td>
<td align="center" colspan="1" rowspan="1" valign="middle">605405</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10p14</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3847437</td>
<td align="center" colspan="1" rowspan="1" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.04 (T)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ZSWIM7</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Zinc finger SWIM-type containing 7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">125150</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">614535</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">17p12</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs10491104</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">T</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">0.41 (T)</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-21-03059-t002" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-03059-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>Pharmacogenetics of conventional anti-dementia drugs.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#F3F3F3" valign="middle">Drug</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#F3F3F3" valign="middle">Properties</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#F3F3F3" valign="middle">Pharmacogenetics</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i001.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Donepezil hydrochloride,</styled-content></bold> Aricept, 120011-70-3, Donepezil HCl, BNAG, E-2020, E2020</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>APOE</italic>, <italic>CHAT</italic><break></break><bold>Mechanistic genes:</bold><italic>CHAT</italic>, <italic>ACHE</italic>, <italic>BCHE</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major), <italic>UGTs</italic>, <italic>ACHE</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ACHE</italic>, <italic>BCHE</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one;hydrochloride</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>24</sub>H<sub>30</sub>ClNO<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 415.9529 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Cholinesterase inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Centrally active, reversible acetylcholinesterase inhibitor; increases the acetylcholine available for synaptic transmission in the CNS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Nootropic agent, cholinesterase inhibitor, parasympathomimetic effect</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i002.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Galantamine hydrobromide</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>APOE, APP</italic><break></break><bold>Mechanistic genes:</bold><italic>ACHE, BCHE, CHRNA4, CHRNA7, CHRNB2</italic><break></break><bold>Metabollic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major), <italic>UGT1A1</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ACHE, BCHE</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6,8,10(17),15-tetraen-14-ol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>22</sub>BrNO<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 368.26548 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Cholinesterase inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Reversible and competitive acetylcholinesterase inhibition leading to an increased concentration of acetylcholine at cholinergic synapses; modulates nicotinic acetylcholine receptor; may increase glutamate and serotonin levels</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Nootropic agent, cholinesterase inhibitor, parasympathomimetic effect</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i003.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Memantine Hydrochloride</styled-content></bold>, 41100-52-1, Namenda, Memantine HCL, Axura, 3,5-Dimethyl-1-adamantanamine hydrochloride, 3,5-dimethyladamantan-1-amine hydrochloride</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>APOE, MAPT, PSEN1</italic><break></break><bold>Mechanistic genes:</bold><italic>CHRFAM7A, DLGAP1, FOS, GRIN2A, GRIN2B, GRIN3A, HOMER1, HTR3A</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Inhibitor</bold><italic>:CYP1A2</italic> (weak), <italic>CYP2A6</italic> (weak), <italic>CYP2B6</italic> (strong), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (strong), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (weak), <italic>NR1I2</italic><break></break><bold>Transporter genes:</bold>
<italic>NR1I2</italic>;<break></break><bold>Pleiotropic genes:</bold>
<italic>APOE, MAPT, MT-TK, PSEN1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 3,5-dimethyladamantan-1-amine;hydrochloride</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>12</sub>H<sub>22</sub>ClN</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 215.76278 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> N-Methyl-D-Aspartate receptor antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds preferentially to NMDA receptor-operated cation channels; may act by blocking actions of glutamate, mediated in part by NMDA receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Dopamine agent, antiparkinson agent, excitatory amino acid antagonist, antidyskinetic</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i004.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Rivastigmine tartrate</styled-content></bold>, 129101-54-8, SDZ-ENA 713, Rivastigmine hydrogentartrate, Rivastigmine Hydrogen Tartrate, ENA 713, ENA-713</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<bold>Pathogenic genes:</bold>
<italic>APOE, APP, CHAT</italic>
<break></break>
<bold>Mechanistic genes:</bold>
<italic>ACHE, BCHE, CHAT, CHRNA4, CHRNB2</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Inhibitor:</bold>
<italic>ACHE, BCHE</italic>
<break></break>
<bold>Pleiotropic genes:</bold>
<italic>APOE, MAPT</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> (2R,3R)-2,3-dihydroxybutanedioic acid;[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>18</sub>H<sub>28</sub>N<sub>2</sub>O<sub>8</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 400.42352 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Cholinesterase inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Increases acetylcholine in CNS through reversible inhibition of its hydrolysis by cholinesterase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Neuroprotective agent, cholinesterase inhibitor, cholinergic agent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i005.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Tacrine Hydrochloride</styled-content></bold>, Tacrine HCl, 1684-40-8, Hydroaminacrine, tacrine.HCl, 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE, Tenakrin</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<bold>Pathogenic genes:</bold>
<italic>APOE</italic>
<break></break>
<bold>Mechanistic genes:</bold>
<italic>ACHE, BCHE, CHRNA4, CHRNB2</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP1A2 (major), CYP2D6 (minor), CYP3A4 (major)</italic>
<break></break>
<bold>  Inhibitor:</bold>
<italic>ACHE, BCHE, CYP1A2 (weak)</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>SCN1A</italic>
<break></break>
<bold>Pleiotropic genes:</bold>
<italic>APOE, CES1, GSTM1, GSTT1, LEPR, MTHFR</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 1,2,3,4-tetrahydroacridin-9-amine;hydrochloride</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>13</sub>H<sub>15</sub>ClN<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 234.7246 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Cholinesterase inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Elevates acetylcholine in cerebral cortex by slowing degradation of acetylcholine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Nootropic agent, cholinesterase inhibitor, Parasympathomimetic effect</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p><bold>AADAC</bold>: arylacetamide deacetylase; <bold>AANAT</bold>: aralkylamine N-acetyltransferase; <bold>ABAT:</bold> 4-aminobutyrate aminotransferase; <bold>ABCB1</bold>: ATP-binding cassette, sub-family B (MDR/TAP), member 1; <bold>ABCB11:</bold> ATP-binding cassette, sub-family B (MDR/TAP), member 11; <bold>ABCC1</bold>: ATP-binding cassette, sub-family C (CFTR/MRP), member 1; <bold>ABCC2:</bold> ATP-binding cassette, sub-family C (CFTR/MRP), member 2; <bold>ABCC3:</bold> ATP-binding cassette, sub-family C (CFTR/MRP), member 3; <bold>ABCC4:</bold> ATP-binding cassette, sub-family C (CFTR/MRP), member 4; <bold>ABCC6:</bold> ATP-binding cassette, sub-family C (CFTR/MRP), member 6; <bold>ABCC8:</bold> ATP-binding cassette, sub-family C (CFTR/MRP), member 8; <bold>ABCG2:</bold> ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group); <bold>ACACA</bold>: acetyl-CoA carboxylase alpha; <bold>ACADSB:</bold> acyl-CoA dehydrogenase short/branched chain; <bold>ACHE:</bold> acetylcholinesterase (Yt blood group); <bold>ACSL1</bold>: acyl-CoA synthetase long-chain family member 1; <bold>ACSL3</bold>: acyl-CoA synthetase long-chain family member 3; <bold>ACSL4</bold>: acyl-CoA synthetase long-chain family member 4; <bold>ACSM1</bold>: acyl-CoA synthetase medium-chain family member 1; <bold>ACSM2B</bold>: acyl-CoA synthetase medium-chain family member 2B; <bold>ACSM3</bold>: acyl-CoA synthetase medium-chain family, member 3; <bold>ADCY1:</bold> adenylate cyclase 1 (brain); <bold>ADH1A</bold>: alcohol dehydrogenase 1A (class I), alpha polypeptide; <bold>ADH1B</bold>: alcohol dehydrogenase 1B (class I), beta polypeptide; <bold>ADH1C</bold>: alcohol dehydrogenase 1C (class I), gamma polypeptide; <bold>ADH4</bold>: alcohol dehydrogenase 4 (class II), pi polypeptide; <bold>ADH5</bold>: alcohol dehydrogenase 5 (class III), chi polypeptide; <bold>ADH6</bold>: alcohol dehydrogenase 6 (class V); <bold>ADH7</bold>: alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide; <bold>ADHs</bold>: alcohol dehydrogenases; <bold>ADHFE1</bold>: alcohol dehydrogenase, iron containing, 1; <bold>ADIPOQ:</bold> adiponectin, C1Q and collagen domain containing; <bold>ADRA1A</bold>: adrenoceptor alpha 1A; <bold>ADRA1B</bold>: adrenoceptor alpha 1B; <bold>ADRA1D</bold>: adrenoceptor alpha 1D; <bold>ADRA1s</bold>: alpha 1-adrenergic receptor family; <bold>ADRA2A</bold>: adrenoceptor alpha 2A; <bold>ADRA2B</bold>: adrenoceptor alpha 2B; <bold>ADRA2C</bold>: adrenoceptor alpha 2C; <bold>ADRA2s</bold>: alpha 2-adrenergic receptor family; <bold>ADRAs</bold>: alpha-adrenergic receptor family; <bold>ADRB1</bold>: adrenoceptor beta 1; <bold>ADRB2</bold>: adrenoceptor beta 2, Surface; <bold>ADRB3</bold>: adrenoceptor beta 3; <bold>ADRBs</bold>: beta-adrenergic receptor family; <bold>ADRs:</bold> adrenoceptors; <bold>AGXT</bold>: alanine-glyoxylate aminotransferase; <bold>AHR</bold>: aryl hydrocarbon receptor; <bold>AKR1A1</bold>: aldo-keto reductase family 1, member A1 (aldehyde reductase); <bold>AKR1B1</bold>: aldo-keto reductase family 1, member B1 (aldose reductase); <bold>AKR1C1</bold>: aldo-keto reductase family 1, member C1; <bold>AKR1D1</bold>: aldo-keto reductase family 1, member D1; <bold>ALB:</bold> albumin; <bold>ALDH1A1</bold>: aldehyde dehydrogenase 1 family, member A1; <bold>ALDH1A2</bold>: aldehyde dehydrogenase family 1, subfamily A2; <bold>ALDH1A3</bold>: aldehyde dehydrogenase family 1, subfamily A3; <bold>ALDH1B1</bold>: aldehyde dehydrogenase 1 family, member B1; <bold>ALDH2</bold>: aldehyde dehydrogenase 2 family (mitochondrial); <bold>ALDH3A1</bold>: aldehyde dehydrogenase 3 family, member A1; <bold>ALDH3A2</bold>: aldehyde dehydrogenase 3 family, member A2; <bold>ALDH3B1</bold>: aldehyde dehydrogenase 3 family, member B1; <bold>ALDH3B2</bold>: aldehyde dehydrogenase 3 family, member B2; <bold>ALDH4A1</bold>: aldehyde dehydrogenase 4 family, member A1; <bold>ALDH5A1</bold>: aldehyde dehydrogenase 5 family, member A1; <bold>ALDH6A1</bold>: aldehyde dehydrogenase 6 family, member A1; <bold>ALDH7A1</bold>: aldehyde dehydrogenase 7 family, member A1; <bold>ALDH8A1</bold>: aldehyde dehydrogenase 8 family, member A1; <bold>ALDH9A1</bold>: aldehyde dehydrogenase 9 family, member A1; <bold>ANKK1</bold>: ankyrin repeat and kinase domain containing 1; <bold>AOX1</bold>: aldehyde oxidase 1; <bold>APOA1:</bold> apolipoprotein A-I; <bold>APOA5</bold>: apolipoprotein A-V; <bold>APOC3</bold>: apolipoprotein C-III; <bold>APOD</bold>: apolipoprotein D; <bold>APOE:</bold> apolipoprotein E; <bold>APP:</bold> amyloid beta (A4) precursor protein; <bold>AQP1:</bold> aquaporin-1; <bold>AS3MT</bold>: arsenic (+3 oxidation state) methyltransferase; <bold>ASMT</bold>: acetylserotonin O-methyltransferase; <bold>BAAT</bold>: bile acid CoA: amino acid N-acyltransferase (glycine N-choloyltransferase); <bold>BCHE:</bold> butyrylcholinesterase; <bold>BCL2</bold>: B-cell CLL/lymphoma 2; <bold>BCL2L1</bold>: BCL2-like 1; <bold>BDNF</bold>: brain-derived neurotrophic factor; <bold>BLK:</bold> BLK proto-oncogene, Src family tyrosine kinase; <bold>CA1:</bold> carbonic anhydrase 1; <bold>CA2:</bold> carbonic anhydrase 2; <bold>CA3:</bold> carbonic anhydrase 3; <bold>CA4:</bold> carbonic anhydrase 4; <bold>CA7:</bold> carbonic anhydrase 7; <bold>CA12:</bold> carbonic anhydrase 12; <bold>CA14:</bold> carbonic anhydrase 14; <bold>CACNA1C:</bold> calcium channel, voltage-dependent, L type, alpha 1C subunit; <bold>CACNs</bold>: calcium channel, voltage-dependent family; <bold>CALM1</bold>: calmodulin 1 (phosphorylase kinase, delta); <bold>CALMs</bold>: calmodulins; <bold>CALY:</bold> Calcyon neuron specific vesicular protein; <bold>CASR:</bold> calcium-sensing receptor; <bold>CAT:</bold> catalase; <bold>CBR1</bold>: carbonyl reductase 1; <bold>CBR3</bold>: carbonyl reductase 3; <bold>CBR4</bold>: carbonyl reductase 4; <bold>CBS:</bold> cystathionine-beta-synthase; <bold>CCBL1</bold>: cysteine conjugate-beta lyase, cytoplasmic; <bold>CCND1:</bold> cyclin D1; <bold>CDA</bold>: cytidine deaminase; <bold>CEL</bold>: carboxyl ester lipase; <bold>CELF4</bold>: CUGBP, Elav-like family member 4; <bold>CERKL</bold>: ceramide kinase-like; <bold>CES1</bold>: carboxylesterase 1; <bold>CES1P1</bold>: carboxylesterase 1 pseudogene 1; <bold>CES2</bold>: carboxylesterase 2; <bold>CES3</bold>: carboxylesterase 3; <bold>CES5A</bold>: carboxylesterase 5A; <bold>CFTR</bold>: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7); <bold>CHRM1</bold>: cholinergic receptor, muscarinic 1; <bold>CHRM2</bold>: cholinergic receptor, muscarinic 2; <bold>CHRM3</bold>: cholinergic receptor, muscarinic 3; <bold>CHRM4</bold>: cholinergic receptor, muscarinic 4; <bold>CHRM5</bold>: cholinergic receptor, muscarinic 5; <bold>CHRMs</bold>: muscarinic cholinergic receptor family; <bold>CHRNA2:</bold> Cholinergic receptor nicotinic alpha 2 subunit; <bold>CHRNA3:</bold> Cholinergic receptor nicotinic alpha 3 subunit; <bold>CHRNA4:</bold> cholinergic receptor, nicotinic, alpha 4 (neuronal); <bold>CHRNA7:</bold> cholinergic receptor, nicotinic, alpha 7 (neuronal); <bold>CHRNAs:</bold> nicotinic cholinergic receptors, alpha type; <bold>CHRNB2:</bold> cholinergic receptor, nicotinic, beta 2 (neuronal); <bold>CHRNB4:</bold> cholinergic receptor nicotinic beta 4 subunit; <bold>CHRNs</bold>: nicotinic cholinergic receptor family; <bold>CHST1</bold>: carbohydrate (keratan sulfate Gal-6) sulfotransferase 1; <bold>CHST2</bold>: carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2; <bold>CHST3</bold>: carbohydrate (chondroitin 6) sulfotransferase 3; <bold>CHST4</bold>: carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4; <bold>CHST5</bold>: carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5; <bold>CHST6</bold>: carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6; <bold>CHST7</bold>: carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7; <bold>CHST8</bold>: carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8; <bold>CHST9</bold>: carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9; <bold>CHST10</bold>: carbohydrate sulfotransferase 10; <bold>CHST11</bold>: carbohydrate (chondroitin 4) sulfotransferase 11; <bold>CHST12</bold>: carbohydrate (chondroitin 4) sulfotransferase 12; <bold>CHST13</bold>: carbohydrate (chondroitin 4) sulfotransferase 13; <bold>CKS1B:</bold> CDC28 protein kinase regulatory subunit 1B; <bold>CLCNs:</bold> voltage-sensitive chloride channel family; <bold>CNR1</bold>: cannabinoid receptor 1 (brain); <bold>CNTF</bold>: ciliary neurotrophic factor; <bold>COMT</bold>: Catechol-O-methyltransferase; <bold>CREB1:</bold> cAMP responsive element binding protein 1; <bold>CRHR1:</bold> corticotropin releasing hormone receptor 1; <bold>CRHR2:</bold> corticotropin releasing hormone receptor 2; <bold>CXCR2:</bold> chemokine (C-X-C motif) receptor 2; <bold>CYB5R3</bold>: cytochrome b5 reductase 3; <bold>CYP1A1</bold>: cytochrome P450, family 1, subfamily A, polypeptide 1; <bold>CYP1A2</bold>: cytochrome P450, family 1, subfamily A, polypeptide 2; <bold>CYP1B1</bold>: cytochrome P450, family 1, subfamily B, polypeptide 1; <bold>CYP2A6</bold>: cytochrome P450, family 2, subfamily A, polypeptide 6; <bold>CYP2A7</bold>: cytochrome P450, family 2, subfamily A, polypeptide 7; <bold>CYP2A13</bold>: cytochrome P450, family 2, subfamily A, polypeptide 13; <bold>CYP2B6</bold>: cytochrome P450, family 2, subfamily B, polypeptide 6; <bold>CYP2C8</bold>: cytochrome P450, family 2, subfamily C, polypeptide 8; <bold>CYP2C9</bold>: cytochrome P450, family 2, subfamily C, polypeptide 9; <bold>CYP2C18</bold>: cytochrome P450, family 2, subfamily C, polypeptide 18; <bold>CYP2C19</bold>: cytochrome P450, family 2, subfamily C, polypeptide 19; <bold>CYP2D6</bold>: cytochrome P450, family 2, subfamily D, polypeptide 6; <bold>CYP2D7P1</bold>: cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 1; <bold>CYP2E1</bold>: cytochrome P450, family 2, subfamily E, polypeptide 1; <bold>CYP2F1</bold>: cytochrome P450, family 2, subfamily F, polypeptide 1; <bold>CYP2J2</bold>: cytochrome P450, family 2, subfamily J, polypeptide 2; <bold>CYP2R1</bold>: cytochrome P450, family 2, subfamily R, polypeptide 1; <bold>CYP2S1</bold>: cytochrome P450, family 2, subfamily S, polypeptide 1; <bold>CYP2W1</bold>: cytochrome P450, family 2, subfamily W, polypeptide 1; <bold>CYP3A4</bold>: cytochrome P450, family 3, subfamily A, polypeptide 4; <bold>CYP3A4/5:</bold> cytochrome P450, family 3, subfamily A, polypeptide 4/5; <bold>CYP3A5</bold>: cytochrome P450, family 3, subfamily A, polypeptide 5; <bold>CYP3A7</bold>: cytochrome P450, family 3, subfamily A, polypeptide 7; <bold>CYP3A43</bold>: cytochrome P450, family 3, subfamily A, polypeptide 43; <bold>CYP3As</bold>: cytochrome P450, family 3, subfamily A; <bold>CYP4A11</bold>: cytochrome P450, family 4, subfamily A, polypeptide 11; <bold>CYP4A22</bold>: cytochrome P450, family 4, subfamily A, polypeptide 22; <bold>CYP4B1</bold>: cytochrome P450, family 4, subfamily B, polypeptide 1; <bold>CYP4F2</bold>: cytochrome P450, family 4, subfamily F, polypeptide 2; <bold>CYP4F3</bold>: cytochrome P450, family 4, subfamily F, polypeptide 3; <bold>CYP4F8</bold>: cytochrome P450, family 4, subfamily F, polypeptide 8; <bold>CYP4F11</bold>: cytochrome P450, family 4, subfamily F, polypeptide 11; <bold>CYP4F12</bold>: cytochrome P450, family 4, subfamily F, polypeptide 12; <bold>CYP4Z1</bold>: cytochrome P450, family 4, subfamily Z, polypeptide 1; <bold>CYP7A1</bold>: cytochrome P450, family 7, subfamily A, polypeptide 1; <bold>CYP7B1</bold>: cytochrome P450, family 7, subfamily B, polypeptide 1; <bold>CYP8B1</bold>: cytochrome P450, family 8, subfamily B, polypeptide 1; <bold>CYP11A1</bold>: cytochrome P450, family 11, subfamily A, polypeptide 1; <bold>CYP11B1</bold>: cytochrome P450, family 11, subfamily B, polypeptide 1: <bold>CYP11B2</bold>: cytochrome P450, family 11, subfamily B, polypeptide 2; <bold>CYP17A1</bold>: cytochrome P450, family 17, subfamily A, polypeptide 1; <bold>CYP19A1</bold>: cytochrome P450, family 19, subfamily A, polypeptide 1; <bold>CYP20A1</bold>: cytochrome P450, family 20, subfamily A, polypeptide 1; <bold>CYP21A2</bold>: cytochrome P450, family 21, subfamily A, polypeptide 2; <bold>CYP24A1</bold>: cytochrome P450, family 24, subfamily A, polypeptide 1; <bold>CYP26A1</bold>: cytochrome P450, family 26, subfamily A, polypeptide 1; <bold>CYP26B1</bold>: cytochrome P450, family 26, subfamily B, polypeptide 1; <bold>CYP26C1</bold>: cytochrome P450, family 26, subfamily C, polypeptide 1; <bold>CYP27A1</bold>: cytochrome P450, family 27, subfamily A, polypeptide 1; <bold>CYP27B1</bold>: cytochrome P450, family 27, subfamily B, polypeptide 1; <bold>CYP39A1</bold>: cytochrome P450, family 39, subfamily A, polypeptide 1; <bold>CYP46A1</bold>: cytochrome P450, family 46, subfamily A, polypeptide 1; <bold>CYP51A1</bold>: cytochrome P450, family 51, subfamily A, polypeptide 1; <bold>DAO</bold>: D-amino-acid oxidase; <bold>DDC:</bold> dopa decarboxylase (aromatic L-amino acid decarboxylase); <bold>DDOST</bold>: dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit (non-catalytic); <bold>DHRS1</bold>: dehydrogenase/reductase (SDR family) member 1; <bold>DHRS2</bold>: dehydrogenase/reductase (SDR family) member 2; <bold>DHRS3</bold>: dehydrogenase/reductase (SDR family) member 3; <bold>DHRS4</bold>: dehydrogenase/reductase (SDR family) member 4; <bold>DHRS7</bold>: dehydrogenase/reductase (SDR family) member 7; <bold>DHRS9</bold>: dehydrogenase/reductase (SDR family) member 9; <bold>DHRS12</bold>: dehydrogenase/reductase (SDR family) member 12; <bold>DHRS13</bold>: dehydrogenase/reductase (SDR family) member 13; <bold>DHRSX</bold>: dehydrogenase/reductase (SDR family) X-linked; <bold>DIO2:</bold> deiodinase, iodothyronine, type II; <bold>DLGAP1</bold>: discs, large (Drosophila) homolog-associated protein 1; <bold>DPEP1</bold>: dipeptidase 1 (renal); <bold>DPP4:</bold> dipeptidyl-peptidase 4; <bold>DPYD</bold>: dihydropyrimidine dehydrogenase; <bold>DRD1</bold>: dopamine receptor D1; <bold>DRD2</bold>: dopamine receptor D2; <bold>DRD3</bold>: dopamine receptor D3; <bold>DRD4</bold>: dopamine receptor D4; <bold>DRD5</bold>: dopamine receptor D5; <bold>DRDs:</bold> dopamine receptors; <bold>DTNBP1</bold>: dystrobrevin binding protein 1; <bold>EPHX1</bold>: Epoxide hydrolase 1, microsomal (xenobiotic); <bold>EPHX2</bold>: epoxide hydrolase 2, microsomal (xenobiotic); <bold>ESD</bold>: esterase D; <bold>FABP1</bold>: fatty acid binding protein 1, liver; <bold>FGB:</bold> fibrinogen beta chain; <bold>FKBP5:</bold> binding protein 5; <bold>FMO1</bold>: flavin containing monooxygenase 1; <bold>FMO2</bold>: flavin containing monooxygenase 2; <bold>FMO3</bold>: flavin containing monooxygenase 3; <bold>FMO4</bold>: flavin containing monooxygenase 4; <bold>FMO5</bold>: flavin containing monooxygenase 5; <bold>FMO6P</bold>: flavin containing monooxygenase 6 pseudogene; <bold>FMOs</bold>: flavin containing monooxygenases; <bold>FOS:</bold> FBJ murine osteosarcoma viral oncogene homolog; <bold>GABBRs:</bold> gamma-aminobutyric acid (GABA) A receptors, beta; <bold>GABRA1:</bold> gamma-aminobutyric acid (GABA) A receptor, alpha 1; <bold>GABRA2:</bold> gamma-aminobutyric acid (GABA) A receptor, alpha 2; <bold>GABRA3:</bold> gamma-aminobutyric acid (GABA) A receptor, alpha 3; <bold>GABRA4:</bold> gamma-aminobutyric acid (GABA) A receptor, alpha 4; <bold>GABRA5:</bold> gamma-aminobutyric acid (GABA) A receptor, alpha 5; <bold>GABRA6:</bold> gamma-aminobutyric acid (GABA) A receptor, alpha 6; <bold>GABRAs:</bold> gamma-aminobutyric acid (GABA) A receptors; <bold>GABRB1:</bold> gamma-aminobutyric acid type A receptor beta1 subunit; <bold>GABRB2:</bold> gamma-aminobutyric acid type A receptor beta2 subunit; <bold>GABRB3:</bold> gamma-aminobutyric acid (GABA) A receptor, beta 3; <bold>GABRBs:</bold> gamma-aminobutyric acid (GABA) A receptors, beta subtype; <bold>GABRD:</bold> gamma-aminobutyric acid (GABA) A receptor, delta; <bold>GABRE:</bold> gamma-aminobutyric acid (GABA) A receptor, épsilon; <bold>GABRG1:</bold> gamma-aminobutyric acid type A receptor gamma1 subunit; <bold>GABRG2:</bold> gamma-aminobutyric acid (GABA) A receptor, gamma 2; <bold>GABRG3:</bold> gamma-aminobutyric acid type A receptor pi subunit; <bold>GABRGs:</bold> gamma-aminobutyric acid (GABA) A receptors, gamma subtype; <bold>GABRP:</bold> gamma-aminobutyric acid (GABA) A receptor, pi; <bold>GABRQ:</bold> gamma-aminobutyric acid (GABA) A receptor, theta; receptor rho1 subunit; <bold>GABRR2:</bold> gamma-aminobutyric acid type A receptor rho2 subunit; <bold>GABRR3:</bold> gamma-aminobutyric acid type A receptor rho3 subunit; <bold>GABRs</bold>: gamma-aminobutyric acid (GABA) receptors; <bold>GAL3ST1</bold>: galactose-3-O-sulfotransferase 1; <bold>GAMT</bold>: guanidinoacetate N-methyltransferase; <bold>GFRA2</bold>: GDNF family receptor alpha 2; <bold>GH1:</bold> growth hormone 1; <bold>GLRs:</bold> glycine receptors; <bold>GLRX</bold>: glutaredoxin (thioltransferase); <bold>GLYAT</bold>: glycine-N-acyltransferase; <bold>GNAS:</bold> GNAS complex locus; <bold>GNB3</bold>: guanine nucleotide binding protein (G protein), beta polypeptide 3; <bold>GNMT</bold>: glycine N-methyltransferase; <bold>GPX1</bold>: glutathione peroxidase 1; <bold>GPR35:</bold> G protein-coupled receptor 35; <bold>GPX2</bold>: glutathione peroxidase 2 (gastrointestinal); <bold>GPX3</bold>: glutathione peroxidase 3 (plasma); <bold>GPX4</bold>: glutathione peroxidase 4; <bold>GPX5</bold>: glutathione peroxidase 5; <bold>GPX6</bold>: glutathione peroxidase 6 (olfactory); <bold>GPX7</bold>: glutathione peroxidase 7; <bold>GRIA1:</bold> glutamate receptor, ionotropic, AMPA 1; <bold>GRIA2:</bold> glutamate receptor, ionotropic, AMPA 2; <bold>GRIA3:</bold> glutamate receptor, ionotropic, AMPA 3; <bold>GRIA4</bold>: glutamate receptor, ionotropic, AMPA 4; <bold>GRIAs:</bold> ionotropic glutamate receptors; <bold>GRIK2:</bold> glutamate receptor, ionotropic, kainate 2; <bold>GRIK4:</bold> glutamate receptor, ionotropic, kainate 4; <bold>GRK5:</bold> G protein-coupled receptor kinase 5; <bold>GRIN1:</bold> glutamate ionotropic receptor NMDA type subunit 1; <bold>GRIN2A</bold>: glutamate receptor, ionotropic, N-methyl D-aspartate 2A; <bold>GRIN2B</bold>: glutamate receptor, ionotropic, N-methyl D-aspartate 2B; <bold>GRIN2C</bold>: glutamate receptor, ionotropic, N-methyl D-aspartate 2C; <bold>GRIN2D:</bold> glutamate ionotropic receptor NMDA type subunit 2D; <bold>GRIN3A:</bold> glutamate ionotropic receptor NMDA type subunit 3A; <bold>GRIN3B</bold>: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B; <bold>GRM3</bold>: glutamate receptor, metabotropic 3; <bold>GSK3B</bold>: glycogen synthase kinase 3 beta; <bold>GSR</bold>: glutathione reductase; <bold>GSTA1</bold>: glutathione S-transferase alpha 1; <bold>GSTA2</bold>: glutathione S-transferase alpha 2; <bold>GSTA3</bold>: glutathione S-transferase alpha 3; <bold>GSTA4</bold>: glutathione S-transferase alpha 4; <bold>GSTA5</bold>: Glutathione S-transferase alpha 5; <bold>GSTCD</bold>: glutathione S-transferase, C-terminal domain containing; <bold>GSTK1</bold>: glutathione S-transferase kappa 1; <bold>GSTM1</bold>: glutathione S-transferase mu 1; <bold>GSTM2</bold>: glutathione S-transferase mu 2 (muscle); <bold>GSTM3</bold>: glutathione S-transferase mu 3 (brain); <bold>GSTM4</bold>: glutathione S-transferase mu 4; <bold>GSTM5</bold>: glutathione S-transferase mu 5; <bold>GSTO1</bold>: glutathione S-transferase omega 1; <bold>GSTO2</bold>: glutathione S-transferase omega 2; <bold>GSTP1</bold>: glutathione S-transferase pi 1; <bold>GSTs:</bold> glutathione S-transferases; <bold>GSTT1</bold>: glutathione S-transferase theta 1; <bold>GSTT2</bold>: glutathione S-transferase theta 2; <bold>GSTZ1</bold>: glutathione S-transferase zeta 1; <bold>GZMA</bold>: granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3; <bold>GZMB</bold>: granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1); <bold>HCRTR1:</bold> hypocretin (orexin) receptor 1; <bold>HCRTR2:</bold> hypocretin (orexin) receptor 2; <bold>HDAC2:</bold> histone deacetylase 2; <bold>HDAC9:</bold> histone deacetylase 9; <bold>HDC:</bold> histidine decarboxylase; <bold>HLA-B:</bold> major histocompatibility complex, class I, B; <bold>HNF4A:</bold> hepatocyte nuclear factor 4, alpha; <bold>HNMT</bold>: histamine N-methyltransferase; <bold>HOMER1:</bold> homer homolog 1 (Drosophila); <bold>HRH1</bold>: histamine receptor H1; <bold>HRH2</bold>: histamine receptor H2; <bold>HRH4:</bold> histamine receptor H4; <bold>HRHs</bold>: histamine receptor family; <bold>HSD11B1</bold>: hydroxysteroid (11-beta) dehydrogenase 1; <bold>HSD17B10</bold>: hydroxysteroid (17-beta) dehydrogenase 10; <bold>HSD17B11</bold>: hydroxysteroid (17-beta) dehydrogenase 11; <bold>HSD17B14</bold>: hydroxysteroid (17-beta) dehydrogenase 14; <bold>HTR1A</bold>: 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled; <bold>HTR1B</bold>; 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled; <bold>HTR1D</bold>: 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled; <bold>HTR1E</bold>: 5-hydroxytryptamine (serotonin) receptor 1E, G protein-coupled; <bold>HTR1F</bold>: 5-hydroxytryptamine (serotonin) receptor 1F, G protein-coupled; <bold>HTR1s</bold>: 5-hydroxytryptamine (serotonin) receptors, family 1; <bold>HTR2A</bold>: 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled; <bold>HTR2B</bold>: 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled; <bold>HTR2C</bold>: 5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled; <bold>HTR2s</bold>: 5-hydroxytryptamine (serotonin) receptors, family 2; <bold>HTR3:</bold> histone H3; <bold>HTR3A</bold>: 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic<bold>;</bold>
<bold>HTR3B:</bold> 5-hydroxytryptamine (serotonin) receptor 3B, ionotropic; <bold>HTR3C</bold>: 5-hydroxytryptamine (serotonin) receptor 3C, ionotropic; <bold>HTR5A</bold>: 5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled; <bold>HTR6</bold>: 5-hydroxytryptamine (serotonin) receptor 6, G protein-coupled; <bold>HTR7</bold>: 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled; ); <bold>HTRs:</bold> 5-hydroxytryptamine (serotonin) receptors; <bold>HTT</bold>: huntingtin; <bold>ICAM1:</bold> intercellular adhesion molecule 1; <bold>IDO1:</bold> indoleamine 2,3-dioxygenase 1; <bold>IFNA1:</bold> interferon, alpha 1; <bold>IGF1:</bold> insulin-like growth factor 1 (somatomedin C); <bold>IL1B:</bold> interleukin 1, beta; <bold>IL1RN</bold>: interleukin 1 receptor antagonist; <bold>IL6:</bold> interleukin 6; <bold>IL12B</bold>: interleukin 12B; <bold>INMT</bold>: indolethylamine N-methyltransferase; <bold>ITGB3:</bold> integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61); <bold>KCNE1</bold>: potassium channel, voltage gated subfamily E regulatory beta subunit 1; <bold>KCNE2</bold>: potassium channel, voltage gated subfamily E regulatory beta subunit 2; <bold>KCNH2</bold>: potassium channel, voltage gated eag related subfamily H, member 2; <bold>KCNH6</bold>: potassium channel, voltage gated eag related subfamily H, member 6; <bold>KCNJ11</bold>: potassium channel, inwardly rectifying subfamily J, member 11; <bold>KCNKs</bold>: potassium channel, subfamily K; <bold>KCNQ1</bold>: potassium channel, voltage gated KQT-like subfamily Q, member 1; <bold>KRAS:</bold> Kirsten rat sarcoma viral oncogene homolog; <bold>LEP</bold>: leptin; <bold>LEPR</bold>: leptin receptor; <bold>LIPC:</bold> lipase, hepatic; <bold>LPL</bold>: lipoprotein lipase; <bold>MAO:</bold> monoamine oxidase; <bold>MAOA</bold>: Monoamine oxidase A; <bold>MAOB</bold>: monoamine oxidase B; <bold>MCHR1:</bold> Melanin concentrating hormone receptor 1; <bold>MET:</bold> MET proto-oncogene, receptor tyrosine kinase; <bold>METAP1</bold>: Methionyl aminopeptidase 1; <bold>MGST1</bold>: Microsomal glutathione S-transferase 1; <bold>MGST2</bold>: Microsomal glutathione S-transferase 1; <bold>MGST3</bold>: Microsomal glutathione S-transferase 3; <bold>MTNR1A:</bold> melatonin receptor 1A; <bold>MTNR1B:</bold> melatonin receptor 1B; <bold>NAA20</bold>: N(alpha)-acetyltransferase 20, NatB catalytic subunit; <bold>NAT1</bold>: N-acetyltransferase 1 (arylamine N-acetyltransferase); <bold>NAT2</bold>: N-acetyltransferase 2 (arylamine N-acetyltransferase); <bold>NDUFs:</bold> NADH dehydrogenase (ubiquinone) family; <bold>NNMT</bold>: nicotinamide N-methyltransferase; <bold>NPAS3</bold>: neuronal PAS domain protein 3; <bold>NPPA:</bold> natriuretic peptide A; <bold>NPY</bold>: neuropeptide Y; <bold>NQO1</bold>: NAD(P)H dehydrogenase, quinone 1; <bold>NQO2</bold>: NAD(P)H dehydrogenase, quinone 2; <bold>NR1I2</bold>: nuclear receptor subfamily 1, group I, member 2; <bold>NR1I3:</bold> nuclear receptor subfamily 1, group I, member 3; <bold>NR3C1:</bold> nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor); <bold>NRG3</bold>: neuregulin 3; <bold>NRXN1</bold>: neurexin 1; <bold>NTRK1:</bold> neurotrophic tyrosine kinase, receptor, type 1; <bold>NTRK2:</bold> neurotrophic tyrosine kinase, receptor, type 2; <bold>NUBPL</bold>: nucleotide binding protein-like; <bold>NUDT9P1</bold>: nudix (nucleoside diphosphate linked moiety X)-type motif 9 pseudogene 1; <bold>OGDH:</bold> Oxoglutarate dehydrogenase; <bold>ORM1:</bold> orosomucoid 1; <bold>ORM2:</bold> orosomucoid 2; <bold>PALLD</bold>: alladin, cytoskeletal associated protein; <bold>PARK2</bold>: parkin RBR E3 ubiquitin protein ligase; <bold>PDE1C:</bold> phosphodiesterase 1C, calmodulin-dependent 70kDa; <bold>PDE5A:</bold> phosphodiesterase 5A, cGMP-specific; <bold>PNMT</bold>: Phenylethanolamine N-methyltransferase; <bold>POMC:</bold> proopiomelanocortin; <bold>PON1</bold>: Paraoxonase 1; <bold>PON2</bold>: Paraoxonase 2; <bold>PON3</bold>: Paraoxonase 3; <bold>POR</bold>: P450 (cytochrome) oxidoreductase; <bold>PPARA:</bold> Peroxisome proliferator activated receptor alpha; <bold>PPARD:</bold> Peroxisome proliferator activated receptor delta; <bold>PPARG:</bold> Peroxisome proliferator activated receptor gamma; <bold>PPARGC1A:</bold> peroxisome proliferator-activated receptor gamma, coactivator 1 alpha; <bold>PRKAB1:</bold> protein kinase, AMP-activated, beta 1 non-catalytic subunit; <bold>PRKCSH:</bold> protein kinase C substrate 80K-H; <bold>PRL:</bold> prolactin; <bold>PRLH</bold>: prolactin releasing hormone; <bold>PSEN1:</bold> presenilin 1; <bold>PSEN2:</bold> presenilin 2; <bold>PSMD9:</bold> proteasome (prosome, macropain) 26S subunit, non-ATPase, 9; <bold>PTGES</bold>: Prostaglandin E synthase; <bold>PTGS1</bold>: Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase); <bold>PTGS2</bold>: Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase); <bold>RB1:</bold> retinoblastoma 1; <bold>RGS2</bold>: regulator of G-protein signaling 2; <bold>RGS4</bold>: regulator of G-protein signaling 4; <bold>RGS7</bold>: regulator of G-protein signaling 7; <bold>RRAS2</bold>: related RAS viral (r-ras) oncogene homolog 2; <bold>RXRA:</bold> retinoid X receptor, alpha; <bold>SAT1</bold>: spermidine/spermine N1-acetyltransferase 1; <bold>SCL6A4:</bold> solute carrier family 6 (neurotransmitter transporter), member 4; <bold>SCN1A:</bold> sodium channel, voltage gated, type I alpha subunit; <bold>SCN3A:</bold> Sodium voltage-gated channel alpha subunit 3; <bold>SCN5A</bold>: sodium channel, voltage gated, type V alpha subunit; <bold>SCNA</bold>: synuclein, alpha (non A4 component of amyloid precursor); <bold>SCN1B:</bold> sodium voltage-gated channel beta subunit 1; <bold>SCNs:</bold> sodium channels, voltage gated; <bold>SIGMAR1:</bold> sigma non-opioid intracellular receptor 1; <bold>SLC6A2</bold>: solute carrier family 6 (neurotransmitter transporter), member 2; <bold>SLC6A3</bold>: solute carrier family 6 (neurotransmitter transporter), member 3; <bold>SLC6A4</bold>: solute carrier family 6 (neurotransmitter transporter), member 4; <bold>SLC10A1:</bold> solute carrier family 10 (sodium/bile acid cotransporter), member 1; <bold>SLC16A1:</bold> solute carrier family 16 member 1; <bold>SLC18A2:</bold> solute carrier family 18 member 2; <bold>SLC22A1:</bold> solute carrier family 22 (organic cation transporter), member 1; <bold>SLC22A2:</bold> solute carrier family 22 (organic cation transporter), member 2; <bold>SLC22A3:</bold> solute carrier family 22 (organic cation transporter), member 3; <bold>SLC22A4:</bold> solute carrier family 22 member 4; <bold>SLC22A5:</bold> solute carrier family 22 member 5; <bold>SLC22A6:</bold> solute carrier family 22 member 6; <bold>SLC22A7:</bold> solute carrier family 22 member 7; <bold>SLC22A8:</bold> solute carrier family 22 member 8; <bold>SLCO1B1:</bold> solute carrier organic anion transporter family, member 1B1; <bold>SLCO1B3:</bold> solute carrier organic anion transporter family, member 1B3; <bold>SLCO1C1:</bold> Solute carrier organic anion transporter family member 1C1; <bold>SLCO2A1:</bold> Solute carrier organic anion transporter family member 2A1; <bold>SLCO2B1:</bold> solute carrier organic anion transporter family, member 2B1; <bold>SLCO3A1</bold>: solute carrier organic anion transporter family, member 3A1; <bold>SMOX</bold>: spermine oxidase; <bold>SOD1</bold>: Superoxide dismutase 1, soluble; <bold>SOD2</bold>: superoxide dismutase 2, mitochondrial; <bold>SPG7:</bold> spastic paraplegia 7 (pure and complicated autosomal recessive); <bold>STAT3</bold>: signal transducer and activator of transcription 3 (acute-phase response factor); <bold>SULT1A1</bold>: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1; <bold>SULT1A2</bold>: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2; <bold>SULT1A3</bold>: sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3; <bold>SULT1B1</bold>: sulfotransferase family, cytosolic, 1B, member 1; <bold>SULT1C1</bold>: sulfotransferase family, cytosolic, 1C, member 1; <bold>SULT1C2</bold>: sulfotransferase family, cytosolic, 1C, member 2; <bold>SULT1C3</bold>: sulfotransferase family, cytosolic, 1C, member 3; <bold>SULT1C4</bold>: sulfotransferase family, cytosolic, 1C, member 4; <bold>SULT1E1</bold>: sulfotransferase family 1E, estrogen-preferring, member 1; <bold>SULT2A1</bold>: sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1; <bold>SULT2B1</bold>: sulfotransferase family, cytosolic, 2B, member 1; <bold>SULT4A1</bold>: sulfotransferase family 4A, member 1; <bold>SULT6B1</bold>: sulfotransferase family, cytosolic, 6B, member 1; <bold>TBX21:</bold> T-box 21; <bold>TBXAS1</bold>: thromboxane A synthase 1 (platelet); <bold>TDO2:</bold> tryptophan 2,3-dioxygenase; <bold>TGFB1:</bold> transforming growth factor, beta 1; <bold>TMEM163</bold>: transmembrane protein 163; <bold>TNF</bold>: tumor necrosis factor; <bold>TNFRSF1A:</bold> tumor necrosis factor receptor superfamily, member 1A; <bold>TNR</bold>: tenascin R; <bold>TPH1:</bold> tryptophan hydroxylase 1; <bold>TPH2:</bold> tryptophan hydroxylase 2; <bold>TPMT</bold>: thiopurine S-methyltransferase; <bold>TSPO:</bold> translocator protein (18kDa); <bold>TST</bold>: thiopurine S-methyltransferase; <bold>UCHL1</bold>: ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase); <bold>UCHL3</bold>: ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase); <bold>UGT1A1</bold>: UDP glucuronosyltransferase 1 family, polypeptide A1; <bold>UGT1A3</bold>: UDP glucuronosyltransferase 1 family, polypeptide A3; <bold>UGT1A4</bold>: UDP glucuronosyltransferase 1 family, polypeptide A4; <bold>UGT1A5</bold>: UDP glucuronosyltransferase 1 family, polypeptide A5; <bold>UGT1A6</bold>: UDP glucuronosyltransferase 1 family, polypeptide A6; <bold>UGT1A7</bold>: UDP glucuronosyltransferase 1 family, polypeptide A7; <bold>UGT1A8</bold>: UDP glucuronosyltransferase 1 family, polypeptide A8; <bold>UGT1A9</bold>: UDP glucuronosyltransferase 1 family, polypeptide A9; <bold>UGT1A10</bold>: UDP glucuronosyltransferase 1 family, polypeptide A10; <bold>UGT2A1</bold>: UDP glucuronosyltransferase 2 family, polypeptide A1, complex locus; <bold>UGT2A3</bold>: UDP glucuronosyltransferase 2 family, polypeptide A3; <bold>UGT2B4</bold>: UDP glucuronosyltransferase 2 family, polypeptide B4; <bold>UGT2B7</bold>: UDP glucuronosyltransferase 2 family, polypeptide B7; <bold>UGT2B10</bold>: UDP glucuronosyltransferase 2 family, polypeptide B10; <bold>UGT2B11</bold>: UDP glucuronosyltransferase 2 family, polypeptide B11; <bold>UGT2B15</bold>: UDP glucuronosyltransferase 2 family, polypeptide B15; <bold>UGT2B17</bold>: UDP glucuronosyltransferase 2 family, polypeptide B17; <bold>UGT2B28</bold>: UDP glucuronosyltransferase 2 family, polypeptide B28; <bold>UGT3A1</bold>: UDP glycosyltransferase 3 family, polypeptide A1; <bold>UGT8</bold>: UDP glycosyltransferase 8; <bold>UGTs</bold>: glucuronosyltransferase family; <bold>XDH</bold>: Xanthine dehydrogenase; <bold>XKR4</bold>: XK, Kell blood group complex subunit-related family, member 4; <bold>WARS:</bold> tryptophanyl-tRNA synthetase; <bold>WARS2:</bold> tryptophanyl tRNA synthetase 2, mitochondrial.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijms-21-03059-t003" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-03059-t003_Table 3</object-id>
<label>Table 3</label>
<caption>
<p>Pharmacological profile and pharmacogenetics of selected antipsychotics.</p>
</caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Atypical Antipsychotics</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i006.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Aripiprazole</styled-content></bold>; 129722-12-9; Abilify; Abilitat; Abilify Discmelt; OPC-1459</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>DRD2</italic>, <italic>DRD3</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4, HRHs</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>HTR2B, HTR2C, HTR7</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major), <italic>CYP3A5</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 7-{4-[4-(2,3-dichlorophenyl) piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> 448.38538 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> C<sub>23</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Partial agonist at the D<sub>2</sub> and 5-HT<sub>1A</sub> receptors, and as an antagonist at the 5-HT<sub>2A</sub> receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; H1-receptor antagonist; Serotonergic agonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i007.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Asenapine maleate</styled-content></bold>; Saphris; Org5222 maleate; 85650-56-2; Org 5222 maleate; Org-5222 maleate</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>HTR7</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>ADRA2A</italic>, <italic>ADRA2B</italic>, <italic>ADRA2C</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HRH1</italic>, <italic>HRH2</italic>, <italic>HTR1A</italic>, <italic>HTR1B</italic>, <italic>HTR2A</italic>, <italic>HTR2B</italic>, <italic>HTR2C</italic>, <italic>HTR5A</italic>, <italic>HTR6</italic>, <italic>HTR7</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A1</italic>, <italic>CYP1A2</italic> (major), <italic>CYP2D6</italic> (minor), <italic>CYP3A4</italic> (minor), <italic>UGT1A4</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2D6</italic> (weak)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> (2Z)-but-2-enedioic acid; 17-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.0<sup>2</sup>,<sup>6</sup>.0<sup>7</sup>,<sup>12</sup>]octadeca-1(14),7,9,11,15,17-hexaene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>20</sub>ClNO<sub>5</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 401.8402 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Its main activity is associated to combination of antagonistic actions at D<sub>2</sub> and 5-HT<sub>2A</sub> receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; Serotonergic antagonist; Alpha-adrenergic antagonist; Beta-adrenergic antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i008.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Clozapine</styled-content></bold>; Leponex; Fazaclo; Iprox; CLOZARIL; Clozapin</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>DTNBP1</italic>, <italic>HTR2A</italic>, <italic>LPL</italic>, <italic>NRXN1</italic>, <italic>TNF</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRAs</italic>, <italic>CHRMs</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HRH1</italic>, <italic>HTR1F</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>HTR3A</italic>, <italic>HTR6</italic>, <italic>NRXN1</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2A6</italic> (minor), <italic>CYP2C8</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (minor), <italic>CYP3A4/5</italic> (major), <italic>FMO3</italic>, <italic>UGT1A1, UGT1A3</italic>, <italic>UGT1A4</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (weak), <italic>CYP2C9</italic> (moderate), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (weak)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>APOA5</italic>, <italic>APOC3</italic>, <italic>APOD</italic>, <italic>CNR1</italic>, <italic>FABP1</italic>, <italic>GNB3</italic>, <italic>GSK3B</italic>, <italic>LPL</italic>, <italic>RGS2</italic>, <italic>TNF</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 6-chloro-10-(4-methylpiperazin-1-yl)-2,9-diazatricyclo[9.4.0.0<sup>3</sup>,<sup>8</sup>]pentadeca-1(15),3,5,7,9,11,13-heptaene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>18</sub>H<sub>19</sub>ClN<sub>4</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 326.82326 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It shows serotonergic, adrenergic, and cholinergic neurotransmitter systems in addition to more selective, regionally specific effects on the mesolimbic dopaminergic system. It also displays antagonistic activity at H1-receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Dopaminergic antagonist; Serotonergic antagonist; Histamine antagonist; Muscarinic antagonist; GABA antagonist; GABA modulator; Antipsychotic agent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i200.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Iloperidone</styled-content></bold>; Zomaril; 133454-47-4; Fanapt; Fanapta; HP 873</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>CNTF</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HTR2A</italic>, <italic>HTR7</italic>, <italic>NRG3</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>ADRA2A</italic>, <italic>ADRA2B</italic>, <italic>ADRA2C</italic>, <italic>ADRB1</italic>, <italic>ADRB2</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>DRD5</italic>, <italic>GFRA2</italic>, <italic>GRIA4</italic>, <italic>HRH1</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>HTR6</italic>, <italic>HTR7</italic>, <italic>NPAS3</italic>, <italic>NUDT9P1</italic>, <italic>TNR</italic>, <italic>XKR4</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic>, <italic>CYP2E1</italic>, <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>SLC6A2</italic>, <italic>SLCO3A1</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>ADRB2</italic>, <italic>CELF4</italic>, <italic>CERKL</italic>, <italic>DRD5</italic>, <italic>HTR1F</italic>, <italic>NPAS3</italic>, <italic>NRG3</italic>, <italic>NUBPL</italic>, <italic>PALLD</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 1-(4-{3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy}-3-methoxyphenyl)ethan-1-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>24</sub>H<sub>27</sub>FN<sub>2</sub>O<sub>4</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 426.480583 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It has mixed D<sub>2</sub>/5-HT<sub>2</sub> antagonist activity. It exhibits high affinity for 5-HT<sub>2A</sub>, D<sub>2</sub>, and D<sub>3</sub> receptors, low to moderate affinity for D<sub>1</sub>, D<sub>4</sub>, H<sub>1</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>6</sub>, 5HT<sub>7</sub>, and ADR<sub>α</sub><sub>1/</sub><sub>α</sub><sub>2C</sub> receptors, and no affinity for muscarinic receptors. It has low affinity for histamine H<sub>1</sub> receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; Serotonergic antagonist; Antidepressant effects; Anxiolytic activity; Reduction of risk for weight gain; Cognitive Function Improved</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i009.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Olanzapine</styled-content></bold>; Zyprexa; 132539-06-1; Zyprexa Zydis; Olansek; Symbyax</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>COMT</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>GRM3</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>LPL</italic><break></break><bold>Mechanistic genes:</bold><italic>ABCB1, ADRA1A</italic>, <italic>ADRB3</italic>, <italic>AHR, BDNF, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5</italic>, <italic>COMT</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3, DRD4</italic>, <italic>GABRs</italic>, <italic>GRIN2B, HRH1</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>HTR3A</italic>, <italic>HTR6, LEP</italic>, <italic>RGS2</italic>, <italic>RGS7</italic>, <italic>SLC6A4, STAT3</italic>, <italic>TMEM163</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>COMT</italic>, <italic>CYP1A2</italic> (major), <italic>CYP2C9, CYP2D6</italic> (major), <italic>CYP3A43, CYP3A5, FMO1</italic>, <italic>FMO3, GSTM3, TPMT, UGT1A1, UGT1A4, UGT2B10</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP1A2</italic> (weak), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (weak), <italic>CYP3A4</italic> (weak) <break></break><bold>  Inducer:</bold>
<italic>GSTM1, MAOB, SLCO3A1</italic><break></break><bold>Transporter genes:</bold>
<italic>KCNH2</italic>, <italic>SLC6A2, SLC6A4, SLCO3A1</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>APOA5</italic>, <italic>APOC3</italic>, <italic>GNB3</italic>, <italic>LEP</italic>, <italic>LEPR</italic>, <italic>LPL</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>20</sub>N<sub>4</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 312.4325 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It displays potent antagonism of serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub>, dopamine D<sub>1-4</sub>, histamine H<sub>1</sub> and α<sub>1</sub>-adrenergic receptors. It shows moderate antagonism of 5-HT<sub>3</sub> and muscarinic M<sub>1-5</sub> receptors, and weak binding to GABA-A, BZD, and β-adrenergic receptors. </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; GABA modulator; Muscarinic antagonist; Serotonin uptake inhibitor; Dopaminergic antagonist; Serotonergic antagonist; Histamine antagonist; Antiemetic activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i010.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Paliperidone</styled-content></bold>; Paliperidone; 9-Hydroxyrisperidone; Invega; 144598-75-4; 9-OH-risperidone; Invega Sustenna</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>ADRA1B</italic>, <italic>ADRA1D</italic>, <italic>ADRA2s</italic>, <italic>BDNF, DRD2</italic>, <italic>HRH1</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>ADH</italic>, <italic>CYP2D6</italic>(minor), <italic>CYP3A4/5</italic> (major), <italic>UGTs</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP2D6</italic> (moderate), <italic>CYP3A4/5</italic> (moderate)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>23</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 426.483883 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Mixed central serotonergic and dopaminergic antagonism. Demonstrates high affinity to α<sub>1</sub>, D<sub>2</sub>, H<sub>1</sub>, and 5-HT<sub>2C</sub> receptors, and low affinity for muscarinic and 5-HT<sub>1A</sub> receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Neuroprotective agent; H1-receptor antagonist; Alpha-adrenergic antagonist; Serotonergic antagonist; Dopaminergic antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i011.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Quetiapine Fumarate</styled-content></bold>; Seroquel; Quetiapine hemifumarate; 111974-72-2; Seroquel XR; UNII-2S3PL1B6UJ</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD4</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>RGS4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1s</italic>, <italic>ADRA2s</italic>, <italic>BDNF, CHRM1, CHRM3, CHRM5, DRD1</italic>, <italic>DRD2</italic>, <italic>DRD4</italic>, <italic>HRH1</italic>, <italic>HTR1A</italic>, <italic>HTR1E, HTR2A</italic>, <italic>HTR2B, HTR7</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (minor), <italic>CYP3A4/5</italic> (major), <italic>CYP3A7</italic>, <italic>CYP2C19</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, SLC6A2</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>KCNE1</italic>, <italic>KCNE2</italic>, <italic>KCNH2</italic>, <italic>KCNQ1</italic>, <italic>SCN5A, SLC6A2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>46</sub>H<sub>54</sub>N<sub>6</sub>O<sub>8</sub>S<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 883.08636 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Antagonist at multiple neurotransmitter receptors: serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub>, dopamine D<sub>1</sub> and D<sub>2</sub>, histamine H<sub>1</sub>, and adrenergic α<sub>1</sub>- and α<sub>2</sub>-receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Adrenergic antagonist; Histamine antagonist; Serotonergic antagonist; Dopaminergic antagonist; Sedative activity; Orthostatic hypotension</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i012.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Risperidone</styled-content></bold>; Risperdal; Risperidal; 106266-06-2; Risperdal Consta; Rispolept</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>BDNF</italic>, <italic>COMT</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>GRM3</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>HTR7, PON1</italic>, <italic>RGS4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>ADRA1B</italic>, <italic>ADRA2s</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>FOS</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>HTR3A</italic>, <italic>HTR3C</italic>, <italic>HTR6</italic>, <italic>HTR7, NR1I2, STAT3</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>COMT, CYP2D6</italic> (major), <italic>CYP3A4/5</italic> (minor) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP2D6</italic> (weak), <italic>CYP3A4</italic> (weak) Inducer: <italic>MAOB</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1, KCNH2</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>APOA5, BDNF, RGS2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>23</sub>H<sub>27</sub>FN<sub>4</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 410.484483 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Antagonist at multiple neurotransmitter receptors: serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2</sub>, dopamine D<sub>1</sub> and D<sub>2</sub>, histamine H<sub>1</sub>, and adrenergic α<sub>1</sub>- and α<sub>2</sub>-receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; H<sub>1</sub>-receptor antagonist; Dopaminergic antagonist; Alpha-adrenergic antagonist; Serotonergic antagonist; Somnolence; Orthostatic hypotension</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i013.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Ziprasidone</styled-content></bold>; Geodon; 146939-27-7; Zeldox; Ziprazidone; Ziprasidone hydrochloride</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic>, <italic>RGS4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>HRH1</italic>, <italic>HTR1A</italic>, <italic>HTR1B, HTR1D</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>AOX1</italic> (major), <italic>CYP1A2</italic> (minor), <italic>CYP3A4</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>CYP2D6</italic> (moderate), <italic>CYP3A4</italic> (moderate), <italic>SLC6A2, SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>KCNH2, SLC6A2, SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>CHRM1</italic>, <italic>RRAS2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>21</sub>ClN<sub>4</sub>OS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 412.93564 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It has high affinity for D<sub>2</sub>, D<sub>3</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>1D</sub>, and α<sub>1</sub>-adrenergic, and moderate affinity for histamine H<sub>1</sub> receptors. It functions as antagonist at D<sub>2</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>1D</sub> receptors and as agonist at 5-HT<sub>1A</sub> receptor. It moderately inhibits reuptake of serotonin and norepinephrine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Histamine antagonist; Dopaminergic antagonist; Serotonergic antagonist; Muscarinic antagonist; Serotonin–norepinephrine reuptake inhibitor</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Typical Antipsychotics</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">
<bold>Butyrophenones</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i014.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Bromperidol</styled-content></bold>; Impromen; Bromoperidol; Tesoprel; 10457-90-6; Azurene</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>DRD2</italic>, <italic>HTR2A</italic><break></break><bold>Mechanistic genes:</bold><italic>DRD2</italic>, <italic>HTR2A</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (minor), <italic>CYP3A4</italic> (major), <italic>UGTs</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2D6</italic> (moderate)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>23</sub>BrFNO<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 420.315223 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Potent dopaminergic D<sub>2</sub> antagonist. Has weak α<sub>1</sub>-adrenolitic activity. It is a moderate serotonin 5-HT<sub>2</sub> antagonist. Has no antihistaminic or anticholinergic effects. It acts on the mesocortex, limbic system, and basal ganglia (nigrostriate pathway)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopamine antagonist; α<sub>1</sub>-adrenolitic activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i015.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Haloperidol</styled-content></bold>; Haldol; Eukystol; Serenace; Aloperidin; Aloperidol</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A, BDNF, DRD1, DRD2, DRD4, DTNBP1, GRIN2B, HTR2A</italic><break></break><bold>Mechanistic genes:</bold><italic>ANKK1, BDNF, COMT, DRD1, DRD2, DTNBP1, GRIN2A, GRIN3B, GRIN2C, GRIN2B, SLC6A3</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CBR1</italic>, <italic>CYP1A1</italic> (minor), <italic>CYP1A2</italic> (minor), <italic>CYP2A6</italic>, <italic>CYP2C8</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic>/<italic>5</italic> (major), <italic>GSTP1</italic>, <italic>UGTs</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, CYP2D6</italic> (moderate), <italic>CYP3A4</italic> (moderate)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1, ABCC1, KCNE1, KCNE2, KCNH2, KCNJ11, KCNQ1, SLC6A3</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>CHRM2, FOS, GSK3B, HRH1, HTR2A, HTT, IL1RN</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>23</sub>ClFNO<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 375.864223 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Haloperidol is a butyrophenone antipsychotic which blocks postsynaptic mesolimbic dopaminergic D<sub>1</sub> and D<sub>2</sub> receptors in brain. Depresses release of hypothalamic and hypophyseal hormones. Believed to depress reticular activating system</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Serotonergic antagonist; Dopaminergic antagonist; Antiemetic; Antidyskinesia agent; Sedative effects; Hypotension</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">
<bold>Phenothiazines</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i016.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Chlorpromazine</styled-content></bold>; Largactil; Thorazine; Contomin; Chloropromazine; Aminazine</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>BDNF</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HTR2A</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A, ADRA1B, CHRM1, CHRM2, DRD1, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR2A, HTR2C</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2A6, CYP2C9, CYP2C19, CYP2D6</italic> (major), <italic>CYP3A4</italic> (minor), <italic>FMO1</italic>, <italic>UGT1A3</italic>, <italic>UGT1A4</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2, CYP2D6</italic> (strong), <italic>CYP2C19, CYP2E1</italic> (weak), <italic>CYP3A4, DAO</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>CFTR</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>ACACA, BDNF, FABP1, LEP, NPY</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> [3-(2-chloro-10H-phenothiazin-10-yl)propyl]dimethylamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>19</sub>ClN<sub>2</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 318.86416 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks postsynaptic mesolimbic dopaminergic receptors in the brain. Has actions at all levels of CNS, particularly at subcortical levels; also acts on multiple organ systems. Also exhibits weak ganglionic blocking, has a strong α-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones. Depresses the reticular activating system</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; Antiemetic; Anticholinergic effects; Sedative effects; Antihistaminic effects; Anti-serotonergic activity; Hypotension</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i017.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Fluphenazine</styled-content></bold>; Triflumethazine; Fluorophenazine; Fluorfenazine; Fluorphenazine; Siqualine</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>DRD1, DRD2</italic><break></break><bold>Mechanistic genes:</bold><italic>CALM1, DRD1, DRD2</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2B6, CYP2D6</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, CYP1A2</italic> (weak), <italic>CYP2A6, CYP2C9</italic> (weak), <italic>CYP2C19, CYP2D6</italic> (strong), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethan-1-ol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>22</sub>H<sub>26</sub>F<sub>3</sub>N<sub>3</sub>OS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 437.52155 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks postsynaptic mesolimbic dopaminergic D<sub>1</sub> and D<sub>2</sub> receptors in the brain. Depresses release of hypothalamic and hypophyseal hormones. Believed to depress reticular activating system, thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; Antiemesis; Anticholinergic effects; Sedative effects</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i018.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Perphenazine</styled-content></bold>; Trilafon; Perphenazin; Etaperazine; Perfenazine; Fentazin</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>HTR2A, HTR2C, RGS4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>HTR2A, HTR2C, RGS4</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2C8</italic> (major), <italic>CYP2C9</italic> (major), <italic>CYP2C18</italic> (major), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (minor), <italic>CYP3A4/5</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (weak), <italic>CYP2D6</italic> (strong)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>26</sub>ClN<sub>3</sub>OS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 403.96864 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks postsynaptic mesolimbic dopaminergic receptors in brain. Exhibits α-adrenergic-blocking effect and depresses release of hypothalamic and hypophyseal hormones. Binds to the dopamine D<sub>1</sub> and D<sub>2</sub> receptors and inhibits their activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Antiemetic; Dopaminergic antagonist; Antiemesis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i019.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Thioridazine</styled-content></bold>; Mellaril; Melleril; Thioridazin; Meleril; Sonapax</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1s</italic>, <italic>ADRA2s</italic>, <italic>DRD1</italic>, <italic>DRD2</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2C19</italic> (minor), <italic>CYP2A6</italic>, <italic>CYP2D6</italic> (major), <italic>CYP2J2</italic> (major), <italic>CYP3A4</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, CYP1A2</italic> (weak), <italic>CYP2A6, CYP2C9</italic> (weak), <italic>CYP2C19</italic> (weak)<italic>, CYP2D6</italic> (moderate), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (weak), <italic>KCNH</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>KCNE1</italic>, <italic>KCNE2</italic>, <italic>KCNH2</italic>, <italic>KCNJ11</italic>, <italic>KCNQ1</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>ADRBs</italic>, <italic>CHRM2</italic>, <italic>FABP1</italic>, <italic>HRH1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>S<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 370.57454 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks postsynaptic mesolimbic dopaminergic receptors in brain. Exhibits strong α-adrenergic-blocking effect and depresses release of hypothalamic and hypophyseal hormones</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; Alpha-adrenergic antagonist; H<sub>1</sub>-receptor antagonist; Serotonergic antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i020.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Trifluoperazine</styled-content></bold>; Trifluperazine; Trifluoroperazine; Trifluoperazina; Triflurin; Triperazine</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>DRD2</italic>, <italic>IL12B</italic><break></break><bold>Mechanistic genes:</bold><italic>ABCB1, ADRA1A</italic>, <italic>ADRA1B, CALMs, DRD2, HRH1</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>UGT1A4</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CALMs, POR</italic>
<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>IL12B</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>24</sub>F<sub>3</sub>N<sub>3</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 407.49557 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks postsynaptic mesolimbic dopaminergic receptors in brain. Exhibits α-adrenergic-blocking effect and depresses release of hypothalamic and hypophyseal hormones. This agent also functions as a calmodulin inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; Antiemesis; Cytosolic calcium elevation</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">
<bold>Thioxanthenes</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i021.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Thiothixene</styled-content></bold>, Tiotixene; Cis-Thiothixene; Navane; Thiothixine; Navan</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HTR2A</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1s</italic>, <italic>ADRA2s</italic>, <italic>CHRM1</italic>, <italic>CHRM2</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>DRD3</italic>, <italic>DRD4</italic>, <italic>HRH1, HRH2</italic>, <italic>HTR1s</italic>, <italic>HTR2s</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>CYP2D6</italic> (moderate)<break></break><bold>Transporter genes:</bold>
<italic>KCNE1</italic>, <italic>KCNE2</italic>, <italic>KCNH6</italic>, <italic>KCNQ1</italic>, <italic>SCN5A</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> (9Z)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]thioxanthene-2-sulfonamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>23</sub>H<sub>29</sub>N<sub>3</sub>O<sub>2</sub>S<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 443.62526 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Elicits antipsychotic activity by postsynaptic blockade of CNS dopamine receptors resulting in inhibition of dopamine-mediated effects. Also has α-adrenergic blocking activity. Antagonistic effect on dopaminergic (D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>), histaminergic (H<sub>1</sub>), sertoninergic (5-HT<sub>1</sub>, 5-HT<sub>2</sub>), adrenergic (α<sub>1</sub>- and α<sub>2</sub>) and muscarinic (M<sub>1</sub> and M<sub>2</sub>) receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopamine antagonist; Antisympathomimetic properties; Anticholinergic effects; Antidepressant effects, Antiaggressive properties; H<sub>1</sub>-receptor antagonist; Serotonergic agonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i022.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Zuclopenthixol</styled-content></bold>; Zuclopentixol; Clopixol; Zuclopenthixolum; Acuphase; Cisordinol</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ADRA2A</italic>, <italic>DRD1</italic>, <italic>DRD2</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1s</italic>, <italic>ADRA2s</italic>, <italic>CHRMs</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>HRH1</italic>, <italic>HTR2s</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><bold><italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major)</bold></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 2-[4-[(3Z)-3-(2-chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>22</sub>H<sub>25</sub>ClN<sub>2</sub>OS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 400.9647 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It mainly acts by antagonism of D<sub>1</sub> and D<sub>2</sub> dopamine receptors. It also has high affinity for alpha1-adrenergic and 5-HT<sub>2</sub> receptors. It has weaker histamine H<sub>1</sub> receptor blocking activity, and even lower affinity for muscarinic cholinergic and alpha2-adrenergic receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; H<sub>1</sub>-receptor antagonist; Serotonergic antagonist; Alpha-adrenergic antagonist.</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:#BFBFBF" valign="middle">
<bold>Typical Antipsychotics, Miscellaneous</bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i023.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Loxapine Succinate</styled-content></bold>; 27833-64-3; Loxapac; Loxapine succinate salt; Cloxazepin; Daxolin</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>DRD1</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic><break></break><bold>Mechanistic genes:</bold><italic>DRD1</italic>, <italic>DRD2</italic>, <italic>HTR2A</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major), <italic>FMOs</italic>, <italic>UGT1A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>HTR2A</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>22</sub>H<sub>24</sub>ClN<sub>3</sub>O<sub>5</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 445.89606 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks postsynaptic mesolimbic D<sub>1</sub> and D<sub>2</sub> receptors in brain; also possesses serotonin 5-HT<sub>2</sub>-blocking activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopamine antagonist; Serotonergic antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i024.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Pimozide</styled-content></bold>; Orap; Opiran; Neoperidole; Pimozidum; 2062-78-4</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>CACNs</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>KCNH2</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2D6</italic> (minor), <italic>CYP3A4</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (strong), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (moderate), <italic>KCNH2</italic><break></break><bold>Transporter genes:</bold>
<italic>KCNE1</italic>, <italic>KCNE2</italic>, <italic>KCNH2</italic>, <italic>KCNJ11</italic>, <italic>KCNKs, KCNQ1</italic>, <italic>SCN5A</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>CHRM2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> 3-[1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl]-1H-benzimidazol-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>28</sub>H<sub>29</sub>F<sub>2</sub>N<sub>3</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 461.546166 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a potent centrally-acting dopamine-receptor antagonist resulting in its characteristic neuroleptic effects. Binds and inhibits the dopamine D2 receptor in the CNS. It is antagonist of ADRA<sub>1A</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; H1-receptor antagonist; Dopaminergic antagonist; Antidyskinesia agent; Serotonergic antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i025.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Sulpiride</styled-content></bold>; Sulpyrid; Aiglonyl; Dogmatil; Dolmatil; Sulpirid</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>DRD2</italic>, <italic>DRD</italic><break></break><bold>Mechanistic genes:</bold><italic>DRD2</italic>, <italic>DRD3</italic>, <italic>PRLH</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic>, <italic>CYP2B1</italic>, <italic>CYP3As</italic><break></break><bold>  Inhibitor:</bold><italic>CYP1A2, CYP2B1, CYP3As</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name:</bold> N-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>23</sub>N<sub>3</sub>O<sub>4</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 341.42582 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a selective antagonist at postsynaptic D<sub>2</sub> and D<sub>3</sub>-receptors. It appears to lack effects on norepinephrine, acetylcholine, serotonin, histamine, or GABA receptors. It also stimulates secretion of prolactin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antipsychotic agent; Dopaminergic antagonist; Antidepressant effect; Antiemesis. Sedation (&gt;600 mg/day); Dopamine reuptake inhibition (&lt;200 mg/day); Antiemesis, Antimigraine effects; Antivertiginous activity; Prolactin-releasing stimulation</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-21-03059-t004" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-03059-t004_Table 4</object-id>
<label>Table 4</label>
<caption>
<p>Pharmacological profile and pharmacogenetics of selected antidepressants.</p>
</caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Monoamine Oxidase Inhibitors (MAOIs)</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#EEECE1" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#EEECE1" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#EEECE1" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i026.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Moclobemide</styled-content></bold>; Aurorix; Moclamine; Manerix; Moclobemidum; Moclobemid</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>MAOA</italic><break></break><bold>Mechanistic genes:</bold><italic>MAOA</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>Substrate:</bold><italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (major), CYP2E1 <break></break>
<bold>Inhibitor:</bold>
<italic>CYP1A2</italic> (weak)<italic>, CYP2C19</italic> (weak), <italic>CYP2D6</italic> (weak), <italic>MAOA</italic> (strong), <italic>MAOB</italic> (moderate)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>13</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 268.73928 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Monoamine oxidase A inhibitors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antidepressant agent; Monoamine Oxidase inhibition.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i027.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Phenelzine sulfate</styled-content></bold>; Estinerval; Nardelzine; Kalgan; Phenethylhydrazin; Phenelzine sulfate salt</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>MAOA</italic><break></break><bold>Mechanistic genes:</bold><italic>MAOA, MAOB</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>Substrate:</bold><italic>COMT, MAOA, MAOB</italic><break></break><bold>  Inhibitor:</bold><italic>CYP2C8</italic> (moderate), <italic>CYP2D6, CYP3A4</italic> (moderate), <italic>MAOA, MAOB</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (2-phenylethyl)hydrazine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 234.27276 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Monoamine oxidase inhibitors, non-selective</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Irreversible, non-selective inhibition of MAO. It causes an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antidepressant activity; Monoamine Oxidase inhibition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i028.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Rasagiline mesylate</styled-content></bold>; 161735-79-1; Azilect; Rasagiline mesilate; TVP-1012; Agilect</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>PARK2</italic><break></break><bold>Mechanistic genes:</bold><italic>BCL2, BCL2L1, MAOB</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2D6</italic>, <italic>UGT1A1</italic>, <italic>UGT1A3</italic>, <italic>UGT1A4</italic>, <italic>UGT1A6</italic>, <italic>UGT1A7</italic>, <italic>UGT1A9</italic>, <italic>UGT1A10</italic>, <italic>UGT2B7</italic>, <italic>UGT2B15</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>MAOB</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>13</sub>H<sub>17</sub>NO<sub>3</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 267.34398 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Monoamine oxidase B inhibitors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Potent, irreversible, selective inhibitor of brain monoamine oxidase (MAO) type B, which plays a major role in catabolism of dopamine.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antidepressant activity; Monoamine Oxidase inhibition; Neuroprotective agent; Antiparkinsonian agent.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i029.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Selegiline</styled-content></bold>; Selegiline hydrochloride; L-Deprenyl hydrochloride; 14611-52-0; Eldepryl; Selegiline Hcl; Zelapar</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>MAOA, PARK2</italic><break></break><bold>Mechanistic genes:</bold><italic>MAOA, MAOB</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2A6</italic> (minor), <italic>CYP2B6</italic> (major), <italic>CYP2C8</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (minor), <italic>CYP2E1</italic> (minor), <italic>CYP3A4</italic> (minor), <italic>MAOA</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (weak), <italic>CYP2A6</italic> (weak), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (weak), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (weak), <italic>MAOB</italic> (strong), <italic>MAOA</italic><break></break><bold>Transporter genes:</bold>
<italic>SCNA</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>13</sub>H<sub>18</sub>ClN</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 223.74172 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Monoamine oxidase B inhibitors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Selective, irreversible inhibition of MAO-B. It binds to MAO-B within the nigrostriatal pathways in the central nervous system, thus blocking microsomal metabolism of dopamine and enhancing the dopaminergic activity in the substantia nigra. It may also increase dopaminergic activity through mechanisms other than inhibition of MAO-B. At higher doses, it can also inhibit MAO-A.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antidepressant activity; Monoamine Oxidase inhibition Neuroprotective agent; Antiparkinsonian agent.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i030.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Tranylcypromine sulphate</styled-content></bold>; Tylciprine; Phenylcyclopromine sulfate; Dl-Tranylcypromine sulfate; EINECS 236-807-1; 1-Amino-2-phenylcyclopropane sulfate</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>MAOA, NTRK2, SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>MAOA, MAOB</italic><break></break><bold>Metabolic genes:</bold><break></break><break></break><bold>  Substrate:</bold><italic>CYP2A6</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (moderate), <italic>CYP2A6</italic> (strong), <italic>CYP2C8</italic> (weak), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (weak), <italic>MAOA, MAOB</italic><break></break><bold>Transporter genes:</bold>
<italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>FOS, NTRK2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (1R)-2-phenylcyclopropan-1-amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 364.45916 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Monoamine oxidase inhibitors, non-selective</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It increases endogenous concentrations of epinephrine, norepinephrine, dopamine, serotonin through inhibition of MAO responsible for breakdown of these neurotransmitters</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Monoamine Oxidase inhibition; Antidepressant activity; Anti-anxiety activity</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<bold><styled-content style="color:white">Tricyclics (TCA) and other Norepinephrinereuptake inhibitors</styled-content></bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i031.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Amitriptyline Hydrochloride</styled-content></bold>; Annoyltin; Amitriptyline HCl; 549-18-8; Tryptizol; Domical</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>GNB3</italic>, <italic>HTRs</italic>, <italic>NTRK2</italic>, <italic>SLC6A4</italic>, <italic>TNF</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>HTRs</italic>, <italic>NTRK1</italic>, <italic>NTRK2</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>ABCB1</italic>, <italic>CYP1A2</italic> (minor), <italic>CYP2B6</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (major), <italic>CYP3A4/5</italic> (major), <italic>GSTP1, UGT1A3</italic>, <italic>UGT1A4</italic>, <italic>UGT2B10</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>ABCC2</italic>, <italic>ABCG2</italic>, <italic>CYP1A2</italic> (moderate), <italic>CYP2C9</italic> (moderate), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP2E1</italic> (weak)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>ABCC2</italic>, <italic>ABCG2</italic>, <italic>KCNE2</italic>, <italic>KCNH2</italic>, <italic>KCNQ1</italic>, <italic>SCN5A</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>FABP1</italic>, <italic>GNAS</italic>, <italic>GNB3</italic>, <italic>NTRK1</italic>, <italic>TNF</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>20</sub>H<sub>24</sub>ClN</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 313.86426 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Increases synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibiting their reuptake in the presynaptic neuronal membrane</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Adrenergic Uptake inhibition; Antimigraine activity; Analgesic (nonnarcotic) activity; Antidepressant action</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i032.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Amoxapine</styled-content></bold>; Asendin; Demolox; 14028-44-5; Asendis; Moxadi</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GNB3</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>ADRA2A</italic>, <italic>CHRMs</italic>, <italic>DRD1</italic>, <italic>DRD2</italic>, <italic>GABRs</italic>, <italic>GABBRs</italic>, <italic>HTRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>DRD2</italic>, <italic>GNAS</italic>, <italic>GNB3</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>16</sub>ClN<sub>3</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 313.78144 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Reduces reuptake of serotonin and norepinephrine. The metabolite, 7-OH-amoxapine, has significant dopamine receptor-blocking activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Adrenergic uptake inhibition; Dopamine antagonism; Neurotransmitter uptake inhibition; Antidepressant action; Anti-anxiety activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i033.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Clomipramine Hydrochloride</styled-content></bold>; Anafranil; Clomipramine HCL; 17321-77-6; Anaphranil; 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>HTR2A</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1s</italic>, <italic>CHRMs</italic>, <italic>CHRNs</italic>, <italic>HRH1</italic>, <italic>HTR2s, HTR3</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2A6</italic>, <italic>CYP2B6</italic>, <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (minor), <italic>CYP3A4</italic> (major), <italic>CYP3A5</italic> (major), <italic>UGT1A4</italic><break></break><bold>  Inhibitor:</bold>
<italic>CYP2C9</italic> (moderate), <italic>CYP2C19</italic> (strong), <italic>CYP2D6</italic> (moderate), <italic>GSTP1</italic>, <italic>SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>FABP1, PTGS2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (3-{14-chloro-2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl}propyl)dimethylamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 351.31326 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a strong, but not completely selective serotonin reuptake inhibitor; as its active main metabolite desmethyclomipramine acts preferably as an inhibitor of noradrenaline reuptake. α1-receptor blockage and β-down-regulation have been noted and most likely play a role in its short term effects. A blockade of sodium-channels and NDMA-receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Antidepressant action; Anti-anxiety activity; Antiobsessional effects; Analgesic effects</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i034.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Desipramine Hydrochloride</styled-content></bold>; Norpramin; Desipramine Hcl; DMI hydrochloride; Pertofrane; Pertofran</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>CRHR1</italic>, <italic>CRHR2</italic>, <italic>FKBP5</italic>, <italic>HTR1A</italic>, <italic>IL1B</italic>, <italic>NR3C1</italic>, <italic>NTRK2</italic>, <italic>PDE5A</italic>, <italic>SLC6A4</italic>, <italic>TBX21</italic><break></break><bold>Mechanistic genes:</bold><italic>ADCY1</italic>, <italic>ADRA1A</italic>, <italic>ADRBs</italic>, <italic>CHRMs</italic>, <italic>HTR1A</italic>, <italic>IFNA1</italic>, <italic>PDE1C</italic>, <italic>PSMD9</italic>, <italic>PRKCSH</italic>, <italic>STAT3</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2C9</italic>, <italic>CYP2D6</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, CYP2A6</italic> (moderate), <italic>CYP2B6</italic> (moderate), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (moderate), <italic>SLC6A2</italic>, <italic>SLC22A3</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic>, <italic>SLC22A3</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>NTRK2</italic>, <italic>FOS</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (3-{2-azatricyclo[9.4.0.0³,<sup>8</sup>]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)(methyl)amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>18</sub>H<sub>23</sub>ClN<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 302.84162 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Increases the synaptic concentration of norepinephrine in the CNS by inhibition of its reuptake by the presynaptic neuronal membrane. Additional receptor effects including desensitization of adenyl cyclase, down-regulation of β-adrenergic receptors, and down-regulation of serotonin receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Enzyme inhibition; Adrenergic uptake inhibition; Antidepressant action; Analgesic activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i035.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Doxepin Hydrochloride</styled-content></bold>; Silenor; Adapin; Novoxapin; Toruan; Curatin</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRBs</italic>, <italic>CHRMs</italic>, <italic>HRH1</italic>, <italic>HRH2</italic>, <italic>HTRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A1</italic> (minor), <italic>CYP1A2</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (major), <italic>CYP3A4/5</italic> (minor), <italic>GSTP1</italic>, <italic>UGT1A3</italic>, <italic>UGT1A4</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2C19</italic> (strong), <italic>CYP2D6</italic> (moderate)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>KCNH2</italic>, <italic>SLC6A2</italic>, <italic>SLC6A4</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: dimethyl(3-{9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>22</sub>ClNO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 315.83708 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It increases the synaptic concentration of serotonin and norepinephrine in the CNS by inhibition of their reuptake by the presynaptic neuronal membrane</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Adrenergic uptake inhibition; Histamine Antagonism; Antidepressant action; Analgesic effects; Pruritus reduction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i036.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Imipramine Hydrochloride;</styled-content></bold> Tofranil; Imipramine Hcl; 113-52-0; Chimoreptin; Feinalmin</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>BDNF</italic>, <italic>HTR2A</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRB2</italic>, <italic>DRD2</italic>, <italic>CHRMs</italic>, <italic>HTR2A</italic>, <italic>SCNs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2B6</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (minor), <italic>CYP3A7</italic>, <italic>GSTP1</italic>, <italic>UGT1A3</italic>, <italic>UGT1A4</italic>, <italic>UGT2B10</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (weak), <italic>CYP2C9</italic> (moderate), <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (moderate), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (moderate), <italic>FMO1</italic>, <italic>SLC22A2</italic>, <italic>SLC22A3</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A4</italic>, <italic>SLC22A2</italic>, <italic>SLC22A3</italic>
<break></break><bold>Pleiotropic genes:</bold>
<italic>ADRB2</italic>, <italic>BDNF</italic>, <italic>FABP1</italic>, <italic>FOS</italic>, <italic>ORM1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (3-{2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}propyl)dimethylamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>25</sub>ClN<sub>2</sub>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 316.8682 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. It causes down-regulation of cerebral cortical beta-adrenergic receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Adrenergic uptake inhibition; Antidepressant action; Antienuretic effects; Analgesic activity; attention enhancer</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i037.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Nortriptyline Hydrochloride;</styled-content></bold> Pamelor; Allegron; Altilev; Nortrilen; 894-71-3</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>GNB3</italic>, <italic>HTR1B</italic>, <italic>NR3C1</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADCY1</italic>, <italic>ADRA2s</italic>, <italic>ADRBs</italic>, <italic>GNB3</italic>, <italic>HRH1</italic>, <italic>HTRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (minor), <italic>UGTs</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2C8</italic> (moderate), <italic>CYP2C9</italic> (moderate), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (weak), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (moderate)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>HTR1B</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>22</sub>ClN</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 299.83768 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Inhibits the reuptake of the neurotransmitter serotonin at the neuronal membrane or acts at beta-adrenergic receptors. It has additional receptor effects including desensitization of adenyl cyclase, down-regulation of β-adrenergic receptors, and down-regulation of serotonin receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Adrenergic uptake inhibitor; Antidepressant agent; Analgesic activity; Hypno-sedative activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i038.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#4F81BD">Protriptyline Hydrochloride</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (minor) <break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (moderate), <italic>CYP2C9</italic> (moderate), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP3A4</italic> (moderate)<break></break><bold>Transporter genes:</bold>
<italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>ADRA1A</italic>, <italic>GNAS</italic>, <italic>ITGB3</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>22</sub>ClN</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 299.83768 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Increases synaptic concentration of serotonin and/or norepinephrine in CNS by inhibition of their reuptake by presynaptic neuronal membrane</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Adrenergic uptake inhibitor; Antidepressant agent; Analgesic activity; Anti-migraine effect</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i039.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Trimipramine;</styled-content></bold> Sapilent; Surmontil; Beta-Methylimipramine; Trimeprimina</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>SLC6A2</italic>, <italic>SLC6A4</italic>, <italic>SLC22A1</italic>, <italic>SLC22A2</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (major), <italic>CYP3A4/5</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic><break></break><bold>Transporter genes:</bold>
<italic>SLC6A2</italic>, <italic>SLC6A4</italic>, <italic>SLC22A1</italic>, <italic>SLC22A2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (3-{2-azatricyclo[9.4.0.0³,<sup>8</sup>]pentadeca-1(15),3,5,7,11,13-hexaen-2-yl}-2-methylpropyl)dimethylamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>20</sub>H<sub>26</sub>N<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 294.43384 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Tricyclics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Increases synaptic concentration of serotonin and/or norepinephrine in CNS by inhibition of their reuptake by presynaptic neuronal membrane</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Adrenergic uptake inhibition; Antidepressant action; Antihistaminic activity; Sedative effect</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRI)</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i040.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Desvenlafaxine;</styled-content></bold> O-Desmethylvenlafaxine; 93413-62-8; 4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol; 4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol; Desvenlafaxine (INN)</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>HTR1A</italic>, <italic>SLC6A2</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP3A4</italic> (minor), <italic>UGTs</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2D6</italic> (weak), <italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A4</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>25</sub>NO<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 263.3752 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a potent and selective serotonin and norepinephrine reuptake inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Norepinephrine uptake inhibition; Antidepressant activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i041.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Duloxetine Hydrochloride</styled-content></bold>; 136434-34-9; Duloxetine HCl; Cymbalta; (S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride; (S)-Duloxetine HCl</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>COMT</italic>, <italic>HTR1A</italic>, <italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2D6</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, CYP1A2</italic> (moderate), <italic>CYP2B6</italic> (moderate), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP3A4/5</italic> (moderate), <italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A4</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: methyl[(3S)-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>18</sub>H<sub>20</sub>ClNOS</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 333.8755 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a selective serotonin- and norepinephrine-reuptake inhibitor and a weak inhibitor of dopamine reuptake</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antidepressant activity; Anti-anxiety activity; Serotonin uptake inhibition; Norepinephrine uptake inhibition; Anti-Fibromyalgia agent; Analgesic activity; Urinary continence improvement</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i042.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Levomilnacipran</styled-content></bold>; UNII-UGM0326TXX; UGM0326TXX; Fetzima; (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide; F2695</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>HCRTR1, HCRTR2, HDC, HRH1, SLC6A2, SLC6A4</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>ABCB1</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2C8</italic> (minor), <italic>CYP2D6</italic> (minor), <italic>CYP2J2</italic> (minor), <italic>CYP3A4</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>SLC6A2</italic>, <italic>SLC6A4</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 246.34798 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Potentiation of serotonin and norephinephrine in the central nervous system through inhibition of reuptake at serotonin and norepinephrine transporters</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Norepinephrine uptake inhibition; Antidepressant activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i043.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Milnacipran Hydrochloride</styled-content></bold>; Toledomin; Midalcipran; Ixel; Savella; Milnacipranum</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>BDNF</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA2A</italic>, <italic>BDNF</italic>, <italic>SLC6A2</italic>, <italic>SLC6A4</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>COMT</italic>, <italic>CYP1A2</italic> (minor), <italic>CYP2A6</italic> (minor), <italic>CYP2B6</italic> (minor), <italic>CYP2C8</italic>, <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (minor), <italic>CYP2E1</italic> (minor), <italic>CYP3A4/5</italic> (minor), <italic>UGTs</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP3A4/5</italic> (moderate) <break></break><bold>  Inducer:</bold>
<italic>CYP1A2</italic>, <italic>CYP2B6</italic>, <italic>CYP2C8</italic>, <italic>CYP2C9</italic>, <italic>CYP2C19</italic>, <italic>CYP3A4/5</italic><break></break><bold>Transporter genes:</bold>
<italic>SLC6A2</italic>, <italic>SLC6A4</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>22</sub>N<sub>2</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 246.34798 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a potent inhibitor of neuronal norepinephrine and serotonin reuptake. It inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other neurotransmitters</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Analgesic action; Anti-fibromyalgia action; Serotonin uptake inhibition; Adrenergic uptake inhibition; Antidepressant activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i044.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Venlafaxine Hydrochloride</styled-content></bold>; 99300-78-4; VENLAFAXINE HCl; Effexor XR; Dobupal; Trevilor</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1, BDNF, CREB1, FKBP5, HTR1A, HTR2A, NR3C1, SLC6A3, SLC6A4, TPH2</italic><break></break><bold>Mechanistic genes:</bold><italic>BDNF, FKBP5</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate</bold>: <italic>ABCB1, CYP2C9</italic> (minor)<italic>, CYP2C19</italic> (minor)<italic>, CYP2D6</italic> (major)<italic>, CYP3A4</italic> (major)<break></break><bold>  Inhibitor</bold>: <italic>ABCB1, CYP1A2</italic> (weak)<italic>, CYP2B6</italic> (weak)<italic>, CYP2D6</italic> (weak)<italic>, CYP3A4</italic> (weak)<italic>, SLC6A2, SLC6A3, SLC6A4</italic><break></break><bold>Transporter genes</bold>: <italic>ABCB1, ABCC1, ABCG2, SLC6A2, SLC6A3, SLC6A4</italic><break></break><bold>Pleiotropic genes</bold>: <italic>DRD2, HTR2A, TPH2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>28</sub>ClNO<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 313.86272 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Active metabolite, O-desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Norepinephrine uptake inhibition; Antidepressant activity; Anti-anxiety activity, Analgesic effects</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Selective Serotonin Reuptake Inhibitors (SSRI)</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i045.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Citalopram Hydrobromide</styled-content></bold>; Nitalapram; Cipram; Celexa; Celapram; Ciprapine</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>BDNF</italic>, <italic>CREB1</italic>, <italic>CRHR1</italic>, <italic>CRHR2</italic>, <italic>FKBP5</italic>, <italic>GRIA3</italic>, <italic>GRIK2</italic>, <italic>GRIK4</italic>, <italic>GSK3B</italic>, <italic>HTR1A</italic>, <italic>HTR1B</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>SLC6A4</italic>, <italic>TPH1</italic>, <italic>TPH2</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRs</italic>, <italic>CHRMs</italic>, <italic>DRDs</italic>, <italic>FKBP5</italic>, <italic>GABRs</italic>, <italic>GRIK4</italic>, <italic>HRHs</italic>, <italic>HTR1A</italic>, <italic>HTR1B</italic>, <italic>HTR1D</italic>, <italic>HTR2A</italic>, <italic>SLC6A4</italic>, <italic>TPH1</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>ABCC1</italic>, <italic>COMT</italic>, <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (minor), <italic>CYP3A4</italic> (major), <italic>CYP3A5</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP1A2</italic> (weak), <italic>CYP2B6</italic> (weak), <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (weak), <italic>MAOA</italic>, <italic>MAOB</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>BDNF</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>20</sub>H<sub>21</sub>FN<sub>2</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 324.391943 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Selectively inhibits serotonin reuptake in the presynaptic neurons and has minimal effects on norepinephrine or dopamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Serotonergic neurotransmission enhancer; Antidepressive activity, Agitation reduction, Anti-Anxiety activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i046.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Escitalopram oxalate</styled-content></bold>; Lexapro; Cipralex; 219861-08-2; UNII-5U85DBW7LO; Esertia</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>CREB1</italic>, <italic>FKBP5</italic>, <italic>GRIA3</italic>, <italic>GRIK2</italic>, <italic>GRIK4</italic>, <italic>NR3C1</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRAs</italic>, <italic>ADRBs</italic>, <italic>DDC</italic>, <italic>DRDs</italic>, <italic>CHRMs</italic>, <italic>GABRs</italic>, <italic>HRHs</italic>, <italic>HTRs</italic>, <italic>IL6</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>Substrate:</bold><italic>ABCB1</italic>, <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major) <break></break>
<bold>Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP1A2</italic> (weak), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (moderate), <italic>CYP2E1</italic> (weak), <italic>CYP3A4</italic> (weak), <italic>SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>IL6</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>22</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>5</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 414.426823 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Inhibits the reuptake of serotonin with little to no effect on norepinephrine or dopamine reuptake. It has very low affinity for 5-HT<sub>1-7</sub>, α - and β-adrenergic, D<sub>1-5</sub>, H<sub>1-3</sub>, M<sub>1-5</sub>, and benzodiazepine receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Serotonergic neurotransmission enhancer; Antidepressive activity; Anti-anxiety activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i047.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Fluoxetine Hydrochloride</styled-content></bold>; Prozac; Fluoxetine Hcl; 59333-67-4; Sarafem; Fluctin</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>BDNF</italic>, <italic>CREB1</italic>, <italic>FKBP5</italic>, <italic>GSK3B</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>NR3C1</italic>, <italic>NTRK2</italic>, <italic>SLC6A4</italic>, <italic>TBX21</italic>, <italic>TPH1</italic>, <italic>TPH2</italic><break></break><bold>Mechanistic genes:</bold><italic>BDNF</italic>, <italic>CHRMs</italic>, <italic>CREB1</italic>, <italic>DRD3</italic>, <italic>GSK3B</italic>, <italic>HTRs</italic>, <italic>MAOA</italic>, <italic>SLC6A4</italic>, <italic>TPH2</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2B6</italic> (major), <italic>CYP2C8</italic> (major), <italic>CYP2C9</italic> (major), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (major), <italic>CYP2E1</italic> (minor), <italic>CYP3A4/5</italic> (major), <italic>POR</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP1A2</italic> (moderate), <italic>CYP2B6</italic> (weak), <italic>CYP2C8</italic> (moderate), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (strong), <italic>CYP3A4</italic> (moderate), <italic>MAOA</italic>, <italic>SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>KCNH2, SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>DRD3</italic>, <italic>FABP1</italic>, <italic>HTR2A</italic>, <italic>IFNA1</italic>, <italic>NTRK2</italic>, <italic>PDE5A</italic>, <italic>TPH1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>19</sub>ClF<sub>3</sub>NO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 345.78707 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Potentiates serotonergic activity in CNS resulting from its inhibition of CNS neuronal reuptake of serotonin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Serotonin agent; Antidepressive activity; Anti-obsessive activity; Anti-anxiety activity; Anorexigenic effects</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i048.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Fluvoxamine Maleate</styled-content></bold>; Luvox; 61718-82-9; Fevarin; Faverin; Floxyfral</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>BDNF</italic>, <italic>HTR2A</italic>, <italic>SIGMAR1</italic>, <italic>TPH1</italic><break></break><bold>Mechanistic genes:</bold><italic>BDNF</italic>, <italic>HTRs</italic>, <italic>SLC6A4</italic>, <italic>SIGMAR1</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP1A2</italic> (strong), <italic>CYP2B6</italic> (weak), <italic>CYP2C9</italic> (moderate), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP3A4</italic> (weak), <italic>MAOA</italic>, <italic>SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>KCNH2</italic>, <italic>SCL6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>CREB1</italic>, <italic>TPH1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (2-aminoethoxy)({5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene})amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>25</sub>F<sub>3</sub>N<sub>2</sub>O<sub>6</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 434.40681 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Inhibits CNS neuron serotonin uptake</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Antidepressive activity; Anti-anxiety activity; Serotonin uptake inhibition</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i049.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Paroxetine</styled-content></bold>; Paxil; Aropax; Paxil CR; Seroxat; Pexeva</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>CREB1</italic>, <italic>HTR1B</italic>, <italic>HTR2A</italic>, <italic>HTR3B</italic>, <italic>MAOA</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic>, <italic>TNF</italic>, <italic>TPH1</italic>, <italic>TPH2</italic><break></break><bold>Mechanistic genes:</bold><italic>CREB1</italic>, <italic>HTR2A</italic>, <italic>HTR3A</italic>, <italic>SLC6A4, STAT3</italic>, <italic>TNF</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>ABCB1</italic>, <italic>COMT</italic>, <italic>CYP1A2</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major), <italic>MAOA</italic>, <italic>MAOB</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP1A2</italic> (weak), <italic>CYP2B6</italic> (moderate), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (weak), <italic>CYP2D6</italic> (strong), <italic>CYP3A4</italic> (weak), <italic>SLC6A3</italic>, <italic>SLC6A4</italic>
<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic>
<break></break><bold>Pleiotropic genes:</bold>
<italic>HTR1D</italic>, <italic>HTR3C</italic>, <italic>HTR6</italic>, <italic>HTT</italic>, <italic>TPH1</italic>, <italic>TPH2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>20</sub>FNO<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 329.365403 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is an SSRI. Presumably acts by inhibiting serotonin reuptake from brain synapse stimulating its activity in the brain</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Serotonergic neurotransmission enhancer; Antidepressant activity; Anti-anxiety activity; Anti-obsessive activity.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i050.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Sertraline Hydrochloride;</styled-content></bold> 79559-97-0; Sertraline HCl; Zoloft; Lustral; Gladem</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>CREB1</italic>, <italic>GNB3</italic>, <italic>HTR1B</italic>, <italic>MAOA</italic>, <italic>SIGMAR1</italic>, <italic>SLC6A4</italic>, <italic>TNF</italic>, <italic>TPH1</italic>, <italic>TPH2</italic><break></break><bold>Mechanistic genes:</bold><italic>HTR1B</italic>, <italic>HTR1D</italic>, <italic>SIGMAR1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic>, <italic>TNF</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2A6</italic>, <italic>CYP2B6</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic> (minor), <italic>CYP3A4</italic> (minor), <italic>MAOA</italic>, <italic>MAOB</italic>, <italic>UGT1A1</italic>, <italic>UGT2B7</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>ACHE</italic>, <italic>CYP1A1</italic>, <italic>CYP1A2</italic> (weak), <italic>CYP2B6</italic> (moderate), <italic>CYP2C8</italic> (weak), <italic>CYP2C9</italic> (weak), <italic>CYP2C19</italic> (moderate), <italic>CYP2D6</italic> (moderate), <italic>CYP3A4</italic> (moderate), <italic>SLC6A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>FABP1</italic>, <italic>FOS</italic>, <italic>GNB3</italic>, <italic>TPH1</italic>, <italic>TPH2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>18</sub>Cl<sub>3</sub>N</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 342.69052 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It has selective inhibitory effects on presynaptic serotonin reuptake and only very weak effects on norepinephrine and dopamine neuronal uptake</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Serotonergic neurotransmission enhancer; Antidepressant activity; Anti-anxiety activity; Anti-obsessive activity</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Serotonin Modulators</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i051.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Nefazodone Hydrochloride</styled-content></bold>; Serzone; Nefazodone Hcl; Dutonin; 82752-99-6; Menfazon</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>HTR1s</italic>, <italic>HTR2s</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major), <italic>CYP3A5</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>ABCC2</italic>, <italic>CYP1A2</italic> (weak), <italic>CYP2B6</italic> (weak), <italic>CYP2C8</italic> (weak), <italic>CYP2D6</italic> (weak), <italic>CYP3A4</italic> (strong), <italic>SLC6A2</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>ABCC2</italic>, <italic>ABCB11, SLC6A2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 1-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-3-ethyl-4-(2-phenoxyethyl)-4,5-dihydro-1H-1,2,4-triazol-5-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>25</sub>H<sub>33</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 506.46782 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks potently and selectively postsynaptic 5-HT<sub>2A</sub> receptors and moderately inhibits serotonin and noradrenaline reuptake. Also blocks α1 receptors. Antagonist of adrenoceptors alpha 1 and 5-hydroxytryptamine receptors 2</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibition; Noradrenaline uptake inhibition; Alpha-adrenergic antagonism; Antidepressant activity; Muscle relaxation, Sedation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i052.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Trazodone Hydrochloride</styled-content></bold>; Desyrel; 25332-39-2; Trazodone Hcl; Molipaxin; Trittico</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>GNB3</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1s</italic>, <italic>ADRA2s</italic>, <italic>HRH1</italic>, <italic>HTR2A</italic>, <italic>HTR2C</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2D6</italic> (minor), <italic>CYP3A4</italic> (major), <italic>GSTs</italic>, <italic>SOD2</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2D6</italic> (moderate), <italic>CYP3A4</italic> (weak), <italic>SLC6A4</italic>
<break></break><bold>  Inducer:</bold>
<italic>ABCB1</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>GNAS</italic>, <italic>GNB3</italic>, <italic>HTR2A</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>19</sub>H<sub>23</sub>Cl<sub>2</sub>N<sub>5</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 408.32482 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Inhibits reuptake of serotonin, causes adrenoreceptor subsensitivity, and induces significant changes in 5-HT presynaptic receptor adrenoreceptors. Also significantly blocks histamine (H<sub>1</sub>) and α<sub>1</sub>-adrenergic receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin uptake inhibitor; Anti-anxiety activity; Antidepressant agent; Hypnotic effects</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Miscellaneous Antidepressants</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#D9D9D9" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i053.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Agomelatine;</styled-content></bold> 138112-76-2; Valdoxan; Thymanax; Melitor; N-(2-(7-Methoxynaphthalen-1-yl)ethyl)acetamide</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>HTR2C, MTNR1A, MTNR1B</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A1</italic> (major), <italic>CYP1A2</italic> (major), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (minor)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>17</sub>NO<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 243.30098 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Melatonergic agonist and 5-HT2C antagonists</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It behaves as an agonist at melatonin receptors and as an antagonist at serotonin (5-HT)(2C) receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Norepinephrine-dopamine disinhibitor; Antidepressant activity; Anti-anxiety activity; Sleep induction; Circadian rhythms resynchronization; Psychological excitement reduction</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i054.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Bupropion Hydrochloride;</styled-content></bold> 31677-93-7; Wellbutrin; Zyban; Bupropion Hcl</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>SLC6A3</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>CHRNB2</italic>, <italic>DRD2</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>COMT</italic>, <italic>CYP1A2</italic> (minor), <italic>CYP2A6</italic> (minor), <italic>CYP2B6</italic> (major) <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic> (minor), <italic>CYP2E1</italic> (minor), <italic>CYP3A4</italic> (minor) <break></break><bold>  Inhibitor:</bold>
<italic>CYP2D6</italic> (strong)<break></break><bold>Transporter genes:</bold>
<italic>SLC6A2</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>DRD2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>13</sub>H<sub>19</sub>Cl<sub>2</sub>NO</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 276.20206 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Dopamine-Reuptake Inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Dopamine uptake inhibition; Anti-addiction/Substance abuse treatment agent; Smoking cessation enhancer; Antidepressant activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i055.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Mirtazapine;</styled-content></bold> Zispin; Remergil; Remeron; 6-Azamianserin; Remergon</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>FKBP5</italic>, <italic>HTR1A</italic>, <italic>HTR2A</italic>, <italic>MAOA</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic>, <italic>TPH2</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRA1s</italic>, <italic>ADRA2A</italic>, <italic>CHRMs, FKBP5</italic>, <italic>HRH1</italic>, <italic>HTR2s, HTR3s</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major), <italic>CYP2C9</italic> (minor), <italic>CYP2D6</italic> (major), <italic>CYP3A4</italic> (major), <italic>UGT1A1</italic>, <italic>UGT1A3</italic>, <italic>UGT1A4</italic>, <italic>UGT1A6</italic>, <italic>UGT1A7</italic>, <italic>UGT1A9</italic>, <italic>UGT1A10</italic>, <italic>UGT2B7</italic>, <italic>UGT2B15</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (weak), <italic>CYP3A4</italic> (weak), <italic>CYP2D6</italic> (weak), <italic>MAOA</italic>, <italic>MAOB</italic>
<break></break><bold>  Inducer:</bold>
<italic>CYP1A2, CYP2D6, CYP3A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>TPH2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5-methyl-2,5,19-triazatetracyclo[13.4.0.0<sup>2</sup>, .0<sup>8</sup>,<sup>13</sup>]nonadeca-1(15),8,10,12,16,18-hexaene</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>19</sub>N<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 265.35286 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> α2-Adrenergic Antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It has central presynaptic α<sub>2</sub>-adrenergic antagonist effects, which result in increased release of norepinephrine and serotonin. Also a potent antagonist of 5-HT<sub>2</sub> and 5-HT<sub>3</sub> serotonin receptors, H<sub>1</sub> histamine receptors and a moderate peripheral α<sub>1</sub>-adrenergic and muscarinic antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Histamine H1 antagonism; Adrenergic alpha-antagonism; Antidepressant activity; Anxiolytic effects</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i056.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Reboxetine Mesylate;</styled-content></bold> Vestra mesylate; Davedax mesylate; Reboxetine mesilate; Edronax; 98769-84-7</td>
<td align="left" colspan="1" rowspan="7" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>ABCB1</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic><break></break><bold>Mechanistic genes:</bold><italic>ADRs</italic>, <italic>CHRMs</italic>, <italic>CHRNs</italic>, <italic>HRHs</italic>, <italic>DRDs</italic>, <italic>GH1</italic>, <italic>HTRs</italic>, <italic>POMC</italic>, <italic>PRL</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP3A4</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>ABCB1</italic>, <italic>CYP2D6</italic> (weak), <italic>CYP3A4</italic> (weak)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic>, <italic>SLC6A2</italic>, <italic>SLC6A3</italic>, <italic>SLC6A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>ADRB2</italic>, <italic>POMC</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: (2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>20</sub>H<sub>27</sub>NO<sub>6</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 409.49648 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Category:</bold> Norepinephrine inhibitor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a highly selective and potent inhibitor of noradrenaline reuptake. Only has weak effect on 5-HT reuptake</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Adrenergic uptake inhibitor; Antidepressant activity; Anti-anxiety activity; Attention enhancer</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-21-03059-t005" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-03059-t005_Table 5</object-id>
<label>Table 5</label>
<caption>
<p>Pharmacological profile and pharmacogenetics of selected anxiolytics, sedatives, and hypnotics.</p>
</caption>
<table frame="hsides" rules="groups">
<tbody>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:black" valign="middle">
<bold><styled-content style="color:white">Barbiturates</styled-content></bold>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i057.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Amobarbital</styled-content></bold>; Amylobarbitone; Barbamyl; Pentymal; Amytal; Barbamil</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Pathogenic genes:</bold>
<italic>GABRs</italic>
<break></break>
<bold>Mechanistic genes:</bold>
<italic>CHRNAs, CLCNs, GABRAs, GABRBs, GRIA2, NDUFs</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>UGT2B7, UGT2B15</italic>
<break></break>
<bold>  Inducer:</bold>
<italic>CYP2A6</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>CLCNs</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5-ethyl-5-(3-methylbutyl)-1,3-diazinane-2,4,6-trione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 226.27222 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Interferes with transmission of impulses resulting in an imbalance in central inhibitory and facilitatory mechanisms. Binds to alpha or beta subunits of GABA-A receptor. Decreases input resistance, depresses burst and tonic firing, especially in ventrobasal and intralaminar neurons. Increases burst duration and mean conductance at individual chloride channels and the amplitude and decay time of inhibitory postsynaptic currents. Blocks the AMPA receptor and appears to bind neuronal nicotinic acetylcholine receptors.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; GABA modulator</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i058.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Mephobarbital; </styled-content></bold>Mebaral; Mephobarbitone; Enphenemal; Prominal; Methylphenobarbitone</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRA1, GABRB3, GABRG2, GABRD</italic><break></break><bold>Mechanistic genes:</bold><italic>GABRAs, GABRBs, GABRD, GABRE, GABRGs, GABRP, GABRQ, GABRRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2B6</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP2D6</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2C19 (</italic>weak<italic>)</italic>
<break></break><bold>  Inducer:</bold>
<italic>CYP2A6</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>13</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 246.26186 g/mol </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Increases seizure threshold in motor cortex. Depresses monosynaptic and polysynaptic transmission in CNS.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; Anti-anxiety; GABA Modulator, Anticonvulsant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i059.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Pentobarbital</styled-content></bold>; Pentobarbitone; Nembutal; Mebubarbital; Mebumal; Ethamina</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>BDNF, IL6, TNF</italic><break></break><bold>Mechanistic genes:</bold><italic>GABRA6, GABRB3, GRIA1, GRIA2, NPY</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2, CYP2B6, CYP2D6, PTGS1, PTGS2</italic> Inducer: <italic>CYP2A6, CYP3A4</italic><break></break><bold>Transporter genes:</bold>
<italic>KCNE1, KCNH2, NR1I2, NR1I3,</italic>
<break></break><bold>Pleiotropic genes:</bold>
<italic>APP, BDNF, BLK, CNR1, CRHR1, FOS, ICAM1, IL1B, IL6, KRAS, NPPA, NPY, TNF, TNFRSF1A</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 226.27222 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Prolongs the post-synaptic inhibitory effect of GABA in the thalamus. Inhibits the excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; GABA Modulator; Anticonvulsant; Anesthesia (Adjuvant)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i060.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Phenobarbital</styled-content></bold>; Luminal; Phenobarbitone; Phenobarbitol; Gardenal; Phenemal</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>CASR, GABRA6, LEP, PSEN1, PTGS2, TGFB1, TNF</italic><break></break><bold>Mechanistic genes:</bold><italic>CACNs, CLCNs, GABRAs, GRIAs, GSTA1, NR1I3</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>ABCC2, ACSL4, CBR3, CES1, CES2, COMT, CYP1A2</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP2E1</italic> (minor), <italic>CYP4B1, CYP7A1, EPHX1, GSTM1, GSTP1, GSTT1, NNMT, NQO1, TBXAS1, TPMT</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, ABCC2, ABCC4, ABCG2, CYP2C19</italic> (strong), <italic>CYP2J2</italic> (strong), <italic>CYP27A1</italic> (strong), <italic>SLC10A1, SULT1A1</italic>
<break></break><bold>  Inducer:</bold>
<italic>ABCB1, ABCC1, ABCC2, ABCC3, ABCC4, CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP4A11, CYP4F3, CYP7A1, CYP8B1, CYP24A1, SCN1A, SLC22A1, SLCO1B1, SULT1C2, SULT2A1, TPMT, UGT1A1, UGT1A4, UGT1A7, UGT1A9, UGT2B7</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1, ABCB11, ABCC1, ABCC2, ABCC3, ABCC4, ABCC6, ABCG2, SCN1A, SLC22A1, SLCO1B1, SLCO1B3, SLCO2B1, SLC10A1</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>ACHE, ADIPOQ, AHR, APOA1, APOE, CAT, CBS, CCND1, CDA, CXCR2, DDC, DPP4, FGB, FKBP5, GH1, GNAS, GRK5, HLA-B, HNF4A, IGF1, IL1B, IL6, LEP, LEPR, LIPC, MET, MTNR1A, NR1I2, NR3C1, PPARGC1A, PRKAB1, PSEN2, RB1, RXRA, TGFB1, TNF</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 232.23528 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is a barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates action on GABA-A receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; GABA Modulator; Anticonvulsant; Carcinogen; Central Nervous System Depressant; Excitatory Amino Acid Antagonist; Respiratory depression (dose-dependent)</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Benzodiazepines</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i061.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name<styled-content style="color:#0070C0">: Alprazolam; </styled-content></bold>Xanax; Trankimazin; Tafil; Cassadan; Tranquinal</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes</bold>: <italic>GABRs</italic><break></break><bold>Mechanistic genes</bold>: <italic>CLCNs, GABRs</italic><break></break><bold>Metabolic genes</bold>: <break></break><bold>  Substrate:</bold> CYP1A1 (minor), CYP1A2 (minor), CYP2B6, CYP2C9, CYP2C19 (minor), CYP2D6 (minor), CYP3A4/5 (major)<break></break><bold>Transporter genes:</bold> CLCNs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>13</sub>ClN<sub>4</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 308.76492 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to the GABA benzodiazepine receptor complex, particularly in the limbic system and reticular formation. The inhibitory effect of GABA on neuronal excitability increases the neuronal membrane permeability to chloride ions resulting in hyperpolarization and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anti-Anxiety Agent; Hypnotic activity; Sedation; GABA Modulator</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i062.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Bromazepam</styled-content></bold>; Compedium; Creosedin; Lectopam; Lexaurin; Lexilium</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRs</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2, CYP2C19, CYP3A4</italic> (major), <italic>CYP3A5</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2E1</italic> (weak)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1, CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-bromo-5-pyridin-2-yl-1,3-dihydro-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>14</sub>H<sub>10</sub>BrN<sub>3</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 316.1527 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron in the Central Nervous System (limbic system, reticular formation). Enhances the inhibitory GABA-effect on neuronal excitability by increasing cellular permeability to chloride ions, resulting in hyperpolarization (a less excitable state) and stabilization of cellular membrane</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anti-Anxiety Agent; GABA Modulator; Skeletal muscle relaxant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i063.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Chlordiazepoxide</styled-content></bold>; Chlozepid; Elenium; Chlorodiazepoxide; Methaminodiazepoxide; Chlordiazepoxid</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>BDNF, CLCNs, GABRs</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6, CYP3A4</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1, CLCNs</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>BDNF</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>14</sub>ClN<sub>3</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 299.75486 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to the GABA receptor type A and increases the inhibitory effect of GABA on neuronal excitability by enhancing neuronal membrane permeability to chloride ions, thus resulting in hyperpolarization and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Sedation; Anti-Anxiety Agent; GABA Modulator, Skeletal muscle relaxant, Anticonvulsant; Amnesic properties, Anesthesia (Adjuvant)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i064.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Clobazam</styled-content></bold>; Urbanyl; Chlorepin; Clorepin; Frisium; Clobazamum</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRA1</italic>, <italic>GABRB3</italic>, <italic>GABRG2</italic>, <italic>GABRD</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs</italic>, <italic>GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2B6</italic> (minor), <italic>CYP2C18</italic> (minor), <italic>CYP2C19</italic> (major), <italic>CYP3A4</italic> (major), <italic>CYP3A5</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-1-methyl-5-phenyl-1,5-benzodiazepine-2,4-dione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 300.73962 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific receptors on the postsynaptic GABA neuron at several sites within the CNS (limbic system, reticular formation). Enhances the inhibitory effect of GABA on neuronal excitability by increasing neuronal membrane permeability to chloride ions, which results in hyperpolarization (a less excitable state) and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anti-Anxiety Agent; GABA Modulator; Anticonvulsant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i065.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Clonazepam</styled-content></bold>; Rivotril; Antelepsin; Iktorivil; Chlonazepam; Cloazepam</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRA1</italic><break></break><bold>Mechanistic genes:</bold><italic>GABRAs</italic>Metabolic genes: <break></break> <bold>Substrate:</bold><italic>CYP3A4/5</italic> (major), <italic>NAT2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>10</sub>ClN<sub>3</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 315.7112 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Enhance the activity of γ-aminobutyric acid (GABA). Suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex. Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the GABA receptor complex and modulating GABA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsant; GABA Modulator; Antipanic effect</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i066.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Clorazepate Dipotassium</styled-content></bold>; Tranxilium; Tranxene; Abbott-35616; 4306 CB; Dipotassium clorazepate</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRs</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP3A4</italic> (major), <italic>CYP3A5</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: dipotassium;7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylate;hydroxide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>11</sub>ClK<sub>2</sub>N<sub>2</sub>O<sub>4</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 408.91914 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the γ-aminobutyric acid (GABA) receptor complex and modulating GABA, resulting in an increased neuronal membrane permeability to chloride ions which produces a hyperpolarization and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Skeletal muscle relaxant. Anti-Anxiety Agent; GABA Modulator; Anticonvulsant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i067.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Diazepam</styled-content></bold>; Valium; Ansiolisina; Diazemuls; Apaurin; Faustan</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>BDNF, CNR1, GABRD</italic><break></break><bold>Mechanistic genes:</bold><italic>ACHE, BCHE, BDNF, CACNA1C, CHRMs, GABRs, TSPO</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor), <italic>CYP2B6</italic> (minor), <italic>CYP2C9</italic> (minor), <italic>CYP2C19</italic> (minor), <italic>CYP3A4/5</italic> (major), <italic>UGTs</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2C19</italic> (weak), <italic>CYP3A4</italic> (weak), <italic>UGT2B7</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>FOS, IL6, SPG7</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>13</sub>ClN<sub>2</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 284.74022 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions, thus resulting in hyperpolarization and stabilization. It antagonizes with translocator protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Sedation; Anti-Anxiety Agent; GABA Modulator, Skeletal muscle relaxant, Anticonvulsant; Amnesic properties, Anesthesia; Antiemetics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i068.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Estazolam</styled-content></bold>; Eurodin; Nuctalon; ProSom; Esilgan; Julodin</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRB3</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRAs, GABRBs, GABRD, GABRE, GABRGs, GABRP, GABRQ, GABRRs, TSPO</italic><break></break><bold>Metabolic genes:</bold><break></break> <bold>Substrate:</bold><italic>CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 (</italic>major<italic>), CYP3A5 (</italic>major<italic>)</italic><break></break><bold>Transporter genes:</bold><italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>11</sub>ClN<sub>4</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 294.73834 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anti-Anxiety Agent; GABA Modulator; Hypnotic activity; Sedation; Skeletal muscle relaxant; Anticonvulsant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i069.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Flurazepam</styled-content></bold>; Dalmane; Dalmadorm; Flurazepamum; Felmane; Noctosom</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRB3</italic><break></break><bold>Mechanistic genes:</bold><italic>CACNA1C, CLCNs, GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP3A4</italic> (major)<italic>, CYP3A5</italic> (major)<italic>, MAO</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>ABCB1, CYP2E1</italic> (weak)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1, CACNA1C, CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-3H-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>23</sub>ClFN<sub>3</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 387.878223 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS, including the limbic system, reticular formation. Enhancement of inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anti-Anxiety Agent; GABA Modulator; Sedation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i070.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Lorazepam</styled-content></bold>; Ativan; Temesta; O-Chloroxazepam; O-Chlorooxazepam; Almazine</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRs</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs, TSPO</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP3A4</italic> (minor)<italic>, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B15</italic><break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 321.1581 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on postsynaptic GABA neuron at several sites within CNS, including limbic system, reticular formation. Enhancement of inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Binds to GABAA receptors enhancing the effects of GABA by increasing GABA affinity for its receptor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anti-Anxiety Agent; GABA Modulator; Sedation; Skeletal muscle relaxant; Anticonvulsant. Antiemetic; Hypnotic activity; Preanesthetic agent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i071.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Midazolam</styled-content></bold>; Versed; Dormicum; Midazolamum; 59467-70-8; Midazolamum</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2, CYP2A6, CYP2B6</italic> (minor)<italic>, CYP2C19</italic> (minor)<italic>, CYP2D6, CYP2E1, CYP3A4</italic> (major)<italic>, CYP3A5</italic> (major)<italic>, CYP3A7, UGT1A4, UGT2B7, UGT2B10</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP2C8</italic> (weak)<italic>, CYP2C9</italic> (weak), <italic>CYP3A4</italic> (strong) Inducer: <italic>CYP3A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1, CLCNs, NR1I2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>18</sub>H<sub>13</sub>ClFN<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 325.767323 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on postsynaptic GABA neuron. Enhancement of inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Sedation; Hypnotic activity; Anti-Anxiety Agent; GABA Modulator, Skeletal muscle relaxant; Amnestic properties; Anesthesia; Preanesthetia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i072.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Nitrazepam</styled-content></bold>; Benzalin; Mogadon; Remnos; Nitrados; Imeson</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRA1, GABRB3, GABRG2, GABRD</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs, GLRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP3A4</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 281.26614 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on postsynaptic GABA neuron at CNS (limbic system, reticular formation). Enhances inhibitory effect of GABA on neuronal excitability by increasing neuronal membrane permeability to chloride ions</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Sedation; Hypnotic activity; Anticonvulsant; Anti-Anxiety Agent; GABA Modulator</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i073.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Oxazepam</styled-content></bold>; Adumbran; Tazepam; Serax; Anxiolit; Praxiten</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRs</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6, UGT2B7, UGT2B15</italic><break></break><bold>  Inhibitor:</bold><italic>UGT2B7</italic> Inducer: <italic>CYP1A2</italic><break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>11</sub>ClN<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 286.71304 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Effects appear to be mediated through inhibitory neurotransmitter GABA; site and mechanism of action within the CNS appear to involve macromolecular complex (GABA<sub>A</sub>-receptor-chloride ionophore complex) which includes GABA<sub>A</sub> receptors, high-affinity benzodiazepine receptors, and chloride channels. Enhancement of inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (less excitable state) and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Sedation; GABA Modulator; Anti-Anxiety Agent; Anti-Alcohol withdrawal agent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i074.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Quazepam</styled-content></bold>; Doral; Dormalin; Prosedar; Oniria; Quazium</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRB3</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2C9</italic> (minor)<italic>, CYP2C19</italic> (minor)<italic>, CYP3A4</italic> (major)<italic>, FMO1, FMO3</italic><break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-5-(2-fluorophenyl)-1-(2,2,2-trifluoroethyl)-3H-1,4-benzodiazepine-2-thione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>11</sub>ClF<sub>4</sub>N<sub>2</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 386.794253 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on postsynaptic GABA neuron at several sites within CNS (limbic system, reticular formation). Enhances inhibitory effect of GABA on neuronal excitability by increasing neuronal membrane permeability to chloride ions, resulting in hyperpolarization and stabilization</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; GABA Modulator; Anti-Anxiety Agent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i075.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Temazepam</styled-content></bold>; Euhypnos; Restoril; Hydroxydiazepam; Methyloxazepam; Crisonar</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRB3</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs, TSPO</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2B6</italic> (major)<italic>, CYP2C9</italic> (major)<italic>, CYP2C19</italic> (major)<italic>, CYP3A4</italic> (major)<italic>, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT1A10, UGT2B7, UGT2B15</italic><break></break><bold>Inhibitor:</bold>
<italic>UGT1A3, UGT2B7</italic><break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 7-chloro-3-hydroxy-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>13</sub>ClN<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 300.73962 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> A short half-life benzodiazepine. Binds to stereospecific benzodiazepine receptors on postsynaptic GABA neuron at several sites within CNS, including limbic system. Enhances inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. It antagonizes with translocator protein</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; GABA Modulator; Anti-Anxiety Agent; Antidepressant activity; Anticonvulsant</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i076.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Triazolam</styled-content></bold>; Halcion; Songar; Clorazolam; Novidorm; Trilam</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>GABRB3</italic><break></break><bold>Mechanistic genes:</bold><italic>CLCNs, GABRs, TSPO</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP3A4</italic> (major)<italic>, CYP3A5</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>CYP2C8</italic> (weak)<italic>, CYP2C9</italic> (weak) <break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>4</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 343.20998 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to stereospecific benzodiazepine receptors on postsynaptic GABA neuron at several sites within CNS, including limbic system, reticular formation. Enhancement of inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (less excitable state) and stabilization.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Sedation; GABA Modulator; Anesthesia (Adjuvant)</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1" style="border-bottom:solid thin;background:black" valign="middle">
<styled-content style="color:white">
<bold>Miscellaneous</bold>
</styled-content>
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Drug</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Properties</bold>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">
<bold>Pharmacogenetics</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i077.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Buspirone</styled-content></bold>; Ansial; Buspirona; Buspironum; Bespar; Anxiron</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>DRD2, HTR1A, HTR2A, HTR3s</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2D6</italic> (minor)<italic>, CYP3A4</italic> (major), <italic>CYP3A5</italic> (minor) Inducer: <italic>CYP3A4</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>DRD2, HTR2A</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>21</sub>H<sub>31</sub>N<sub>5</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 385.50314 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Decreases the spontaneous firing of serotonin-containing neurons in the CNS by selectively binding to and acting as agonist at presynaptic CNS serotonin 5-HT<sub>1A</sub> receptors. Possesses partial agonist activity (mixed agonist/antagonist) at postsynaptic 5-HT<sub>2A</sub> receptors. Does not bind to benzodiazepine-GABA receptors. Binds to dopamine D<sub>2</sub> receptors</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Serotonin receptor agonist; Anti-Anxiety Agent</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i078.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Chloral Hydrate</styled-content></bold>; Noctec; Tosyl; 302-17-0; 2,2,2-Trichloroethane-1,1-diol; Trichloroacetaldehyde hydrate</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Pathogenic genes:</bold>
<italic>GABRAs</italic>
<break></break>
<bold>Mechanistic genes:</bold>
<italic>GABRAs; GLRs; HTR3s</italic>
<break></break>
<bold>Pleiotropic genes:</bold>
<italic>FOS, IL1B, IL6</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2,2,2-trichloroethane-1,1-diol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>2</sub>H<sub>3</sub>Cl<sub>3</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 165.40302 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> It is converted to the active compound trichloroethanol by hepatic alcohol dehydrogenase. The agent interacts with various neurotransmitter-operated ion channels, thereby enhancing gamma-aminobutyric acid (GABA)-A receptor mediated chloride currents and inhibiting amino acid receptor-activated ion currents. Enhances the agonistic effects of glycine receptors, inhibits AMPA-induced calcium influx in cortical neurons, and facilitates 5-HT 3 receptor-mediated currents in ganglionic neurons. Overall, this results in a depressive effect on the central nervous system</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; Anticonvulsant; Anesthesia; Analgesic activity; GABA Modulator</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i079.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Dexmedetomidine Hydrochloride</styled-content></bold>; Dexmedetomidina; Dexmedetomidinum; MPV 1440; Precedex; CHEBI:4466</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>ADRA2A, ADRA2B, ADRA2C</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2A6</italic> (major), <italic>UGT1A4, UGT2B10</italic>
<break></break><bold>  Inhibitor:</bold>
<italic>CYP1A2</italic> (weak), <italic>CYP2C9</italic> (weak)<italic>, CYP2D6</italic> (strong)<italic>, CYP3A4</italic> (weak) <break></break><bold>  Inducer:</bold>
<italic>ABCC2</italic>, <italic>CYP7A1</italic>, <italic>CYP27A1</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCC2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>13</sub>H<sub>16</sub>N<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 200.27954 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Binds to the presynaptic alpha-2 adrenoceptors and inhibits the release of norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> α2-Adrenergic Agonist; Anesthesia; Sedation; Analgesia</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i080.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Promethazine Hydrochloride; </styled-content></bold>Phenergan; Promethazine Hcl; 58-33-3; Fenergan; Atosil</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>ADRA1A</italic>, <italic>CHRM2</italic>, <italic>DRD2</italic>, <italic>HRH1</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2B6</italic> (major), <italic>CYP2D6</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>CYP2C9</italic> (weak), <italic>CYP2D6</italic> (weak)<break></break><bold>Transporter genes:</bold>
<italic>ABCB1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine;hydrochloride</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>21</sub>ClN<sub>2</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 320.88004 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks postsynaptic mesolimbic dopaminergic receptors in brain. Exhibits strong α-adrenergic-blocking effect and depresses release of hypothalamic and hypophyseal hormones. Competes with histamine for H1-receptor. Reduces stimuli to brainstem reticular system. The relief of nausea is related to central anticholinergic actions</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Sedation; Anti-Allergic Agent; Antiemetic; Antipruritic; Histamine H1 Antagonist</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i081.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Ramelteon</styled-content></bold>; Rozerem; 196597-26-9; TAK-375; Rozerem</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Pathogenic genes:</bold><italic>MTNR1A, MTNR1B</italic><break></break><bold>Mechanistic genes:</bold><italic>MTNR1A, MTNR1B</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (major)<italic>, CYP2C19</italic> (minor)<italic>, CYP3A4</italic> (minor)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e][1]benzofuran-8-yl]ethyl]propanamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>16</sub>H<sub>21</sub>NO<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 259.34344 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Potent, selective agonist of melatonin receptors MT<sub>1</sub> and MT<sub>2</sub> (with little affinity for MT<sub>3</sub>) within suprachiasmic nucleus of hypothalamus</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Melatonin receptor agonist; Hyptonic activity; circadian rhythm regulation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i082.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Zaleplon</styled-content></bold>; Sonata; 151319-34-5; CL-284846; Zerene; CL 284846</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>GABRA1</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>AOX1, CYP3A4</italic> (major), <italic>CYP2D6, POR</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>HRH1</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>15</sub>N<sub>5</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 305.3339 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Interacts with benzodiazepine GABA receptor complex. Nonclinical studies have shown that it binds selectively to brain ω<sub>1</sub> receptor situated on α-subunit of GABA-A receptor complex</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation; Skeletal muscle relaxant; Anti-anxiety agent; Anticonvulsant; GABA Modulator</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i083.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#4F81BD">Zolpidem Tartrate</styled-content></bold>; 99294-93-6; schembl40721; MLS001401453; Bio-0153; chembl1723343</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>CLCNs, GABRA1, TSPO</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2</italic> (minor)<italic>, CYP2C9</italic> (minor)<italic>, CYP2C19</italic> (minor)<italic>, CYP2D6</italic> (minor)<italic>, CYP3A4</italic> (major) <break></break><bold>  Inhibitor:</bold>
<italic>CYP3A4</italic> (strong)<break></break><bold>Transporter genes:</bold>
<italic>CLCNs, NR1I2</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2,3-dihydroxybutanedioic acid;N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>7</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 457.47638 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Enhances activity of inhibitory neurotransmitter, GABA, via selective agonism at benzodiazepine-1 (BZ1) receptor. Result is increased chloride conductance, neuronal hyperpolarization, inhibition of action potential, and decrease in neuronal excitability</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Central nervous system depression; GABA-A receptor agonist; Hypnotic activity; Sedation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i084.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Name: <styled-content style="color:#0070C0">Zopiclone</styled-content></bold>; Imovane; Zimovane; Amoban; (+-)-Zopiclone; 43200-80-2</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>CLCNs, GABRAs</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP2C8</italic> (major), <italic>CYP2C9</italic> (major), <italic>CYP2C19</italic> (minor), <italic>CYP2D6</italic>, <italic>CYP3A4</italic> (major)<break></break><bold>Transporter genes:</bold>
<italic>CLCNs</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>17</sub>ClN<sub>6</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 388.80828 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Reduces sleep latency, increases duration of sleep, and decreases number of nocturnal awakenings. Binds to the benzodiazepine receptor complex and modulates the GABABZ receptor chloride channel macromolecular complex. Acts on α1, α2, α3 and α5 GABAA containing receptors as a full agonist causing an enhancement of the inhibitory actions of GABA.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Hypnotic activity; Sedation</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="ijms-21-03059-t006" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-03059-t006_Table 6</object-id>
<label>Table 6</label>
<caption>
<p>Pharmacological properties and pharmacogenetics of selected antiepileptic drugs.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="3" rowspan="1" style="border-top:solid thin;border-bottom:solid thin;background:#D9D9D9" valign="middle">Antiepileptics</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">Drug</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">Properties</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin;background:#F2F2F2" valign="middle">Pharmacogenetics</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i085.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#2E74B5">Carbamazepine</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle"><bold>Mechanistic genes:</bold><italic>EPHX1,</italic><italic>HSPA1L, MTHFR, SCN1A</italic><break></break><bold>Metabolic genes:</bold><break></break><bold>  Substrate:</bold><italic>CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP3A4, CYP3A5, CYP3A7, GSTM1, GSTT1, UGT2B7</italic><break></break><bold>  Inhibitor:</bold><italic>CYP1A2</italic> Inducer: <italic>ABCB1, ABCB4, ABCC2, ABCG2, CYP1A1, CYP1A2, CYP2A6, CYP2B6; CYP2C8; CYP2C9; CYP2C19; CYP2D6, CYP3A4, GSTA1, SULT1A1, UGT1A4</italic><break></break><bold>Transporter genes:</bold>
<italic>ABCB1, ABCB4, ABCC2</italic><break></break><bold>Pleiotropic genes:</bold>
<italic>HLA-A, HLA-B, IL6</italic></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5H-Dibenz[b,f]azepine-5-carboxamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 236.27 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> The anticonvulsant activity of carbamazepine, like phenytoin, principally involves limitation of seizure propagation by reduction of post-tetanic potentiation of synaptic transmission. Carbamazepine has only slight analgesic properties. Carbamazepine appears to provide relief of pain in trigeminal neuralgia by reducing synaptic transmission within the trigeminal nucleus. The drug has also demonstrated sedative, anticholinergic, antidepressant, muscle relaxant, antiarrhythmic, antidiuretic, and neuromuscular transmission-inhibitory actions. May depress activity in the nucleus ventralis of the thalamus or decrease synaptic transmission or decrease summation of temporal stimulation leading to neural discharge by limiting influx of sodium ions across cell membrane or other unknown mechanism. May decrease the turnover of γ- aminobutyric acid (GABA). Stimulates the release of ADH and potentiates its action in promoting reabsorption of water. Chemically related to tricyclic antidepressants.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants, Miscellaneous. Antimanic Agents</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i086.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#2E74B5">Clonazepam</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>ALB, GABA-A</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP2E1, CYP3A4, NAT2</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-; 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>10</sub>ClN<sub>3</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 315.71 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Exact mechanism of anticonvulsant, sedative, and antipanic effects is unknown; however, mechanism appears to be related to the drug’s ability to enhance the activity of γ-aminobutyric acid (GABA). Suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex. Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the GABA receptor complex and modulating GABA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anxiolytics, Sedatives, and Hypnotics; Benzodiazepines. Anticonvulsants; Benzodiazepines</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<styled-content style="color:red">
<inline-graphic xlink:href="ijms-21-03059-i087.jpg"></inline-graphic>
</styled-content>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#2E74B5">Eslicarbazepine</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>ABCB1, UGT1A1, UGT1A4, UGT1A9, UGT2B7</italic>
<break></break>
<bold>  Inhibitor:</bold>
<italic>CYP2C19</italic>
<break></break>
<bold>  Inducer:</bold>
<italic>CYP3A4, UGT1A4, UGT1A9, UGT2B4, UGT2B7, UGT2B17</italic>
<break></break>
<bold>Pleiotropic genes:</bold>
<italic>HLA-B</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: [S-(-)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide]; BIA 2-093</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 296.32 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> The precise mechanisms of action of eslicarbazepine acetate are unknown. However, in vitro electrophysiological studies indicate that both eslicarbazepine acetate and its metabolites stabilize the inactivated state of voltage-gated sodium channels, preventing their return to the activated state and thereby sustaining repetitive neuronal firing</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants, Miscellaneous. Antiepileptics, Carboxamide Derivatives</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i088.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Ethosuximide</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>CACNA1G</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP2E1, CYP3A4, CYP3A5</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-, (±)-; (±)-2-Ethyl-2-methylsuccinimide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>7</sub>H<sub>11</sub>NO<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 141.17 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> A succinimide-derivative anticonvulsant. Exact mechanism of anticonvulsant action unknown. Increases seizure threshold in cortex and basal ganglia and reduces synaptic response to low-frequency repetitive stimulation. Suppresses paroxysmal spike and wave activity of the EEG associated with lapses of consciousness common in absence seizures</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants; Succinimides</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i089.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#4472C4">Felbamate</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>GABR, GRIN1, GRIN2B</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP2E1, CYP3A4, CYP3A5</italic>
<break></break>
<bold>  Inhibitor:</bold>
<italic>CYP2C19</italic>
<break></break>
<bold>  Inducer:</bold>
<italic>CYP3A4</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ABCB1</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2-Phenyl-1,3-propanediol dicarbamate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>11</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 238.24 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Felbamate, a dicarbamate, is an anticonvulsant agent. Exact mechanism of action unknown, but it is suggested that it increases seizure threshold and reduces seizure spread. <italic>In vitro</italic> studies indicate that felbamate has weak inhibitory effects on binding at GABA receptors and benzodiazepine receptors. The monocarbamate, p-hydroxy, and 2-hydroxy metabolites of felbamate appear to contribute little, if any, to the anticonvulsant action of the drug</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i090.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#4472C4">Gabapentin</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>GABRR1, GABRR2, KCNH2, SCN2A</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Inhibitor:</bold>
<italic>CYP2A6</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ABCB1, SLC22A4</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2-[1-(aminomethyl) cyclohexyl] acetic acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>9</sub>H<sub>17</sub>NO<sub>2</sub>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 171.24 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Gabapentin is an anticonvulsant agent structurally related to the inhibitory CNS neurotransmitter GABA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants, Analgesics and Antipyretics</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i091.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Lamotrigine</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>ADORA1, ADORA2A, ADRA1A, ADRA2A, ADRB1, CACNA1E, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, GABRA1, GABRA2, GABRA3, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRG1, GABRG2, GABRG3, GABRD, GABRE, GABRP, GABRR1, GABRR2, GABRR3, GABRQ, HRH1, HTR2A, HTR3A, OPRK1, SCN2A</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>DHFR, UGT1A1, UGT1A3, UGT1A4, UGT2A7</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ABCB1, SLC22A2</italic>
<break></break>
<bold>Pleiotropic genes:</bold>
<italic>HLA-B</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-; (2) 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 256.09 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Possibly involves inhibition of voltage-sensitive sodium channels, which stabilizes neuronal membranes and consequently modulates release of excitatory amino acid neurotransmitters (e.g. glutamate, aspartate) which play a role in generation and spread of epileptic seizures</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants, Miscellaneous</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i092.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Levetiracetam</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP2D6</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ABCB1</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 1-Pyrrolidineacetamide, α-ethyl-2-oxo-, (α S)-; (2)(-)-(S) - α-Ethyl-2-oxo-1-pyrrolidineacetamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 170.21 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> The precise mechanism by which levetiracetam exerts its antiepileptic effect is unknown and does not appear to derive from any interaction with known mechanisms involved in inhibitory and excitatory neurotransmission</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i093.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Oxcarbazepine</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>SCN2A</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP3A4, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A7, UGT1A9, UGT1A10, UGT2B7, UGT2B15</italic>
<break></break>
<bold>  Inhibitor:</bold>
<italic>CYP2C19</italic>
<break></break>
<bold>  Inducer:</bold>
<italic>ABCB1, CYP3A4, CYP3A5</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo-; 10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 252.27 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Pharmacological activity results from both oxcarbazepine and its monohydroxy metabolite (MHD). Oxcarbazepine and MHD block voltage-sensitive sodium channels, stabilizing hyperexcited neuronal membranes, inhibiting repetitive firing, and decreasing propagation of synaptic impulses. These actions are believed to prevent spread of seizures. Oxcarbazepine and MHD also increase potassium conductance and modulate activity of high-voltage activated calcium channels. Protects against electrically induced tonic extension seizures and, to a lesser degree, chemically-induced clonic seizures. May abolish or reduce frequency of chronically recurring focal seizures</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i094.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Phenobarbital</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>COMT, GABRA1, CHRNA4, CHRNA7, GRIA2, GRIK2, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D, GRIN3A, GRIN3B, NR1I2</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2E1, CYP3A4, CYP3A5, CYP3A7, CYP4A11, CYP4B1, EPHX1, UGT1A1</italic>
<break></break>
<bold>  Inhibitor:</bold>
<italic>CYP2C19, CYP2J2, CYP27A1, SLC10A1, SULT1A1</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ABCB1, ABCB11, ABCC1, ABCC2, ABCC3, SLCO2A1</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-; (2) 5-Ethyl-5-phenylbarbituric acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 232.24 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Long-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. Barbiturates depress sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity. They also produce dose-dependent respiratory depression</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants; Barbiturates. Anxiolytics, Sedatives, and Hypnotics; Barbiturates</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i095.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Phenytoin</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>NR1I2, SCN1A, SCN1B, SCN3A, SCN5A</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP3A4, CYP3A5, CYP3A7, CYP11B1, EPHX1, UGT1A1, UGT1A6, UGT1A9</italic>
<break></break>
<bold>  Inhibitor:</bold>
<italic>SCN2A, SULT1A1</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ALB, ABCB1, ABCC2, SLCO1B1, SLCO1C1</italic>
<break></break>
<bold>Pleiotropic genes:</bold>
<italic>HLA-B</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 5,5-Diphenylhydantoin</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 252.27 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Stabilizes neuronal membranes and decreases seizure activity by increasing efflux or decreasing influx of sodium ions across cell membranes in motor cortex during generation of nerve impulses. Prolongs effective refractory period and suppresses ventricular pacemaker automaticity, shortens action potential in heart</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Class Ib Antiarrhythmics. Anticonvulsants; Hydantoins</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i096.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Primidone</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>GABRAs</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Inducer:</bold>
<italic>CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP3A4</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 4,6(1H,5H)-Pyrimidinedione, 5-ethyldihydro-5-phenyl-; 5-Ethyldihydro-5-phenyl-4,6(1H,5H)-pyrimidinedione</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>12</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 218.25 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Decreases neuron excitability, raises seizure threshold similar to phenobarbital. Primidone has two active metabolites, phenobarbital and phenylethylmalonamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants; Barbiturates</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i097.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Rufinamide</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>MAPK10, SCN1A</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>  Substrate:</bold>
<italic>CES</italic>
<break></break>
<bold>  Inhibitor:</bold>
<italic>CYP2E1</italic>
<break></break>
<bold>  Inducer:</bold>
<italic>CYP3A4</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>10</sub>H<sub>8</sub>F<sub>2</sub>N<sub>4</sub>O</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 238.2 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> The precise mechanism(s) by which rufinamide exerts its antiepileptic effect are unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide (≥ 1 μM) significantly slowed sodium channel recovery from inactivation after a prolonged prepulse in cultured cortical neurons, and limited sustained repetitive firing of sodium-dependent action potentials</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants; Triazole Derivative</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i098.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Tiagabine</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>ABAT</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>Substrate:</bold>
<italic>CYP3A4</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>SLC6A1</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: 3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, hydrochloride, (R)-; (-)-(R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid, hydrochloride.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>20</sub>H<sub>25</sub>NO<sub>2</sub>S<sub>2</sub> HCl</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 412.01 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Exact mechanism not definitively known; however, in vitro experiments demonstrate that it enhances activity of gamma-aminobutyric acid (GABA). It is thought that binding to GABA uptake carrier inhibits uptake of GABA into presynaptic neurons, allowing availability of increased amount of GABA to postsynaptic neurons. Based on in vitro studies, tiagabine does not inhibit uptake of dopamine, norepinephrine, serotonin, glutamate, or choline</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i099.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Topimarate</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>ACSL4, AGXT, CA1-5, GABRA1, IGF1, KCNH2, NR1I2, SCN1A, SCN2A</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>Substrate:</bold>
<italic>CYP3A4</italic>
<break></break>
<bold>Inhibitor:</bold>
<italic>CYP2C19</italic>
<break></break>
<bold>Inducer:</bold>
<italic>ABCB1, CYP3A4</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ABCB1</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: β-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate; 2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>12</sub>H<sub>21</sub>NO<sub>8</sub>S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 339.36 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Blocks neuronal voltage-dependent sodium channels, enhances GABA(A) activity, antagonizes AMPA/kainate glutamate receptors, and weakly inhibits carbonic anhydrase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<inline-graphic xlink:href="ijms-21-03059-i100.jpg"></inline-graphic>
</td>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<bold>Name: <styled-content style="color:#0070C0">Valproic acid</styled-content></bold>
</td>
<td align="left" colspan="1" rowspan="6" style="border-bottom:solid thin" valign="middle">
<bold>Mechanistic genes:</bold>
<italic>ABAT, ACADSB, ALDH5A1, HDAC2, HDAC9, OGDH, PPARA, PPARD, PPARG</italic>
<break></break>
<bold>Metabolic genes:</bold>
<break></break>
<bold>Substrate:</bold>
<italic>CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2E1, CYP3A4, CYP3A5, CYP4B1, CYP4F2, PTGS1, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, UGT2B15</italic>
<break></break>
<bold>Inhibitor:</bold>
<italic>CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP3A4, HDAC9, UGT1A9, UGT2B7, UGT2B15</italic>
<break></break>
<bold>Transporter genes:</bold>
<italic>ALB, SLC16A1, SLC22A5, SLC22A6, SLC22A7, SLC22A8, SLCO2B1</italic>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>IUPAC Name</bold>: Pentanoic acid, 2-propyl-; (2) Propylvaleric acid</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Formula:</bold> C<sub>8</sub>H<sub>16</sub>O<sub>2</sub></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Molecular Weight:</bold> 144.21 g/mol</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Mechanism:</bold> Causes increased availability of gamma-aminobutyric acid (GABA), to brain neurons or may enhance action of GABA or mimic its action at postsynaptic receptor sites</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle"><bold>Effect:</bold> Anticonvulsants, Miscellaneous. Antimanic Agents; Histone Deacetylase Inhibitor</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>